"abacavir","{'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the exposure to abacavir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to abacavir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to decrease the exposure to abacavir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to decrease the exposure to abacavir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Primidone': ['Moderate', 'Primidone is predicted to decrease the exposure to abacavir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tipranavir': ['Severe', 'Tipranavir slightly decreases the exposure to abacavir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study']}","abatacept","{'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Golimumab': ['Severe', 'Abatacept is predicted to increase the risk of generalised infection (possibly life-threatening) when given with golimumab. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical']}","abemaciclib","{'Aprepitant': ['Moderate', 'Aprepitant is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atazanavir': ['Severe', 'Atazanavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Carbamazepine': ['Severe', 'Carbamazepine is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Clarithromycin': ['Severe', 'Clarithromycin is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cobicistat': ['Severe', 'Cobicistat is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Crizotinib': ['Moderate', 'Crizotinib is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Darunavir': ['Severe', 'Darunavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Diltiazem': ['Moderate', 'Diltiazem is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Enzalutamide': ['Severe', 'Enzalutamide is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosamprenavir': ['Severe', 'Fosamprenavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosphenytoin': ['Severe', 'Fosphenytoin is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Grapefruit juice': ['Moderate', 'Grapefruit juice is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Idelalisib': ['Severe', 'Idelalisib is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Imatinib': ['Moderate', 'Imatinib is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Isavuconazole': ['Moderate', 'Isavuconazole is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Itraconazole': ['Severe', 'Itraconazole is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketoconazole': ['Severe', 'Ketoconazole is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Lopinavir': ['Severe', 'Lopinavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Mitotane': ['Severe', 'Mitotane is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Netupitant': ['Moderate', 'Netupitant is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nilotinib': ['Moderate', 'Nilotinib is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenobarbital': ['Severe', 'Phenobarbital is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenytoin': ['Severe', 'Phenytoin is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Primidone': ['Severe', 'Primidone is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Rifampicin': ['Severe', 'Rifampicin is predicted to markedly decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ritonavir': ['Severe', 'Ritonavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Saquinavir': ['Severe', 'Saquinavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], ""St John's Wort"": ['Severe', ""St John's Wort is predicted to decrease the exposure to abemaciclib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study""], 'Tipranavir': ['Severe', 'Tipranavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Verapamil': ['Moderate', 'Verapamil is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Voriconazole': ['Severe', 'Voriconazole is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study']}","abiratero","{'Carbamazepine': ['Severe', 'Carbamazepine is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Eliglustat': ['Severe', 'Abiraterone is predicted to increase the exposure to eliglustat. Manufacturer advises avoid or adjust dose—consult product literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Enzalutamide': ['Severe', 'Enzalutamide is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosphenytoin': ['Severe', 'Fosphenytoin is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Metoprolol': ['Moderate', 'Abiraterone is predicted to increase the exposure to metoprolol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mitotane': ['Severe', 'Mitotane is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenobarbital': ['Severe', 'Phenobarbital is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenytoin': ['Severe', 'Phenytoin is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Primidone': ['Severe', 'Primidone is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Rifampicin': ['Severe', 'Rifampicin is predicted to decrease the exposure to abiraterone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study']}","acarbose","{'Alogliptin': ['NotSet', 'Both acarbose and alogliptin can increase the risk of hypoglycaemia.'], 'Canagliflozin': ['NotSet', 'Both acarbose and canagliflozin can increase the risk of hypoglycaemia.'], 'Dapagliflozin': ['NotSet', 'Both acarbose and dapagliflozin can increase the risk of hypoglycaemia.'], 'Digoxin': ['Moderate', 'Acarbose decreases the concentration of digoxin. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dulaglutide': ['NotSet', 'Both acarbose and dulaglutide can increase the risk of hypoglycaemia.'], 'Empagliflozin': ['NotSet', 'Both acarbose and empagliflozin can increase the risk of hypoglycaemia.'], 'Ertugliflozin': ['NotSet', 'Both acarbose and ertugliflozin can increase the risk of hypoglycaemia.'], 'Exenatide': ['NotSet', 'Both acarbose and exenatide can increase the risk of hypoglycaemia.'], 'Glibenclamide': ['NotSet', 'Both acarbose and glibenclamide can increase the risk of hypoglycaemia.'], 'Gliclazide': ['NotSet', 'Both acarbose and gliclazide can increase the risk of hypoglycaemia.'], 'Glimepiride': ['NotSet', 'Both acarbose and glimepiride can increase the risk of hypoglycaemia.'], 'Glipizide': ['NotSet', 'Both acarbose and glipizide can increase the risk of hypoglycaemia.'], 'Insulins': ['NotSet', 'Both acarbose and insulins can increase the risk of hypoglycaemia.'], 'Linagliptin': ['NotSet', 'Both acarbose and linagliptin can increase the risk of hypoglycaemia.'], 'Liraglutide': ['NotSet', 'Both acarbose and liraglutide can increase the risk of hypoglycaemia.'], 'Lixisenatide': ['NotSet', 'Both acarbose and lixisenatide can increase the risk of hypoglycaemia.'], 'Metformin': ['NotSet', 'Both acarbose and metformin can increase the risk of hypoglycaemia.'], 'Nateglinide': ['NotSet', 'Both acarbose and nateglinide can increase the risk of hypoglycaemia.'], 'Pancreatin': ['Moderate', 'Pancreatin is predicted to decrease the effects of acarbose. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pioglitazone': ['NotSet', 'Both acarbose and pioglitazone can increase the risk of hypoglycaemia.'], 'Repaglinide': ['NotSet', 'Both acarbose and repaglinide can increase the risk of hypoglycaemia.'], 'Saxagliptin': ['NotSet', 'Both acarbose and saxagliptin can increase the risk of hypoglycaemia.'], 'Semaglutide': ['NotSet', 'Both acarbose and semaglutide can increase the risk of hypoglycaemia.'], 'Sitagliptin': ['NotSet', 'Both acarbose and sitagliptin can increase the risk of hypoglycaemia.'], 'Tolbutamide': ['NotSet', 'Both acarbose and tolbutamide can increase the risk of hypoglycaemia.'], 'Vildagliptin': ['NotSet', 'Both acarbose and vildagliptin can increase the risk of hypoglycaemia.']}","acebutolol","{'Adrenaline/epinephrine': ['Severe', 'Acebutolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Alcohol (beverage)': ['NotSet', 'Both acebutolol and alcohol (beverage) can increase the risk of hypotension.'], 'Alectinib': ['NotSet', 'Both acebutolol and alectinib can increase the risk of bradycardia.'], 'Alfentanil': ['NotSet', 'Both acebutolol and alfentanil can increase the risk of bradycardia.'], 'Alfuzosin': ['NotSet', 'Both acebutolol and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both acebutolol and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both acebutolol and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both acebutolol and amantadine can increase the risk of hypotension.'], 'Aminophylline': ['Severe', 'Acebutolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['NotSet', 'Both acebutolol and amiodarone can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Amitriptyline': ['NotSet', 'Both acebutolol and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both acebutolol and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both acebutolol and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both acebutolol and apraclonidine can increase the risk of bradycardia. Both acebutolol and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both acebutolol and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both acebutolol and asenapine can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both acebutolol and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both acebutolol and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both acebutolol and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both acebutolol and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both acebutolol and benperidol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both acebutolol and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both acebutolol and brimonidine can increase the risk of bradycardia. Both acebutolol and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both acebutolol and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both acebutolol and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both acebutolol and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both acebutolol and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both acebutolol and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both acebutolol and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', 'Both acebutolol and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both acebutolol and carvedilol can increase the risk of bradycardia. Both acebutolol and carvedilol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both acebutolol and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both acebutolol and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both acebutolol and chlortalidone can increase the risk of hypotension.'], 'Cisatracurium': ['NotSet', 'Both acebutolol and cisatracurium can increase the risk of bradycardia.'], 'Clomipramine': ['NotSet', 'Both acebutolol and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both acebutolol and clonidine can increase the risk of bradycardia. Both acebutolol and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both acebutolol and clozapine can increase the risk of hypotension.'], 'Crizotinib': ['NotSet', 'Both acebutolol and crizotinib can increase the risk of bradycardia.'], 'Dapagliflozin': ['NotSet', 'Both acebutolol and dapagliflozin can increase the risk of hypotension.'], 'Desflurane': ['NotSet', 'Both acebutolol and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both acebutolol and diazoxide can increase the risk of hypotension.'], 'Digoxin': ['NotSet', 'Both acebutolol and digoxin can increase the risk of bradycardia.'], 'Diltiazem': ['NotSet', 'Both acebutolol and diltiazem can increase the risk of bradycardia. Both acebutolol and diltiazem can increase the risk of hypotension. Diltiazem is predicted to increase the risk of cardiodepression when given with acebutolol. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Dipyridamole': ['NotSet', 'Both acebutolol and dipyridamole can increase the risk of hypotension.'], 'Disopyramide': ['Severe', 'Disopyramide is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Dobutamine': ['Moderate', 'Acebutolol increases the risk of hypertension and bradycardia when given with dobutamine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Donepezil': ['NotSet', 'Both acebutolol and donepezil can increase the risk of bradycardia. Donepezil is predicted to increase the risk of bradycardia when given with acebutolol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Dosulepin': ['NotSet', 'Both acebutolol and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both acebutolol and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both acebutolol and doxepin can increase the risk of hypotension.'], 'Dronedarone': ['Severe', 'Dronedarone is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Droperidol': ['NotSet', 'Both acebutolol and droperidol can increase the risk of hypotension.'], 'Empagliflozin': ['NotSet', 'Both acebutolol and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both acebutolol and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both acebutolol and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both acebutolol and eprosartan can increase the risk of hypotension.'], 'Ergometrine': ['Severe', 'Acebutolol is predicted to increase the risk of peripheral vasoconstriction when given with ergometrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Ergotamine': ['Severe', 'Acebutolol is predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Ertugliflozin': ['NotSet', 'Both acebutolol and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', 'Both acebutolol and esketamine can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both acebutolol and etomidate can increase the risk of hypotension.'], 'Felodipine': ['NotSet', 'Both acebutolol and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', 'Both acebutolol and fentanyl can increase the risk of bradycardia.'], 'Fingolimod': ['NotSet', 'Both acebutolol and fingolimod can increase the risk of bradycardia.'], 'Flecainide': ['NotSet', 'Both acebutolol and flecainide can increase the risk of bradycardia. Flecainide is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Flupentixol': ['NotSet', 'Both acebutolol and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both acebutolol and fluphenazine can increase the risk of hypotension.'], 'Fosinopril': ['NotSet', 'Both acebutolol and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both acebutolol and furosemide can increase the risk of hypotension.'], 'Galantamine': ['NotSet', 'Both acebutolol and galantamine can increase the risk of bradycardia. Galantamine is predicted to increase the risk of bradycardia when given with acebutolol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Glyceryl trinitrate': ['NotSet', 'Both acebutolol and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both acebutolol and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both acebutolol and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both acebutolol and haloperidol can increase the risk of hypotension.'], 'Hydralazine': ['NotSet', 'Both acebutolol and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both acebutolol and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both acebutolol and hydroflumethiazide can increase the risk of hypotension.'], 'Imidapril': ['NotSet', 'Both acebutolol and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both acebutolol and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both acebutolol and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both acebutolol and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both acebutolol and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both acebutolol and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both acebutolol and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both acebutolol and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both acebutolol and isosorbide mononitrate can increase the risk of hypotension.'], 'Ivabradine': ['NotSet', 'Both acebutolol and ivabradine can increase the risk of bradycardia.'], 'Ketamine': ['NotSet', 'Both acebutolol and ketamine can increase the risk of hypotension.'], 'Labetalol': ['NotSet', 'Both acebutolol and labetalol can increase the risk of bradycardia. Both acebutolol and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both acebutolol and lacidipine can increase the risk of hypotension.'], 'Lanreotide': ['Moderate', 'Acebutolol is predicted to increase the risk of bradycardia when given with lanreotide. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lercanidipine': ['NotSet', 'Both acebutolol and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both acebutolol and levobunolol can increase the risk of bradycardia. Both acebutolol and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both acebutolol and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both acebutolol and levomepromazine can increase the risk of hypotension.'], 'Lidocaine': ['Severe', 'Lidocaine is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Lisinopril': ['NotSet', 'Both acebutolol and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both acebutolol and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both acebutolol and lofexidine can increase the risk of hypotension.'], 'Losartan': ['NotSet', 'Both acebutolol and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both acebutolol and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both acebutolol and lurasidone can increase the risk of hypotension.'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of bradycardia when given with acebutolol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['NotSet', 'Both acebutolol and methadone can increase the risk of bradycardia.'], 'Methoxyflurane': ['NotSet', 'Both acebutolol and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both acebutolol and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both acebutolol and metolazone can increase the risk of hypotension.'], 'Mexiletine': ['Severe', 'Mexiletine potentially increases the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises avoid or monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Minoxidil': ['NotSet', 'Both acebutolol and minoxidil can increase the risk of hypotension.'], 'Moxisylyte': ['NotSet', 'Both acebutolol and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both acebutolol and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both acebutolol and nadolol can increase the risk of bradycardia. Both acebutolol and nadolol can increase the risk of hypotension.'], 'Neostigmine': ['NotSet', 'Both acebutolol and neostigmine can increase the risk of bradycardia.'], 'Nicardipine': ['NotSet', 'Both acebutolol and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both acebutolol and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both acebutolol and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both acebutolol and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both acebutolol and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both acebutolol and nitrous oxide can increase the risk of hypotension.'], 'Noradrenaline/norepinephrine': ['Severe', 'Acebutolol is predicted to increase the risk of hypertension and bradycardia when given with noradrenaline/norepinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nortriptyline': ['NotSet', 'Both acebutolol and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both acebutolol and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both acebutolol and olmesartan can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both acebutolol and paliperidone can increase the risk of hypotension.'], 'Pasireotide': ['NotSet', 'Both acebutolol and pasireotide can increase the risk of bradycardia.'], 'Pergolide': ['NotSet', 'Both acebutolol and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both acebutolol and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both acebutolol and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both acebutolol and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to decrease the exposure to acebutolol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['NotSet', 'Both acebutolol and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both acebutolol and pindolol can increase the risk of bradycardia. Both acebutolol and pindolol can increase the risk of hypotension.'], 'Pramipexole': ['NotSet', 'Both acebutolol and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both acebutolol and prazosin can increase the risk of hypotension.'], 'Primidone': ['Moderate', 'Primidone is predicted to decrease the exposure to acebutolol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Prochlorperazine': ['NotSet', 'Both acebutolol and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both acebutolol and promazine can increase the risk of hypotension.'], 'Propafenone': ['Severe', 'Propafenone is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Propofol': ['NotSet', 'Both acebutolol and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both acebutolol and propranolol can increase the risk of bradycardia. Both acebutolol and propranolol can increase the risk of hypotension.'], 'Pyridostigmine': ['NotSet', 'Both acebutolol and pyridostigmine can increase the risk of bradycardia.'], 'Quetiapine': ['NotSet', 'Both acebutolol and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both acebutolol and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both acebutolol and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both acebutolol and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', 'Both acebutolol and remifentanil can increase the risk of bradycardia.'], 'Riociguat': ['NotSet', 'Both acebutolol and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both acebutolol and risperidone can increase the risk of hypotension.'], 'Rivastigmine': ['NotSet', 'Both acebutolol and rivastigmine can increase the risk of bradycardia. Rivastigmine is predicted to increase the risk of bradycardia when given with acebutolol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ropinirole': ['NotSet', 'Both acebutolol and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both acebutolol and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both acebutolol and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both acebutolol and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both acebutolol and selegiline can increase the risk of bradycardia. Both acebutolol and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both acebutolol and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both acebutolol and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both acebutolol and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both acebutolol and sotalol can increase the risk of bradycardia. Both acebutolol and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both acebutolol and spironolactone can increase the risk of hypotension.'], 'Sufentanil': ['NotSet', 'Both acebutolol and sufentanil can increase the risk of bradycardia.'], 'Sulpiride': ['NotSet', 'Both acebutolol and sulpiride can increase the risk of hypotension.'], 'Tadalafil': ['NotSet', 'Both acebutolol and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both acebutolol and tamsulosin can increase the risk of hypotension.'], 'Telmisartan': ['NotSet', 'Both acebutolol and telmisartan can increase the risk of hypotension.'], 'Terazosin': ['NotSet', 'Both acebutolol and terazosin can increase the risk of hypotension.'], 'Thalidomide': ['NotSet', 'Both acebutolol and thalidomide can increase the risk of bradycardia.'], 'Theophylline': ['Severe', 'Acebutolol is predicted to increase the risk of bronchospasm when given with theophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Thiopental': ['NotSet', 'Both acebutolol and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both acebutolol and timolol can increase the risk of bradycardia. Both acebutolol and timolol can increase the risk of hypotension.'], 'Tizanidine': ['NotSet', 'Both acebutolol and tizanidine can increase the risk of bradycardia. Both acebutolol and tizanidine can increase the risk of hypotension.'], 'Torasemide': ['NotSet', 'Both acebutolol and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both acebutolol and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both acebutolol and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both acebutolol and trifluoperazine can increase the risk of hypotension.'], 'Trimipramine': ['NotSet', 'Both acebutolol and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both acebutolol and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both acebutolol and vardenafil can increase the risk of hypotension.'], 'Verapamil': ['NotSet', 'Both acebutolol and verapamil can increase the risk of bradycardia. Both acebutolol and verapamil can increase the risk of hypotension. Intravenous verapamil increases the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study Oral verapamil increases the risk of cardiovascular side-effects when given with acebutolol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Vernakalant': ['NotSet', 'Both acebutolol and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both acebutolol and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both acebutolol and zuclopenthixol can increase the risk of hypotension.']}","aceclofenac","{'Acenocoumarol': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Aciclovir': ['NotSet', 'Both aceclofenac and aciclovir can increase the risk of nephrotoxicity.'], 'Adefovir': ['NotSet', 'Both aceclofenac and adefovir can increase the risk of nephrotoxicity.'], 'Alendronate': ['Moderate', 'Aceclofenac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aliskiren': ['NotSet', 'Both aceclofenac and aliskiren can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Alteplase': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amikacin': ['NotSet', 'Both aceclofenac and amikacin can increase the risk of nephrotoxicity.'], 'Amiloride': ['NotSet', 'Both aceclofenac and amiloride can increase the risk of hyponatraemia. Both aceclofenac and amiloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Amitriptyline': ['NotSet', 'Both aceclofenac and amitriptyline can increase the risk of hyponatraemia.'], 'Amphotericin': ['NotSet', 'Both aceclofenac and amphotericin can increase the risk of nephrotoxicity.'], 'Anagrelide': ['NotSet', 'Both aceclofenac and anagrelide can increase the risk of bleeding.'], 'Apixaban': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Argatroban': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Aspirin': ['NotSet', 'Both aceclofenac and aspirin can increase the risk of bleeding.'], 'Azilsartan': ['NotSet', 'Both aceclofenac and azilsartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Bacitracin': ['NotSet', 'Both aceclofenac and bacitracin can increase the risk of nephrotoxicity.'], 'Beclometasone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with beclometasone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Bendroflumethiazide': ['NotSet', 'Both aceclofenac and bendroflumethiazide can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with bendroflumethiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with betamethasone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Bevacizumab': ['NotSet', 'Both aceclofenac and bevacizumab can increase the risk of bleeding.'], 'Bivalirudin': ['Severe', 'Bivalirudin is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Budesonide': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with budesonide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Bumetanide': ['NotSet', 'Both aceclofenac and bumetanide can increase the risk of hyponatraemia.'], 'Candesartan': ['NotSet', 'Both aceclofenac and candesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Cangrelor': ['NotSet', 'Both aceclofenac and cangrelor can increase the risk of bleeding.'], 'Capreomycin': ['NotSet', 'Both aceclofenac and capreomycin can increase the risk of nephrotoxicity.'], 'Captopril': ['NotSet', 'Both aceclofenac and captopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Carbamazepine': ['NotSet', 'Both aceclofenac and carbamazepine can increase the risk of hyponatraemia.'], 'Carboplatin': ['NotSet', 'Both aceclofenac and carboplatin can increase the risk of nephrotoxicity.'], 'Cefaclor': ['NotSet', 'Both aceclofenac and cefaclor can increase the risk of nephrotoxicity.'], 'Cefadroxil': ['NotSet', 'Both aceclofenac and cefadroxil can increase the risk of nephrotoxicity.'], 'Cefalexin': ['NotSet', 'Both aceclofenac and cefalexin can increase the risk of nephrotoxicity.'], 'Cefepime': ['NotSet', 'Both aceclofenac and cefepime can increase the risk of nephrotoxicity.'], 'Cefixime': ['NotSet', 'Both aceclofenac and cefixime can increase the risk of nephrotoxicity.'], 'Cefotaxime': ['NotSet', 'Both aceclofenac and cefotaxime can increase the risk of nephrotoxicity.'], 'Cefoxitin': ['NotSet', 'Both aceclofenac and cefoxitin can increase the risk of nephrotoxicity.'], 'Cefradine': ['NotSet', 'Both aceclofenac and cefradine can increase the risk of nephrotoxicity.'], 'Ceftaroline': ['NotSet', 'Both aceclofenac and ceftaroline can increase the risk of nephrotoxicity.'], 'Ceftazidime': ['NotSet', 'Both aceclofenac and ceftazidime can increase the risk of nephrotoxicity.'], 'Ceftobiprole': ['NotSet', 'Both aceclofenac and ceftobiprole can increase the risk of nephrotoxicity.'], 'Ceftolozane': ['NotSet', 'Both aceclofenac and ceftolozane can increase the risk of nephrotoxicity.'], 'Ceftriaxone': ['NotSet', 'Both aceclofenac and ceftriaxone can increase the risk of nephrotoxicity.'], 'Cefuroxime': ['NotSet', 'Both aceclofenac and cefuroxime can increase the risk of nephrotoxicity.'], 'Chlorothiazide': ['NotSet', 'Both aceclofenac and chlorothiazide can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with chlorothiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlortalidone': ['NotSet', 'Both aceclofenac and chlortalidone can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with chlortalidone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ciclesonide': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with ciclesonide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciclosporin': ['NotSet', 'Both aceclofenac and ciclosporin can increase the risk of nephrotoxicity. Both aceclofenac and ciclosporin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Cidofovir': ['NotSet', 'Both aceclofenac and cidofovir can increase the risk of nephrotoxicity.'], 'Cilostazol': ['NotSet', 'Both aceclofenac and cilostazol can increase the risk of bleeding.'], 'Ciprofloxacin': ['Severe', 'Aceclofenac potentially increases the risk of seizures when given with ciprofloxacin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cisplatin': ['NotSet', 'Both aceclofenac and cisplatin can increase the risk of nephrotoxicity.'], 'Citalopram': ['NotSet', 'Both aceclofenac and citalopram can increase the risk of hyponatraemia. Both aceclofenac and citalopram can increase the risk of bleeding.'], 'Clodronate': ['Moderate', 'Aceclofenac is predicted to increase the risk of renal impairment when given with clodronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clomipramine': ['NotSet', 'Both aceclofenac and clomipramine can increase the risk of hyponatraemia.'], 'Clopidogrel': ['NotSet', 'Both aceclofenac and clopidogrel can increase the risk of bleeding.'], 'Colistimethate': ['Severe', 'Colistimethate (particularly intravenous) potentially increases the risk of nephrotoxicity when given with aceclofenac. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dabigatran': ['Severe', 'Dabigatran is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dalteparin': ['NotSet', 'Both aceclofenac and dalteparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Dalteparin is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Danaparoid': ['Severe', 'Danaparoid is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dapoxetine': ['NotSet', 'Both aceclofenac and dapoxetine can increase the risk of hyponatraemia. Both aceclofenac and dapoxetine can increase the risk of bleeding.'], 'Daptomycin': ['Moderate', 'Aceclofenac increases the risk of renal impairment when given with daptomycin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Darbepoetin alfa': ['NotSet', 'Both aceclofenac and darbepoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dasatinib': ['NotSet', 'Both aceclofenac and dasatinib can increase the risk of bleeding.'], 'Deferasirox': ['Severe', 'Aceclofenac is predicted to increase the risk of gastrointestinal bleeding when given with deferasirox. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Deflazacort': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with deflazacort. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Desmopressin': ['NotSet', 'Both aceclofenac and desmopressin can increase the risk of hyponatraemia.'], 'Dexamethasone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with dexamethasone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Dipyridamole': ['NotSet', 'Both aceclofenac and dipyridamole can increase the risk of bleeding.'], 'Dosulepin': ['NotSet', 'Both aceclofenac and dosulepin can increase the risk of hyponatraemia.'], 'Doxepin': ['NotSet', 'Both aceclofenac and doxepin can increase the risk of hyponatraemia.'], 'Drospirenone': ['NotSet', 'Both aceclofenac and drospirenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Duloxetine': ['NotSet', 'Both aceclofenac and duloxetine can increase the risk of hyponatraemia. Both aceclofenac and duloxetine can increase the risk of bleeding.'], 'Edoxaban': ['Severe', 'Edoxaban is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Enalapril': ['NotSet', 'Both aceclofenac and enalapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Enoxaparin': ['NotSet', 'Both aceclofenac and enoxaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Enoxaparin is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eplerenone': ['NotSet', 'Both aceclofenac and eplerenone can increase the risk of hyponatraemia. Both aceclofenac and eplerenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin alfa': ['NotSet', 'Both aceclofenac and epoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin beta': ['NotSet', 'Both aceclofenac and epoetin beta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin zeta': ['NotSet', 'Both aceclofenac and epoetin zeta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoprostenol': ['NotSet', 'Both aceclofenac and epoprostenol can increase the risk of bleeding.'], 'Eprosartan': ['NotSet', 'Both aceclofenac and eprosartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eptifibatide': ['NotSet', 'Both aceclofenac and eptifibatide can increase the risk of bleeding.'], 'Erlotinib': ['Severe', 'Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with aceclofenac. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Escitalopram': ['NotSet', 'Both aceclofenac and escitalopram can increase the risk of hyponatraemia. Both aceclofenac and escitalopram can increase the risk of bleeding.'], 'Fludrocortisone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with fludrocortisone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Fluoxetine': ['NotSet', 'Both aceclofenac and fluoxetine can increase the risk of hyponatraemia. Both aceclofenac and fluoxetine can increase the risk of bleeding.'], 'Fluticasone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with fluticasone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Fluvoxamine': ['NotSet', 'Both aceclofenac and fluvoxamine can increase the risk of hyponatraemia. Both aceclofenac and fluvoxamine can increase the risk of bleeding.'], 'Fondaparinux': ['Severe', 'Fondaparinux is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Foscarnet': ['NotSet', 'Both aceclofenac and foscarnet can increase the risk of nephrotoxicity.'], 'Furosemide': ['NotSet', 'Both aceclofenac and furosemide can increase the risk of hyponatraemia.'], 'Gabapentin': ['NotSet', 'Both aceclofenac and gabapentin can increase the risk of hyponatraemia.'], 'Ganciclovir': ['NotSet', 'Both aceclofenac and ganciclovir can increase the risk of nephrotoxicity.'], 'Gentamicin': ['NotSet', 'Both aceclofenac and gentamicin can increase the risk of nephrotoxicity.'], 'Heparin (unfractionated)': ['NotSet', 'Both aceclofenac and heparin (unfractionated) can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Heparin (unfractionated) is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrochlorothiazide': ['NotSet', 'Both aceclofenac and hydrochlorothiazide can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with hydrochlorothiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with hydrocortisone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Hydroflumethiazide': ['NotSet', 'Both aceclofenac and hydroflumethiazide can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with hydroflumethiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibandronate': ['Moderate', 'Aceclofenac is predicted to increase the risk of gastrointestinal irritation when given with ibandronate. Manufacturer advises caution and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ibrutinib': ['NotSet', 'Both aceclofenac and ibrutinib can increase the risk of bleeding.'], 'Ifosfamide': ['NotSet', 'Both aceclofenac and ifosfamide can increase the risk of nephrotoxicity.'], 'Iloprost': ['NotSet', 'Both aceclofenac and iloprost can increase the risk of bleeding.'], 'Imidapril': ['NotSet', 'Both aceclofenac and imidapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Imipramine': ['NotSet', 'Both aceclofenac and imipramine can increase the risk of hyponatraemia.'], 'Indapamide': ['NotSet', 'Both aceclofenac and indapamide can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with indapamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotersen': ['NotSet', 'Both aceclofenac and inotersen can increase the risk of bleeding.'], 'Irbesartan': ['NotSet', 'Both aceclofenac and irbesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Levofloxacin': ['Severe', 'Aceclofenac potentially increases the risk of seizures when given with levofloxacin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lisinopril': ['NotSet', 'Both aceclofenac and lisinopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Lithium': ['Severe', 'Aceclofenac increases the concentration of lithium. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Losartan': ['NotSet', 'Both aceclofenac and losartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Methotrexate': ['NotSet', 'Both aceclofenac and methotrexate can increase the risk of nephrotoxicity. Aceclofenac is predicted to increase the risk of toxicity when given with methotrexate. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Methylprednisolone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with methylprednisolone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Metolazone': ['NotSet', 'Both aceclofenac and metolazone can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with metolazone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mifamurtide': ['Severe', 'Aceclofenac (high-dose) is predicted to decrease the efficacy of mifamurtide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mometasone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with mometasone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Moxifloxacin': ['Severe', 'Aceclofenac potentially increases the risk of seizures when given with moxifloxacin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Neomycin': ['NotSet', 'Both aceclofenac and neomycin can increase the risk of nephrotoxicity.'], 'Nicorandil': ['Severe', 'Nicorandil is predicted to increase the risk of gastrointestinal perforation when given with aceclofenac. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nicotinic acid': ['Severe', 'Nicotinic acid is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nortriptyline': ['NotSet', 'Both aceclofenac and nortriptyline can increase the risk of hyponatraemia.'], 'Ofloxacin': ['Severe', 'Aceclofenac potentially increases the risk of seizures when given with ofloxacin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Olmesartan': ['NotSet', 'Both aceclofenac and olmesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Omega-3-acid ethyl esters': ['Severe', 'Omega-3-acid ethyl esters is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Oxaliplatin': ['NotSet', 'Both aceclofenac and oxaliplatin can increase the risk of nephrotoxicity.'], 'Paroxetine': ['NotSet', 'Both aceclofenac and paroxetine can increase the risk of hyponatraemia. Both aceclofenac and paroxetine can increase the risk of bleeding.'], 'Pemetrexed': ['NotSet', 'Both aceclofenac and pemetrexed can increase the risk of nephrotoxicity. Aceclofenac is predicted to increase the exposure to pemetrexed. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Penicillamine': ['NotSet', 'Both aceclofenac and penicillamine can increase the risk of nephrotoxicity.'], 'Pentamidine': ['NotSet', 'Both aceclofenac and pentamidine can increase the risk of nephrotoxicity.'], 'Perindopril': ['NotSet', 'Both aceclofenac and perindopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Phenindione': ['Severe', 'Phenindione is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Polymyxin b': ['NotSet', 'Both aceclofenac and polymyxin b can increase the risk of nephrotoxicity.'], 'Potassium aminobenzoate': ['NotSet', 'Both aceclofenac and potassium aminobenzoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium canrenoate': ['NotSet', 'Both aceclofenac and potassium canrenoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium chloride': ['NotSet', 'Both aceclofenac and potassium chloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Prasugrel': ['NotSet', 'Both aceclofenac and prasugrel can increase the risk of bleeding.'], 'Prednisolone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with prednisolone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Quinapril': ['NotSet', 'Both aceclofenac and quinapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ramipril': ['NotSet', 'Both aceclofenac and ramipril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Regorafenib': ['NotSet', 'Both aceclofenac and regorafenib can increase the risk of bleeding.'], 'Rivaroxaban': ['Severe', 'Rivaroxaban is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sertraline': ['NotSet', 'Both aceclofenac and sertraline can increase the risk of hyponatraemia. Both aceclofenac and sertraline can increase the risk of bleeding.'], 'Sodium picosulfate': ['NotSet', 'Both aceclofenac and sodium picosulfate can increase the risk of hyponatraemia.'], 'Spironolactone': ['NotSet', 'Both aceclofenac and spironolactone can increase the risk of hyponatraemia. Both aceclofenac and spironolactone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Streptokinase': ['Severe', 'Streptokinase is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Streptomycin': ['NotSet', 'Both aceclofenac and streptomycin can increase the risk of nephrotoxicity.'], 'Streptozocin': ['NotSet', 'Both aceclofenac and streptozocin can increase the risk of nephrotoxicity.'], 'Tacrolimus': ['NotSet', 'Both aceclofenac and tacrolimus can increase the risk of nephrotoxicity. Both aceclofenac and tacrolimus can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Telavancin': ['NotSet', 'Both aceclofenac and telavancin can increase the risk of nephrotoxicity.'], 'Telmisartan': ['NotSet', 'Both aceclofenac and telmisartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tenecteplase': ['Severe', 'Tenecteplase is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenofovir disoproxil': ['NotSet', 'Both aceclofenac and tenofovir disoproxil can increase the risk of nephrotoxicity.'], 'Ticagrelor': ['NotSet', 'Both aceclofenac and ticagrelor can increase the risk of bleeding.'], 'Tinzaparin': ['NotSet', 'Both aceclofenac and tinzaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Tinzaparin is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tirofiban': ['NotSet', 'Both aceclofenac and tirofiban can increase the risk of bleeding.'], 'Tobramycin': ['NotSet', 'Both aceclofenac and tobramycin can increase the risk of nephrotoxicity.'], 'Tolvaptan': ['NotSet', 'Both aceclofenac and tolvaptan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Torasemide': ['NotSet', 'Both aceclofenac and torasemide can increase the risk of hyponatraemia.'], 'Trandolapril': ['NotSet', 'Both aceclofenac and trandolapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trastuzumab emtansine': ['NotSet', 'Both aceclofenac and trastuzumab emtansine can increase the risk of bleeding.'], 'Triamcinolone': ['Severe', 'Aceclofenac increases the risk of gastrointestinal bleeding when given with triamcinolone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Triamterene': ['NotSet', 'Both aceclofenac and triamterene can increase the risk of hyponatraemia. Both aceclofenac and triamterene can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trimethoprim': ['NotSet', 'Both aceclofenac and trimethoprim can increase the risk of hyponatraemia. Both aceclofenac and trimethoprim can increase the risk of nephrotoxicity. Both aceclofenac and trimethoprim can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trimipramine': ['NotSet', 'Both aceclofenac and trimipramine can increase the risk of hyponatraemia.'], 'Urokinase': ['Severe', 'Urokinase is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Valaciclovir': ['NotSet', 'Both aceclofenac and valaciclovir can increase the risk of nephrotoxicity.'], 'Valganciclovir': ['NotSet', 'Both aceclofenac and valganciclovir can increase the risk of nephrotoxicity.'], 'Valsartan': ['NotSet', 'Both aceclofenac and valsartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Vancomycin': ['NotSet', 'Both aceclofenac and vancomycin can increase the risk of nephrotoxicity.'], 'Venlafaxine': ['NotSet', 'Both aceclofenac and venlafaxine can increase the risk of bleeding.'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with aceclofenac. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vortioxetine': ['NotSet', 'Both aceclofenac and vortioxetine can increase the risk of bleeding.'], 'Warfarin': ['Severe', 'Warfarin is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Xipamide': ['NotSet', 'Both aceclofenac and xipamide can increase the risk of hyponatraemia. Aceclofenac increases the risk of acute renal failure when given with xipamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both aceclofenac and zidovudine can increase the risk of nephrotoxicity. Zidovudine increases the risk of haematological toxicity when given with aceclofenac. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Zoledronate': ['NotSet', 'Both aceclofenac and zoledronate can increase the risk of nephrotoxicity.']}","acenocoumarol","{'Aceclofenac': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Alcohol (beverage)': ['Severe', 'Alcohol (beverage) (in those who drink heavily) potentially decreases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Alteplase': ['NotSet', 'Both acenocoumarol and alteplase can increase the risk of bleeding.'], 'Amiodarone': ['Severe', 'Amiodarone increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Amoxicillin': ['Severe', 'Amoxicillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ampicillin': ['Severe', 'Ampicillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Anagrelide': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apalutamide': ['Mild', 'Apalutamide is predicted to decrease the exposure to acenocoumarol. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Apixaban': ['NotSet', 'Both acenocoumarol and apixaban can increase the risk of bleeding.'], 'Aprepitant': ['Moderate', 'Aprepitant decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR during treatment and for 14 days after. Severity of interaction: Moderate Evidence for interaction: Study'], 'Argatroban': ['NotSet', 'Both acenocoumarol and argatroban can increase the risk of bleeding.'], 'Aspirin': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Axitinib': ['Severe', 'Axitinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Azathioprine': ['Moderate', 'Azathioprine decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Beclometasone': ['Moderate', 'Beclometasone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Benzylpenicillin': ['Severe', 'Benzylpenicillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Betamethasone': ['Moderate', 'Betamethasone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bevacizumab': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with bevacizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bezafibrate': ['Severe', 'Bezafibrate is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Bivalirudin': ['NotSet', 'Both acenocoumarol and bivalirudin can increase the risk of bleeding.'], 'Bosentan': ['Moderate', 'Bosentan decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bosutinib': ['Severe', 'Bosutinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Budesonide': ['Moderate', 'Budesonide is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cabozantinib': ['Severe', 'Cabozantinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cangrelor': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with cangrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Capecitabine': ['Moderate', 'Capecitabine increases the effects of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Carbamazepine': ['Severe', 'Carbamazepine decreases the effects of acenocoumarol. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ceftriaxone': ['Severe', 'Ceftriaxone potentially increases the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Celecoxib': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with celecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chloramphenicol': ['Moderate', 'Chloramphenicol potentially increases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ciclesonide': ['Moderate', 'Ciclesonide is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cilostazol': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with cilostazol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cimetidine': ['Severe', 'Cimetidine increases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciprofibrate': ['Severe', 'Ciprofibrate is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciprofloxacin': ['Severe', 'Ciprofloxacin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Citalopram': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with citalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clarithromycin': ['Severe', 'Clarithromycin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Clopidogrel': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with clopidogrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Crizotinib': ['Severe', 'Crizotinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dabigatran': ['NotSet', 'Both acenocoumarol and dabigatran can increase the risk of bleeding.'], 'Dabrafenib': ['Severe', 'Dabrafenib is predicted to decrease the anticoagulant effect of acenocoumarol. Manufacturer advises caution and monitor INR. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dalteparin': ['NotSet', 'Both acenocoumarol and dalteparin can increase the risk of bleeding.'], 'Danaparoid': ['NotSet', 'Both acenocoumarol and danaparoid can increase the risk of bleeding.'], 'Danazol': ['Severe', 'Danazol potentially increases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Dapoxetine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with dapoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Darunavir': ['Moderate', 'Darunavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dasatinib': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with dasatinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical Dasatinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Deflazacort': ['Moderate', 'Deflazacort is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Demeclocycline': ['Moderate', 'Demeclocycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Dexamethasone': ['Moderate', 'Dexamethasone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dexibuprofen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with dexibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexketoprofen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with dexketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Diclofenac': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with diclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dipyridamole': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with dipyridamole. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Disulfiram': ['Severe', 'Disulfiram increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Doxycycline': ['Moderate', 'Doxycycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Duloxetine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with duloxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Edoxaban': ['NotSet', 'Both acenocoumarol and edoxaban can increase the risk of bleeding.'], 'Efavirenz': ['Moderate', 'Efavirenz is predicted to affect the concentration of acenocoumarol. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Elvitegravir': ['Moderate', 'Elvitegravir is predicted to decrease the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Enoxaparin': ['NotSet', 'Both acenocoumarol and enoxaparin can increase the risk of bleeding.'], 'Enteral feeds': ['Severe', 'Enteral feeds (vitamin-K containing) potentially decrease the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Enzalutamide': ['Severe', 'Enzalutamide potentially decreases the exposure to acenocoumarol. Manufacturer advises avoid or adjust dose and monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Epoprostenol': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with epoprostenol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eptifibatide': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with eptifibatide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erlotinib': ['Severe', 'Erlotinib increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Erythromycin': ['Severe', 'Erythromycin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Escitalopram': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with escitalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etodolac': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with etodolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etoricoxib': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with etoricoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etravirine': ['Moderate', 'Etravirine increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fenofibrate': ['Severe', 'Fenofibrate is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Flucloxacillin': ['Severe', 'Flucloxacillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fluconazole': ['Severe', 'Fluconazole increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Fludrocortisone': ['Moderate', 'Fludrocortisone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fluorouracil': ['Severe', 'Fluorouracil increases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fluoxetine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with fluoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flurbiprofen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with flurbiprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluticasone': ['Moderate', 'Fluticasone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fluvastatin': ['Severe', 'Fluvastatin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Fluvoxamine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with fluvoxamine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fondaparinux': ['NotSet', 'Both acenocoumarol and fondaparinux can increase the risk of bleeding.'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosaprepitant': ['Moderate', 'Fosaprepitant is predicted to decrease the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR during treatment and for 14 days after. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to alter the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Gefitinib': ['Severe', 'Gefitinib is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Gemfibrozil': ['Severe', 'Gemfibrozil is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Glucosamine': ['Moderate', 'Glucosamine potentially decreases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Griseofulvin': ['Moderate', 'Griseofulvin potentially decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Heparin (unfractionated)': ['NotSet', 'Both acenocoumarol and heparin (unfractionated) can increase the risk of bleeding.'], 'Hydrocortisone': ['Moderate', 'Hydrocortisone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ibrutinib': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with ibrutinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibuprofen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with ibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Iloprost': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with iloprost. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Imatinib': ['Severe', 'Imatinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indometacin': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with indometacin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotersen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with inotersen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Itraconazole': ['Severe', 'Itraconazole potentially increases the anticoagulant effect of acenocoumarol. Manufacturer advises caution and monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ivermectin': ['Severe', 'Ivermectin potentially increases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ketoprofen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with ketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketorolac': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with ketorolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lapatinib': ['Severe', 'Lapatinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Leflunomide': ['Severe', 'Leflunomide increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Levofloxacin': ['Severe', 'Levofloxacin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lymecycline': ['Moderate', 'Lymecycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Mefenamic acid': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with mefenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Meloxicam': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with meloxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mercaptopurine': ['Moderate', 'Mercaptopurine decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Methylprednisolone': ['Moderate', 'Methylprednisolone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Metronidazole': ['Severe', 'Metronidazole increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Miconazole': ['Severe', 'Miconazole greatly increases the anticoagulant effect of acenocoumarol. MHRA advises avoid unless INR can be monitored closely; monitor for signs of bleeding. Severity of interaction: Severe Evidence for interaction: Study'], 'Minocycline': ['Moderate', 'Minocycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Mometasone': ['Moderate', 'Mometasone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Moxifloxacin': ['Severe', 'Moxifloxacin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Nabumetone': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with nabumetone. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nandrolone': ['Severe', 'Nandrolone is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Naproxen': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with naproxen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nevirapine': ['Severe', 'Nevirapine potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Nicotinic acid': ['NotSet', 'Both acenocoumarol and nicotinic acid can increase the risk of bleeding.'], 'Nilotinib': ['Severe', 'Nilotinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ofloxacin': ['Severe', 'Ofloxacin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Omega-3-acid ethyl esters': ['NotSet', 'Both acenocoumarol and omega-3-acid ethyl esters can increase the risk of bleeding.'], 'Oxymetholone': ['Severe', 'Oxymetholone increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Oxytetracycline': ['Moderate', 'Oxytetracycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Paracetamol': ['Moderate', 'Paracetamol increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Parecoxib': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with parecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paritaprevir': ['Severe', 'Paritaprevir (in fixed-dose combination with dasabuvir) decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Paroxetine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with paroxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pazopanib': ['Severe', 'Pazopanib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenindione': ['NotSet', 'Both acenocoumarol and phenindione can increase the risk of bleeding.'], 'Phenobarbital': ['Moderate', 'Phenobarbital decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenoxymethylpenicillin': ['Severe', 'Phenoxymethylpenicillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to alter the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Piperacillin': ['Severe', 'Piperacillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Piroxicam': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with piroxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pivmecillinam': ['Severe', 'Pivmecillinam potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ponatinib': ['Severe', 'Ponatinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prasugrel': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with prasugrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prednisolone': ['Moderate', 'Prednisolone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Primidone': ['Moderate', 'Primidone decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Propafenone': ['Moderate', 'Propafenone increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ranibizumab': ['Severe', 'Ranibizumab increases the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Regorafenib': ['Severe', 'Regorafenib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study Acenocoumarol is predicted to increase the risk of bleeding events when given with regorafenib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rifampicin': ['Severe', 'Rifampicin decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rivaroxaban': ['NotSet', 'Both acenocoumarol and rivaroxaban can increase the risk of bleeding.'], 'Rosuvastatin': ['Severe', 'Rosuvastatin increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ruxolitinib': ['Severe', 'Ruxolitinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sertraline': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with sertraline. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sorafenib': ['Severe', 'Sorafenib increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Anecdotal'], ""St John's Wort"": ['Severe', ""St John's Wort decreases the anticoagulant effect of acenocoumarol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal""], 'Streptokinase': ['NotSet', 'Both acenocoumarol and streptokinase can increase the risk of bleeding.'], 'Sulfadiazine': ['Severe', 'Sulfadiazine is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sulfamethoxazole': ['Severe', 'Sulfamethoxazole increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Sulindac': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with sulindac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sunitinib': ['Severe', 'Sunitinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tamoxifen': ['Severe', 'Tamoxifen increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Tegafur': ['Moderate', 'Tegafur increases the anticoagulant effect of acenocoumarol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Temocillin': ['Severe', 'Temocillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tenecteplase': ['NotSet', 'Both acenocoumarol and tenecteplase can increase the risk of bleeding.'], 'Tenoxicam': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with tenoxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Teriflunomide': ['Severe', 'Teriflunomide affects the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Tetracycline': ['Moderate', 'Tetracycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Tiaprofenic acid': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with tiaprofenic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticagrelor': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with ticagrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticarcillin': ['Severe', 'Ticarcillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tigecycline': ['Moderate', 'Tigecycline increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Tinidazole': ['Severe', 'Tinidazole is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tinzaparin': ['NotSet', 'Both acenocoumarol and tinzaparin can increase the risk of bleeding.'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tirofiban': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with tirofiban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tolfenamic acid': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with tolfenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Toremifene is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trastuzumab emtansine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with trastuzumab emtansine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Triamcinolone': ['Moderate', 'Triamcinolone is predicted to increase the effects of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Trimethoprim': ['Severe', 'Trimethoprim is predicted to increase the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Urokinase': ['NotSet', 'Both acenocoumarol and urokinase can increase the risk of bleeding.'], 'Vandetanib': ['Severe', 'Vandetanib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venlafaxine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with venlafaxine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with acenocoumarol. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Moderate', 'Voriconazole increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Vortioxetine': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with vortioxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","acetazolamide","{'Aspirin': ['Severe', 'Acetazolamide increases the risk of severe toxic reaction when given with aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Lithium': ['Severe', 'Acetazolamide alters the concentration of lithium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Methenamine': ['Moderate', 'Acetazolamide is predicted to decrease the efficacy of methenamine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Methotrexate': ['Moderate', 'Acetazolamide increases the urinary excretion of methotrexate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Valproate': ['Severe', 'Acetazolamide potentially increases the risk of toxicity when given with valproate. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Zonisamide': ['Severe', 'Acetazolamide potentially increases the risk of overheating and dehydration when given with zonisamide. Manufacturer advises avoid in children. Severity of interaction: Severe Evidence for interaction: Theoretical']}","aciclovir","{'Aceclofenac': ['NotSet', 'Both aciclovir and aceclofenac can increase the risk of nephrotoxicity.'], 'Adefovir': ['NotSet', 'Both aciclovir and adefovir can increase the risk of nephrotoxicity.'], 'Amikacin': ['NotSet', 'Both aciclovir and amikacin can increase the risk of nephrotoxicity.'], 'Aminophylline': ['Severe', 'Aciclovir increases the exposure to aminophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Amphotericin': ['NotSet', 'Both aciclovir and amphotericin can increase the risk of nephrotoxicity.'], 'Bacitracin': ['NotSet', 'Both aciclovir and bacitracin can increase the risk of nephrotoxicity.'], 'Capreomycin': ['NotSet', 'Both aciclovir and capreomycin can increase the risk of nephrotoxicity.'], 'Carboplatin': ['NotSet', 'Both aciclovir and carboplatin can increase the risk of nephrotoxicity.'], 'Cefaclor': ['NotSet', 'Both aciclovir and cefaclor can increase the risk of nephrotoxicity.'], 'Cefadroxil': ['NotSet', 'Both aciclovir and cefadroxil can increase the risk of nephrotoxicity.'], 'Cefalexin': ['NotSet', 'Both aciclovir and cefalexin can increase the risk of nephrotoxicity.'], 'Cefepime': ['NotSet', 'Both aciclovir and cefepime can increase the risk of nephrotoxicity.'], 'Cefixime': ['NotSet', 'Both aciclovir and cefixime can increase the risk of nephrotoxicity.'], 'Cefotaxime': ['NotSet', 'Both aciclovir and cefotaxime can increase the risk of nephrotoxicity.'], 'Cefoxitin': ['NotSet', 'Both aciclovir and cefoxitin can increase the risk of nephrotoxicity.'], 'Cefradine': ['NotSet', 'Both aciclovir and cefradine can increase the risk of nephrotoxicity.'], 'Ceftaroline': ['NotSet', 'Both aciclovir and ceftaroline can increase the risk of nephrotoxicity.'], 'Ceftazidime': ['NotSet', 'Both aciclovir and ceftazidime can increase the risk of nephrotoxicity.'], 'Ceftobiprole': ['NotSet', 'Both aciclovir and ceftobiprole can increase the risk of nephrotoxicity.'], 'Ceftolozane': ['NotSet', 'Both aciclovir and ceftolozane can increase the risk of nephrotoxicity.'], 'Ceftriaxone': ['NotSet', 'Both aciclovir and ceftriaxone can increase the risk of nephrotoxicity.'], 'Cefuroxime': ['NotSet', 'Both aciclovir and cefuroxime can increase the risk of nephrotoxicity.'], 'Celecoxib': ['NotSet', 'Both aciclovir and celecoxib can increase the risk of nephrotoxicity.'], 'Ciclosporin': ['NotSet', 'Both aciclovir and ciclosporin can increase the risk of nephrotoxicity.'], 'Cidofovir': ['NotSet', 'Both aciclovir and cidofovir can increase the risk of nephrotoxicity.'], 'Cisplatin': ['NotSet', 'Both aciclovir and cisplatin can increase the risk of nephrotoxicity.'], 'Colistimethate': ['Severe', 'Colistimethate (particularly intravenous) potentially increases the risk of nephrotoxicity when given with aciclovir. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['NotSet', 'Both aciclovir and dexibuprofen can increase the risk of nephrotoxicity.'], 'Dexketoprofen': ['NotSet', 'Both aciclovir and dexketoprofen can increase the risk of nephrotoxicity.'], 'Diclofenac': ['NotSet', 'Both aciclovir and diclofenac can increase the risk of nephrotoxicity.'], 'Etodolac': ['NotSet', 'Both aciclovir and etodolac can increase the risk of nephrotoxicity.'], 'Etoricoxib': ['NotSet', 'Both aciclovir and etoricoxib can increase the risk of nephrotoxicity.'], 'Flurbiprofen': ['NotSet', 'Both aciclovir and flurbiprofen can increase the risk of nephrotoxicity.'], 'Foscarnet': ['NotSet', 'Both aciclovir and foscarnet can increase the risk of nephrotoxicity.'], 'Ganciclovir': ['NotSet', 'Both aciclovir and ganciclovir can increase the risk of nephrotoxicity.'], 'Gentamicin': ['NotSet', 'Both aciclovir and gentamicin can increase the risk of nephrotoxicity.'], 'Ibuprofen': ['NotSet', 'Both aciclovir and ibuprofen can increase the risk of nephrotoxicity.'], 'Ifosfamide': ['NotSet', 'Both aciclovir and ifosfamide can increase the risk of nephrotoxicity.'], 'Indometacin': ['NotSet', 'Both aciclovir and indometacin can increase the risk of nephrotoxicity.'], 'Ketoprofen': ['NotSet', 'Both aciclovir and ketoprofen can increase the risk of nephrotoxicity.'], 'Ketorolac': ['NotSet', 'Both aciclovir and ketorolac can increase the risk of nephrotoxicity.'], 'Mefenamic acid': ['NotSet', 'Both aciclovir and mefenamic acid can increase the risk of nephrotoxicity.'], 'Meloxicam': ['NotSet', 'Both aciclovir and meloxicam can increase the risk of nephrotoxicity.'], 'Methotrexate': ['NotSet', 'Both aciclovir and methotrexate can increase the risk of nephrotoxicity.'], 'Mycophenolate': ['Moderate', 'Mycophenolate is predicted to increase the risk of haematological toxicity when given with aciclovir. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nabumetone': ['NotSet', 'Both aciclovir and nabumetone can increase the risk of nephrotoxicity.'], 'Naproxen': ['NotSet', 'Both aciclovir and naproxen can increase the risk of nephrotoxicity.'], 'Neomycin': ['NotSet', 'Both aciclovir and neomycin can increase the risk of nephrotoxicity.'], 'Oxaliplatin': ['NotSet', 'Both aciclovir and oxaliplatin can increase the risk of nephrotoxicity.'], 'Parecoxib': ['NotSet', 'Both aciclovir and parecoxib can increase the risk of nephrotoxicity.'], 'Pemetrexed': ['NotSet', 'Both aciclovir and pemetrexed can increase the risk of nephrotoxicity.'], 'Penicillamine': ['NotSet', 'Both aciclovir and penicillamine can increase the risk of nephrotoxicity.'], 'Pentamidine': ['NotSet', 'Both aciclovir and pentamidine can increase the risk of nephrotoxicity.'], 'Piroxicam': ['NotSet', 'Both aciclovir and piroxicam can increase the risk of nephrotoxicity.'], 'Polymyxin b': ['NotSet', 'Both aciclovir and polymyxin b can increase the risk of nephrotoxicity.'], 'Streptomycin': ['NotSet', 'Both aciclovir and streptomycin can increase the risk of nephrotoxicity.'], 'Streptozocin': ['NotSet', 'Both aciclovir and streptozocin can increase the risk of nephrotoxicity.'], 'Sulindac': ['NotSet', 'Both aciclovir and sulindac can increase the risk of nephrotoxicity.'], 'Tacrolimus': ['NotSet', 'Both aciclovir and tacrolimus can increase the risk of nephrotoxicity.'], 'Telavancin': ['NotSet', 'Both aciclovir and telavancin can increase the risk of nephrotoxicity.'], 'Tenofovir disoproxil': ['NotSet', 'Both aciclovir and tenofovir disoproxil can increase the risk of nephrotoxicity.'], 'Tenoxicam': ['NotSet', 'Both aciclovir and tenoxicam can increase the risk of nephrotoxicity.'], 'Theophylline': ['Severe', 'Aciclovir is predicted to increase the exposure to theophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tiaprofenic acid': ['NotSet', 'Both aciclovir and tiaprofenic acid can increase the risk of nephrotoxicity.'], 'Tobramycin': ['NotSet', 'Both aciclovir and tobramycin can increase the risk of nephrotoxicity.'], 'Tolfenamic acid': ['NotSet', 'Both aciclovir and tolfenamic acid can increase the risk of nephrotoxicity.'], 'Trimethoprim': ['NotSet', 'Both aciclovir and trimethoprim can increase the risk of nephrotoxicity.'], 'Valaciclovir': ['NotSet', 'Both aciclovir and valaciclovir can increase the risk of nephrotoxicity.'], 'Valganciclovir': ['NotSet', 'Both aciclovir and valganciclovir can increase the risk of nephrotoxicity.'], 'Vancomycin': ['NotSet', 'Both aciclovir and vancomycin can increase the risk of nephrotoxicity.'], 'Zidovudine': ['NotSet', 'Both aciclovir and zidovudine can increase the risk of nephrotoxicity.'], 'Zoledronate': ['NotSet', 'Both aciclovir and zoledronate can increase the risk of nephrotoxicity.']}","acitretin","{'Alcohol (beverage)': ['Moderate', 'Alcohol (beverage) potentially increases the concentration of acitretin. Manufacturer advises avoid and for 2 months after stopping acitretin. Severity of interaction: Moderate Evidence for interaction: Study'], 'Demeclocycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with demeclocycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Doxycycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with doxycycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Lymecycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with lymecycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Methotrexate': ['Moderate', 'Acitretin is predicted to increase the concentration of methotrexate. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Minocycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with minocycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Oxytetracycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with oxytetracycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tetracycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with tetracycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tigecycline': ['Severe', 'Acitretin increases the risk of benign intracranial hypertension when given with tigecycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Vitamin A': ['Severe', 'Acitretin is predicted to increase the risk of vitamin A toxicity when given with vitamin A. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","aclidini","{'Amantadine': ['NotSet', 'Both aclidinium and amantadine can cause antimuscarinic effects.'], 'Amitriptyline': ['NotSet', 'Both aclidinium and amitriptyline can cause antimuscarinic effects.'], 'Atropine': ['NotSet', 'Both aclidinium and atropine can cause antimuscarinic effects.'], 'Baclofen': ['NotSet', 'Both aclidinium and baclofen can cause antimuscarinic effects.'], 'Chlorphenamine': ['NotSet', 'Both aclidinium and chlorphenamine can cause antimuscarinic effects.'], 'Chlorpromazine': ['NotSet', 'Both aclidinium and chlorpromazine can cause antimuscarinic effects.'], 'Clemastine': ['NotSet', 'Both aclidinium and clemastine can cause antimuscarinic effects.'], 'Clomipramine': ['NotSet', 'Both aclidinium and clomipramine can cause antimuscarinic effects.'], 'Clozapine': ['NotSet', 'Both aclidinium and clozapine can cause antimuscarinic effects.'], 'Cyclizine': ['NotSet', 'Both aclidinium and cyclizine can cause antimuscarinic effects.'], 'Cyclopentolate': ['NotSet', 'Both aclidinium and cyclopentolate can cause antimuscarinic effects.'], 'Cyproheptadine': ['NotSet', 'Both aclidinium and cyproheptadine can cause antimuscarinic effects.'], 'Darifenacin': ['NotSet', 'Both aclidinium and darifenacin can cause antimuscarinic effects.'], 'Dicycloverine': ['NotSet', 'Both aclidinium and dicycloverine can cause antimuscarinic effects.'], 'Dimenhydrinate': ['NotSet', 'Both aclidinium and dimenhydrinate can cause antimuscarinic effects.'], 'Disopyramide': ['NotSet', 'Both aclidinium and disopyramide can cause antimuscarinic effects.'], 'Dosulepin': ['NotSet', 'Both aclidinium and dosulepin can cause antimuscarinic effects.'], 'Doxepin': ['NotSet', 'Both aclidinium and doxepin can cause antimuscarinic effects.'], 'Fesoterodine': ['NotSet', 'Both aclidinium and fesoterodine can cause antimuscarinic effects.'], 'Flavoxate': ['NotSet', 'Both aclidinium and flavoxate can cause antimuscarinic effects.'], 'Glycopyrronium': ['NotSet', 'Both aclidinium and glycopyrronium can cause antimuscarinic effects.'], 'Haloperidol': ['NotSet', 'Both aclidinium and haloperidol can cause antimuscarinic effects.'], 'Homatropine': ['NotSet', 'Both aclidinium and homatropine can cause antimuscarinic effects.'], 'Hydroxyzine': ['NotSet', 'Both aclidinium and hydroxyzine can cause antimuscarinic effects.'], 'Hyoscine': ['NotSet', 'Both aclidinium and hyoscine can cause antimuscarinic effects.'], 'Imipramine': ['NotSet', 'Both aclidinium and imipramine can cause antimuscarinic effects.'], 'Ipratropium': ['NotSet', 'Both aclidinium and ipratropium can cause antimuscarinic effects.'], 'Levodopa': ['Moderate', 'Aclidinium decreases the absorption of levodopa. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levomepromazine': ['NotSet', 'Both aclidinium and levomepromazine can cause antimuscarinic effects.'], 'Lofepramine': ['NotSet', 'Both aclidinium and lofepramine can cause antimuscarinic effects.'], 'Loxapine': ['NotSet', 'Both aclidinium and loxapine can cause antimuscarinic effects.'], 'Nefopam': ['NotSet', 'Both aclidinium and nefopam can cause antimuscarinic effects.'], 'Nortriptyline': ['NotSet', 'Both aclidinium and nortriptyline can cause antimuscarinic effects.'], 'Orphenadrine': ['NotSet', 'Both aclidinium and orphenadrine can cause antimuscarinic effects.'], 'Oxybutynin': ['NotSet', 'Both aclidinium and oxybutynin can cause antimuscarinic effects.'], 'Pimozide': ['NotSet', 'Both aclidinium and pimozide can cause antimuscarinic effects.'], 'Prochlorperazine': ['NotSet', 'Both aclidinium and prochlorperazine can cause antimuscarinic effects.'], 'Procyclidine': ['NotSet', 'Both aclidinium and procyclidine can cause antimuscarinic effects.'], 'Promethazine': ['NotSet', 'Both aclidinium and promethazine can cause antimuscarinic effects.'], 'Propafenone': ['NotSet', 'Both aclidinium and propafenone can cause antimuscarinic effects.'], 'Propantheline': ['NotSet', 'Both aclidinium and propantheline can cause antimuscarinic effects.'], 'Propiverine': ['NotSet', 'Both aclidinium and propiverine can cause antimuscarinic effects.'], 'Solifenacin': ['NotSet', 'Both aclidinium and solifenacin can cause antimuscarinic effects.'], 'Tiotropium': ['NotSet', 'Both aclidinium and tiotropium can cause antimuscarinic effects.'], 'Tolterodine': ['NotSet', 'Both aclidinium and tolterodine can cause antimuscarinic effects.'], 'Trifluoperazine': ['NotSet', 'Both aclidinium and trifluoperazine can cause antimuscarinic effects.'], 'Trihexyphenidyl': ['NotSet', 'Both aclidinium and trihexyphenidyl can cause antimuscarinic effects.'], 'Trimipramine': ['NotSet', 'Both aclidinium and trimipramine can cause antimuscarinic effects.'], 'Tropicamide': ['NotSet', 'Both aclidinium and tropicamide can cause antimuscarinic effects.'], 'Trospium': ['NotSet', 'Both aclidinium and trospium can cause antimuscarinic effects.'], 'Umeclidinium': ['NotSet', 'Both aclidinium and umeclidinium can cause antimuscarinic effects.']}","acrivastine","{'Betahistine': ['Moderate', 'Acrivastine is predicted to decrease the effects of betahistine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Isocarboxazid': ['Severe', 'Isocarboxazid is predicted to increase the risk of antimuscarinic side-effects when given with acrivastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenelzine': ['Severe', 'Phenelzine is predicted to increase the risk of antimuscarinic side-effects when given with acrivastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tranylcypromine': ['Severe', 'Tranylcypromine is predicted to increase the risk of antimuscarinic side-effects when given with acrivastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","adalimumab","{'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with adalimumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical']}","adefov","{'Aceclofenac': ['NotSet', 'Both adefovir and aceclofenac can increase the risk of nephrotoxicity.'], 'Aciclovir': ['NotSet', 'Both adefovir and aciclovir can increase the risk of nephrotoxicity.'], 'Amikacin': ['NotSet', 'Both adefovir and amikacin can increase the risk of nephrotoxicity.'], 'Amphotericin': ['NotSet', 'Both adefovir and amphotericin can increase the risk of nephrotoxicity.'], 'Bacitracin': ['NotSet', 'Both adefovir and bacitracin can increase the risk of nephrotoxicity.'], 'Capreomycin': ['NotSet', 'Both adefovir and capreomycin can increase the risk of nephrotoxicity.'], 'Carboplatin': ['NotSet', 'Both adefovir and carboplatin can increase the risk of nephrotoxicity.'], 'Cefaclor': ['NotSet', 'Both adefovir and cefaclor can increase the risk of nephrotoxicity.'], 'Cefadroxil': ['NotSet', 'Both adefovir and cefadroxil can increase the risk of nephrotoxicity.'], 'Cefalexin': ['NotSet', 'Both adefovir and cefalexin can increase the risk of nephrotoxicity.'], 'Cefepime': ['NotSet', 'Both adefovir and cefepime can increase the risk of nephrotoxicity.'], 'Cefixime': ['NotSet', 'Both adefovir and cefixime can increase the risk of nephrotoxicity.'], 'Cefotaxime': ['NotSet', 'Both adefovir and cefotaxime can increase the risk of nephrotoxicity.'], 'Cefoxitin': ['NotSet', 'Both adefovir and cefoxitin can increase the risk of nephrotoxicity.'], 'Cefradine': ['NotSet', 'Both adefovir and cefradine can increase the risk of nephrotoxicity.'], 'Ceftaroline': ['NotSet', 'Both adefovir and ceftaroline can increase the risk of nephrotoxicity.'], 'Ceftazidime': ['NotSet', 'Both adefovir and ceftazidime can increase the risk of nephrotoxicity.'], 'Ceftobiprole': ['NotSet', 'Both adefovir and ceftobiprole can increase the risk of nephrotoxicity.'], 'Ceftolozane': ['NotSet', 'Both adefovir and ceftolozane can increase the risk of nephrotoxicity.'], 'Ceftriaxone': ['NotSet', 'Both adefovir and ceftriaxone can increase the risk of nephrotoxicity.'], 'Cefuroxime': ['NotSet', 'Both adefovir and cefuroxime can increase the risk of nephrotoxicity.'], 'Celecoxib': ['NotSet', 'Both adefovir and celecoxib can increase the risk of nephrotoxicity.'], 'Ciclosporin': ['NotSet', 'Both adefovir and ciclosporin can increase the risk of nephrotoxicity.'], 'Cidofovir': ['NotSet', 'Both adefovir and cidofovir can increase the risk of nephrotoxicity.'], 'Cisplatin': ['NotSet', 'Both adefovir and cisplatin can increase the risk of nephrotoxicity.'], 'Colistimethate': ['Severe', 'Colistimethate (particularly intravenous) potentially increases the risk of nephrotoxicity when given with adefovir. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['NotSet', 'Both adefovir and dexibuprofen can increase the risk of nephrotoxicity.'], 'Dexketoprofen': ['NotSet', 'Both adefovir and dexketoprofen can increase the risk of nephrotoxicity.'], 'Diclofenac': ['NotSet', 'Both adefovir and diclofenac can increase the risk of nephrotoxicity.'], 'Etodolac': ['NotSet', 'Both adefovir and etodolac can increase the risk of nephrotoxicity.'], 'Etoricoxib': ['NotSet', 'Both adefovir and etoricoxib can increase the risk of nephrotoxicity.'], 'Flurbiprofen': ['NotSet', 'Both adefovir and flurbiprofen can increase the risk of nephrotoxicity.'], 'Foscarnet': ['NotSet', 'Both adefovir and foscarnet can increase the risk of nephrotoxicity.'], 'Ganciclovir': ['NotSet', 'Both adefovir and ganciclovir can increase the risk of nephrotoxicity.'], 'Gentamicin': ['NotSet', 'Both adefovir and gentamicin can increase the risk of nephrotoxicity.'], 'Ibuprofen': ['NotSet', 'Both adefovir and ibuprofen can increase the risk of nephrotoxicity.'], 'Ifosfamide': ['NotSet', 'Both adefovir and ifosfamide can increase the risk of nephrotoxicity.'], 'Indometacin': ['NotSet', 'Both adefovir and indometacin can increase the risk of nephrotoxicity.'], 'Ketoprofen': ['NotSet', 'Both adefovir and ketoprofen can increase the risk of nephrotoxicity.'], 'Ketorolac': ['NotSet', 'Both adefovir and ketorolac can increase the risk of nephrotoxicity.'], 'Leflunomide': ['Moderate', 'Leflunomide is predicted to increase the exposure to adefovir. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Mefenamic acid': ['NotSet', 'Both adefovir and mefenamic acid can increase the risk of nephrotoxicity.'], 'Meloxicam': ['NotSet', 'Both adefovir and meloxicam can increase the risk of nephrotoxicity.'], 'Methotrexate': ['NotSet', 'Both adefovir and methotrexate can increase the risk of nephrotoxicity.'], 'Nabumetone': ['NotSet', 'Both adefovir and nabumetone can increase the risk of nephrotoxicity.'], 'Naproxen': ['NotSet', 'Both adefovir and naproxen can increase the risk of nephrotoxicity.'], 'Neomycin': ['NotSet', 'Both adefovir and neomycin can increase the risk of nephrotoxicity.'], 'Nitisinone': ['Moderate', 'Nitisinone is predicted to increase the exposure to adefovir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Oxaliplatin': ['NotSet', 'Both adefovir and oxaliplatin can increase the risk of nephrotoxicity.'], 'Parecoxib': ['NotSet', 'Both adefovir and parecoxib can increase the risk of nephrotoxicity.'], 'Pemetrexed': ['NotSet', 'Both adefovir and pemetrexed can increase the risk of nephrotoxicity.'], 'Penicillamine': ['NotSet', 'Both adefovir and penicillamine can increase the risk of nephrotoxicity.'], 'Pentamidine': ['NotSet', 'Both adefovir and pentamidine can increase the risk of nephrotoxicity.'], 'Piroxicam': ['NotSet', 'Both adefovir and piroxicam can increase the risk of nephrotoxicity.'], 'Polymyxin b': ['NotSet', 'Both adefovir and polymyxin b can increase the risk of nephrotoxicity.'], 'Streptomycin': ['NotSet', 'Both adefovir and streptomycin can increase the risk of nephrotoxicity.'], 'Streptozocin': ['NotSet', 'Both adefovir and streptozocin can increase the risk of nephrotoxicity.'], 'Sulindac': ['NotSet', 'Both adefovir and sulindac can increase the risk of nephrotoxicity.'], 'Tacrolimus': ['NotSet', 'Both adefovir and tacrolimus can increase the risk of nephrotoxicity.'], 'Telavancin': ['NotSet', 'Both adefovir and telavancin can increase the risk of nephrotoxicity.'], 'Tenofovir disoproxil': ['NotSet', 'Both adefovir and tenofovir disoproxil can increase the risk of nephrotoxicity.'], 'Tenoxicam': ['NotSet', 'Both adefovir and tenoxicam can increase the risk of nephrotoxicity.'], 'Teriflunomide': ['Moderate', 'Teriflunomide is predicted to increase the exposure to adefovir. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tiaprofenic acid': ['NotSet', 'Both adefovir and tiaprofenic acid can increase the risk of nephrotoxicity.'], 'Tobramycin': ['NotSet', 'Both adefovir and tobramycin can increase the risk of nephrotoxicity.'], 'Tolfenamic acid': ['NotSet', 'Both adefovir and tolfenamic acid can increase the risk of nephrotoxicity.'], 'Trimethoprim': ['NotSet', 'Both adefovir and trimethoprim can increase the risk of nephrotoxicity.'], 'Valaciclovir': ['NotSet', 'Both adefovir and valaciclovir can increase the risk of nephrotoxicity.'], 'Valganciclovir': ['NotSet', 'Both adefovir and valganciclovir can increase the risk of nephrotoxicity.'], 'Vancomycin': ['NotSet', 'Both adefovir and vancomycin can increase the risk of nephrotoxicity.'], 'Zidovudine': ['NotSet', 'Both adefovir and zidovudine can increase the risk of nephrotoxicity.'], 'Zoledronate': ['NotSet', 'Both adefovir and zoledronate can increase the risk of nephrotoxicity.']}","adenosine","{'Aminophylline': ['Mild', 'Aminophylline is predicted to decrease the efficacy of adenosine. Manufacturer advises separate administration by 24 hours. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Bupivacaine': ['Severe', 'Bupivacaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Caffeine citrate': ['Mild', 'Caffeine citrate decreases the efficacy of adenosine. Manufacturer advises separate administration by 24 hours. Severity of interaction: Mild Evidence for interaction: Study'], 'Dipyridamole': ['Severe', 'Dipyridamole increases the exposure to adenosine. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Levobupivacaine': ['Severe', 'Levobupivacaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mepivacaine': ['Severe', 'Mepivacaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mexiletine': ['Severe', 'Mexiletine increases the risk of torsade de pointes when given with adenosine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Oxybuprocaine': ['Severe', 'Oxybuprocaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prilocaine': ['Severe', 'Prilocaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Proxymetacaine': ['Severe', 'Proxymetacaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ropivacaine': ['Severe', 'Ropivacaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetracaine': ['Severe', 'Tetracaine is predicted to increase the risk of cardiodepression when given with adenosine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Theophylline': ['Mild', 'Theophylline decreases the efficacy of adenosine. Manufacturer advises separate administration by 24 hours. Severity of interaction: Mild Evidence for interaction: Study']}","adrenalineepinephrine","{'Acebutolol': ['Severe', 'Acebutolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Amitriptyline': ['Severe', 'Amitriptyline increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Apraclonidine': ['Severe', 'Adrenaline/epinephrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Atenolol': ['Severe', 'Atenolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Betaxolol': ['Severe', 'Betaxolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Bisoprolol': ['Severe', 'Bisoprolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Carvedilol': ['Severe', 'Carvedilol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Celiprolol': ['Severe', 'Celiprolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Clomipramine': ['Severe', 'Clomipramine increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Dosulepin': ['Severe', 'Dosulepin increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Doxepin': ['Severe', 'Doxepin increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Entacapone': ['Moderate', 'Entacapone is predicted to increase the risk of cardiovascular side-effects when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Esmolol': ['Severe', 'Esmolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Guanethidine': ['Moderate', 'Guanethidine is predicted to increase the effects of adrenaline/epinephrine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imipramine': ['Severe', 'Imipramine increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Isocarboxazid': ['Severe', 'Isocarboxazid is predicted to increase the risk of a hypertensive crisis when given with adrenaline/epinephrine. Manufacturer advises avoid and for 14 days after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Study'], 'Labetalol': ['Severe', 'Labetalol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Levobunolol': ['Severe', 'Levobunolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Linezolid': ['Severe', 'Adrenaline/epinephrine is predicted to increase the risk of elevated blood pressure when given with linezolid. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lofepramine': ['Severe', 'Lofepramine increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Metoprolol': ['Severe', 'Metoprolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nadolol': ['Severe', 'Nadolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nebivolol': ['Severe', 'Nebivolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nortriptyline': ['Severe', 'Nortriptyline increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Opicapone': ['Severe', 'Opicapone is predicted to increase the risk of cardiovascular side-effects when given with adrenaline/epinephrine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenelzine': ['Severe', 'Phenelzine is predicted to increase the risk of a hypertensive crisis when given with adrenaline/epinephrine. Manufacturer advises avoid and for 14 days after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Study'], 'Pindolol': ['Severe', 'Pindolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Propranolol': ['Severe', 'Propranolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Rasagiline': ['Severe', 'Rasagiline is predicted to increase the risk of a hypertensive crisis when given with adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Safinamide': ['Severe', 'Safinamide is predicted to increase the risk of a hypertensive crisis when given with adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Selegiline': ['Severe', 'Selegiline is predicted to increase the risk of a hypertensive crisis when given with adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Sotalol': ['Severe', 'Sotalol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Timolol': ['Severe', 'Timolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Tolcapone': ['Moderate', 'Tolcapone is predicted to increase the effects of adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tranylcypromine': ['Severe', 'Tranylcypromine is predicted to increase the risk of a hypertensive crisis when given with adrenaline/epinephrine. Manufacturer advises avoid and for 14 days after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Study'], 'Trimipramine': ['Severe', 'Trimipramine increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study']}","afatinib","{'Aflibercept': ['NotSet', 'Both afatinib and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both afatinib and alemtuzumab can increase the risk of myelosuppression.'], 'Amiodarone': ['Moderate', 'Amiodarone is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Amsacrine': ['NotSet', 'Both afatinib and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both afatinib and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both afatinib and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both afatinib and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both afatinib and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both afatinib and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both afatinib and azathioprine can increase the risk of myelosuppression.'], 'Azithromycin': ['Moderate', 'Azithromycin is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Balsalazide': ['NotSet', 'Both afatinib and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both afatinib and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both afatinib and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both afatinib and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both afatinib and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both afatinib and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both afatinib and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both afatinib and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both afatinib and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both afatinib and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both afatinib and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both afatinib and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both afatinib and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both afatinib and capecitabine can increase the risk of myelosuppression.'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the exposure to afatinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Carbimazole': ['NotSet', 'Both afatinib and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both afatinib and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both afatinib and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both afatinib and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both afatinib and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both afatinib and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both afatinib and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both afatinib and chlormethine can increase the risk of myelosuppression.'], 'Ciclosporin': ['Moderate', 'Ciclosporin is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cisplatin': ['NotSet', 'Both afatinib and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both afatinib and cladribine can increase the risk of myelosuppression.'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clofarabine': ['NotSet', 'Both afatinib and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both afatinib and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both afatinib and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both afatinib and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both afatinib and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both afatinib and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both afatinib and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both afatinib and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both afatinib and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both afatinib and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both afatinib and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both afatinib and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both afatinib and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both afatinib and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both afatinib and doxorubicin can increase the risk of myelosuppression.'], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Epirubicin': ['NotSet', 'Both afatinib and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both afatinib and eribulin can increase the risk of myelosuppression.'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Estramustine': ['NotSet', 'Both afatinib and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both afatinib and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both afatinib and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both afatinib and everolimus can increase the risk of myelosuppression.'], 'Fludarabine': ['NotSet', 'Both afatinib and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both afatinib and fluorouracil can increase the risk of myelosuppression.'], 'Ganciclovir': ['NotSet', 'Both afatinib and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both afatinib and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both afatinib and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both afatinib and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both afatinib and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both afatinib and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both afatinib and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both afatinib and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both afatinib and imatinib can increase the risk of myelosuppression.'], 'Interferon alfa': ['NotSet', 'Both afatinib and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both afatinib and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both afatinib and irinotecan can increase the risk of myelosuppression.'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lapatinib': ['Moderate', 'Lapatinib is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Leflunomide': ['NotSet', 'Both afatinib and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both afatinib and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both afatinib and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both afatinib and lomustine can increase the risk of myelosuppression.'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Melphalan': ['NotSet', 'Both afatinib and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both afatinib and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both afatinib and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both afatinib and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both afatinib and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both afatinib and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both afatinib and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both afatinib and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both afatinib and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both afatinib and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both afatinib and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both afatinib and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both afatinib and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both afatinib and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both afatinib and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both afatinib and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both afatinib and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both afatinib and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both afatinib and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both afatinib and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both afatinib and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both afatinib and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both afatinib and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both afatinib and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both afatinib and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both afatinib and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both afatinib and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both afatinib and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both afatinib and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both afatinib and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both afatinib and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both afatinib and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both afatinib and ramucirumab can increase the risk of myelosuppression.'], 'Ranolazine': ['Moderate', 'Ranolazine is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Regorafenib': ['NotSet', 'Both afatinib and regorafenib can increase the risk of myelosuppression.'], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to decrease the exposure to afatinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rituximab': ['NotSet', 'Both afatinib and rituximab can increase the risk of myelosuppression.'], 'Ruxolitinib': ['NotSet', 'Both afatinib and ruxolitinib can increase the risk of myelosuppression.'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Siltuximab': ['NotSet', 'Both afatinib and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both afatinib and sorafenib can increase the risk of myelosuppression.'], ""St John's Wort"": ['Moderate', ""St John's Wort is predicted to decrease the exposure to afatinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study""], 'Sulfadiazine': ['NotSet', 'Both afatinib and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both afatinib and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both afatinib and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both afatinib and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both afatinib and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both afatinib and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both afatinib and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both afatinib and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both afatinib and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both afatinib and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both afatinib and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both afatinib and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both afatinib and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both afatinib and trimethoprim can increase the risk of myelosuppression.'], 'Valganciclovir': ['NotSet', 'Both afatinib and valganciclovir can increase the risk of myelosuppression.'], 'Vemurafenib': ['Moderate', 'Vemurafenib is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Verapamil': ['Moderate', 'Verapamil is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Vinblastine': ['NotSet', 'Both afatinib and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both afatinib and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both afatinib and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both afatinib and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both afatinib and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both afatinib and vismodegib can increase the risk of myelosuppression.'], 'Zidovudine': ['NotSet', 'Both afatinib and zidovudine can increase the risk of myelosuppression.']}","aflibercept","{'Afatinib': ['NotSet', 'Both aflibercept and afatinib can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both aflibercept and alemtuzumab can increase the risk of myelosuppression.'], 'Amsacrine': ['NotSet', 'Both aflibercept and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both aflibercept and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both aflibercept and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both aflibercept and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both aflibercept and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both aflibercept and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both aflibercept and azathioprine can increase the risk of myelosuppression.'], 'Balsalazide': ['NotSet', 'Both aflibercept and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both aflibercept and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both aflibercept and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both aflibercept and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both aflibercept and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both aflibercept and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both aflibercept and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both aflibercept and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both aflibercept and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both aflibercept and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both aflibercept and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both aflibercept and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both aflibercept and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both aflibercept and capecitabine can increase the risk of myelosuppression.'], 'Carbimazole': ['NotSet', 'Both aflibercept and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both aflibercept and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both aflibercept and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both aflibercept and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both aflibercept and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both aflibercept and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both aflibercept and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both aflibercept and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both aflibercept and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both aflibercept and cladribine can increase the risk of myelosuppression.'], 'Clofarabine': ['NotSet', 'Both aflibercept and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both aflibercept and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both aflibercept and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both aflibercept and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both aflibercept and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both aflibercept and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both aflibercept and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both aflibercept and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both aflibercept and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both aflibercept and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both aflibercept and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both aflibercept and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both aflibercept and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both aflibercept and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both aflibercept and doxorubicin can increase the risk of myelosuppression.'], 'Epirubicin': ['NotSet', 'Both aflibercept and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both aflibercept and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both aflibercept and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both aflibercept and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both aflibercept and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both aflibercept and everolimus can increase the risk of myelosuppression.'], 'Fludarabine': ['NotSet', 'Both aflibercept and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both aflibercept and fluorouracil can increase the risk of myelosuppression.'], 'Ganciclovir': ['NotSet', 'Both aflibercept and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both aflibercept and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both aflibercept and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both aflibercept and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both aflibercept and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both aflibercept and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both aflibercept and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both aflibercept and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both aflibercept and imatinib can increase the risk of myelosuppression.'], 'Interferon alfa': ['NotSet', 'Both aflibercept and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both aflibercept and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both aflibercept and irinotecan can increase the risk of myelosuppression.'], 'Leflunomide': ['NotSet', 'Both aflibercept and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both aflibercept and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both aflibercept and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both aflibercept and lomustine can increase the risk of myelosuppression.'], 'Melphalan': ['NotSet', 'Both aflibercept and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both aflibercept and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both aflibercept and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both aflibercept and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both aflibercept and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both aflibercept and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both aflibercept and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both aflibercept and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both aflibercept and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both aflibercept and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both aflibercept and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both aflibercept and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both aflibercept and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both aflibercept and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both aflibercept and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both aflibercept and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both aflibercept and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both aflibercept and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both aflibercept and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both aflibercept and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both aflibercept and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both aflibercept and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both aflibercept and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both aflibercept and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both aflibercept and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both aflibercept and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both aflibercept and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both aflibercept and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both aflibercept and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both aflibercept and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both aflibercept and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both aflibercept and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both aflibercept and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both aflibercept and regorafenib can increase the risk of myelosuppression.'], 'Rituximab': ['NotSet', 'Both aflibercept and rituximab can increase the risk of myelosuppression.'], 'Ruxolitinib': ['NotSet', 'Both aflibercept and ruxolitinib can increase the risk of myelosuppression.'], 'Siltuximab': ['NotSet', 'Both aflibercept and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both aflibercept and sorafenib can increase the risk of myelosuppression.'], 'Sulfadiazine': ['NotSet', 'Both aflibercept and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both aflibercept and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both aflibercept and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both aflibercept and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both aflibercept and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both aflibercept and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both aflibercept and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both aflibercept and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both aflibercept and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both aflibercept and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both aflibercept and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both aflibercept and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both aflibercept and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both aflibercept and trimethoprim can increase the risk of myelosuppression.'], 'Valganciclovir': ['NotSet', 'Both aflibercept and valganciclovir can increase the risk of myelosuppression.'], 'Vinblastine': ['NotSet', 'Both aflibercept and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both aflibercept and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both aflibercept and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both aflibercept and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both aflibercept and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both aflibercept and vismodegib can increase the risk of myelosuppression.'], 'Zidovudine': ['NotSet', 'Both aflibercept and zidovudine can increase the risk of myelosuppression.']}","agalsidase-alfa","{'Amikacin': ['Moderate', 'Amikacin is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amiodarone': ['Moderate', 'Amiodarone is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chloroquine': ['Moderate', 'Chloroquine is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gentamicin': ['Moderate', 'Gentamicin is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Hydroxychloroquine': ['Moderate', 'Hydroxychloroquine is predicted to decrease the effects of agalsidase alfa. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Streptomycin': ['Moderate', 'Streptomycin is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tobramycin': ['Moderate', 'Tobramycin is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","agalsidase-beta","{'Amikacin': ['Moderate', 'Amikacin is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amiodarone': ['Moderate', 'Amiodarone is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chloroquine': ['Moderate', 'Chloroquine is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gentamicin': ['Moderate', 'Gentamicin is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Hydroxychloroquine': ['Moderate', 'Hydroxychloroquine is predicted to decrease the exposure to agalsidase beta. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Streptomycin': ['Moderate', 'Streptomycin is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tobramycin': ['Moderate', 'Tobramycin is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","agomelatine","{'Alcohol (beverage)': ['NotSet', ""Both agomelatine and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both agomelatine and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alimemazine': ['NotSet', ""Both agomelatine and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprazolam': ['NotSet', ""Both agomelatine and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amisulpride': ['NotSet', ""Both agomelatine and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both agomelatine and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Apraclonidine': ['NotSet', ""Both agomelatine and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both agomelatine and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both agomelatine and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both agomelatine and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Baclofen': ['NotSet', ""Both agomelatine and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Benperidol': ['NotSet', ""Both agomelatine and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Brimonidine': ['NotSet', ""Both agomelatine and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buclizine': ['NotSet', ""Both agomelatine and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupivacaine': ['NotSet', ""Both agomelatine and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both agomelatine and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cannabidiol': ['NotSet', ""Both agomelatine and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cariprazine': ['NotSet', ""Both agomelatine and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chloral hydrate': ['NotSet', ""Both agomelatine and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both agomelatine and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorphenamine': ['NotSet', ""Both agomelatine and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both agomelatine and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cinnarizine': ['NotSet', ""Both agomelatine and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ciprofloxacin': ['Moderate', 'Ciprofloxacin is predicted to increase the exposure to agomelatine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clemastine': ['NotSet', ""Both agomelatine and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both agomelatine and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both agomelatine and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both agomelatine and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both agomelatine and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both agomelatine and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both agomelatine and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both agomelatine and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Combined hormonal contraceptives': ['Moderate', 'Combined hormonal contraceptives are predicted to increase the exposure to agomelatine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cyclizine': ['NotSet', ""Both agomelatine and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both agomelatine and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Desflurane': ['NotSet', ""Both agomelatine and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both agomelatine and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both agomelatine and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both agomelatine and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dihydrocodeine': ['NotSet', ""Both agomelatine and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipipanone': ['NotSet', ""Both agomelatine and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dosulepin': ['NotSet', ""Both agomelatine and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxepin': ['NotSet', ""Both agomelatine and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both agomelatine and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both agomelatine and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esketamine': ['NotSet', ""Both agomelatine and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Etomidate': ['NotSet', ""Both agomelatine and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fentanyl': ['NotSet', ""Both agomelatine and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flupentixol': ['NotSet', ""Both agomelatine and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both agomelatine and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both agomelatine and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluvoxamine': ['Severe', 'Fluvoxamine very markedly increases the exposure to agomelatine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to agomelatine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gabapentin': ['NotSet', ""Both agomelatine and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Guanfacine': ['NotSet', ""Both agomelatine and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both agomelatine and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydromorphone': ['NotSet', ""Both agomelatine and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both agomelatine and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imipramine': ['NotSet', ""Both agomelatine and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isoflurane': ['NotSet', ""Both agomelatine and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketamine': ['NotSet', ""Both agomelatine and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketotifen': ['NotSet', ""Both agomelatine and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lamotrigine': ['NotSet', ""Both agomelatine and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Leflunomide': ['Moderate', 'Leflunomide is predicted to decrease the exposure to agomelatine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levetiracetam': ['NotSet', ""Both agomelatine and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levomepromazine': ['NotSet', ""Both agomelatine and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both agomelatine and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofepramine': ['NotSet', ""Both agomelatine and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both agomelatine and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both agomelatine and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both agomelatine and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both agomelatine and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loxapine': ['NotSet', ""Both agomelatine and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both agomelatine and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both agomelatine and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both agomelatine and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both agomelatine and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both agomelatine and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both agomelatine and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both agomelatine and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both agomelatine and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mexiletine': ['Moderate', 'Mexiletine is predicted to increase the exposure to agomelatine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mianserin': ['NotSet', ""Both agomelatine and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both agomelatine and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mirtazapine': ['NotSet', ""Both agomelatine and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Morphine': ['NotSet', ""Both agomelatine and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxonidine': ['NotSet', ""Both agomelatine and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both agomelatine and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrazepam': ['NotSet', ""Both agomelatine and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrous oxide': ['NotSet', ""Both agomelatine and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both agomelatine and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both agomelatine and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxazepam': ['NotSet', ""Both agomelatine and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both agomelatine and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both agomelatine and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pentazocine': ['NotSet', ""Both agomelatine and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both agomelatine and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pericyazine': ['NotSet', ""Both agomelatine and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pethidine': ['NotSet', ""Both agomelatine and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenobarbital': ['NotSet', ""Both agomelatine and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to decrease the exposure to agomelatine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pimozide': ['NotSet', ""Both agomelatine and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pizotifen': ['NotSet', ""Both agomelatine and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pregabalin': ['NotSet', ""Both agomelatine and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both agomelatine and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both agomelatine and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prochlorperazine': ['NotSet', ""Both agomelatine and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both agomelatine and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both agomelatine and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both agomelatine and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quetiapine': ['NotSet', ""Both agomelatine and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Remifentanil': ['NotSet', ""Both agomelatine and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to decrease the exposure to agomelatine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Risperidone': ['NotSet', ""Both agomelatine and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to decrease the exposure to agomelatine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ropivacaine': ['NotSet', ""Both agomelatine and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sevoflurane': ['NotSet', ""Both agomelatine and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sodium oxybate': ['NotSet', ""Both agomelatine and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sufentanil': ['NotSet', ""Both agomelatine and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both agomelatine and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tapentadol': ['NotSet', ""Both agomelatine and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Temazepam': ['NotSet', ""Both agomelatine and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Teriflunomide': ['Moderate', 'Teriflunomide is predicted to decrease the exposure to agomelatine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tetracaine': ['NotSet', ""Both agomelatine and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both agomelatine and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both agomelatine and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tizanidine': ['NotSet', ""Both agomelatine and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tramadol': ['NotSet', ""Both agomelatine and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trazodone': ['NotSet', ""Both agomelatine and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both agomelatine and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both agomelatine and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Venlafaxine': ['NotSet', ""Both agomelatine and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zolpidem': ['NotSet', ""Both agomelatine and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both agomelatine and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","albendazole","{'Carbamazepine': ['Moderate', 'Carbamazepine decreases the concentration of albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cimetidine': ['Moderate', 'Cimetidine decreases the clearance of albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin decreases the concentration of albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Levamisole': ['Moderate', 'Albendazole slightly decreases the exposure to levamisole and levamisole moderately decreases the exposure to albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenobarbital': ['Moderate', 'Phenobarbital decreases the concentration of albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenytoin': ['Moderate', 'Phenytoin decreases the concentration of albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Primidone': ['Moderate', 'Primidone decreases the concentration of albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ritonavir': ['Moderate', 'Ritonavir decreases the exposure to albendazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study']}","alcohol-bevera","{'Acebutolol': ['NotSet', 'Both alcohol (beverage) and acebutolol can increase the risk of hypotension.'], 'Acenocoumarol': ['Severe', 'Alcohol (beverage) (in those who drink heavily) potentially decreases the anticoagulant effect of acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Acitretin': ['Moderate', 'Alcohol (beverage) potentially increases the concentration of acitretin. Manufacturer advises avoid and for 2 months after stopping acitretin. Severity of interaction: Moderate Evidence for interaction: Study'], 'Agomelatine': ['NotSet', ""Both alcohol (beverage) and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alectinib': ['NotSet', 'Both alcohol (beverage) and alectinib can increase the risk of hepatotoxicity.'], 'Alfentanil': ['NotSet', ""Both alcohol (beverage) and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfuzosin': ['NotSet', 'Both alcohol (beverage) and alfuzosin can increase the risk of hypotension.'], 'Alimemazine': ['NotSet', ""Both alcohol (beverage) and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aliskiren': ['NotSet', 'Both alcohol (beverage) and aliskiren can increase the risk of hypotension.'], 'Alprazolam': ['NotSet', ""Both alcohol (beverage) and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprostadil': ['NotSet', 'Both alcohol (beverage) and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both alcohol (beverage) and amantadine can increase the risk of hypotension.'], 'Amisulpride': ['NotSet', ""Both alcohol (beverage) and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both alcohol (beverage) and amitriptyline can increase the risk of hypotension. Both alcohol (beverage) and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amlodipine': ['NotSet', 'Both alcohol (beverage) and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both alcohol (beverage) and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', ""Both alcohol (beverage) and apraclonidine can increase the risk of hypotension. Both alcohol (beverage) and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both alcohol (beverage) and aripiprazole can increase the risk of hypotension. Both alcohol (beverage) and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both alcohol (beverage) and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both alcohol (beverage) and asenapine can increase the risk of hypotension. Both alcohol (beverage) and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asparaginase': ['NotSet', 'Both alcohol (beverage) and asparaginase can increase the risk of hepatotoxicity.'], 'Atenolol': ['NotSet', 'Both alcohol (beverage) and atenolol can increase the risk of hypotension.'], 'Atorvastatin': ['NotSet', 'Both alcohol (beverage) and atorvastatin can increase the risk of hepatotoxicity.'], 'Avanafil': ['NotSet', 'Both alcohol (beverage) and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both alcohol (beverage) and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', ""Both alcohol (beverage) and baclofen can increase the risk of hypotension. Both alcohol (beverage) and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bedaquiline': ['NotSet', 'Both alcohol (beverage) and bedaquiline can increase the risk of hepatotoxicity.'], 'Bendroflumethiazide': ['NotSet', 'Both alcohol (beverage) and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', ""Both alcohol (beverage) and benperidol can increase the risk of hypotension. Both alcohol (beverage) and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betaxolol': ['NotSet', 'Both alcohol (beverage) and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both alcohol (beverage) and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both alcohol (beverage) and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', ""Both alcohol (beverage) and brimonidine can increase the risk of hypotension. Both alcohol (beverage) and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bromocriptine': ['NotSet', 'Both alcohol (beverage) and bromocriptine can increase the risk of hypotension.'], 'Buclizine': ['NotSet', ""Both alcohol (beverage) and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bumetanide': ['NotSet', 'Both alcohol (beverage) and bumetanide can increase the risk of hypotension.'], 'Bupivacaine': ['NotSet', ""Both alcohol (beverage) and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both alcohol (beverage) and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cabergoline': ['NotSet', 'Both alcohol (beverage) and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both alcohol (beverage) and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both alcohol (beverage) and candesartan can increase the risk of hypotension.'], 'Cannabidiol': ['NotSet', ""Both alcohol (beverage) and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Captopril': ['NotSet', 'Both alcohol (beverage) and captopril can increase the risk of hypotension.'], 'Carbamazepine': ['NotSet', 'Both alcohol (beverage) and carbamazepine can increase the risk of hepatotoxicity.'], 'Cariprazine': ['NotSet', ""Both alcohol (beverage) and cariprazine can increase the risk of hypotension. Both alcohol (beverage) and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carvedilol': ['NotSet', 'Both alcohol (beverage) and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both alcohol (beverage) and celiprolol can increase the risk of hypotension.'], 'Chloral hydrate': ['NotSet', ""Both alcohol (beverage) and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both alcohol (beverage) and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorothiazide': ['NotSet', 'Both alcohol (beverage) and chlorothiazide can increase the risk of hypotension.'], 'Chlorphenamine': ['NotSet', ""Both alcohol (beverage) and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both alcohol (beverage) and chlorpromazine can increase the risk of hypotension. Both alcohol (beverage) and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlortalidone': ['NotSet', 'Both alcohol (beverage) and chlortalidone can increase the risk of hypotension.'], 'Cinnarizine': ['NotSet', ""Both alcohol (beverage) and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clavulanate': ['NotSet', 'Both alcohol (beverage) and clavulanate can increase the risk of hepatotoxicity.'], 'Clemastine': ['NotSet', ""Both alcohol (beverage) and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both alcohol (beverage) and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both alcohol (beverage) and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Alcohol (beverage) causes serious, potentially fatal, CNS depression when given with clomethiazole. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study""], 'Clomipramine': ['NotSet', ""Both alcohol (beverage) and clomipramine can increase the risk of hypotension. Both alcohol (beverage) and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both alcohol (beverage) and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both alcohol (beverage) and clonidine can increase the risk of hypotension. Both alcohol (beverage) and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both alcohol (beverage) and clozapine can increase the risk of hypotension. Both alcohol (beverage) and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both alcohol (beverage) and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Crisantaspase': ['NotSet', 'Both alcohol (beverage) and crisantaspase can increase the risk of hepatotoxicity.'], 'Cyclizine': ['NotSet', ""Both alcohol (beverage) and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both alcohol (beverage) and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dactinomycin': ['NotSet', 'Both alcohol (beverage) and dactinomycin can increase the risk of hepatotoxicity.'], 'Dantrolene': ['NotSet', 'Both alcohol (beverage) and dantrolene can increase the risk of hepatotoxicity.'], 'Dapagliflozin': ['NotSet', 'Both alcohol (beverage) and dapagliflozin can increase the risk of hypotension.'], 'Demeclocycline': ['NotSet', 'Both alcohol (beverage) and demeclocycline can increase the risk of hepatotoxicity.'], 'Desflurane': ['NotSet', ""Both alcohol (beverage) and desflurane can increase the risk of hypotension. Both alcohol (beverage) and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both alcohol (beverage) and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both alcohol (beverage) and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both alcohol (beverage) and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazoxide': ['NotSet', 'Both alcohol (beverage) and diazoxide can increase the risk of hypotension.'], 'Didanosine': ['NotSet', 'Both alcohol (beverage) and didanosine can increase the risk of hepatotoxicity.'], 'Dihydrocodeine': ['NotSet', ""Both alcohol (beverage) and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diltiazem': ['NotSet', 'Both alcohol (beverage) and diltiazem can increase the risk of hypotension.'], 'Dimethyl fumarate': ['Moderate', 'Alcohol (beverage) (excessive consumption) potentially increases the risk of gastrointestinal side-effects when given with dimethyl fumarate. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Dipipanone': ['NotSet', ""Both alcohol (beverage) and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipyridamole': ['NotSet', 'Both alcohol (beverage) and dipyridamole can increase the risk of hypotension.'], 'Disulfiram': ['Severe', 'Alcohol (beverage) causes an extremely unpleasant systemic reaction when given with disulfiram. Manufacturer advises avoid for at least 24 hours before and up to 14 days after stopping treatment. Severity of interaction: Severe Evidence for interaction: Study'], 'Dosulepin': ['NotSet', ""Both alcohol (beverage) and dosulepin can increase the risk of hypotension. Both alcohol (beverage) and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxazosin': ['NotSet', 'Both alcohol (beverage) and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', ""Both alcohol (beverage) and doxepin can increase the risk of hypotension. Both alcohol (beverage) and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxycycline': ['NotSet', 'Both alcohol (beverage) and doxycycline can increase the risk of hepatotoxicity.'], 'Dronabinol': ['NotSet', ""Both alcohol (beverage) and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both alcohol (beverage) and droperidol can increase the risk of hypotension. Both alcohol (beverage) and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Empagliflozin': ['NotSet', 'Both alcohol (beverage) and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both alcohol (beverage) and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both alcohol (beverage) and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both alcohol (beverage) and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both alcohol (beverage) and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', ""Both alcohol (beverage) and esketamine can increase the risk of hypotension. Both alcohol (beverage) and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esmolol': ['NotSet', 'Both alcohol (beverage) and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', ""Both alcohol (beverage) and etomidate can increase the risk of hypotension. Both alcohol (beverage) and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Felodipine': ['NotSet', 'Both alcohol (beverage) and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', ""Both alcohol (beverage) and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flucloxacillin': ['NotSet', 'Both alcohol (beverage) and flucloxacillin can increase the risk of hepatotoxicity.'], 'Fluconazole': ['NotSet', 'Both alcohol (beverage) and fluconazole can increase the risk of hepatotoxicity.'], 'Flupentixol': ['NotSet', ""Both alcohol (beverage) and flupentixol can increase the risk of hypotension. Both alcohol (beverage) and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both alcohol (beverage) and fluphenazine can increase the risk of hypotension. Both alcohol (beverage) and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both alcohol (beverage) and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluvastatin': ['NotSet', 'Both alcohol (beverage) and fluvastatin can increase the risk of hepatotoxicity.'], 'Fosinopril': ['NotSet', 'Both alcohol (beverage) and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both alcohol (beverage) and furosemide can increase the risk of hypotension.'], 'Gabapentin': ['NotSet', ""Both alcohol (beverage) and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Glyceryl trinitrate': ['NotSet', 'Both alcohol (beverage) and glyceryl trinitrate can increase the risk of hypotension.'], 'Griseofulvin': ['Moderate', 'Alcohol (beverage) potentially causes a disulfiram-like reaction when given with griseofulvin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Guanethidine': ['NotSet', 'Both alcohol (beverage) and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', ""Both alcohol (beverage) and guanfacine can increase the risk of hypotension. Both alcohol (beverage) and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both alcohol (beverage) and haloperidol can increase the risk of hypotension. Both alcohol (beverage) and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydralazine': ['NotSet', 'Both alcohol (beverage) and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both alcohol (beverage) and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both alcohol (beverage) and hydroflumethiazide can increase the risk of hypotension.'], 'Hydromorphone': ['NotSet', ""Both alcohol (beverage) and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Alcohol (beverage) causes rapid release of hydromorphone (from extended-release preparations). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study""], 'Hydroxyzine': ['NotSet', ""Both alcohol (beverage) and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imidapril': ['NotSet', 'Both alcohol (beverage) and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', ""Both alcohol (beverage) and imipramine can increase the risk of hypotension. Both alcohol (beverage) and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Indapamide': ['NotSet', 'Both alcohol (beverage) and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both alcohol (beverage) and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both alcohol (beverage) and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both alcohol (beverage) and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', ""Both alcohol (beverage) and isoflurane can increase the risk of hypotension. Both alcohol (beverage) and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isoniazid': ['NotSet', 'Both alcohol (beverage) and isoniazid can increase the risk of hepatotoxicity.'], 'Isosorbide dinitrate': ['NotSet', 'Both alcohol (beverage) and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both alcohol (beverage) and isosorbide mononitrate can increase the risk of hypotension.'], 'Itraconazole': ['NotSet', 'Both alcohol (beverage) and itraconazole can increase the risk of hepatotoxicity.'], 'Ketamine': ['NotSet', ""Both alcohol (beverage) and ketamine can increase the risk of hypotension. Both alcohol (beverage) and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketoconazole': ['Moderate', 'Alcohol (beverage) potentially causes a disulfiram-like reaction when given with ketoconazole. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ketotifen': ['NotSet', ""Both alcohol (beverage) and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Labetalol': ['NotSet', 'Both alcohol (beverage) and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both alcohol (beverage) and lacidipine can increase the risk of hypotension.'], 'Lamotrigine': ['NotSet', ""Both alcohol (beverage) and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Leflunomide': ['NotSet', 'Both alcohol (beverage) and leflunomide can increase the risk of hepatotoxicity.'], 'Lenalidomide': ['NotSet', 'Both alcohol (beverage) and lenalidomide can increase the risk of hepatotoxicity.'], 'Lercanidipine': ['NotSet', 'Both alcohol (beverage) and lercanidipine can increase the risk of hypotension.'], 'Levamisole': ['Moderate', 'Alcohol (beverage) potentially causes a disulfiram-like reaction when given with levamisole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Levetiracetam': ['NotSet', ""Both alcohol (beverage) and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levobunolol': ['NotSet', 'Both alcohol (beverage) and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both alcohol (beverage) and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', ""Both alcohol (beverage) and levomepromazine can increase the risk of hypotension. Both alcohol (beverage) and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both alcohol (beverage) and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lisinopril': ['NotSet', 'Both alcohol (beverage) and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', ""Both alcohol (beverage) and lofepramine can increase the risk of hypotension. Both alcohol (beverage) and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both alcohol (beverage) and lofexidine can increase the risk of hypotension. Both alcohol (beverage) and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lomitapide': ['NotSet', 'Both alcohol (beverage) and lomitapide can increase the risk of hepatotoxicity.'], 'Loprazolam': ['NotSet', ""Both alcohol (beverage) and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both alcohol (beverage) and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both alcohol (beverage) and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Losartan': ['NotSet', 'Both alcohol (beverage) and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', ""Both alcohol (beverage) and loxapine can increase the risk of hypotension. Both alcohol (beverage) and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both alcohol (beverage) and lurasidone can increase the risk of hypotension. Both alcohol (beverage) and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lymecycline': ['NotSet', 'Both alcohol (beverage) and lymecycline can increase the risk of hepatotoxicity.'], 'Melatonin': ['NotSet', ""Both alcohol (beverage) and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both alcohol (beverage) and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both alcohol (beverage) and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both alcohol (beverage) and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mercaptopurine': ['NotSet', 'Both alcohol (beverage) and mercaptopurine can increase the risk of hepatotoxicity.'], 'Metformin': ['Moderate', 'Alcohol (beverage) (excessive consumption) potentially increases the risk of lactic acidosis when given with metformin. Manufacturer advises avoid excessive alcohol consumption. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Methadone': ['NotSet', ""Both alcohol (beverage) and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both alcohol (beverage) and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methotrexate': ['NotSet', 'Both alcohol (beverage) and methotrexate can increase the risk of hepatotoxicity.'], 'Methoxyflurane': ['NotSet', ""Both alcohol (beverage) and methoxyflurane can increase the risk of hypotension. Both alcohol (beverage) and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methyldopa': ['NotSet', 'Both alcohol (beverage) and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both alcohol (beverage) and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both alcohol (beverage) and metoprolol can increase the risk of hypotension.'], 'Metronidazole': ['Moderate', 'Alcohol (beverage) potentially causes a disulfiram-like reaction when given with metronidazole. Manufacturer advises avoid for at least 48 hours stopping treatment. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mianserin': ['NotSet', ""Both alcohol (beverage) and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Micafungin': ['NotSet', 'Both alcohol (beverage) and micafungin can increase the risk of hepatotoxicity.'], 'Midazolam': ['NotSet', ""Both alcohol (beverage) and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Minocycline': ['NotSet', 'Both alcohol (beverage) and minocycline can increase the risk of hepatotoxicity.'], 'Minoxidil': ['NotSet', 'Both alcohol (beverage) and minoxidil can increase the risk of hypotension.'], 'Mirtazapine': ['NotSet', ""Both alcohol (beverage) and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Morphine': ['NotSet', ""Both alcohol (beverage) and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Alcohol (beverage) causes rapid release of morphine (from extended-release preparations). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study""], 'Moxisylyte': ['NotSet', 'Both alcohol (beverage) and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', ""Both alcohol (beverage) and moxonidine can increase the risk of hypotension. Both alcohol (beverage) and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both alcohol (beverage) and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nadolol': ['NotSet', 'Both alcohol (beverage) and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both alcohol (beverage) and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both alcohol (beverage) and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both alcohol (beverage) and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both alcohol (beverage) and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both alcohol (beverage) and nimodipine can increase the risk of hypotension.'], 'Nitrazepam': ['NotSet', ""Both alcohol (beverage) and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitroprusside': ['NotSet', 'Both alcohol (beverage) and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', ""Both alcohol (beverage) and nitrous oxide can increase the risk of hypotension. Both alcohol (beverage) and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both alcohol (beverage) and nortriptyline can increase the risk of hypotension. Both alcohol (beverage) and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both alcohol (beverage) and olanzapine can increase the risk of hypotension. Both alcohol (beverage) and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olmesartan': ['NotSet', 'Both alcohol (beverage) and olmesartan can increase the risk of hypotension.'], 'Oxazepam': ['NotSet', ""Both alcohol (beverage) and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both alcohol (beverage) and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxytetracycline': ['NotSet', 'Both alcohol (beverage) and oxytetracycline can increase the risk of hepatotoxicity.'], 'Paliperidone': ['NotSet', ""Both alcohol (beverage) and paliperidone can increase the risk of hypotension. Both alcohol (beverage) and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paracetamol': ['NotSet', 'Both alcohol (beverage) and paracetamol can increase the risk of hepatotoxicity. Alcohol (beverage) (in those who drink heavily) causes severe liver damage when given with paracetamol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Pegaspargase': ['NotSet', 'Both alcohol (beverage) and pegaspargase can increase the risk of hepatotoxicity.'], 'Pentazocine': ['NotSet', ""Both alcohol (beverage) and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both alcohol (beverage) and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pergolide': ['NotSet', 'Both alcohol (beverage) and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', ""Both alcohol (beverage) and pericyazine can increase the risk of hypotension. Both alcohol (beverage) and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perindopril': ['NotSet', 'Both alcohol (beverage) and perindopril can increase the risk of hypotension.'], 'Pethidine': ['NotSet', ""Both alcohol (beverage) and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['NotSet', 'Both alcohol (beverage) and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['NotSet', ""Both alcohol (beverage) and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pimecrolimus': ['Moderate', 'Alcohol (beverage) increases the risk of facial flushing and skin irritation when given with topical pimecrolimus. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['NotSet', ""Both alcohol (beverage) and pimozide can increase the risk of hypotension. Both alcohol (beverage) and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pindolol': ['NotSet', 'Both alcohol (beverage) and pindolol can increase the risk of hypotension.'], 'Pizotifen': ['NotSet', ""Both alcohol (beverage) and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pramipexole': ['NotSet', 'Both alcohol (beverage) and pramipexole can increase the risk of hypotension.'], 'Pravastatin': ['NotSet', 'Both alcohol (beverage) and pravastatin can increase the risk of hepatotoxicity.'], 'Prazosin': ['NotSet', 'Both alcohol (beverage) and prazosin can increase the risk of hypotension.'], 'Pregabalin': ['NotSet', ""Both alcohol (beverage) and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both alcohol (beverage) and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both alcohol (beverage) and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Procarbazine': ['Moderate', 'Alcohol (beverage) potentially causes a disulfiram-like reaction when given with procarbazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Prochlorperazine': ['NotSet', ""Both alcohol (beverage) and prochlorperazine can increase the risk of hypotension. Both alcohol (beverage) and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both alcohol (beverage) and promazine can increase the risk of hypotension. Both alcohol (beverage) and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both alcohol (beverage) and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both alcohol (beverage) and propofol can increase the risk of hypotension. Both alcohol (beverage) and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propranolol': ['NotSet', 'Both alcohol (beverage) and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', ""Both alcohol (beverage) and quetiapine can increase the risk of hypotension. Both alcohol (beverage) and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quinagolide': ['NotSet', 'Both alcohol (beverage) and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both alcohol (beverage) and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both alcohol (beverage) and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', ""Both alcohol (beverage) and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Retigabine': ['Moderate', 'Alcohol (beverage) potentially increases the risk of visual disturbances when given with retigabine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Riociguat': ['NotSet', 'Both alcohol (beverage) and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', ""Both alcohol (beverage) and risperidone can increase the risk of hypotension. Both alcohol (beverage) and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ropinirole': ['NotSet', 'Both alcohol (beverage) and ropinirole can increase the risk of hypotension.'], 'Ropivacaine': ['NotSet', ""Both alcohol (beverage) and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rosuvastatin': ['NotSet', 'Both alcohol (beverage) and rosuvastatin can increase the risk of hepatotoxicity.'], 'Rotigotine': ['NotSet', 'Both alcohol (beverage) and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both alcohol (beverage) and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both alcohol (beverage) and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both alcohol (beverage) and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', ""Both alcohol (beverage) and sevoflurane can increase the risk of hypotension. Both alcohol (beverage) and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sildenafil': ['NotSet', 'Both alcohol (beverage) and sildenafil can increase the risk of hypotension.'], 'Simvastatin': ['NotSet', 'Both alcohol (beverage) and simvastatin can increase the risk of hepatotoxicity.'], 'Sodium oxybate': ['NotSet', ""Both alcohol (beverage) and sodium oxybate can increase the risk of hypotension. Both alcohol (beverage) and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sotalol': ['NotSet', 'Both alcohol (beverage) and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both alcohol (beverage) and spironolactone can increase the risk of hypotension.'], 'Streptozocin': ['NotSet', 'Both alcohol (beverage) and streptozocin can increase the risk of hepatotoxicity.'], 'Sufentanil': ['NotSet', ""Both alcohol (beverage) and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulfasalazine': ['NotSet', 'Both alcohol (beverage) and sulfasalazine can increase the risk of hepatotoxicity.'], 'Sulpiride': ['NotSet', ""Both alcohol (beverage) and sulpiride can increase the risk of hypotension. Both alcohol (beverage) and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tacrolimus': ['Moderate', 'Alcohol (beverage) increases the risk of facial flushing and skin irritation when given with topical tacrolimus. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tadalafil': ['NotSet', 'Both alcohol (beverage) and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both alcohol (beverage) and tamsulosin can increase the risk of hypotension.'], 'Tapentadol': ['NotSet', ""Both alcohol (beverage) and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Telmisartan': ['NotSet', 'Both alcohol (beverage) and telmisartan can increase the risk of hypotension.'], 'Temazepam': ['NotSet', ""Both alcohol (beverage) and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Terazosin': ['NotSet', 'Both alcohol (beverage) and terazosin can increase the risk of hypotension.'], 'Tetracaine': ['NotSet', ""Both alcohol (beverage) and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tetracycline': ['NotSet', 'Both alcohol (beverage) and tetracycline can increase the risk of hepatotoxicity.'], 'Thalidomide': ['NotSet', ""Both alcohol (beverage) and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both alcohol (beverage) and thiopental can increase the risk of hypotension. Both alcohol (beverage) and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tigecycline': ['NotSet', 'Both alcohol (beverage) and tigecycline can increase the risk of hepatotoxicity.'], 'Timolol': ['NotSet', 'Both alcohol (beverage) and timolol can increase the risk of hypotension.'], 'Tinidazole': ['Moderate', 'Alcohol (beverage) potentially causes a disulfiram-like reaction when given with tinidazole. Manufacturer advises avoid for 72 hours stopping treatment. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tizanidine': ['NotSet', ""Both alcohol (beverage) and tizanidine can increase the risk of hypotension. Both alcohol (beverage) and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Torasemide': ['NotSet', 'Both alcohol (beverage) and torasemide can increase the risk of hypotension.'], 'Trabectedin': ['NotSet', 'Both alcohol (beverage) and trabectedin can increase the risk of hepatotoxicity.'], 'Tramadol': ['NotSet', ""Both alcohol (beverage) and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trandolapril': ['NotSet', 'Both alcohol (beverage) and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both alcohol (beverage) and tranylcypromine can increase the risk of hypotension.'], 'Trazodone': ['NotSet', ""Both alcohol (beverage) and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both alcohol (beverage) and trifluoperazine can increase the risk of hypotension. Both alcohol (beverage) and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both alcohol (beverage) and trimipramine can increase the risk of hypotension. Both alcohol (beverage) and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Valproate': ['NotSet', 'Both alcohol (beverage) and valproate can increase the risk of hepatotoxicity.'], 'Valsartan': ['NotSet', 'Both alcohol (beverage) and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both alcohol (beverage) and vardenafil can increase the risk of hypotension.'], 'Venlafaxine': ['NotSet', ""Both alcohol (beverage) and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['NotSet', 'Both alcohol (beverage) and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both alcohol (beverage) and vernakalant can increase the risk of hypotension.'], 'Vincristine': ['NotSet', 'Both alcohol (beverage) and vincristine can increase the risk of hepatotoxicity.'], 'Warfarin': ['Severe', 'Alcohol (beverage) (in those who drink heavily) potentially decreases the anticoagulant effect of warfarin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Xipamide': ['NotSet', 'Both alcohol (beverage) and xipamide can increase the risk of hypotension.'], 'Zolpidem': ['NotSet', ""Both alcohol (beverage) and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both alcohol (beverage) and zuclopenthixol can increase the risk of hypotension. Both alcohol (beverage) and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","alectinib","{'Acebutolol': ['NotSet', 'Both alectinib and acebutolol can increase the risk of bradycardia.'], 'Alcohol (beverage)': ['NotSet', 'Both alectinib and alcohol (beverage) can increase the risk of hepatotoxicity.'], 'Alfentanil': ['NotSet', 'Both alectinib and alfentanil can increase the risk of bradycardia.'], 'Amiodarone': ['NotSet', 'Both alectinib and amiodarone can increase the risk of bradycardia.'], 'Apraclonidine': ['NotSet', 'Both alectinib and apraclonidine can increase the risk of bradycardia.'], 'Asparaginase': ['NotSet', 'Both alectinib and asparaginase can increase the risk of hepatotoxicity.'], 'Atenolol': ['NotSet', 'Both alectinib and atenolol can increase the risk of bradycardia.'], 'Atorvastatin': ['NotSet', 'Both alectinib and atorvastatin can increase the risk of hepatotoxicity.'], 'Bedaquiline': ['NotSet', 'Both alectinib and bedaquiline can increase the risk of hepatotoxicity.'], 'Betaxolol': ['NotSet', 'Both alectinib and betaxolol can increase the risk of bradycardia.'], 'Bisoprolol': ['NotSet', 'Both alectinib and bisoprolol can increase the risk of bradycardia.'], 'Brimonidine': ['NotSet', 'Both alectinib and brimonidine can increase the risk of bradycardia.'], 'Carbamazepine': ['NotSet', 'Both alectinib and carbamazepine can increase the risk of hepatotoxicity.'], 'Carvedilol': ['NotSet', 'Both alectinib and carvedilol can increase the risk of bradycardia.'], 'Celiprolol': ['NotSet', 'Both alectinib and celiprolol can increase the risk of bradycardia.'], 'Cisatracurium': ['NotSet', 'Both alectinib and cisatracurium can increase the risk of bradycardia.'], 'Clavulanate': ['NotSet', 'Both alectinib and clavulanate can increase the risk of hepatotoxicity.'], 'Clonidine': ['NotSet', 'Both alectinib and clonidine can increase the risk of bradycardia.'], 'Crisantaspase': ['NotSet', 'Both alectinib and crisantaspase can increase the risk of hepatotoxicity.'], 'Crizotinib': ['NotSet', 'Both alectinib and crizotinib can increase the risk of bradycardia.'], 'Dactinomycin': ['NotSet', 'Both alectinib and dactinomycin can increase the risk of hepatotoxicity.'], 'Dantrolene': ['NotSet', 'Both alectinib and dantrolene can increase the risk of hepatotoxicity.'], 'Demeclocycline': ['NotSet', 'Both alectinib and demeclocycline can increase the risk of hepatotoxicity.'], 'Didanosine': ['NotSet', 'Both alectinib and didanosine can increase the risk of hepatotoxicity.'], 'Digoxin': ['NotSet', 'Both alectinib and digoxin can increase the risk of bradycardia.'], 'Diltiazem': ['NotSet', 'Both alectinib and diltiazem can increase the risk of bradycardia.'], 'Donepezil': ['NotSet', 'Both alectinib and donepezil can increase the risk of bradycardia.'], 'Doxycycline': ['NotSet', 'Both alectinib and doxycycline can increase the risk of hepatotoxicity.'], 'Esmolol': ['NotSet', 'Both alectinib and esmolol can increase the risk of bradycardia.'], 'Fentanyl': ['NotSet', 'Both alectinib and fentanyl can increase the risk of bradycardia.'], 'Fingolimod': ['NotSet', 'Both alectinib and fingolimod can increase the risk of bradycardia.'], 'Flecainide': ['NotSet', 'Both alectinib and flecainide can increase the risk of bradycardia.'], 'Flucloxacillin': ['NotSet', 'Both alectinib and flucloxacillin can increase the risk of hepatotoxicity.'], 'Fluconazole': ['NotSet', 'Both alectinib and fluconazole can increase the risk of hepatotoxicity.'], 'Fluvastatin': ['NotSet', 'Both alectinib and fluvastatin can increase the risk of hepatotoxicity.'], 'Galantamine': ['NotSet', 'Both alectinib and galantamine can increase the risk of bradycardia.'], 'Isoniazid': ['NotSet', 'Both alectinib and isoniazid can increase the risk of hepatotoxicity.'], 'Itraconazole': ['NotSet', 'Both alectinib and itraconazole can increase the risk of hepatotoxicity.'], 'Ivabradine': ['NotSet', 'Both alectinib and ivabradine can increase the risk of bradycardia.'], 'Labetalol': ['NotSet', 'Both alectinib and labetalol can increase the risk of bradycardia.'], 'Leflunomide': ['NotSet', 'Both alectinib and leflunomide can increase the risk of hepatotoxicity.'], 'Lenalidomide': ['NotSet', 'Both alectinib and lenalidomide can increase the risk of hepatotoxicity.'], 'Levobunolol': ['NotSet', 'Both alectinib and levobunolol can increase the risk of bradycardia.'], 'Lomitapide': ['NotSet', 'Both alectinib and lomitapide can increase the risk of hepatotoxicity.'], 'Lymecycline': ['NotSet', 'Both alectinib and lymecycline can increase the risk of hepatotoxicity.'], 'Mercaptopurine': ['NotSet', 'Both alectinib and mercaptopurine can increase the risk of hepatotoxicity.'], 'Methadone': ['NotSet', 'Both alectinib and methadone can increase the risk of bradycardia.'], 'Methotrexate': ['NotSet', 'Both alectinib and methotrexate can increase the risk of hepatotoxicity.'], 'Metoprolol': ['NotSet', 'Both alectinib and metoprolol can increase the risk of bradycardia.'], 'Micafungin': ['NotSet', 'Both alectinib and micafungin can increase the risk of hepatotoxicity.'], 'Minocycline': ['NotSet', 'Both alectinib and minocycline can increase the risk of hepatotoxicity.'], 'Nadolol': ['NotSet', 'Both alectinib and nadolol can increase the risk of bradycardia.'], 'Nebivolol': ['NotSet', 'Both alectinib and nebivolol can increase the risk of bradycardia.'], 'Neostigmine': ['NotSet', 'Both alectinib and neostigmine can increase the risk of bradycardia.'], 'Oxytetracycline': ['NotSet', 'Both alectinib and oxytetracycline can increase the risk of hepatotoxicity.'], 'Paracetamol': ['NotSet', 'Both alectinib and paracetamol can increase the risk of hepatotoxicity.'], 'Pasireotide': ['NotSet', 'Both alectinib and pasireotide can increase the risk of bradycardia.'], 'Pegaspargase': ['NotSet', 'Both alectinib and pegaspargase can increase the risk of hepatotoxicity.'], 'Pindolol': ['NotSet', 'Both alectinib and pindolol can increase the risk of bradycardia.'], 'Pravastatin': ['NotSet', 'Both alectinib and pravastatin can increase the risk of hepatotoxicity.'], 'Propranolol': ['NotSet', 'Both alectinib and propranolol can increase the risk of bradycardia.'], 'Pyridostigmine': ['NotSet', 'Both alectinib and pyridostigmine can increase the risk of bradycardia.'], 'Remifentanil': ['NotSet', 'Both alectinib and remifentanil can increase the risk of bradycardia.'], 'Rivastigmine': ['NotSet', 'Both alectinib and rivastigmine can increase the risk of bradycardia.'], 'Rosuvastatin': ['NotSet', 'Both alectinib and rosuvastatin can increase the risk of hepatotoxicity.'], 'Selegiline': ['NotSet', 'Both alectinib and selegiline can increase the risk of bradycardia.'], 'Simvastatin': ['NotSet', 'Both alectinib and simvastatin can increase the risk of hepatotoxicity.'], 'Sotalol': ['NotSet', 'Both alectinib and sotalol can increase the risk of bradycardia.'], 'Streptozocin': ['NotSet', 'Both alectinib and streptozocin can increase the risk of hepatotoxicity.'], 'Sufentanil': ['NotSet', 'Both alectinib and sufentanil can increase the risk of bradycardia.'], 'Sulfasalazine': ['NotSet', 'Both alectinib and sulfasalazine can increase the risk of hepatotoxicity.'], 'Tetracycline': ['NotSet', 'Both alectinib and tetracycline can increase the risk of hepatotoxicity.'], 'Thalidomide': ['NotSet', 'Both alectinib and thalidomide can increase the risk of bradycardia.'], 'Tigecycline': ['NotSet', 'Both alectinib and tigecycline can increase the risk of hepatotoxicity.'], 'Timolol': ['NotSet', 'Both alectinib and timolol can increase the risk of bradycardia.'], 'Tizanidine': ['NotSet', 'Both alectinib and tizanidine can increase the risk of bradycardia.'], 'Trabectedin': ['NotSet', 'Both alectinib and trabectedin can increase the risk of hepatotoxicity.'], 'Valproate': ['NotSet', 'Both alectinib and valproate can increase the risk of hepatotoxicity.'], 'Verapamil': ['NotSet', 'Both alectinib and verapamil can increase the risk of bradycardia.'], 'Vincristine': ['NotSet', 'Both alectinib and vincristine can increase the risk of hepatotoxicity.']}","alemtuzumab","{'Afatinib': ['NotSet', 'Both alemtuzumab and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both alemtuzumab and aflibercept can increase the risk of myelosuppression.'], 'Amsacrine': ['NotSet', 'Both alemtuzumab and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both alemtuzumab and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both alemtuzumab and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both alemtuzumab and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both alemtuzumab and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both alemtuzumab and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both alemtuzumab and azathioprine can increase the risk of myelosuppression.'], 'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Balsalazide': ['NotSet', 'Both alemtuzumab and balsalazide can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both alemtuzumab and bendamustine can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both alemtuzumab and bleomycin can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both alemtuzumab and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both alemtuzumab and bosutinib can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both alemtuzumab and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both alemtuzumab and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both alemtuzumab and cabozantinib can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both alemtuzumab and capecitabine can increase the risk of myelosuppression.'], 'Carbimazole': ['NotSet', 'Both alemtuzumab and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both alemtuzumab and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both alemtuzumab and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both alemtuzumab and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both alemtuzumab and ceritinib can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both alemtuzumab and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both alemtuzumab and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both alemtuzumab and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both alemtuzumab and cladribine can increase the risk of myelosuppression.'], 'Clofarabine': ['NotSet', 'Both alemtuzumab and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both alemtuzumab and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both alemtuzumab and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both alemtuzumab and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both alemtuzumab and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both alemtuzumab and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both alemtuzumab and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both alemtuzumab and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both alemtuzumab and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both alemtuzumab and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both alemtuzumab and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both alemtuzumab and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both alemtuzumab and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both alemtuzumab and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both alemtuzumab and doxorubicin can increase the risk of myelosuppression.'], 'Epirubicin': ['NotSet', 'Both alemtuzumab and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both alemtuzumab and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both alemtuzumab and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both alemtuzumab and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both alemtuzumab and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both alemtuzumab and everolimus can increase the risk of myelosuppression.'], 'Fludarabine': ['NotSet', 'Both alemtuzumab and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both alemtuzumab and fluorouracil can increase the risk of myelosuppression.'], 'Ganciclovir': ['NotSet', 'Both alemtuzumab and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both alemtuzumab and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both alemtuzumab and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both alemtuzumab and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both alemtuzumab and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both alemtuzumab and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both alemtuzumab and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both alemtuzumab and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both alemtuzumab and imatinib can increase the risk of myelosuppression.'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Interferon alfa': ['NotSet', 'Both alemtuzumab and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both alemtuzumab and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both alemtuzumab and irinotecan can increase the risk of myelosuppression.'], 'Leflunomide': ['NotSet', 'Both alemtuzumab and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both alemtuzumab and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both alemtuzumab and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both alemtuzumab and lomustine can increase the risk of myelosuppression.'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Melphalan': ['NotSet', 'Both alemtuzumab and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both alemtuzumab and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both alemtuzumab and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both alemtuzumab and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both alemtuzumab and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both alemtuzumab and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both alemtuzumab and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both alemtuzumab and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both alemtuzumab and nilotinib can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both alemtuzumab and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both alemtuzumab and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both alemtuzumab and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both alemtuzumab and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both alemtuzumab and paclitaxel can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both alemtuzumab and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both alemtuzumab and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both alemtuzumab and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both alemtuzumab and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both alemtuzumab and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both alemtuzumab and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both alemtuzumab and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both alemtuzumab and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both alemtuzumab and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both alemtuzumab and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both alemtuzumab and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both alemtuzumab and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both alemtuzumab and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both alemtuzumab and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both alemtuzumab and raltitrexed can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both alemtuzumab and regorafenib can increase the risk of myelosuppression.'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ruxolitinib': ['NotSet', 'Both alemtuzumab and ruxolitinib can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both alemtuzumab and sorafenib can increase the risk of myelosuppression.'], 'Sulfadiazine': ['NotSet', 'Both alemtuzumab and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both alemtuzumab and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both alemtuzumab and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both alemtuzumab and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both alemtuzumab and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both alemtuzumab and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both alemtuzumab and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both alemtuzumab and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both alemtuzumab and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both alemtuzumab and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both alemtuzumab and trabectedin can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both alemtuzumab and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both alemtuzumab and trimethoprim can increase the risk of myelosuppression.'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Valganciclovir': ['NotSet', 'Both alemtuzumab and valganciclovir can increase the risk of myelosuppression.'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both alemtuzumab and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both alemtuzumab and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both alemtuzumab and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both alemtuzumab and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both alemtuzumab and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both alemtuzumab and vismodegib can increase the risk of myelosuppression.'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with alemtuzumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both alemtuzumab and zidovudine can increase the risk of myelosuppression.']}","alendrona","{'Aceclofenac': ['Moderate', 'Aceclofenac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aluminium hydroxide': ['Moderate', 'Aluminium hydroxide decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Amikacin': ['Moderate', 'Amikacin increases the risk of hypocalcaemia when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Aspirin': ['Moderate', 'Aspirin (high-dose) is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Benzydamine': ['Moderate', 'Benzydamine is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bromfenac': ['Moderate', 'Bromfenac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Calcium acetate': ['Moderate', 'Oral calcium acetate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before calcium acetate. Severity of interaction: Moderate Evidence for interaction: Study'], 'Calcium carbonate': ['Moderate', 'Oral calcium carbonate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before calcium carbonate. Severity of interaction: Moderate Evidence for interaction: Study'], 'Calcium chloride': ['Moderate', 'Oral calcium chloride decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before calcium chloride. Severity of interaction: Moderate Evidence for interaction: Study'], 'Calcium gluconate': ['Moderate', 'Oral calcium gluconate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before calcium gluconate. Severity of interaction: Moderate Evidence for interaction: Study'], 'Calcium lactate': ['Moderate', 'Oral calcium lactate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before calcium lactate. Severity of interaction: Moderate Evidence for interaction: Study'], 'Calcium phosphate': ['Moderate', 'Oral calcium phosphate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before calcium phosphate. Severity of interaction: Moderate Evidence for interaction: Study'], 'Celecoxib': ['Moderate', 'Celecoxib is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Deferasirox': ['Severe', 'Alendronate is predicted to increase the risk of gastrointestinal bleeding when given with deferasirox. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['Moderate', 'Dexibuprofen is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dexketoprofen': ['Moderate', 'Dexketoprofen is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Diclofenac': ['Moderate', 'Diclofenac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Etodolac': ['Moderate', 'Etodolac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Etoricoxib': ['Moderate', 'Etoricoxib is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Felbinac': ['Moderate', 'Felbinac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Flurbiprofen': ['Moderate', 'Flurbiprofen is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Gentamicin': ['Moderate', 'Gentamicin increases the risk of hypocalcaemia when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ibuprofen': ['Moderate', 'Ibuprofen is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Indometacin': ['Moderate', 'Indometacin is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketoprofen': ['Moderate', 'Ketoprofen is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketorolac': ['Moderate', 'Ketorolac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Magnesium': ['Moderate', 'Oral magnesium decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before magnesium (magnesium aspartate, magnesium glycerophosphate, magnesium hydroxide, magnesium sulfate). Severity of interaction: Moderate Evidence for interaction: Study'], 'Magnesium carbonate': ['Moderate', 'Magnesium carbonate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Magnesium trisilicate': ['Moderate', 'Magnesium trisilicate decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mefenamic acid': ['Moderate', 'Mefenamic acid is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Meloxicam': ['Moderate', 'Meloxicam is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nabumetone': ['Moderate', 'Nabumetone is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Naproxen': ['Moderate', 'Naproxen is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nepafenac': ['Moderate', 'Nepafenac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Parathyroid hormone': ['Moderate', 'Alendronate is predicted to decrease the effects of parathyroid hormone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Parecoxib': ['Moderate', 'Parecoxib is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Piroxicam': ['Moderate', 'Piroxicam is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Streptomycin': ['Moderate', 'Streptomycin increases the risk of hypocalcaemia when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Sulindac': ['Moderate', 'Sulindac is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tenoxicam': ['Moderate', 'Tenoxicam is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tiaprofenic acid': ['Moderate', 'Tiaprofenic acid is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tobramycin': ['Moderate', 'Tobramycin increases the risk of hypocalcaemia when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Tolfenamic acid': ['Moderate', 'Tolfenamic acid is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Zinc': ['Moderate', 'Oral zinc decreases the absorption of oral alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before zinc (zinc acetate, zinc sulfate). Severity of interaction: Moderate Evidence for interaction: Study']}","alfacalcidol","{'Bendroflumethiazide': ['Moderate', 'Bendroflumethiazide increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the effects of alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Chlorothiazide': ['Moderate', 'Chlorothiazide increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chlortalidone': ['Moderate', 'Chlortalidone increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Digoxin': ['Severe', 'Alfacalcidol is predicted to increase the risk of toxicity when given with digoxin. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin decreases the effects of alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Hydrochlorothiazide': ['Moderate', 'Hydrochlorothiazide increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Moderate', 'Hydroflumethiazide increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Indapamide': ['Moderate', 'Indapamide increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Metolazone': ['Moderate', 'Metolazone increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to decrease the effects of alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Phenytoin': ['Moderate', 'Phenytoin decreases the effects of alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Primidone': ['Moderate', 'Primidone is predicted to decrease the effects of alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Xipamide': ['Moderate', 'Xipamide increases the risk of hypercalcaemia when given with alfacalcidol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","alfentanil","{'Acebutolol': ['NotSet', 'Both alfentanil and acebutolol can increase the risk of bradycardia.'], 'Agomelatine': ['NotSet', ""Both alfentanil and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both alfentanil and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alectinib': ['NotSet', 'Both alfentanil and alectinib can increase the risk of bradycardia.'], 'Alimemazine': ['NotSet', ""Both alfentanil and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprazolam': ['NotSet', ""Both alfentanil and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amiodarone': ['NotSet', 'Both alfentanil and amiodarone can increase the risk of bradycardia.'], 'Amisulpride': ['NotSet', ""Both alfentanil and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both alfentanil and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Apalutamide': ['Moderate', 'Apalutamide is predicted to decrease the exposure to alfentanil. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Apraclonidine': ['NotSet', ""Both alfentanil and apraclonidine can increase the risk of bradycardia. Both alfentanil and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aprepitant': ['Moderate', 'Aprepitant is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aripiprazole': ['NotSet', ""Both alfentanil and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both alfentanil and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both alfentanil and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Atazanavir': ['Severe', 'Atazanavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Atenolol': ['NotSet', 'Both alfentanil and atenolol can increase the risk of bradycardia.'], 'Baclofen': ['NotSet', ""Both alfentanil and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Benperidol': ['NotSet', ""Both alfentanil and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betaxolol': ['NotSet', 'Both alfentanil and betaxolol can increase the risk of bradycardia.'], 'Bisoprolol': ['NotSet', 'Both alfentanil and bisoprolol can increase the risk of bradycardia.'], 'Brigatinib': ['Moderate', 'Brigatinib potentially decreases the concentration of alfentanil. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Brimonidine': ['NotSet', ""Both alfentanil and brimonidine can increase the risk of bradycardia. Both alfentanil and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buclizine': ['NotSet', ""Both alfentanil and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupivacaine': ['NotSet', ""Both alfentanil and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['Severe', 'Buprenorphine is predicted to increase the risk of opiate withdrawal when given with alfentanil. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cannabidiol': ['NotSet', ""Both alfentanil and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cariprazine': ['NotSet', ""Both alfentanil and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carvedilol': ['NotSet', 'Both alfentanil and carvedilol can increase the risk of bradycardia.'], 'Celiprolol': ['NotSet', 'Both alfentanil and celiprolol can increase the risk of bradycardia.'], 'Ceritinib': ['Severe', 'Ceritinib is predicted to increase the exposure to alfentanil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chloral hydrate': ['NotSet', ""Both alfentanil and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both alfentanil and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorphenamine': ['NotSet', ""Both alfentanil and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both alfentanil and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cimetidine': ['Severe', 'Cimetidine increases the concentration of alfentanil. Manufacturer advises use with caution and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cinnarizine': ['NotSet', ""Both alfentanil and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cisatracurium': ['NotSet', 'Both alfentanil and cisatracurium can increase the risk of bradycardia.'], 'Clarithromycin': ['Severe', 'Clarithromycin is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Clemastine': ['NotSet', ""Both alfentanil and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both alfentanil and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both alfentanil and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both alfentanil and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both alfentanil and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both alfentanil and clonidine can increase the risk of bradycardia. Both alfentanil and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both alfentanil and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cobicistat': ['Severe', 'Cobicistat is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Crizotinib': ['NotSet', 'Both alfentanil and crizotinib can increase the risk of bradycardia. Crizotinib is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cyclizine': ['NotSet', ""Both alfentanil and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both alfentanil and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Darunavir': ['Severe', 'Darunavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Desflurane': ['NotSet', ""Both alfentanil and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both alfentanil and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both alfentanil and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Digoxin': ['NotSet', 'Both alfentanil and digoxin can increase the risk of bradycardia.'], 'Diltiazem': ['NotSet', 'Both alfentanil and diltiazem can increase the risk of bradycardia. Diltiazem is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Donepezil': ['NotSet', 'Both alfentanil and donepezil can increase the risk of bradycardia.'], 'Dosulepin': ['NotSet', ""Both alfentanil and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxepin': ['NotSet', ""Both alfentanil and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both alfentanil and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Droperidol': ['NotSet', ""Both alfentanil and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Enzalutamide': ['Moderate', 'Enzalutamide is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Esketamine': ['NotSet', ""Both alfentanil and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esmolol': ['NotSet', 'Both alfentanil and esmolol can increase the risk of bradycardia.'], 'Etomidate': ['NotSet', ""Both alfentanil and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fingolimod': ['NotSet', 'Both alfentanil and fingolimod can increase the risk of bradycardia.'], 'Flecainide': ['NotSet', 'Both alfentanil and flecainide can increase the risk of bradycardia.'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Flupentixol': ['NotSet', ""Both alfentanil and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both alfentanil and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both alfentanil and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fosamprenavir': ['Severe', 'Fosamprenavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Gabapentin': ['NotSet', ""Both alfentanil and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Galantamine': ['NotSet', 'Both alfentanil and galantamine can increase the risk of bradycardia.'], 'Guanfacine': ['NotSet', ""Both alfentanil and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both alfentanil and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both alfentanil and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Idelalisib': ['Severe', 'Idelalisib is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Imatinib': ['Moderate', 'Imatinib is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imipramine': ['NotSet', ""Both alfentanil and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isavuconazole': ['Moderate', 'Isavuconazole is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Isocarboxazid': ['Severe', 'Alfentanil is predicted to increase the risk of CNS excitation or depression when given with isocarboxazid. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Isoflurane': ['NotSet', ""Both alfentanil and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Itraconazole': ['Severe', 'Itraconazole is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ivabradine': ['NotSet', 'Both alfentanil and ivabradine can increase the risk of bradycardia.'], 'Ketamine': ['NotSet', ""Both alfentanil and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketoconazole': ['Severe', 'Ketoconazole is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketotifen': ['NotSet', ""Both alfentanil and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Labetalol': ['NotSet', 'Both alfentanil and labetalol can increase the risk of bradycardia.'], 'Lamotrigine': ['NotSet', ""Both alfentanil and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Larotrectinib': ['Mild', 'Larotrectinib is predicted to increase the exposure to alfentanil. Manufacturer advises use with caution and adjust dose. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Letermovir': ['Moderate', 'Letermovir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Levetiracetam': ['NotSet', ""Both alfentanil and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levobunolol': ['NotSet', 'Both alfentanil and levobunolol can increase the risk of bradycardia.'], 'Levomepromazine': ['NotSet', ""Both alfentanil and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both alfentanil and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofepramine': ['NotSet', ""Both alfentanil and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both alfentanil and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lopinavir': ['Severe', 'Lopinavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Loprazolam': ['NotSet', ""Both alfentanil and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both alfentanil and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorlatinib': ['Moderate', 'Lorlatinib is predicted to decrease the exposure to alfentanil. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lormetazepam': ['NotSet', ""Both alfentanil and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loxapine': ['NotSet', ""Both alfentanil and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both alfentanil and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both alfentanil and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both alfentanil and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both alfentanil and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both alfentanil and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both alfentanil and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Metoprolol': ['NotSet', 'Both alfentanil and metoprolol can increase the risk of bradycardia.'], 'Mexiletine': ['Moderate', 'Alfentanil potentially decreases the absorption of oral mexiletine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mianserin': ['NotSet', ""Both alfentanil and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Miconazole': ['Moderate', 'Miconazole is predicted to increase the exposure to alfentanil. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Midazolam': ['NotSet', ""Both alfentanil and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mirtazapine': ['NotSet', ""Both alfentanil and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mitotane': ['Moderate', 'Mitotane is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Moxonidine': ['NotSet', ""Both alfentanil and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both alfentanil and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nadolol': ['NotSet', 'Both alfentanil and nadolol can increase the risk of bradycardia.'], 'Nalmefene': ['Severe', 'Nalmefene is predicted to decrease the efficacy of alfentanil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nebivolol': ['NotSet', 'Both alfentanil and nebivolol can increase the risk of bradycardia.'], 'Neostigmine': ['NotSet', 'Both alfentanil and neostigmine can increase the risk of bradycardia.'], 'Netupitant': ['Moderate', 'Netupitant is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nilotinib': ['Moderate', 'Nilotinib is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nitrazepam': ['NotSet', ""Both alfentanil and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrous oxide': ['NotSet', ""Both alfentanil and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both alfentanil and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both alfentanil and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxazepam': ['NotSet', ""Both alfentanil and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Palbociclib': ['Moderate', 'Palbociclib is predicted to increase the exposure to alfentanil. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Paliperidone': ['NotSet', ""Both alfentanil and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pasireotide': ['NotSet', 'Both alfentanil and pasireotide can increase the risk of bradycardia.'], 'Pentazocine': ['Severe', 'Pentazocine is predicted to increase the risk of opiate withdrawal when given with alfentanil. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Perampanel': ['NotSet', ""Both alfentanil and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pericyazine': ['NotSet', ""Both alfentanil and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['Severe', 'Alfentanil is predicted to increase the risk of CNS excitation or depression when given with phenelzine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenobarbital': ['NotSet', ""Both alfentanil and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Phenobarbital is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['NotSet', ""Both alfentanil and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pindolol': ['NotSet', 'Both alfentanil and pindolol can increase the risk of bradycardia.'], 'Pizotifen': ['NotSet', ""Both alfentanil and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pregabalin': ['NotSet', ""Both alfentanil and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both alfentanil and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both alfentanil and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Primidone is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Prochlorperazine': ['NotSet', ""Both alfentanil and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both alfentanil and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both alfentanil and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both alfentanil and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propranolol': ['NotSet', 'Both alfentanil and propranolol can increase the risk of bradycardia.'], 'Pyridostigmine': ['NotSet', 'Both alfentanil and pyridostigmine can increase the risk of bradycardia.'], 'Quetiapine': ['NotSet', ""Both alfentanil and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ribociclib': ['Moderate', 'Ribociclib is predicted to increase the exposure to alfentanil. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to decrease the exposure to alfentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Risperidone': ['NotSet', ""Both alfentanil and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ritonavir': ['Severe', 'Ritonavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Rivastigmine': ['NotSet', 'Both alfentanil and rivastigmine can increase the risk of bradycardia.'], 'Ropivacaine': ['NotSet', ""Both alfentanil and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rucaparib': ['Moderate', 'Rucaparib is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Saquinavir': ['Severe', 'Saquinavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Selegiline': ['NotSet', 'Both alfentanil and selegiline can increase the risk of bradycardia.'], 'Sevoflurane': ['NotSet', ""Both alfentanil and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sodium oxybate': ['NotSet', ""Both alfentanil and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sotalol': ['NotSet', 'Both alfentanil and sotalol can increase the risk of bradycardia.'], 'Sulpiride': ['NotSet', ""Both alfentanil and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Temazepam': ['NotSet', ""Both alfentanil and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tetracaine': ['NotSet', ""Both alfentanil and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both alfentanil and thalidomide can increase the risk of bradycardia. Both alfentanil and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both alfentanil and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Timolol': ['NotSet', 'Both alfentanil and timolol can increase the risk of bradycardia.'], 'Tipranavir': ['Severe', 'Tipranavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Tizanidine': ['NotSet', ""Both alfentanil and tizanidine can increase the risk of bradycardia. Both alfentanil and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tranylcypromine': ['Severe', 'Alfentanil is predicted to increase the risk of CNS excitation or depression when given with tranylcypromine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Trazodone': ['NotSet', ""Both alfentanil and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both alfentanil and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both alfentanil and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Venlafaxine': ['NotSet', ""Both alfentanil and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['NotSet', 'Both alfentanil and verapamil can increase the risk of bradycardia. Verapamil is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Voriconazole': ['Severe', 'Voriconazole is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Zolpidem': ['NotSet', ""Both alfentanil and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both alfentanil and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","alfuzos","{'Acebutolol': ['NotSet', 'Both alfuzosin and acebutolol can increase the risk of hypotension.'], 'Alcohol (beverage)': ['NotSet', 'Both alfuzosin and alcohol (beverage) can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both alfuzosin and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both alfuzosin and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both alfuzosin and amantadine can increase the risk of hypotension.'], 'Amitriptyline': ['NotSet', 'Both alfuzosin and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both alfuzosin and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both alfuzosin and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both alfuzosin and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both alfuzosin and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both alfuzosin and asenapine can increase the risk of hypotension.'], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atenolol': ['NotSet', 'Both alfuzosin and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both alfuzosin and avanafil can increase the risk of hypotension. Alfuzosin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Azilsartan': ['NotSet', 'Both alfuzosin and azilsartan can increase the risk of first-dose hypotension. Both alfuzosin and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both alfuzosin and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both alfuzosin and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both alfuzosin and benperidol can increase the risk of hypotension.'], 'Betaxolol': ['NotSet', 'Both alfuzosin and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both alfuzosin and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both alfuzosin and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both alfuzosin and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both alfuzosin and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both alfuzosin and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both alfuzosin and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both alfuzosin and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both alfuzosin and candesartan can increase the risk of first-dose hypotension. Both alfuzosin and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both alfuzosin and captopril can increase the risk of first-dose hypotension. Both alfuzosin and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', 'Both alfuzosin and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both alfuzosin and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both alfuzosin and celiprolol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both alfuzosin and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both alfuzosin and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both alfuzosin and chlortalidone can increase the risk of hypotension.'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clomipramine': ['NotSet', 'Both alfuzosin and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both alfuzosin and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both alfuzosin and clozapine can increase the risk of hypotension.'], 'Cobicistat': ['Moderate', 'Cobicistat is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dapagliflozin': ['NotSet', 'Both alfuzosin and dapagliflozin can increase the risk of hypotension.'], 'Darunavir': ['Moderate', 'Darunavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Desflurane': ['NotSet', 'Both alfuzosin and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both alfuzosin and diazoxide can increase the risk of hypotension.'], 'Diltiazem': ['NotSet', 'Both alfuzosin and diltiazem can increase the risk of hypotension.'], 'Dipyridamole': ['NotSet', 'Both alfuzosin and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', 'Both alfuzosin and dosulepin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both alfuzosin and doxepin can increase the risk of hypotension.'], 'Droperidol': ['NotSet', 'Both alfuzosin and droperidol can increase the risk of hypotension.'], 'Empagliflozin': ['NotSet', 'Both alfuzosin and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both alfuzosin and enalapril can increase the risk of first-dose hypotension. Both alfuzosin and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both alfuzosin and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both alfuzosin and eprosartan can increase the risk of first-dose hypotension. Both alfuzosin and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both alfuzosin and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', 'Both alfuzosin and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both alfuzosin and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both alfuzosin and etomidate can increase the risk of hypotension.'], 'Felodipine': ['NotSet', 'Both alfuzosin and felodipine can increase the risk of hypotension.'], 'Flupentixol': ['NotSet', 'Both alfuzosin and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both alfuzosin and fluphenazine can increase the risk of hypotension.'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosinopril': ['NotSet', 'Both alfuzosin and fosinopril can increase the risk of first-dose hypotension. Both alfuzosin and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both alfuzosin and furosemide can increase the risk of hypotension.'], 'Glyceryl trinitrate': ['NotSet', 'Both alfuzosin and glyceryl trinitrate can increase the risk of first-dose hypotension. Both alfuzosin and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both alfuzosin and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both alfuzosin and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both alfuzosin and haloperidol can increase the risk of hypotension.'], 'Hydralazine': ['NotSet', 'Both alfuzosin and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both alfuzosin and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both alfuzosin and hydroflumethiazide can increase the risk of hypotension.'], 'Idelalisib': ['Moderate', 'Idelalisib is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imidapril': ['NotSet', 'Both alfuzosin and imidapril can increase the risk of first-dose hypotension. Both alfuzosin and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both alfuzosin and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both alfuzosin and indapamide can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both alfuzosin and irbesartan can increase the risk of first-dose hypotension. Both alfuzosin and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both alfuzosin and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both alfuzosin and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both alfuzosin and isosorbide dinitrate can increase the risk of first-dose hypotension. Both alfuzosin and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both alfuzosin and isosorbide mononitrate can increase the risk of first-dose hypotension. Both alfuzosin and isosorbide mononitrate can increase the risk of hypotension.'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketamine': ['NotSet', 'Both alfuzosin and ketamine can increase the risk of hypotension.'], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Labetalol': ['NotSet', 'Both alfuzosin and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both alfuzosin and lacidipine can increase the risk of hypotension.'], 'Lercanidipine': ['NotSet', 'Both alfuzosin and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both alfuzosin and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both alfuzosin and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both alfuzosin and levomepromazine can increase the risk of hypotension.'], 'Lisinopril': ['NotSet', 'Both alfuzosin and lisinopril can increase the risk of first-dose hypotension. Both alfuzosin and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both alfuzosin and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both alfuzosin and lofexidine can increase the risk of hypotension.'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Losartan': ['NotSet', 'Both alfuzosin and losartan can increase the risk of first-dose hypotension. Both alfuzosin and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both alfuzosin and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both alfuzosin and lurasidone can increase the risk of hypotension.'], 'Methoxyflurane': ['NotSet', 'Both alfuzosin and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both alfuzosin and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both alfuzosin and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both alfuzosin and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both alfuzosin and minoxidil can increase the risk of hypotension.'], 'Moxisylyte': ['NotSet', 'Both alfuzosin and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both alfuzosin and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both alfuzosin and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both alfuzosin and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both alfuzosin and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both alfuzosin and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both alfuzosin and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both alfuzosin and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both alfuzosin and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both alfuzosin and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both alfuzosin and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both alfuzosin and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both alfuzosin and olmesartan can increase the risk of first-dose hypotension. Both alfuzosin and olmesartan can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both alfuzosin and paliperidone can increase the risk of hypotension.'], 'Pergolide': ['NotSet', 'Both alfuzosin and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both alfuzosin and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both alfuzosin and perindopril can increase the risk of first-dose hypotension. Both alfuzosin and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both alfuzosin and phenelzine can increase the risk of hypotension.'], 'Pimozide': ['NotSet', 'Both alfuzosin and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both alfuzosin and pindolol can increase the risk of hypotension.'], 'Pramipexole': ['NotSet', 'Both alfuzosin and pramipexole can increase the risk of hypotension.'], 'Prochlorperazine': ['NotSet', 'Both alfuzosin and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both alfuzosin and promazine can increase the risk of hypotension.'], 'Propofol': ['NotSet', 'Both alfuzosin and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both alfuzosin and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both alfuzosin and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both alfuzosin and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both alfuzosin and quinapril can increase the risk of first-dose hypotension. Both alfuzosin and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both alfuzosin and ramipril can increase the risk of first-dose hypotension. Both alfuzosin and ramipril can increase the risk of hypotension.'], 'Ribociclib': ['Moderate', 'Ribociclib (high-dose) is predicted to increase the exposure to alfuzosin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Riociguat': ['NotSet', 'Both alfuzosin and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both alfuzosin and risperidone can increase the risk of hypotension.'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ropinirole': ['NotSet', 'Both alfuzosin and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both alfuzosin and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both alfuzosin and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both alfuzosin and sapropterin can increase the risk of hypotension.'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Selegiline': ['NotSet', 'Both alfuzosin and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both alfuzosin and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both alfuzosin and sildenafil can increase the risk of hypotension. Alfuzosin causes significant hypotensive effects when given with sildenafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Sodium oxybate': ['NotSet', 'Both alfuzosin and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both alfuzosin and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both alfuzosin and spironolactone can increase the risk of hypotension.'], 'Sulpiride': ['NotSet', 'Both alfuzosin and sulpiride can increase the risk of hypotension.'], 'Tadalafil': ['NotSet', 'Both alfuzosin and tadalafil can increase the risk of hypotension. Alfuzosin causes significant hypotensive effects when given with tadalafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Telmisartan': ['NotSet', 'Both alfuzosin and telmisartan can increase the risk of first-dose hypotension. Both alfuzosin and telmisartan can increase the risk of hypotension.'], 'Thiopental': ['NotSet', 'Both alfuzosin and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both alfuzosin and timolol can increase the risk of hypotension.'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tizanidine': ['NotSet', 'Both alfuzosin and tizanidine can increase the risk of hypotension.'], 'Torasemide': ['NotSet', 'Both alfuzosin and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both alfuzosin and trandolapril can increase the risk of first-dose hypotension. Both alfuzosin and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both alfuzosin and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both alfuzosin and trifluoperazine can increase the risk of hypotension.'], 'Trimipramine': ['NotSet', 'Both alfuzosin and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both alfuzosin and valsartan can increase the risk of first-dose hypotension. Both alfuzosin and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both alfuzosin and vardenafil can increase the risk of hypotension. Alfuzosin causes significant hypotensive effects when given with vardenafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Verapamil': ['NotSet', 'Both alfuzosin and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both alfuzosin and vernakalant can increase the risk of hypotension.'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Xipamide': ['NotSet', 'Both alfuzosin and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both alfuzosin and zuclopenthixol can increase the risk of hypotension.']}","alimemazi","{'Agomelatine': ['NotSet', ""Both alimemazine and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both alimemazine and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both alimemazine and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprazolam': ['NotSet', ""Both alimemazine and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amisulpride': ['NotSet', ""Both alimemazine and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both alimemazine and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Apraclonidine': ['NotSet', ""Both alimemazine and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both alimemazine and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both alimemazine and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both alimemazine and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Baclofen': ['NotSet', ""Both alimemazine and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Benperidol': ['NotSet', ""Both alimemazine and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betahistine': ['Moderate', 'Alimemazine is predicted to decrease the effects of betahistine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Brimonidine': ['NotSet', ""Both alimemazine and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupivacaine': ['NotSet', ""Both alimemazine and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both alimemazine and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cannabidiol': ['NotSet', ""Both alimemazine and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cariprazine': ['NotSet', ""Both alimemazine and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chloral hydrate': ['NotSet', ""Both alimemazine and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both alimemazine and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both alimemazine and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both alimemazine and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both alimemazine and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both alimemazine and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both alimemazine and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both alimemazine and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both alimemazine and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both alimemazine and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Desflurane': ['NotSet', ""Both alimemazine and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both alimemazine and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both alimemazine and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both alimemazine and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dihydrocodeine': ['NotSet', ""Both alimemazine and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipipanone': ['NotSet', ""Both alimemazine and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dosulepin': ['NotSet', ""Both alimemazine and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxepin': ['NotSet', ""Both alimemazine and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both alimemazine and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both alimemazine and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esketamine': ['NotSet', ""Both alimemazine and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Etomidate': ['NotSet', ""Both alimemazine and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fentanyl': ['NotSet', ""Both alimemazine and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flupentixol': ['NotSet', ""Both alimemazine and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both alimemazine and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both alimemazine and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Gabapentin': ['NotSet', ""Both alimemazine and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Guanfacine': ['NotSet', ""Both alimemazine and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both alimemazine and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydromorphone': ['NotSet', ""Both alimemazine and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imipramine': ['NotSet', ""Both alimemazine and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isocarboxazid': ['Severe', 'Isocarboxazid is predicted to increase the risk of antimuscarinic side-effects when given with alimemazine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Isoflurane': ['NotSet', ""Both alimemazine and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketamine': ['NotSet', ""Both alimemazine and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lamotrigine': ['NotSet', ""Both alimemazine and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levetiracetam': ['NotSet', ""Both alimemazine and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levomepromazine': ['NotSet', ""Both alimemazine and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both alimemazine and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofepramine': ['NotSet', ""Both alimemazine and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both alimemazine and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both alimemazine and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both alimemazine and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both alimemazine and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loxapine': ['NotSet', ""Both alimemazine and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both alimemazine and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both alimemazine and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both alimemazine and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both alimemazine and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both alimemazine and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both alimemazine and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both alimemazine and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both alimemazine and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mianserin': ['NotSet', ""Both alimemazine and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both alimemazine and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mirtazapine': ['NotSet', ""Both alimemazine and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Morphine': ['NotSet', ""Both alimemazine and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxonidine': ['NotSet', ""Both alimemazine and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both alimemazine and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrazepam': ['NotSet', ""Both alimemazine and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrous oxide': ['NotSet', ""Both alimemazine and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both alimemazine and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both alimemazine and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxazepam': ['NotSet', ""Both alimemazine and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both alimemazine and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both alimemazine and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pentazocine': ['NotSet', ""Both alimemazine and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both alimemazine and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pericyazine': ['NotSet', ""Both alimemazine and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pethidine': ['NotSet', ""Both alimemazine and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['Severe', 'Phenelzine is predicted to increase the risk of antimuscarinic side-effects when given with alimemazine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenobarbital': ['NotSet', ""Both alimemazine and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pimozide': ['NotSet', ""Both alimemazine and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pitolisant': ['Moderate', 'Alimemazine is predicted to decrease the efficacy of pitolisant. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pregabalin': ['NotSet', ""Both alimemazine and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both alimemazine and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both alimemazine and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prochlorperazine': ['NotSet', ""Both alimemazine and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both alimemazine and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both alimemazine and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quetiapine': ['NotSet', ""Both alimemazine and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Remifentanil': ['NotSet', ""Both alimemazine and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Risperidone': ['NotSet', ""Both alimemazine and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ropivacaine': ['NotSet', ""Both alimemazine and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sevoflurane': ['NotSet', ""Both alimemazine and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sodium oxybate': ['NotSet', ""Both alimemazine and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sufentanil': ['NotSet', ""Both alimemazine and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both alimemazine and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tapentadol': ['NotSet', ""Both alimemazine and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Temazepam': ['NotSet', ""Both alimemazine and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tetracaine': ['NotSet', ""Both alimemazine and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both alimemazine and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both alimemazine and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tizanidine': ['NotSet', ""Both alimemazine and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tramadol': ['NotSet', ""Both alimemazine and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tranylcypromine': ['Severe', 'Tranylcypromine is predicted to increase the risk of antimuscarinic side-effects when given with alimemazine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trazodone': ['NotSet', ""Both alimemazine and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both alimemazine and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both alimemazine and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Venlafaxine': ['NotSet', ""Both alimemazine and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zolpidem': ['NotSet', ""Both alimemazine and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both alimemazine and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","aliskiren","{'Acebutolol': ['NotSet', 'Both aliskiren and acebutolol can increase the risk of hypotension.'], 'Aceclofenac': ['NotSet', 'Both aliskiren and aceclofenac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Alcohol (beverage)': ['NotSet', 'Both aliskiren and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both aliskiren and alfuzosin can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both aliskiren and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both aliskiren and amantadine can increase the risk of hypotension.'], 'Amiloride': ['NotSet', 'Both aliskiren and amiloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Amiodarone': ['Severe', 'Amiodarone is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Amitriptyline': ['NotSet', 'Both aliskiren and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both aliskiren and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both aliskiren and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both aliskiren and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both aliskiren and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both aliskiren and asenapine can increase the risk of hypotension.'], 'Atenolol': ['NotSet', 'Both aliskiren and atenolol can increase the risk of hypotension.'], 'Atorvastatin': ['Moderate', 'Atorvastatin slightly to moderately increases the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Avanafil': ['NotSet', 'Both aliskiren and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both aliskiren and azilsartan can increase the risk of hypotension. Both aliskiren and azilsartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Azilsartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Azithromycin': ['Moderate', 'Azithromycin is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Baclofen': ['NotSet', 'Both aliskiren and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both aliskiren and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both aliskiren and benperidol can increase the risk of hypotension.'], 'Betaxolol': ['NotSet', 'Both aliskiren and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both aliskiren and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both aliskiren and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both aliskiren and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both aliskiren and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both aliskiren and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both aliskiren and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both aliskiren and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both aliskiren and candesartan can increase the risk of hypotension. Both aliskiren and candesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Candesartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Captopril': ['NotSet', 'Both aliskiren and captopril can increase the risk of hypotension. Both aliskiren and captopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Captopril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Carbamazepine': ['Moderate', 'Carbamazepine decreases the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cariprazine': ['NotSet', 'Both aliskiren and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both aliskiren and carvedilol can increase the risk of hypotension.'], 'Celecoxib': ['NotSet', 'Both aliskiren and celecoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Celiprolol': ['NotSet', 'Both aliskiren and celiprolol can increase the risk of hypotension.'], 'Ceritinib': ['Moderate', 'Ceritinib is predicted to increase the exposure to aliskiren. Manufacturer advises caution and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chlorothiazide': ['NotSet', 'Both aliskiren and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both aliskiren and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both aliskiren and chlortalidone can increase the risk of hypotension.'], 'Ciclosporin': ['NotSet', 'Both aliskiren and ciclosporin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Ciclosporin markedly increases the exposure to aliskiren. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clomipramine': ['NotSet', 'Both aliskiren and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both aliskiren and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both aliskiren and clozapine can increase the risk of hypotension.'], 'Dalteparin': ['NotSet', 'Both aliskiren and dalteparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dapagliflozin': ['NotSet', 'Both aliskiren and dapagliflozin can increase the risk of hypotension.'], 'Darbepoetin alfa': ['NotSet', 'Both aliskiren and darbepoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Desflurane': ['NotSet', 'Both aliskiren and desflurane can increase the risk of hypotension.'], 'Dexibuprofen': ['NotSet', 'Both aliskiren and dexibuprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dexketoprofen': ['NotSet', 'Both aliskiren and dexketoprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Diazoxide': ['NotSet', 'Both aliskiren and diazoxide can increase the risk of hypotension.'], 'Diclofenac': ['NotSet', 'Both aliskiren and diclofenac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Diltiazem': ['NotSet', 'Both aliskiren and diltiazem can increase the risk of hypotension.'], 'Dipyridamole': ['NotSet', 'Both aliskiren and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', 'Both aliskiren and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both aliskiren and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both aliskiren and doxepin can increase the risk of hypotension.'], 'Dronedarone': ['Severe', 'Dronedarone is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Droperidol': ['NotSet', 'Both aliskiren and droperidol can increase the risk of hypotension.'], 'Drospirenone': ['NotSet', 'Both aliskiren and drospirenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eliglustat': ['Moderate', 'Eliglustat is predicted to increase the exposure to aliskiren. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Empagliflozin': ['NotSet', 'Both aliskiren and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both aliskiren and enalapril can increase the risk of hypotension. Both aliskiren and enalapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Enalapril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Enoxaparin': ['NotSet', 'Both aliskiren and enoxaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eplerenone': ['NotSet', 'Both aliskiren and eplerenone can increase the risk of hypotension. Both aliskiren and eplerenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin alfa': ['NotSet', 'Both aliskiren and epoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin beta': ['NotSet', 'Both aliskiren and epoetin beta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin zeta': ['NotSet', 'Both aliskiren and epoetin zeta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eprosartan': ['NotSet', 'Both aliskiren and eprosartan can increase the risk of hypotension. Both aliskiren and eprosartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Eprosartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Ertugliflozin': ['NotSet', 'Both aliskiren and ertugliflozin can increase the risk of hypotension.'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Esketamine': ['NotSet', 'Both aliskiren and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both aliskiren and esmolol can increase the risk of hypotension.'], 'Etodolac': ['NotSet', 'Both aliskiren and etodolac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Etomidate': ['NotSet', 'Both aliskiren and etomidate can increase the risk of hypotension.'], 'Etoricoxib': ['NotSet', 'Both aliskiren and etoricoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Felodipine': ['NotSet', 'Both aliskiren and felodipine can increase the risk of hypotension.'], 'Flupentixol': ['NotSet', 'Both aliskiren and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both aliskiren and fluphenazine can increase the risk of hypotension.'], 'Flurbiprofen': ['NotSet', 'Both aliskiren and flurbiprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Fosinopril': ['NotSet', 'Both aliskiren and fosinopril can increase the risk of hypotension. Fosinopril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Furosemide': ['NotSet', 'Both aliskiren and furosemide can increase the risk of hypotension. Aliskiren slightly decreases the exposure to furosemide. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Glyceryl trinitrate': ['NotSet', 'Both aliskiren and glyceryl trinitrate can increase the risk of hypotension.'], 'Grapefruit juice': ['Severe', 'Grapefruit juice moderately decreases the exposure to aliskiren. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Guanethidine': ['NotSet', 'Both aliskiren and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both aliskiren and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both aliskiren and haloperidol can increase the risk of hypotension.'], 'Heparin (unfractionated)': ['NotSet', 'Both aliskiren and heparin (unfractionated) can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Hydralazine': ['NotSet', 'Both aliskiren and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both aliskiren and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both aliskiren and hydroflumethiazide can increase the risk of hypotension.'], 'Ibuprofen': ['NotSet', 'Both aliskiren and ibuprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Imidapril': ['NotSet', 'Both aliskiren and imidapril can increase the risk of hypotension. Both aliskiren and imidapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Imidapril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Imipramine': ['NotSet', 'Both aliskiren and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both aliskiren and indapamide can increase the risk of hypotension.'], 'Indometacin': ['NotSet', 'Both aliskiren and indometacin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Indoramin': ['NotSet', 'Both aliskiren and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both aliskiren and irbesartan can increase the risk of hypotension. Both aliskiren and irbesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Irbesartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Isocarboxazid': ['NotSet', 'Both aliskiren and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both aliskiren and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both aliskiren and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both aliskiren and isosorbide mononitrate can increase the risk of hypotension.'], 'Itraconazole': ['Severe', 'Itraconazole markedly increases the exposure to aliskiren. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketamine': ['NotSet', 'Both aliskiren and ketamine can increase the risk of hypotension.'], 'Ketoconazole': ['Moderate', 'Ketoconazole moderately increases the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketoprofen': ['NotSet', 'Both aliskiren and ketoprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ketorolac': ['NotSet', 'Both aliskiren and ketorolac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Labetalol': ['NotSet', 'Both aliskiren and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both aliskiren and lacidipine can increase the risk of hypotension.'], 'Lapatinib': ['Moderate', 'Lapatinib is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lercanidipine': ['NotSet', 'Both aliskiren and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both aliskiren and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both aliskiren and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both aliskiren and levomepromazine can increase the risk of hypotension.'], 'Lisinopril': ['NotSet', 'Both aliskiren and lisinopril can increase the risk of hypotension. Both aliskiren and lisinopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Lisinopril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Lofepramine': ['NotSet', 'Both aliskiren and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both aliskiren and lofexidine can increase the risk of hypotension.'], 'Losartan': ['NotSet', 'Both aliskiren and losartan can increase the risk of hypotension. Both aliskiren and losartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Losartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Loxapine': ['NotSet', 'Both aliskiren and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both aliskiren and lurasidone can increase the risk of hypotension.'], 'Mefenamic acid': ['NotSet', 'Both aliskiren and mefenamic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Meloxicam': ['NotSet', 'Both aliskiren and meloxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Methoxyflurane': ['NotSet', 'Both aliskiren and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both aliskiren and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both aliskiren and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both aliskiren and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both aliskiren and minoxidil can increase the risk of hypotension.'], 'Mirabegron': ['Mild', 'Mirabegron is predicted to increase the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Moxisylyte': ['NotSet', 'Both aliskiren and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both aliskiren and moxonidine can increase the risk of hypotension.'], 'Nabumetone': ['NotSet', 'Both aliskiren and nabumetone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Nadolol': ['NotSet', 'Both aliskiren and nadolol can increase the risk of hypotension.'], 'Naproxen': ['NotSet', 'Both aliskiren and naproxen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Nebivolol': ['NotSet', 'Both aliskiren and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both aliskiren and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both aliskiren and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both aliskiren and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both aliskiren and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both aliskiren and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both aliskiren and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both aliskiren and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both aliskiren and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both aliskiren and olmesartan can increase the risk of hypotension. Both aliskiren and olmesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Olmesartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Paliperidone': ['NotSet', 'Both aliskiren and paliperidone can increase the risk of hypotension.'], 'Parecoxib': ['NotSet', 'Both aliskiren and parecoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Paritaprevir': ['Moderate', 'Paritaprevir (with ritonavir and ombitasvir) is predicted to increase the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pergolide': ['NotSet', 'Both aliskiren and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both aliskiren and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both aliskiren and perindopril can increase the risk of hypotension. Both aliskiren and perindopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Perindopril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenelzine': ['NotSet', 'Both aliskiren and phenelzine can increase the risk of hypotension.'], 'Pibrentasvir': ['Moderate', 'Pibrentasvir (with glecaprevir) is predicted to increase the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['NotSet', 'Both aliskiren and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both aliskiren and pindolol can increase the risk of hypotension.'], 'Piroxicam': ['NotSet', 'Both aliskiren and piroxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Pitolisant': ['Mild', 'Pitolisant is predicted to decrease the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Potassium aminobenzoate': ['NotSet', 'Both aliskiren and potassium aminobenzoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium canrenoate': ['NotSet', 'Both aliskiren and potassium canrenoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium chloride': ['NotSet', 'Both aliskiren and potassium chloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Pramipexole': ['NotSet', 'Both aliskiren and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both aliskiren and prazosin can increase the risk of hypotension.'], 'Prochlorperazine': ['NotSet', 'Both aliskiren and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both aliskiren and promazine can increase the risk of hypotension.'], 'Propofol': ['NotSet', 'Both aliskiren and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both aliskiren and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both aliskiren and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both aliskiren and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both aliskiren and quinapril can increase the risk of hypotension. Both aliskiren and quinapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Quinapril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Ramipril': ['NotSet', 'Both aliskiren and ramipril can increase the risk of hypotension. Both aliskiren and ramipril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Ramipril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Ranolazine': ['Moderate', 'Ranolazine is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Rifampicin': ['Moderate', 'Rifampicin decreases the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Riociguat': ['NotSet', 'Both aliskiren and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both aliskiren and risperidone can increase the risk of hypotension.'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ropinirole': ['NotSet', 'Both aliskiren and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both aliskiren and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both aliskiren and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both aliskiren and sapropterin can increase the risk of hypotension.'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Selegiline': ['NotSet', 'Both aliskiren and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both aliskiren and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both aliskiren and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both aliskiren and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both aliskiren and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both aliskiren and spironolactone can increase the risk of hypotension. Both aliskiren and spironolactone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], ""St John's Wort"": ['Moderate', ""St John's Wort decreases the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Sulindac': ['NotSet', 'Both aliskiren and sulindac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Sulpiride': ['NotSet', 'Both aliskiren and sulpiride can increase the risk of hypotension.'], 'Tacrolimus': ['NotSet', 'Both aliskiren and tacrolimus can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tadalafil': ['NotSet', 'Both aliskiren and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both aliskiren and tamsulosin can increase the risk of hypotension.'], 'Telmisartan': ['NotSet', 'Both aliskiren and telmisartan can increase the risk of hypotension. Both aliskiren and telmisartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Telmisartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Tenoxicam': ['NotSet', 'Both aliskiren and tenoxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Terazosin': ['NotSet', 'Both aliskiren and terazosin can increase the risk of hypotension.'], 'Thiopental': ['NotSet', 'Both aliskiren and thiopental can increase the risk of hypotension.'], 'Tiaprofenic acid': ['NotSet', 'Both aliskiren and tiaprofenic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Timolol': ['NotSet', 'Both aliskiren and timolol can increase the risk of hypotension.'], 'Tinzaparin': ['NotSet', 'Both aliskiren and tinzaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tizanidine': ['NotSet', 'Both aliskiren and tizanidine can increase the risk of hypotension.'], 'Tolfenamic acid': ['NotSet', 'Both aliskiren and tolfenamic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tolvaptan': ['NotSet', 'Both aliskiren and tolvaptan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Torasemide': ['NotSet', 'Both aliskiren and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both aliskiren and trandolapril can increase the risk of hypotension. Both aliskiren and trandolapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Trandolapril increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Tranylcypromine': ['NotSet', 'Both aliskiren and tranylcypromine can increase the risk of hypotension.'], 'Triamterene': ['NotSet', 'Both aliskiren and triamterene can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trifluoperazine': ['NotSet', 'Both aliskiren and trifluoperazine can increase the risk of hypotension.'], 'Trimethoprim': ['NotSet', 'Both aliskiren and trimethoprim can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trimipramine': ['NotSet', 'Both aliskiren and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both aliskiren and valsartan can increase the risk of hypotension. Both aliskiren and valsartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Valsartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Vardenafil': ['NotSet', 'Both aliskiren and vardenafil can increase the risk of hypotension.'], 'Velpatasvir': ['Severe', 'Velpatasvir is predicted to increase the exposure to aliskiren. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vemurafenib': ['Moderate', 'Vemurafenib is predicted to increase the exposure to aliskiren. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Verapamil': ['NotSet', 'Both aliskiren and verapamil can increase the risk of hypotension. Verapamil moderately increases the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Vernakalant': ['NotSet', 'Both aliskiren and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both aliskiren and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both aliskiren and zuclopenthixol can increase the risk of hypotension.']}","alitretinoin","{'Amiodarone': ['Moderate', 'Amiodarone is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Clopidogrel': ['Moderate', 'Clopidogrel is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Cobicistat': ['Moderate', 'Cobicistat is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Darunavir': ['Moderate', 'Darunavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Demeclocycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with demeclocycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Doxycycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with doxycycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gemfibrozil': ['Moderate', 'Gemfibrozil is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Idelalisib': ['Moderate', 'Idelalisib is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lymecycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with lymecycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Miconazole': ['Moderate', 'Miconazole is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Minocycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with minocycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Oxytetracycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with oxytetracycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tetracycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with tetracycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tigecycline': ['Severe', 'Alitretinoin increases the risk of benign intracranial hypertension when given with tigecycline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Vitamin A': ['Severe', 'Alitretinoin is predicted to increase the risk of vitamin A toxicity when given with vitamin A. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","allopurinol","{'Amoxicillin': ['Moderate', 'Allopurinol increases the risk of skin rash when given with amoxicillin. Manufacturer advises consider alternatives. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ampicillin': ['Moderate', 'Allopurinol increases the risk of skin rash when given with ampicillin. Manufacturer advises consider alternatives. Severity of interaction: Moderate Evidence for interaction: Study'], 'Azathioprine': ['Severe', 'Allopurinol potentially increases the risk of haematological toxicity when given with azathioprine. Manufacturer advises adjust azathioprine dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Capecitabine': ['Severe', 'Allopurinol is predicted to decrease the effects of capecitabine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Captopril': ['Severe', 'Captopril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Didanosine': ['Severe', 'Allopurinol moderately increases the exposure to didanosine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Enalapril': ['Severe', 'Enalapril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fosinopril': ['Severe', 'Fosinopril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Imidapril': ['Severe', 'Imidapril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Indapamide': ['Severe', 'Indapamide is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lisinopril': ['Severe', 'Lisinopril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Mercaptopurine': ['Severe', 'Allopurinol potentially increases the risk of haematological toxicity when given with mercaptopurine. Manufacturer advises adjust mercaptopurine dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Metolazone': ['Severe', 'Metolazone is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Perindopril': ['Severe', 'Perindopril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pyrazinamide': ['Moderate', 'Allopurinol is predicted to increase the risk of hyperuricaemia when given with pyrazinamide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quinapril': ['Severe', 'Quinapril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ramipril': ['Severe', 'Ramipril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Trandolapril': ['Severe', 'Trandolapril is predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Xipamide': ['Severe', 'Xipamide is predicted to increase the risk of hypersensitivity reactions when given with allopurinol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical']}","almotriptan","{""St John's Wort"": ['NotSet', ""Both almotriptan and St John's Wort can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Atazanavir': ['Mild', 'Atazanavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Bupropion': ['NotSet', ""Both almotriptan and bupropion can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Buspirone': ['NotSet', ""Both almotriptan and buspirone can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Citalopram': ['NotSet', ""Both almotriptan and citalopram can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Clarithromycin': ['Mild', 'Clarithromycin increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Clomipramine': ['NotSet', ""Both almotriptan and clomipramine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Cobicistat': ['Mild', 'Cobicistat increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Dapoxetine': ['NotSet', ""Both almotriptan and dapoxetine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Darunavir': ['Mild', 'Darunavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Dexamfetamine': ['NotSet', ""Both almotriptan and dexamfetamine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Duloxetine': ['NotSet', ""Both almotriptan and duloxetine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Eletriptan': ['NotSet', ""Both almotriptan and eletriptan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Ergotamine': ['Severe', 'Almotriptan is predicted to increase the risk of vasoconstriction when given with ergotamine. Manufacturer advises ergotamine should be taken at least 24 hours before or 6 hours after almotriptan. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Escitalopram': ['NotSet', ""Both almotriptan and escitalopram can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Fentanyl': ['NotSet', ""Both almotriptan and fentanyl can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Fluoxetine': ['NotSet', ""Both almotriptan and fluoxetine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Fluvoxamine': ['NotSet', ""Both almotriptan and fluvoxamine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Fosamprenavir': ['Mild', 'Fosamprenavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Frovatriptan': ['NotSet', ""Both almotriptan and frovatriptan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Granisetron': ['NotSet', ""Both almotriptan and granisetron can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Idelalisib': ['Mild', 'Idelalisib increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Imipramine': ['NotSet', ""Both almotriptan and imipramine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Isocarboxazid': ['NotSet', ""Both almotriptan and isocarboxazid can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Itraconazole': ['Mild', 'Itraconazole increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Ketoconazole': ['Mild', 'Ketoconazole increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Linezolid': ['NotSet', ""Both almotriptan and linezolid can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Lisdexamfetamine': ['NotSet', ""Both almotriptan and lisdexamfetamine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Lithium': ['NotSet', ""Both almotriptan and lithium can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Lopinavir': ['Mild', 'Lopinavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Methadone': ['NotSet', ""Both almotriptan and methadone can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Methylthioninium chloride': ['NotSet', ""Both almotriptan and methylthioninium chloride can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Mianserin': ['NotSet', ""Both almotriptan and mianserin can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Mirtazapine': ['NotSet', ""Both almotriptan and mirtazapine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Moclobemide': ['NotSet', ""Both almotriptan and moclobemide can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Naratriptan': ['NotSet', ""Both almotriptan and naratriptan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Ondansetron': ['NotSet', ""Both almotriptan and ondansetron can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Palonosetron': ['NotSet', ""Both almotriptan and palonosetron can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Paroxetine': ['NotSet', ""Both almotriptan and paroxetine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Pentazocine': ['NotSet', ""Both almotriptan and pentazocine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Pethidine': ['NotSet', ""Both almotriptan and pethidine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Phenelzine': ['NotSet', ""Both almotriptan and phenelzine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Procarbazine': ['NotSet', ""Both almotriptan and procarbazine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Rasagiline': ['NotSet', ""Both almotriptan and rasagiline can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Ritonavir': ['Mild', 'Ritonavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Rizatriptan': ['NotSet', ""Both almotriptan and rizatriptan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Safinamide': ['NotSet', ""Both almotriptan and safinamide can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Saquinavir': ['Mild', 'Saquinavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Selegiline': ['NotSet', ""Both almotriptan and selegiline can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Sertraline': ['NotSet', ""Both almotriptan and sertraline can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Sumatriptan': ['NotSet', ""Both almotriptan and sumatriptan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Tapentadol': ['NotSet', ""Both almotriptan and tapentadol can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Tipranavir': ['Mild', 'Tipranavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Tramadol': ['NotSet', ""Both almotriptan and tramadol can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Tranylcypromine': ['NotSet', ""Both almotriptan and tranylcypromine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Trazodone': ['NotSet', ""Both almotriptan and trazodone can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Tryptophan': ['NotSet', ""Both almotriptan and tryptophan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Venlafaxine': ['NotSet', ""Both almotriptan and venlafaxine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Voriconazole': ['Mild', 'Voriconazole increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Vortioxetine': ['NotSet', ""Both almotriptan and vortioxetine can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""], 'Zolmitriptan': ['NotSet', ""Both almotriptan and zolmitriptan can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.""]}","alogliptin","{'Acarbose': ['NotSet', 'Both alogliptin and acarbose can increase the risk of hypoglycaemia.'], 'Canagliflozin': ['NotSet', 'Both alogliptin and canagliflozin can increase the risk of hypoglycaemia.'], 'Dapagliflozin': ['NotSet', 'Both alogliptin and dapagliflozin can increase the risk of hypoglycaemia.'], 'Dulaglutide': ['NotSet', 'Both alogliptin and dulaglutide can increase the risk of hypoglycaemia.'], 'Empagliflozin': ['NotSet', 'Both alogliptin and empagliflozin can increase the risk of hypoglycaemia.'], 'Ertugliflozin': ['NotSet', 'Both alogliptin and ertugliflozin can increase the risk of hypoglycaemia.'], 'Exenatide': ['NotSet', 'Both alogliptin and exenatide can increase the risk of hypoglycaemia.'], 'Glibenclamide': ['NotSet', 'Both alogliptin and glibenclamide can increase the risk of hypoglycaemia.'], 'Gliclazide': ['NotSet', 'Both alogliptin and gliclazide can increase the risk of hypoglycaemia.'], 'Glimepiride': ['NotSet', 'Both alogliptin and glimepiride can increase the risk of hypoglycaemia.'], 'Glipizide': ['NotSet', 'Both alogliptin and glipizide can increase the risk of hypoglycaemia.'], 'Insulins': ['NotSet', 'Both alogliptin and insulins can increase the risk of hypoglycaemia.'], 'Linagliptin': ['NotSet', 'Both alogliptin and linagliptin can increase the risk of hypoglycaemia.'], 'Liraglutide': ['NotSet', 'Both alogliptin and liraglutide can increase the risk of hypoglycaemia.'], 'Lixisenatide': ['NotSet', 'Both alogliptin and lixisenatide can increase the risk of hypoglycaemia.'], 'Metformin': ['NotSet', 'Both alogliptin and metformin can increase the risk of hypoglycaemia.'], 'Nateglinide': ['NotSet', 'Both alogliptin and nateglinide can increase the risk of hypoglycaemia.'], 'Pioglitazone': ['NotSet', 'Both alogliptin and pioglitazone can increase the risk of hypoglycaemia.'], 'Repaglinide': ['NotSet', 'Both alogliptin and repaglinide can increase the risk of hypoglycaemia.'], 'Saxagliptin': ['NotSet', 'Both alogliptin and saxagliptin can increase the risk of hypoglycaemia.'], 'Semaglutide': ['NotSet', 'Both alogliptin and semaglutide can increase the risk of hypoglycaemia.'], 'Sitagliptin': ['NotSet', 'Both alogliptin and sitagliptin can increase the risk of hypoglycaemia.'], 'Tolbutamide': ['NotSet', 'Both alogliptin and tolbutamide can increase the risk of hypoglycaemia.'], 'Vildagliptin': ['NotSet', 'Both alogliptin and vildagliptin can increase the risk of hypoglycaemia.']}","alpha-tocopherol","{'Ciclosporin': ['Moderate', 'Alpha tocopherol affects the exposure to ciclosporin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study']}","alpha-tocopheryl-acetate","{'Ciclosporin': ['Moderate', 'Alpha tocopheryl acetate affects the exposure to ciclosporin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study']}","alprazolam","{'Agomelatine': ['NotSet', ""Both alprazolam and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both alprazolam and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both alprazolam and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alimemazine': ['NotSet', ""Both alprazolam and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amisulpride': ['NotSet', ""Both alprazolam and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both alprazolam and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Apraclonidine': ['NotSet', ""Both alprazolam and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aprepitant': ['Severe', 'Aprepitant is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Aripiprazole': ['NotSet', ""Both alprazolam and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both alprazolam and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both alprazolam and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Atazanavir': ['Moderate', 'Atazanavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Baclofen': ['NotSet', ""Both alprazolam and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Benperidol': ['NotSet', ""Both alprazolam and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Brimonidine': ['NotSet', ""Both alprazolam and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buclizine': ['NotSet', ""Both alprazolam and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupivacaine': ['NotSet', ""Both alprazolam and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both alprazolam and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cannabidiol': ['NotSet', ""Both alprazolam and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Cariprazine': ['NotSet', ""Both alprazolam and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chloral hydrate': ['NotSet', ""Both alprazolam and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both alprazolam and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorphenamine': ['NotSet', ""Both alprazolam and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both alprazolam and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cinnarizine': ['NotSet', ""Both alprazolam and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clarithromycin': ['Moderate', 'Clarithromycin moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clemastine': ['NotSet', ""Both alprazolam and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both alprazolam and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both alprazolam and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both alprazolam and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both alprazolam and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both alprazolam and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both alprazolam and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cobicistat': ['Moderate', 'Cobicistat moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Codeine': ['NotSet', ""Both alprazolam and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Crizotinib': ['Severe', 'Crizotinib is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Cyclizine': ['NotSet', ""Both alprazolam and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both alprazolam and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Darunavir': ['Moderate', 'Darunavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Desflurane': ['NotSet', ""Both alprazolam and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both alprazolam and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both alprazolam and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both alprazolam and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dihydrocodeine': ['NotSet', ""Both alprazolam and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diltiazem': ['Severe', 'Diltiazem is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Dipipanone': ['NotSet', ""Both alprazolam and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dosulepin': ['NotSet', ""Both alprazolam and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxepin': ['NotSet', ""Both alprazolam and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both alprazolam and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronedarone': ['Severe', 'Dronedarone is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Droperidol': ['NotSet', ""Both alprazolam and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Enzalutamide': ['Moderate', 'Enzalutamide is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Erythromycin': ['Severe', 'Erythromycin is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Esketamine': ['NotSet', ""Both alprazolam and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Etomidate': ['NotSet', ""Both alprazolam and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fentanyl': ['NotSet', ""Both alprazolam and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluconazole': ['Severe', 'Fluconazole is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Flupentixol': ['NotSet', ""Both alprazolam and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both alprazolam and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both alprazolam and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluvoxamine': ['Moderate', 'Fluvoxamine moderately increases the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosaprepitant': ['Moderate', 'Fosaprepitant is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gabapentin': ['NotSet', ""Both alprazolam and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Guanfacine': ['NotSet', ""Both alprazolam and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both alprazolam and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydromorphone': ['NotSet', ""Both alprazolam and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both alprazolam and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Idelalisib': ['Moderate', 'Idelalisib moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imatinib': ['Severe', 'Imatinib is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Imipramine': ['NotSet', ""Both alprazolam and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isavuconazole': ['Severe', 'Isavuconazole is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Isoflurane': ['NotSet', ""Both alprazolam and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Itraconazole': ['Moderate', 'Itraconazole moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketamine': ['NotSet', ""Both alprazolam and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketoconazole': ['Moderate', 'Ketoconazole moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketotifen': ['NotSet', ""Both alprazolam and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lamotrigine': ['NotSet', ""Both alprazolam and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levetiracetam': ['NotSet', ""Both alprazolam and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levomepromazine': ['NotSet', ""Both alprazolam and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both alprazolam and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofepramine': ['NotSet', ""Both alprazolam and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both alprazolam and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lomitapide': ['Moderate', 'Alprazolam is predicted to increase the exposure to lomitapide. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lopinavir': ['Moderate', 'Lopinavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Loprazolam': ['NotSet', ""Both alprazolam and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both alprazolam and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both alprazolam and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loxapine': ['NotSet', ""Both alprazolam and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both alprazolam and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both alprazolam and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both alprazolam and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both alprazolam and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both alprazolam and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both alprazolam and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both alprazolam and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both alprazolam and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mianserin': ['NotSet', ""Both alprazolam and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Miconazole': ['Moderate', 'Miconazole is predicted to increase the exposure to alprazolam. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Midazolam': ['NotSet', ""Both alprazolam and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mirtazapine': ['NotSet', ""Both alprazolam and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mitotane': ['Moderate', 'Mitotane is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Morphine': ['NotSet', ""Both alprazolam and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxonidine': ['NotSet', ""Both alprazolam and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both alprazolam and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Netupitant': ['Severe', 'Netupitant is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nilotinib': ['Severe', 'Nilotinib is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nitrazepam': ['NotSet', ""Both alprazolam and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrous oxide': ['NotSet', ""Both alprazolam and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both alprazolam and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both alprazolam and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxazepam': ['NotSet', ""Both alprazolam and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both alprazolam and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both alprazolam and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pentazocine': ['NotSet', ""Both alprazolam and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both alprazolam and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pericyazine': ['NotSet', ""Both alprazolam and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pethidine': ['NotSet', ""Both alprazolam and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenobarbital': ['NotSet', ""Both alprazolam and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Phenobarbital is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pimozide': ['NotSet', ""Both alprazolam and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pizotifen': ['NotSet', ""Both alprazolam and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Posaconazole': ['Severe', 'Posaconazole is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Pregabalin': ['NotSet', ""Both alprazolam and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both alprazolam and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both alprazolam and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Primidone is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Prochlorperazine': ['NotSet', ""Both alprazolam and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both alprazolam and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both alprazolam and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both alprazolam and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quetiapine': ['NotSet', ""Both alprazolam and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Remifentanil': ['NotSet', ""Both alprazolam and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to decrease the exposure to alprazolam. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Risperidone': ['NotSet', ""Both alprazolam and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ritonavir': ['Moderate', 'Ritonavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ropivacaine': ['NotSet', ""Both alprazolam and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Saquinavir': ['Moderate', 'Saquinavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sevoflurane': ['NotSet', ""Both alprazolam and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sodium oxybate': ['NotSet', ""Both alprazolam and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], ""St John's Wort"": ['Moderate', ""St John's Wort moderately decreases the exposure to alprazolam. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Sufentanil': ['NotSet', ""Both alprazolam and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both alprazolam and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tapentadol': ['NotSet', ""Both alprazolam and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Temazepam': ['NotSet', ""Both alprazolam and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tetracaine': ['NotSet', ""Both alprazolam and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both alprazolam and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both alprazolam and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tipranavir': ['Moderate', 'Tipranavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tizanidine': ['NotSet', ""Both alprazolam and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tocilizumab': ['Moderate', 'Tocilizumab is predicted to decrease the exposure to alprazolam. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tramadol': ['NotSet', ""Both alprazolam and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trazodone': ['NotSet', ""Both alprazolam and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both alprazolam and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both alprazolam and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Venlafaxine': ['NotSet', ""Both alprazolam and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['Severe', 'Verapamil is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Voriconazole': ['Moderate', 'Voriconazole moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Zolpidem': ['NotSet', ""Both alprazolam and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both alprazolam and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","alprostadil","{'Acebutolol': ['NotSet', 'Both alprostadil and acebutolol can increase the risk of hypotension.'], 'Alcohol (beverage)': ['NotSet', 'Both alprostadil and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both alprostadil and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both alprostadil and aliskiren can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both alprostadil and amantadine can increase the risk of hypotension.'], 'Amitriptyline': ['NotSet', 'Both alprostadil and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both alprostadil and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both alprostadil and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both alprostadil and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both alprostadil and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both alprostadil and asenapine can increase the risk of hypotension.'], 'Atenolol': ['NotSet', 'Both alprostadil and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both alprostadil and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both alprostadil and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both alprostadil and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both alprostadil and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both alprostadil and benperidol can increase the risk of hypotension.'], 'Betaxolol': ['NotSet', 'Both alprostadil and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both alprostadil and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both alprostadil and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both alprostadil and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both alprostadil and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both alprostadil and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both alprostadil and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both alprostadil and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both alprostadil and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both alprostadil and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', 'Both alprostadil and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both alprostadil and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both alprostadil and celiprolol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both alprostadil and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both alprostadil and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both alprostadil and chlortalidone can increase the risk of hypotension.'], 'Clomipramine': ['NotSet', 'Both alprostadil and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both alprostadil and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both alprostadil and clozapine can increase the risk of hypotension.'], 'Dapagliflozin': ['NotSet', 'Both alprostadil and dapagliflozin can increase the risk of hypotension.'], 'Desflurane': ['NotSet', 'Both alprostadil and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both alprostadil and diazoxide can increase the risk of hypotension.'], 'Diltiazem': ['NotSet', 'Both alprostadil and diltiazem can increase the risk of hypotension.'], 'Dipyridamole': ['NotSet', 'Both alprostadil and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', 'Both alprostadil and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both alprostadil and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both alprostadil and doxepin can increase the risk of hypotension.'], 'Droperidol': ['NotSet', 'Both alprostadil and droperidol can increase the risk of hypotension.'], 'Empagliflozin': ['NotSet', 'Both alprostadil and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both alprostadil and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both alprostadil and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both alprostadil and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both alprostadil and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', 'Both alprostadil and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both alprostadil and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both alprostadil and etomidate can increase the risk of hypotension.'], 'Felodipine': ['NotSet', 'Both alprostadil and felodipine can increase the risk of hypotension.'], 'Flupentixol': ['NotSet', 'Both alprostadil and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both alprostadil and fluphenazine can increase the risk of hypotension.'], 'Fosinopril': ['NotSet', 'Both alprostadil and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both alprostadil and furosemide can increase the risk of hypotension.'], 'Glyceryl trinitrate': ['NotSet', 'Both alprostadil and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both alprostadil and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both alprostadil and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both alprostadil and haloperidol can increase the risk of hypotension.'], 'Hydralazine': ['NotSet', 'Both alprostadil and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both alprostadil and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both alprostadil and hydroflumethiazide can increase the risk of hypotension.'], 'Imidapril': ['NotSet', 'Both alprostadil and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both alprostadil and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both alprostadil and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both alprostadil and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both alprostadil and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both alprostadil and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both alprostadil and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both alprostadil and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both alprostadil and isosorbide mononitrate can increase the risk of hypotension.'], 'Ketamine': ['NotSet', 'Both alprostadil and ketamine can increase the risk of hypotension.'], 'Labetalol': ['NotSet', 'Both alprostadil and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both alprostadil and lacidipine can increase the risk of hypotension.'], 'Lercanidipine': ['NotSet', 'Both alprostadil and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both alprostadil and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both alprostadil and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both alprostadil and levomepromazine can increase the risk of hypotension.'], 'Lisinopril': ['NotSet', 'Both alprostadil and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both alprostadil and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both alprostadil and lofexidine can increase the risk of hypotension.'], 'Losartan': ['NotSet', 'Both alprostadil and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both alprostadil and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both alprostadil and lurasidone can increase the risk of hypotension.'], 'Methoxyflurane': ['NotSet', 'Both alprostadil and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both alprostadil and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both alprostadil and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both alprostadil and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both alprostadil and minoxidil can increase the risk of hypotension.'], 'Moxisylyte': ['NotSet', 'Both alprostadil and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both alprostadil and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both alprostadil and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both alprostadil and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both alprostadil and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both alprostadil and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both alprostadil and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both alprostadil and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both alprostadil and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both alprostadil and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both alprostadil and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both alprostadil and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both alprostadil and olmesartan can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both alprostadil and paliperidone can increase the risk of hypotension.'], 'Pergolide': ['NotSet', 'Both alprostadil and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both alprostadil and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both alprostadil and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both alprostadil and phenelzine can increase the risk of hypotension.'], 'Pimozide': ['NotSet', 'Both alprostadil and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both alprostadil and pindolol can increase the risk of hypotension.'], 'Pramipexole': ['NotSet', 'Both alprostadil and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both alprostadil and prazosin can increase the risk of hypotension.'], 'Prochlorperazine': ['NotSet', 'Both alprostadil and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both alprostadil and promazine can increase the risk of hypotension.'], 'Propofol': ['NotSet', 'Both alprostadil and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both alprostadil and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both alprostadil and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both alprostadil and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both alprostadil and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both alprostadil and ramipril can increase the risk of hypotension.'], 'Riociguat': ['NotSet', 'Both alprostadil and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both alprostadil and risperidone can increase the risk of hypotension.'], 'Ropinirole': ['NotSet', 'Both alprostadil and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both alprostadil and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both alprostadil and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both alprostadil and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both alprostadil and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both alprostadil and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both alprostadil and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both alprostadil and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both alprostadil and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both alprostadil and spironolactone can increase the risk of hypotension.'], 'Sulpiride': ['NotSet', 'Both alprostadil and sulpiride can increase the risk of hypotension.'], 'Tadalafil': ['NotSet', 'Both alprostadil and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both alprostadil and tamsulosin can increase the risk of hypotension.'], 'Telmisartan': ['NotSet', 'Both alprostadil and telmisartan can increase the risk of hypotension.'], 'Terazosin': ['NotSet', 'Both alprostadil and terazosin can increase the risk of hypotension.'], 'Thiopental': ['NotSet', 'Both alprostadil and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both alprostadil and timolol can increase the risk of hypotension.'], 'Tizanidine': ['NotSet', 'Both alprostadil and tizanidine can increase the risk of hypotension.'], 'Torasemide': ['NotSet', 'Both alprostadil and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both alprostadil and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both alprostadil and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both alprostadil and trifluoperazine can increase the risk of hypotension.'], 'Trimipramine': ['NotSet', 'Both alprostadil and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both alprostadil and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both alprostadil and vardenafil can increase the risk of hypotension.'], 'Verapamil': ['NotSet', 'Both alprostadil and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both alprostadil and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both alprostadil and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both alprostadil and zuclopenthixol can increase the risk of hypotension.']}","alteplase","{'Aceclofenac': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Acenocoumarol': ['NotSet', 'Both alteplase and acenocoumarol can increase the risk of bleeding.'], 'Anagrelide': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apixaban': ['NotSet', 'Both alteplase and apixaban can increase the risk of bleeding.'], 'Argatroban': ['NotSet', 'Both alteplase and argatroban can increase the risk of bleeding.'], 'Aspirin': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bevacizumab': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with bevacizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bivalirudin': ['NotSet', 'Both alteplase and bivalirudin can increase the risk of bleeding.'], 'Cangrelor': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with cangrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Celecoxib': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with celecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cilostazol': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with cilostazol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with citalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clopidogrel': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with clopidogrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dabigatran': ['NotSet', 'Both alteplase and dabigatran can increase the risk of bleeding.'], 'Dalteparin': ['NotSet', 'Both alteplase and dalteparin can increase the risk of bleeding.'], 'Danaparoid': ['NotSet', 'Both alteplase and danaparoid can increase the risk of bleeding.'], 'Dapoxetine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with dapoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dasatinib': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with dasatinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with dexibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexketoprofen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with dexketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Diclofenac': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with diclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dipyridamole': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with dipyridamole. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Duloxetine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with duloxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Edoxaban': ['NotSet', 'Both alteplase and edoxaban can increase the risk of bleeding.'], 'Enoxaparin': ['NotSet', 'Both alteplase and enoxaparin can increase the risk of bleeding.'], 'Epoprostenol': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with epoprostenol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eptifibatide': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with eptifibatide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Escitalopram': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with escitalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etodolac': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with etodolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etoricoxib': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with etoricoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluoxetine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with fluoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flurbiprofen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with flurbiprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluvoxamine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with fluvoxamine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fondaparinux': ['NotSet', 'Both alteplase and fondaparinux can increase the risk of bleeding.'], 'Heparin (unfractionated)': ['NotSet', 'Both alteplase and heparin (unfractionated) can increase the risk of bleeding.'], 'Ibrutinib': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with ibrutinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibuprofen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with ibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Iloprost': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with iloprost. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indometacin': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with indometacin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotersen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with inotersen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketoprofen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with ketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketorolac': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with ketorolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mefenamic acid': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with mefenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Meloxicam': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with meloxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nabumetone': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with nabumetone. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Naproxen': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with naproxen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nicotinic acid': ['NotSet', 'Both alteplase and nicotinic acid can increase the risk of bleeding.'], 'Omega-3-acid ethyl esters': ['NotSet', 'Both alteplase and omega-3-acid ethyl esters can increase the risk of bleeding.'], 'Parecoxib': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with parecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paroxetine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with paroxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenindione': ['NotSet', 'Both alteplase and phenindione can increase the risk of bleeding.'], 'Piroxicam': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with piroxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prasugrel': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with prasugrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Regorafenib': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with regorafenib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rivaroxaban': ['NotSet', 'Both alteplase and rivaroxaban can increase the risk of bleeding.'], 'Sertraline': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with sertraline. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Streptokinase': ['NotSet', 'Both alteplase and streptokinase can increase the risk of bleeding.'], 'Sulindac': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with sulindac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenecteplase': ['NotSet', 'Both alteplase and tenecteplase can increase the risk of bleeding.'], 'Tenoxicam': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with tenoxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tiaprofenic acid': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with tiaprofenic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticagrelor': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with ticagrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tinzaparin': ['NotSet', 'Both alteplase and tinzaparin can increase the risk of bleeding.'], 'Tirofiban': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with tirofiban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tolfenamic acid': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with tolfenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trastuzumab emtansine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with trastuzumab emtansine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Urokinase': ['NotSet', 'Both alteplase and urokinase can increase the risk of bleeding.'], 'Venlafaxine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with venlafaxine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with alteplase. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vortioxetine': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with vortioxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Warfarin': ['NotSet', 'Both alteplase and warfarin can increase the risk of bleeding.']}","aluminium-hydroxi","{'Alendronate': ['Moderate', 'Aluminium hydroxide decreases the absorption of alendronate. Manufacturer advises alendronate should be taken at least 30 minutes before antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aspirin': ['Moderate', 'Aluminium hydroxide decreases the absorption of aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atazanavir': ['Severe', 'Aluminium hydroxide is predicted to decrease the absorption of atazanavir. Manufacturer advises atazanavir should be taken 2 hours before or 1 hour after antacids. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bictegravir': ['Moderate', 'Aluminium hydroxide decreases the exposure to bictegravir. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bosutinib': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of bosutinib. Manufacturer advises bosutinib should be taken at least 12 hours before antacids. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ceritinib': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of ceritinib. Manufacturer advises separate administration by 2 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chenodeoxycholic acid': ['Moderate', 'Oral aluminium hydroxide decreases the absorption of chenodeoxycholic acid. Manufacturer advises separating administration. Severity of interaction: Moderate Evidence for interaction: Study'], 'Chloroquine': ['Moderate', 'Aluminium hydroxide decreases the absorption of chloroquine. Manufacturer advises separate administration by at least 4 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Chlorpromazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of chlorpromazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Cholic acid': ['Mild', 'Aluminium hydroxide is predicted to decrease the absorption of cholic acid. Manufacturer advises separate administration by 5 hours. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Ciprofloxacin': ['Moderate', 'Aluminium hydroxide decreases the absorption of ciprofloxacin. Manufacturer advises ciprofloxacin should be taken 2 hours before or 4 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clodronate': ['Moderate', 'Aluminium hydroxide decreases the absorption of clodronate. Manufacturer advises avoid antacids for 2 hours before or 1 hour after clodronate. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dasatinib': ['Moderate', 'Aluminium hydroxide decreases the absorption of dasatinib. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Deferasirox': ['Moderate', 'Aluminium hydroxide is predicted to decrease the exposure to deferasirox. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Deferiprone': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of deferiprone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Deflazacort': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of deflazacort. Manufacturer advises separate administration by 2 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Demeclocycline': ['Moderate', 'Aluminium hydroxide decreases the absorption of demeclocycline. Manufacturer advises separate administration by 2 to 3 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dexamethasone': ['Moderate', 'Aluminium hydroxide decreases the absorption of dexamethasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Digoxin': ['Mild', 'Aluminium hydroxide decreases the absorption of digoxin. Manufacturer advises separate administration by 2 hours. Severity of interaction: Mild Evidence for interaction: Study'], 'Dipyridamole': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of dipyridamole (immediate release tablets). Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Dolutegravir': ['Moderate', 'Aluminium hydroxide moderately decreases the exposure to dolutegravir. Manufacturer advises dolutegravir should be taken 2 hours before or 6 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Doxycycline': ['Moderate', 'Aluminium hydroxide decreases the absorption of doxycycline. Manufacturer advises separate administration by 2 to 3 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eltrombopag': ['Severe', 'Aluminium hydroxide decreases the absorption of eltrombopag. Manufacturer advises eltrombopag should be taken 2 hours before or 4 hours after antacids. Severity of interaction: Severe Evidence for interaction: Study'], 'Elvitegravir': ['Moderate', 'Aluminium hydroxide moderately decreases the exposure to elvitegravir. Manufacturer advises separate administration by at least 4 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Enteral feeds': ['Moderate', 'Aluminium hydroxide increases the risk of blocked enteral or nasogastric tubes when given with enteral feeds. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Erlotinib': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of erlotinib. Manufacturer advises erlotinib should be taken 2 hours before or 4 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Estramustine': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of estramustine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ferric maltol': ['Moderate', 'Aluminium hydroxide decreases the absorption of ferric maltol. Manufacturer advises ferric maltol should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ferrous fumarate': ['Moderate', 'Aluminium hydroxide decreases the absorption of ferrous fumarate. Manufacturer advises ferrous fumarate should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ferrous gluconate': ['Moderate', 'Aluminium hydroxide decreases the absorption of ferrous gluconate. Manufacturer advises ferrous gluconate should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ferrous sulfate': ['Moderate', 'Aluminium hydroxide decreases the absorption of ferrous sulfate. Manufacturer advises ferrous sulfate should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fexofenadine': ['Mild', 'Aluminium hydroxide decreases the absorption of fexofenadine. Manufacturer advises separate administration by 2 hours. Severity of interaction: Mild Evidence for interaction: Study'], 'Fluphenazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of fluphenazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Gabapentin': ['Moderate', 'Aluminium hydroxide decreases the absorption of gabapentin. Manufacturer advises gabapentin should be taken 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Gefitinib': ['Moderate', 'Aluminium hydroxide is predicted to slightly decrease the exposure to gefitinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gemfibrozil': ['Moderate', 'Aluminium hydroxide slightly to moderately decreases the exposure to gemfibrozil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Hydroxychloroquine': ['Moderate', 'Aluminium hydroxide decreases the absorption of hydroxychloroquine. Manufacturer advises separate administration by at least 4 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ibandronate': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of ibandronate. Manufacturer advises avoid antacids for at least 6 hours before or 1 hour after ibandronate. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Itraconazole': ['Moderate', 'Aluminium hydroxide decreases the absorption of itraconazole (capsule). Manufacturer advises itraconazole should be taken 2 hours before or 1 hour after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketoconazole': ['Moderate', 'Aluminium hydroxide decreases the absorption of ketoconazole. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lapatinib': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of lapatinib. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ledipasvir': ['Moderate', 'Aluminium hydroxide is predicted to decrease the exposure to ledipasvir. Manufacturer advises separate administration by 4 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levofloxacin': ['Moderate', 'Aluminium hydroxide decreases the absorption of levofloxacin. Manufacturer advises levofloxacin should be taken 2 hours before or 4 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Levomepromazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of levomepromazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Levothyroxine': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of levothyroxine. Manufacturer advises separate administration by at least 4 hours. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Lymecycline': ['Moderate', 'Aluminium hydroxide decreases the absorption of lymecycline. Manufacturer advises separate administration by 2 to 3 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Minocycline': ['Moderate', 'Aluminium hydroxide decreases the absorption of minocycline. Manufacturer advises separate administration by 2 to 3 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Moxifloxacin': ['Moderate', 'Aluminium hydroxide decreases the absorption of moxifloxacin. Manufacturer advises moxifloxacin should be taken 2 hours before or 4 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mycophenolate': ['Moderate', 'Aluminium hydroxide decreases the exposure to mycophenolate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nilotinib': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of nilotinib. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ofloxacin': ['Moderate', 'Aluminium hydroxide decreases the absorption of ofloxacin. Manufacturer advises ofloxacin should be taken 2 hours before or 4 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Oxytetracycline': ['Moderate', 'Aluminium hydroxide decreases the absorption of oxytetracycline. Manufacturer advises separate administration by 2 to 3 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pazopanib': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of pazopanib. Manufacturer advises pazopanib should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Penicillamine': ['Mild', 'Aluminium hydroxide decreases the absorption of penicillamine. Manufacturer advises separate administration by 2 hours. Severity of interaction: Mild Evidence for interaction: Study'], 'Pericyazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of pericyazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Polystyrene sulfonate': ['Severe', 'Aluminium hydroxide increases the risk of metabolic alkalosis when given with polystyrene sulfonate. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Prochlorperazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of prochlorperazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Proguanil': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of proguanil. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Promazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of promazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Raltegravir': ['Moderate', 'Aluminium hydroxide slightly decreases the exposure to raltegravir. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifampicin': ['Moderate', 'Aluminium hydroxide decreases the absorption of rifampicin. Manufacturer advises rifampicin should be taken 1 hour before antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rilpivirine': ['Severe', 'Aluminium hydroxide is predicted to decrease the exposure to rilpivirine. Manufacturer advises rilpivirine should be taken 4 hours before or 2 hours after antacids. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Riociguat': ['Mild', 'Aluminium hydroxide slightly decreases the exposure to riociguat. Manufacturer advises riociguat should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Mild Evidence for interaction: Study'], 'Risedronate': ['Moderate', 'Aluminium hydroxide decreases the absorption of risedronate. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rosuvastatin': ['Moderate', 'Aluminium hydroxide moderately decreases the absorption of rosuvastatin. Manufacturer advises separate administration by 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sodium feredetate': ['Moderate', 'Aluminium hydroxide decreases the absorption of sodium feredetate. Manufacturer advises sodium feredetate should be taken 1 hour before or 2 hours after antacids. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sulpiride': ['Moderate', 'Aluminium hydroxide decreases the absorption of sulpiride. Manufacturer advises separate administration by 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tetracycline': ['Moderate', 'Aluminium hydroxide decreases the absorption of tetracycline. Manufacturer advises separate administration by 2 to 3 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tipranavir': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of tipranavir. Manufacturer advises separate administration by 2 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Trifluoperazine': ['Moderate', 'Aluminium hydroxide decreases the absorption of trifluoperazine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ursodeoxycholic acid': ['Moderate', 'Aluminium hydroxide is predicted to decrease the absorption of ursodeoxycholic acid. Manufacturer advises separate administration by 2 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Velpatasvir': ['Moderate', 'Aluminium hydroxide is predicted to decrease the concentration of velpatasvir. Manufacturer advises separate administration by 4 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","amantadi","{'Acebutolol': ['NotSet', 'Both amantadine and acebutolol can increase the risk of hypotension.'], 'Aclidinium': ['NotSet', 'Both amantadine and aclidinium can cause antimuscarinic effects.'], 'Alcohol (beverage)': ['NotSet', 'Both amantadine and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both amantadine and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both amantadine and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both amantadine and alprostadil can increase the risk of hypotension.'], 'Amisulpride': ['Moderate', 'Amisulpride is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amitriptyline': ['NotSet', 'Both amantadine and amitriptyline can increase the risk of hypotension. Both amantadine and amitriptyline can cause antimuscarinic effects.'], 'Amlodipine': ['NotSet', 'Both amantadine and amlodipine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both amantadine and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both amantadine and aripiprazole can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of amantadine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Asenapine': ['NotSet', 'Both amantadine and asenapine can increase the risk of hypotension. Asenapine is predicted to decrease the effects of amantadine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Atenolol': ['NotSet', 'Both amantadine and atenolol can increase the risk of hypotension.'], 'Atropine': ['NotSet', 'Both amantadine and atropine can cause antimuscarinic effects.'], 'Avanafil': ['NotSet', 'Both amantadine and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both amantadine and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both amantadine and baclofen can increase the risk of hypotension. Both amantadine and baclofen can cause antimuscarinic effects.'], 'Bendroflumethiazide': ['NotSet', 'Both amantadine and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both amantadine and benperidol can increase the risk of hypotension. Benperidol is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Betaxolol': ['NotSet', 'Both amantadine and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both amantadine and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both amantadine and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both amantadine and brimonidine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both amantadine and bumetanide can increase the risk of hypotension.'], 'Bupropion': ['Moderate', 'Bupropion increases the risk of side-effects when given with amantadine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Canagliflozin': ['NotSet', 'Both amantadine and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both amantadine and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both amantadine and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', 'Both amantadine and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both amantadine and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both amantadine and celiprolol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both amantadine and chlorothiazide can increase the risk of hypotension.'], 'Chlorphenamine': ['NotSet', 'Both amantadine and chlorphenamine can cause antimuscarinic effects.'], 'Chlorpromazine': ['NotSet', 'Both amantadine and chlorpromazine can increase the risk of hypotension. Both amantadine and chlorpromazine can cause antimuscarinic effects. Chlorpromazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chlortalidone': ['NotSet', 'Both amantadine and chlortalidone can increase the risk of hypotension.'], 'Clemastine': ['NotSet', 'Both amantadine and clemastine can cause antimuscarinic effects.'], 'Clomipramine': ['NotSet', 'Both amantadine and clomipramine can increase the risk of hypotension. Both amantadine and clomipramine can cause antimuscarinic effects.'], 'Clonidine': ['NotSet', 'Both amantadine and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both amantadine and clozapine can increase the risk of hypotension. Both amantadine and clozapine can cause antimuscarinic effects. Clozapine is predicted to decrease the effects of amantadine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Cyclizine': ['NotSet', 'Both amantadine and cyclizine can cause antimuscarinic effects.'], 'Cyclopentolate': ['NotSet', 'Both amantadine and cyclopentolate can cause antimuscarinic effects.'], 'Cyproheptadine': ['NotSet', 'Both amantadine and cyproheptadine can cause antimuscarinic effects.'], 'Dapagliflozin': ['NotSet', 'Both amantadine and dapagliflozin can increase the risk of hypotension.'], 'Darifenacin': ['NotSet', 'Both amantadine and darifenacin can cause antimuscarinic effects.'], 'Desflurane': ['NotSet', 'Both amantadine and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both amantadine and diazoxide can increase the risk of hypotension.'], 'Dicycloverine': ['NotSet', 'Both amantadine and dicycloverine can cause antimuscarinic effects.'], 'Diltiazem': ['NotSet', 'Both amantadine and diltiazem can increase the risk of hypotension.'], 'Dimenhydrinate': ['NotSet', 'Both amantadine and dimenhydrinate can cause antimuscarinic effects.'], 'Dipyridamole': ['NotSet', 'Both amantadine and dipyridamole can increase the risk of hypotension.'], 'Disopyramide': ['NotSet', 'Both amantadine and disopyramide can cause antimuscarinic effects.'], 'Dosulepin': ['NotSet', 'Both amantadine and dosulepin can increase the risk of hypotension. Both amantadine and dosulepin can cause antimuscarinic effects.'], 'Doxazosin': ['NotSet', 'Both amantadine and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both amantadine and doxepin can increase the risk of hypotension. Both amantadine and doxepin can cause antimuscarinic effects.'], 'Droperidol': ['NotSet', 'Both amantadine and droperidol can increase the risk of hypotension. Droperidol is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Empagliflozin': ['NotSet', 'Both amantadine and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both amantadine and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both amantadine and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both amantadine and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both amantadine and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', 'Both amantadine and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both amantadine and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both amantadine and etomidate can increase the risk of hypotension.'], 'Felodipine': ['NotSet', 'Both amantadine and felodipine can increase the risk of hypotension.'], 'Fesoterodine': ['NotSet', 'Both amantadine and fesoterodine can cause antimuscarinic effects.'], 'Flavoxate': ['NotSet', 'Both amantadine and flavoxate can cause antimuscarinic effects.'], 'Flupentixol': ['NotSet', 'Both amantadine and flupentixol can increase the risk of hypotension. Flupentixol is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fluphenazine': ['NotSet', 'Both amantadine and fluphenazine can increase the risk of hypotension. Fluphenazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fosinopril': ['NotSet', 'Both amantadine and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both amantadine and furosemide can increase the risk of hypotension.'], 'Glyceryl trinitrate': ['NotSet', 'Both amantadine and glyceryl trinitrate can increase the risk of hypotension.'], 'Glycopyrronium': ['NotSet', 'Both amantadine and glycopyrronium can cause antimuscarinic effects.'], 'Guanethidine': ['NotSet', 'Both amantadine and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both amantadine and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both amantadine and haloperidol can increase the risk of hypotension. Both amantadine and haloperidol can cause antimuscarinic effects. Haloperidol is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Homatropine': ['NotSet', 'Both amantadine and homatropine can cause antimuscarinic effects.'], 'Hydralazine': ['NotSet', 'Both amantadine and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both amantadine and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both amantadine and hydroflumethiazide can increase the risk of hypotension.'], 'Hydroxyzine': ['NotSet', 'Both amantadine and hydroxyzine can cause antimuscarinic effects.'], 'Hyoscine': ['NotSet', 'Both amantadine and hyoscine can cause antimuscarinic effects.'], 'Imidapril': ['NotSet', 'Both amantadine and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both amantadine and imipramine can increase the risk of hypotension. Both amantadine and imipramine can cause antimuscarinic effects.'], 'Indapamide': ['NotSet', 'Both amantadine and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both amantadine and indoramin can increase the risk of hypotension.'], 'Ipratropium': ['NotSet', 'Both amantadine and ipratropium can cause antimuscarinic effects.'], 'Irbesartan': ['NotSet', 'Both amantadine and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both amantadine and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both amantadine and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both amantadine and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both amantadine and isosorbide mononitrate can increase the risk of hypotension.'], 'Ketamine': ['NotSet', 'Both amantadine and ketamine can increase the risk of hypotension.'], 'Labetalol': ['NotSet', 'Both amantadine and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both amantadine and lacidipine can increase the risk of hypotension.'], 'Lercanidipine': ['NotSet', 'Both amantadine and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both amantadine and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both amantadine and levodopa can increase the risk of hypotension. Amantadine decreases the absorption of levodopa. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levomepromazine': ['NotSet', 'Both amantadine and levomepromazine can increase the risk of hypotension. Both amantadine and levomepromazine can cause antimuscarinic effects. Levomepromazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lisinopril': ['NotSet', 'Both amantadine and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both amantadine and lofepramine can increase the risk of hypotension. Both amantadine and lofepramine can cause antimuscarinic effects.'], 'Lofexidine': ['NotSet', 'Both amantadine and lofexidine can increase the risk of hypotension.'], 'Losartan': ['NotSet', 'Both amantadine and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both amantadine and loxapine can increase the risk of hypotension. Both amantadine and loxapine can cause antimuscarinic effects. Loxapine is predicted to decrease the effects of amantadine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lurasidone': ['NotSet', 'Both amantadine and lurasidone can increase the risk of hypotension.'], 'Memantine': ['Severe', 'Amantadine increases the risk of CNS toxicity when given with memantine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methoxyflurane': ['NotSet', 'Both amantadine and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both amantadine and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both amantadine and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both amantadine and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both amantadine and minoxidil can increase the risk of hypotension.'], 'Moxisylyte': ['NotSet', 'Both amantadine and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both amantadine and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both amantadine and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both amantadine and nebivolol can increase the risk of hypotension.'], 'Nefopam': ['NotSet', 'Both amantadine and nefopam can cause antimuscarinic effects.'], 'Nicardipine': ['NotSet', 'Both amantadine and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both amantadine and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both amantadine and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both amantadine and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both amantadine and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both amantadine and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both amantadine and nortriptyline can increase the risk of hypotension. Both amantadine and nortriptyline can cause antimuscarinic effects.'], 'Olanzapine': ['NotSet', 'Both amantadine and olanzapine can increase the risk of hypotension. Olanzapine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Olmesartan': ['NotSet', 'Both amantadine and olmesartan can increase the risk of hypotension.'], 'Orphenadrine': ['NotSet', 'Both amantadine and orphenadrine can cause antimuscarinic effects.'], 'Oxybutynin': ['NotSet', 'Both amantadine and oxybutynin can cause antimuscarinic effects.'], 'Paliperidone': ['NotSet', 'Both amantadine and paliperidone can increase the risk of hypotension. Paliperidone is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pericyazine': ['NotSet', 'Both amantadine and pericyazine can increase the risk of hypotension. Pericyazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Perindopril': ['NotSet', 'Both amantadine and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both amantadine and phenelzine can increase the risk of hypotension.'], 'Pimozide': ['NotSet', 'Both amantadine and pimozide can increase the risk of hypotension. Both amantadine and pimozide can cause antimuscarinic effects. Pimozide is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pindolol': ['NotSet', 'Both amantadine and pindolol can increase the risk of hypotension.'], 'Pramipexole': ['Moderate', 'Amantadine is predicted to increase the exposure to pramipexole. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Prazosin': ['NotSet', 'Both amantadine and prazosin can increase the risk of hypotension.'], 'Prochlorperazine': ['NotSet', 'Both amantadine and prochlorperazine can increase the risk of hypotension. Both amantadine and prochlorperazine can cause antimuscarinic effects. Prochlorperazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Procyclidine': ['NotSet', 'Both amantadine and procyclidine can cause antimuscarinic effects.'], 'Promazine': ['NotSet', 'Both amantadine and promazine can increase the risk of hypotension. Promazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Promethazine': ['NotSet', 'Both amantadine and promethazine can cause antimuscarinic effects.'], 'Propafenone': ['NotSet', 'Both amantadine and propafenone can cause antimuscarinic effects.'], 'Propantheline': ['NotSet', 'Both amantadine and propantheline can cause antimuscarinic effects.'], 'Propiverine': ['NotSet', 'Both amantadine and propiverine can cause antimuscarinic effects.'], 'Propofol': ['NotSet', 'Both amantadine and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both amantadine and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both amantadine and quetiapine can increase the risk of hypotension. Quetiapine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quinapril': ['NotSet', 'Both amantadine and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both amantadine and ramipril can increase the risk of hypotension.'], 'Riociguat': ['NotSet', 'Both amantadine and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both amantadine and risperidone can increase the risk of hypotension. Risperidone is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sacubitril': ['NotSet', 'Both amantadine and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both amantadine and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both amantadine and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both amantadine and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both amantadine and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both amantadine and sodium oxybate can increase the risk of hypotension.'], 'Solifenacin': ['NotSet', 'Both amantadine and solifenacin can cause antimuscarinic effects.'], 'Sotalol': ['NotSet', 'Both amantadine and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both amantadine and spironolactone can increase the risk of hypotension.'], 'Sulpiride': ['NotSet', 'Both amantadine and sulpiride can increase the risk of hypotension. Sulpiride is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tadalafil': ['NotSet', 'Both amantadine and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both amantadine and tamsulosin can increase the risk of hypotension.'], 'Telmisartan': ['NotSet', 'Both amantadine and telmisartan can increase the risk of hypotension.'], 'Terazosin': ['NotSet', 'Both amantadine and terazosin can increase the risk of hypotension.'], 'Thiopental': ['NotSet', 'Both amantadine and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both amantadine and timolol can increase the risk of hypotension.'], 'Tiotropium': ['NotSet', 'Both amantadine and tiotropium can cause antimuscarinic effects.'], 'Tizanidine': ['NotSet', 'Both amantadine and tizanidine can increase the risk of hypotension.'], 'Tolterodine': ['NotSet', 'Both amantadine and tolterodine can cause antimuscarinic effects.'], 'Torasemide': ['NotSet', 'Both amantadine and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both amantadine and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both amantadine and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both amantadine and trifluoperazine can increase the risk of hypotension. Both amantadine and trifluoperazine can cause antimuscarinic effects. Trifluoperazine is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Trihexyphenidyl': ['NotSet', 'Both amantadine and trihexyphenidyl can cause antimuscarinic effects.'], 'Trimipramine': ['NotSet', 'Both amantadine and trimipramine can increase the risk of hypotension. Both amantadine and trimipramine can cause antimuscarinic effects.'], 'Tropicamide': ['NotSet', 'Both amantadine and tropicamide can cause antimuscarinic effects.'], 'Trospium': ['NotSet', 'Both amantadine and trospium can cause antimuscarinic effects.'], 'Umeclidinium': ['NotSet', 'Both amantadine and umeclidinium can cause antimuscarinic effects.'], 'Valsartan': ['NotSet', 'Both amantadine and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both amantadine and vardenafil can increase the risk of hypotension.'], 'Verapamil': ['NotSet', 'Both amantadine and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both amantadine and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both amantadine and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both amantadine and zuclopenthixol can increase the risk of hypotension. Zuclopenthixol is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","ambrisentan","{'Ciclosporin': ['Moderate', 'Ciclosporin moderately increases the exposure to ambrisentan. Manufacturer advises adjust ambrisentan dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifampicin': ['Moderate', 'Rifampicin transiently increases the exposure to ambrisentan. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study']}","amifampridine","{'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both amifampridine and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both amifampridine and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both amifampridine and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apalutamide': ['Severe', 'Both amifampridine and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both amifampridine and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Arsenic trioxide': ['Severe', 'Both amifampridine and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both amifampridine and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both amifampridine and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both amifampridine and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Both amifampridine and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cabozantinib': ['Severe', 'Both amifampridine and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ceritinib': ['Severe', 'Both amifampridine and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both amifampridine and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Both amifampridine and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clarithromycin': ['Severe', 'Both amifampridine and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clomipramine': ['Severe', 'Both amifampridine and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Crizotinib': ['Severe', 'Both amifampridine and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dasatinib': ['Severe', 'Both amifampridine and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both amifampridine and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Disopyramide': ['Severe', 'Both amifampridine and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with amifampridine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Severe', 'Both amifampridine and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', 'Both amifampridine and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Efavirenz': ['Severe', 'Both amifampridine and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both amifampridine and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Eribulin': ['Severe', 'Both amifampridine and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both amifampridine and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both amifampridine and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with amifampridine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both amifampridine and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both amifampridine and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluphenazine': ['Severe', 'Both amifampridine and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with amifampridine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Haloperidol': ['Severe', 'Both amifampridine and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both amifampridine and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both amifampridine and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with amifampridine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lapatinib': ['Severe', 'Both amifampridine and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both amifampridine and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levomepromazine': ['Severe', 'Both amifampridine and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lithium': ['Severe', 'Both amifampridine and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both amifampridine and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['Severe', 'Both amifampridine and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with amifampridine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both amifampridine and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nilotinib': ['Severe', 'Both amifampridine and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both amifampridine and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both amifampridine and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Paliperidone': ['Severe', 'Both amifampridine and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with amifampridine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both amifampridine and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both amifampridine and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both amifampridine and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with amifampridine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pimozide': ['Severe', 'Both amifampridine and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Quinine': ['Severe', 'Both amifampridine and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ranolazine': ['Severe', 'Both amifampridine and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ribociclib': ['Severe', 'Both amifampridine and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Risperidone': ['Severe', 'Both amifampridine and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both amifampridine and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sildenafil': ['Severe', 'Both amifampridine and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sorafenib': ['Severe', 'Both amifampridine and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both amifampridine and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sulpiride': ['Severe', 'Both amifampridine and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['Severe', 'Both amifampridine and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telavancin': ['Severe', 'Both amifampridine and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both amifampridine and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tizanidine': ['Severe', 'Both amifampridine and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolterodine': ['Severe', 'Both amifampridine and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both amifampridine and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vandetanib': ['Severe', 'Both amifampridine and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both amifampridine and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both amifampridine and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both amifampridine and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vernakalant': ['Severe', 'Both amifampridine and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both amifampridine and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Voriconazole': ['Severe', 'Both amifampridine and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['Severe', 'Both amifampridine and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","amikacin","{'Aceclofenac': ['NotSet', 'Both amikacin and aceclofenac can increase the risk of nephrotoxicity.'], 'Aciclovir': ['NotSet', 'Both amikacin and aciclovir can increase the risk of nephrotoxicity.'], 'Adefovir': ['NotSet', 'Both amikacin and adefovir can increase the risk of nephrotoxicity.'], 'Agalsidase alfa': ['Moderate', 'Amikacin is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Agalsidase beta': ['Moderate', 'Amikacin is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Alendronate': ['Moderate', 'Amikacin increases the risk of hypocalcaemia when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Amphotericin': ['NotSet', 'Both amikacin and amphotericin can increase the risk of nephrotoxicity.'], 'Ataluren': ['Severe', 'Ataluren is predicted to increase the risk of nephrotoxicity when given with intravenous amikacin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Atracurium': ['NotSet', 'Both amikacin and atracurium have neuromuscular blocking effects.'], 'Bacitracin': ['NotSet', 'Both amikacin and bacitracin can increase the risk of nephrotoxicity.'], 'Botulinum toxin type A': ['NotSet', 'Both amikacin and botulinum toxin type A have neuromuscular blocking effects.'], 'Botulinum toxin type B': ['NotSet', 'Both amikacin and botulinum toxin type B have neuromuscular blocking effects.'], 'Bumetanide': ['NotSet', 'Both amikacin and bumetanide can increase the risk of ototoxicity. Bumetanide increases the risk of nephrotoxicity when given with amikacin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Capreomycin': ['NotSet', 'Both amikacin and capreomycin can increase the risk of nephrotoxicity. Both amikacin and capreomycin can increase the risk of ototoxicity.'], 'Carboplatin': ['NotSet', 'Both amikacin and carboplatin can increase the risk of nephrotoxicity. Both amikacin and carboplatin can increase the risk of ototoxicity.'], 'Cefaclor': ['NotSet', 'Both amikacin and cefaclor can increase the risk of nephrotoxicity.'], 'Cefadroxil': ['NotSet', 'Both amikacin and cefadroxil can increase the risk of nephrotoxicity.'], 'Cefalexin': ['NotSet', 'Both amikacin and cefalexin can increase the risk of nephrotoxicity.'], 'Cefepime': ['NotSet', 'Both amikacin and cefepime can increase the risk of nephrotoxicity.'], 'Cefixime': ['NotSet', 'Both amikacin and cefixime can increase the risk of nephrotoxicity.'], 'Cefotaxime': ['NotSet', 'Both amikacin and cefotaxime can increase the risk of nephrotoxicity.'], 'Cefoxitin': ['NotSet', 'Both amikacin and cefoxitin can increase the risk of nephrotoxicity.'], 'Cefradine': ['NotSet', 'Both amikacin and cefradine can increase the risk of nephrotoxicity.'], 'Ceftaroline': ['NotSet', 'Both amikacin and ceftaroline can increase the risk of nephrotoxicity.'], 'Ceftazidime': ['NotSet', 'Both amikacin and ceftazidime can increase the risk of nephrotoxicity.'], 'Ceftobiprole': ['NotSet', 'Both amikacin and ceftobiprole can increase the risk of nephrotoxicity.'], 'Ceftolozane': ['NotSet', 'Both amikacin and ceftolozane can increase the risk of nephrotoxicity.'], 'Ceftriaxone': ['NotSet', 'Both amikacin and ceftriaxone can increase the risk of nephrotoxicity.'], 'Cefuroxime': ['NotSet', 'Both amikacin and cefuroxime can increase the risk of nephrotoxicity.'], 'Celecoxib': ['NotSet', 'Both amikacin and celecoxib can increase the risk of nephrotoxicity.'], 'Ciclosporin': ['NotSet', 'Both amikacin and ciclosporin can increase the risk of nephrotoxicity.'], 'Cidofovir': ['NotSet', 'Both amikacin and cidofovir can increase the risk of nephrotoxicity.'], 'Cisatracurium': ['NotSet', 'Both amikacin and cisatracurium have neuromuscular blocking effects.'], 'Cisplatin': ['NotSet', 'Both amikacin and cisplatin can increase the risk of nephrotoxicity. Both amikacin and cisplatin can increase the risk of ototoxicity.'], 'Clodronate': ['Moderate', 'Amikacin increases the risk of hypocalcaemia when given with clodronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Colistimethate': ['NotSet', 'Both amikacin and colistimethate have neuromuscular blocking effects. Colistimethate (particularly intravenous) potentially increases the risk of nephrotoxicity when given with amikacin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['NotSet', 'Both amikacin and dexibuprofen can increase the risk of nephrotoxicity.'], 'Dexketoprofen': ['NotSet', 'Both amikacin and dexketoprofen can increase the risk of nephrotoxicity.'], 'Diclofenac': ['NotSet', 'Both amikacin and diclofenac can increase the risk of nephrotoxicity.'], 'Digoxin': ['Mild', 'Amikacin potentially increases the concentration of digoxin. Manufacturer advises monitor and adjust dose. Severity of interaction: Mild Evidence for interaction: Study'], 'Etodolac': ['NotSet', 'Both amikacin and etodolac can increase the risk of nephrotoxicity.'], 'Etoricoxib': ['NotSet', 'Both amikacin and etoricoxib can increase the risk of nephrotoxicity.'], 'Flurbiprofen': ['NotSet', 'Both amikacin and flurbiprofen can increase the risk of nephrotoxicity.'], 'Foscarnet': ['NotSet', 'Both amikacin and foscarnet can increase the risk of nephrotoxicity.'], 'Furosemide': ['NotSet', 'Both amikacin and furosemide can increase the risk of ototoxicity. Furosemide increases the risk of nephrotoxicity when given with amikacin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ganciclovir': ['NotSet', 'Both amikacin and ganciclovir can increase the risk of nephrotoxicity.'], 'Ibandronate': ['Moderate', 'Amikacin increases the risk of hypocalcaemia when given with ibandronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ibuprofen': ['NotSet', 'Both amikacin and ibuprofen can increase the risk of nephrotoxicity.'], 'Ifosfamide': ['NotSet', 'Both amikacin and ifosfamide can increase the risk of nephrotoxicity.'], 'Indometacin': ['NotSet', 'Both amikacin and indometacin can increase the risk of nephrotoxicity.'], 'Ketoprofen': ['NotSet', 'Both amikacin and ketoprofen can increase the risk of nephrotoxicity.'], 'Ketorolac': ['NotSet', 'Both amikacin and ketorolac can increase the risk of nephrotoxicity.'], 'Mefenamic acid': ['NotSet', 'Both amikacin and mefenamic acid can increase the risk of nephrotoxicity.'], 'Meloxicam': ['NotSet', 'Both amikacin and meloxicam can increase the risk of nephrotoxicity.'], 'Methotrexate': ['NotSet', 'Both amikacin and methotrexate can increase the risk of nephrotoxicity.'], 'Mivacurium': ['NotSet', 'Both amikacin and mivacurium have neuromuscular blocking effects.'], 'Nabumetone': ['NotSet', 'Both amikacin and nabumetone can increase the risk of nephrotoxicity.'], 'Naproxen': ['NotSet', 'Both amikacin and naproxen can increase the risk of nephrotoxicity.'], 'Neomycin': ['NotSet', 'Both amikacin and neomycin can increase the risk of nephrotoxicity. Both amikacin and neomycin can increase the risk of ototoxicity. Both amikacin and neomycin have neuromuscular blocking effects.'], 'Neostigmine': ['Moderate', 'Amikacin is predicted to decrease the effects of neostigmine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Oxaliplatin': ['NotSet', 'Both amikacin and oxaliplatin can increase the risk of nephrotoxicity. Both amikacin and oxaliplatin can increase the risk of ototoxicity.'], 'Pamidronate': ['Moderate', 'Amikacin increases the risk of hypocalcaemia when given with pamidronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Pancuronium': ['NotSet', 'Both amikacin and pancuronium have neuromuscular blocking effects.'], 'Parecoxib': ['NotSet', 'Both amikacin and parecoxib can increase the risk of nephrotoxicity.'], 'Pemetrexed': ['NotSet', 'Both amikacin and pemetrexed can increase the risk of nephrotoxicity.'], 'Penicillamine': ['NotSet', 'Both amikacin and penicillamine can increase the risk of nephrotoxicity.'], 'Pentamidine': ['NotSet', 'Both amikacin and pentamidine can increase the risk of nephrotoxicity.'], 'Piroxicam': ['NotSet', 'Both amikacin and piroxicam can increase the risk of nephrotoxicity.'], 'Polymyxin b': ['NotSet', 'Both amikacin and polymyxin b can increase the risk of nephrotoxicity. Both amikacin and polymyxin b have neuromuscular blocking effects.'], 'Pyridostigmine': ['Moderate', 'Amikacin is predicted to decrease the effects of pyridostigmine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Risedronate': ['Moderate', 'Amikacin increases the risk of hypocalcaemia when given with risedronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Rocuronium': ['NotSet', 'Both amikacin and rocuronium have neuromuscular blocking effects.'], 'Streptozocin': ['NotSet', 'Both amikacin and streptozocin can increase the risk of nephrotoxicity.'], 'Sulindac': ['NotSet', 'Both amikacin and sulindac can increase the risk of nephrotoxicity.'], 'Suxamethonium': ['NotSet', 'Both amikacin and suxamethonium have neuromuscular blocking effects.'], 'Tacrolimus': ['NotSet', 'Both amikacin and tacrolimus can increase the risk of nephrotoxicity.'], 'Telavancin': ['NotSet', 'Both amikacin and telavancin can increase the risk of nephrotoxicity. Both amikacin and telavancin can increase the risk of ototoxicity.'], 'Tenofovir disoproxil': ['NotSet', 'Both amikacin and tenofovir disoproxil can increase the risk of nephrotoxicity.'], 'Tenoxicam': ['NotSet', 'Both amikacin and tenoxicam can increase the risk of nephrotoxicity.'], 'Tiaprofenic acid': ['NotSet', 'Both amikacin and tiaprofenic acid can increase the risk of nephrotoxicity.'], 'Tolfenamic acid': ['NotSet', 'Both amikacin and tolfenamic acid can increase the risk of nephrotoxicity.'], 'Torasemide': ['NotSet', 'Both amikacin and torasemide can increase the risk of ototoxicity. Torasemide increases the risk of nephrotoxicity when given with amikacin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Trimethoprim': ['NotSet', 'Both amikacin and trimethoprim can increase the risk of nephrotoxicity.'], 'Valaciclovir': ['NotSet', 'Both amikacin and valaciclovir can increase the risk of nephrotoxicity.'], 'Valganciclovir': ['NotSet', 'Both amikacin and valganciclovir can increase the risk of nephrotoxicity.'], 'Vancomycin': ['NotSet', 'Both amikacin and vancomycin can increase the risk of nephrotoxicity. Both amikacin and vancomycin can increase the risk of ototoxicity.'], 'Vinblastine': ['NotSet', 'Both amikacin and vinblastine can increase the risk of ototoxicity.'], 'Vincristine': ['NotSet', 'Both amikacin and vincristine can increase the risk of ototoxicity.'], 'Vindesine': ['NotSet', 'Both amikacin and vindesine can increase the risk of ototoxicity.'], 'Vinflunine': ['NotSet', 'Both amikacin and vinflunine can increase the risk of ototoxicity.'], 'Vinorelbine': ['NotSet', 'Both amikacin and vinorelbine can increase the risk of ototoxicity.'], 'Zidovudine': ['NotSet', 'Both amikacin and zidovudine can increase the risk of nephrotoxicity.'], 'Zoledronate': ['NotSet', 'Both amikacin and zoledronate can increase the risk of nephrotoxicity. Amikacin increases the risk of hypocalcaemia when given with zoledronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal']}","amilori","{'Aceclofenac': ['NotSet', 'Both amiloride and aceclofenac can increase the risk of hyponatraemia. Both amiloride and aceclofenac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Aliskiren': ['NotSet', 'Both amiloride and aliskiren can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Amitriptyline': ['NotSet', 'Both amiloride and amitriptyline can increase the risk of hyponatraemia.'], 'Azilsartan': ['NotSet', 'Both amiloride and azilsartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Bendroflumethiazide': ['NotSet', 'Both amiloride and bendroflumethiazide can increase the risk of hyponatraemia.'], 'Bumetanide': ['NotSet', 'Both amiloride and bumetanide can increase the risk of hyponatraemia.'], 'Candesartan': ['NotSet', 'Both amiloride and candesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Captopril': ['NotSet', 'Both amiloride and captopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Carbamazepine': ['NotSet', 'Both amiloride and carbamazepine can increase the risk of hyponatraemia.'], 'Celecoxib': ['NotSet', 'Both amiloride and celecoxib can increase the risk of hyponatraemia. Both amiloride and celecoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Chlorothiazide': ['NotSet', 'Both amiloride and chlorothiazide can increase the risk of hyponatraemia.'], 'Chlortalidone': ['NotSet', 'Both amiloride and chlortalidone can increase the risk of hyponatraemia.'], 'Ciclosporin': ['NotSet', 'Both amiloride and ciclosporin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Citalopram': ['NotSet', 'Both amiloride and citalopram can increase the risk of hyponatraemia.'], 'Clomipramine': ['NotSet', 'Both amiloride and clomipramine can increase the risk of hyponatraemia.'], 'Dalteparin': ['NotSet', 'Both amiloride and dalteparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dapoxetine': ['NotSet', 'Both amiloride and dapoxetine can increase the risk of hyponatraemia.'], 'Darbepoetin alfa': ['NotSet', 'Both amiloride and darbepoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Desmopressin': ['NotSet', 'Both amiloride and desmopressin can increase the risk of hyponatraemia.'], 'Dexibuprofen': ['NotSet', 'Both amiloride and dexibuprofen can increase the risk of hyponatraemia. Both amiloride and dexibuprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dexketoprofen': ['NotSet', 'Both amiloride and dexketoprofen can increase the risk of hyponatraemia. Both amiloride and dexketoprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Diclofenac': ['NotSet', 'Both amiloride and diclofenac can increase the risk of hyponatraemia. Both amiloride and diclofenac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dosulepin': ['NotSet', 'Both amiloride and dosulepin can increase the risk of hyponatraemia.'], 'Doxepin': ['NotSet', 'Both amiloride and doxepin can increase the risk of hyponatraemia.'], 'Drospirenone': ['NotSet', 'Both amiloride and drospirenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Duloxetine': ['NotSet', 'Both amiloride and duloxetine can increase the risk of hyponatraemia.'], 'Enalapril': ['NotSet', 'Both amiloride and enalapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Enoxaparin': ['NotSet', 'Both amiloride and enoxaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eplerenone': ['NotSet', 'Both amiloride and eplerenone can increase the risk of hyponatraemia. Both amiloride and eplerenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin alfa': ['NotSet', 'Both amiloride and epoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin beta': ['NotSet', 'Both amiloride and epoetin beta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin zeta': ['NotSet', 'Both amiloride and epoetin zeta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eprosartan': ['NotSet', 'Both amiloride and eprosartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Escitalopram': ['NotSet', 'Both amiloride and escitalopram can increase the risk of hyponatraemia.'], 'Etodolac': ['NotSet', 'Both amiloride and etodolac can increase the risk of hyponatraemia. Both amiloride and etodolac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Etoricoxib': ['NotSet', 'Both amiloride and etoricoxib can increase the risk of hyponatraemia. Both amiloride and etoricoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Fluoxetine': ['NotSet', 'Both amiloride and fluoxetine can increase the risk of hyponatraemia.'], 'Flurbiprofen': ['NotSet', 'Both amiloride and flurbiprofen can increase the risk of hyponatraemia. Both amiloride and flurbiprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Fluvoxamine': ['NotSet', 'Both amiloride and fluvoxamine can increase the risk of hyponatraemia.'], 'Furosemide': ['NotSet', 'Both amiloride and furosemide can increase the risk of hyponatraemia.'], 'Gabapentin': ['NotSet', 'Both amiloride and gabapentin can increase the risk of hyponatraemia.'], 'Heparin (unfractionated)': ['NotSet', 'Both amiloride and heparin (unfractionated) can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Hydrochlorothiazide': ['NotSet', 'Both amiloride and hydrochlorothiazide can increase the risk of hyponatraemia.'], 'Hydroflumethiazide': ['NotSet', 'Both amiloride and hydroflumethiazide can increase the risk of hyponatraemia.'], 'Ibuprofen': ['NotSet', 'Both amiloride and ibuprofen can increase the risk of hyponatraemia. Both amiloride and ibuprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Imidapril': ['NotSet', 'Both amiloride and imidapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Imipramine': ['NotSet', 'Both amiloride and imipramine can increase the risk of hyponatraemia.'], 'Indapamide': ['NotSet', 'Both amiloride and indapamide can increase the risk of hyponatraemia.'], 'Indometacin': ['NotSet', 'Both amiloride and indometacin can increase the risk of hyponatraemia. Both amiloride and indometacin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Irbesartan': ['NotSet', 'Both amiloride and irbesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ketoprofen': ['NotSet', 'Both amiloride and ketoprofen can increase the risk of hyponatraemia. Both amiloride and ketoprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ketorolac': ['NotSet', 'Both amiloride and ketorolac can increase the risk of hyponatraemia. Both amiloride and ketorolac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Lisinopril': ['NotSet', 'Both amiloride and lisinopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Losartan': ['NotSet', 'Both amiloride and losartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Mefenamic acid': ['NotSet', 'Both amiloride and mefenamic acid can increase the risk of hyponatraemia. Both amiloride and mefenamic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Meloxicam': ['NotSet', 'Both amiloride and meloxicam can increase the risk of hyponatraemia. Both amiloride and meloxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Metolazone': ['NotSet', 'Both amiloride and metolazone can increase the risk of hyponatraemia.'], 'Nabumetone': ['NotSet', 'Both amiloride and nabumetone can increase the risk of hyponatraemia. Both amiloride and nabumetone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Naproxen': ['NotSet', 'Both amiloride and naproxen can increase the risk of hyponatraemia. Both amiloride and naproxen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Nortriptyline': ['NotSet', 'Both amiloride and nortriptyline can increase the risk of hyponatraemia.'], 'Olmesartan': ['NotSet', 'Both amiloride and olmesartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Parecoxib': ['NotSet', 'Both amiloride and parecoxib can increase the risk of hyponatraemia. Both amiloride and parecoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Paroxetine': ['NotSet', 'Both amiloride and paroxetine can increase the risk of hyponatraemia.'], 'Perindopril': ['NotSet', 'Both amiloride and perindopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Piroxicam': ['NotSet', 'Both amiloride and piroxicam can increase the risk of hyponatraemia. Both amiloride and piroxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium aminobenzoate': ['NotSet', 'Both amiloride and potassium aminobenzoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium canrenoate': ['NotSet', 'Both amiloride and potassium canrenoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium chloride': ['NotSet', 'Both amiloride and potassium chloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Quinapril': ['NotSet', 'Both amiloride and quinapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ramipril': ['NotSet', 'Both amiloride and ramipril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Sertraline': ['NotSet', 'Both amiloride and sertraline can increase the risk of hyponatraemia.'], 'Sodium picosulfate': ['NotSet', 'Both amiloride and sodium picosulfate can increase the risk of hyponatraemia.'], 'Spironolactone': ['NotSet', 'Both amiloride and spironolactone can increase the risk of hyponatraemia. Both amiloride and spironolactone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Sulindac': ['NotSet', 'Both amiloride and sulindac can increase the risk of hyponatraemia. Both amiloride and sulindac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tacrolimus': ['NotSet', 'Both amiloride and tacrolimus can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Telmisartan': ['NotSet', 'Both amiloride and telmisartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tenoxicam': ['NotSet', 'Both amiloride and tenoxicam can increase the risk of hyponatraemia. Both amiloride and tenoxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tiaprofenic acid': ['NotSet', 'Both amiloride and tiaprofenic acid can increase the risk of hyponatraemia. Both amiloride and tiaprofenic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tinzaparin': ['NotSet', 'Both amiloride and tinzaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tolfenamic acid': ['NotSet', 'Both amiloride and tolfenamic acid can increase the risk of hyponatraemia. Both amiloride and tolfenamic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tolvaptan': ['NotSet', 'Both amiloride and tolvaptan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Torasemide': ['NotSet', 'Both amiloride and torasemide can increase the risk of hyponatraemia.'], 'Trandolapril': ['NotSet', 'Both amiloride and trandolapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trimethoprim': ['NotSet', 'Both amiloride and trimethoprim can increase the risk of hyponatraemia. Both amiloride and trimethoprim can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trimipramine': ['NotSet', 'Both amiloride and trimipramine can increase the risk of hyponatraemia.'], 'Valsartan': ['NotSet', 'Both amiloride and valsartan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Xipamide': ['NotSet', 'Both amiloride and xipamide can increase the risk of hyponatraemia.']}","aminophylline","{'Acebutolol': ['Severe', 'Acebutolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Aciclovir': ['Severe', 'Aciclovir increases the exposure to aminophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Adenosine': ['Mild', 'Aminophylline is predicted to decrease the efficacy of adenosine. Manufacturer advises separate administration by 24 hours. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Amifampridine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amisulpride': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amphotericin': ['NotSet', 'Both aminophylline and amphotericin can increase the risk of hypokalaemia.'], 'Anagrelide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apalutamide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apomorphine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Arsenic trioxide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Artemether': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Artenimol': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Atenolol': ['Severe', 'Atenolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Azithromycin': ['Moderate', 'Azithromycin is predicted to increase the exposure to aminophylline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bambuterol': ['NotSet', 'Both aminophylline and bambuterol can increase the risk of hypokalaemia.'], 'Beclometasone': ['NotSet', 'Both aminophylline and beclometasone can increase the risk of hypokalaemia.'], 'Bedaquiline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with bedaquiline. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bendroflumethiazide': ['NotSet', 'Both aminophylline and bendroflumethiazide can increase the risk of hypokalaemia.'], 'Betamethasone': ['NotSet', 'Both aminophylline and betamethasone can increase the risk of hypokalaemia.'], 'Betaxolol': ['Severe', 'Betaxolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bisoprolol': ['Severe', 'Bisoprolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Blinatumomab': ['Moderate', 'Blinatumomab is predicted to transiently increase the exposure to aminophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with bosutinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Budesonide': ['NotSet', 'Both aminophylline and budesonide can increase the risk of hypokalaemia.'], 'Bumetanide': ['NotSet', 'Both aminophylline and bumetanide can increase the risk of hypokalaemia.'], 'Cabozantinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with cabozantinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Carvedilol': ['Severe', 'Carvedilol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Celiprolol': ['Severe', 'Celiprolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ceritinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ceritinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorothiazide': ['NotSet', 'Both aminophylline and chlorothiazide can increase the risk of hypokalaemia.'], 'Chlorpromazine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with chlorpromazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlortalidone': ['NotSet', 'Both aminophylline and chlortalidone can increase the risk of hypokalaemia.'], 'Cimetidine': ['Severe', 'Cimetidine increases the concentration of aminophylline. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciprofloxacin': ['Moderate', 'Ciprofloxacin is predicted to increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with citalopram. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clarithromycin': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical Clarithromycin is predicted to increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Clomipramine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clomipramine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Combined hormonal contraceptives': ['Moderate', 'Combined hormonal contraceptives are predicted to increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Crizotinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with crizotinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dasatinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with dasatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Deferasirox': ['Moderate', 'Deferasirox is predicted to increase the exposure to aminophylline. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Deflazacort': ['NotSet', 'Both aminophylline and deflazacort can increase the risk of hypokalaemia.'], 'Delamanid': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with delamanid. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexamethasone': ['NotSet', 'Both aminophylline and dexamethasone can increase the risk of hypokalaemia.'], 'Digoxin': ['Severe', 'Aminophylline is predicted to increase the risk of digoxin toxicity when given with digoxin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Disopyramide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with disopyramide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Doxapram': ['Moderate', 'Aminophylline increases the risk of agitation when given with doxapram. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dronedarone': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with dronedarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Droperidol': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with droperidol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Efavirenz': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with efavirenz. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Encorafenib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with encorafenib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ephedrine': ['Moderate', 'Ephedrine increases the risk of side-effects when given with aminophylline. Manufacturer advises avoid in children. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eribulin': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with eribulin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erythromycin': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with erythromycin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical Aminophylline is predicted to decrease the exposure to erythromycin. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Escitalopram': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with escitalopram. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Esketamine': ['Severe', 'Esketamine is predicted to increase the risk of seizures when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Esmolol': ['Severe', 'Esmolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with flecainide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluconazole': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with fluconazole. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fludrocortisone': ['NotSet', 'Both aminophylline and fludrocortisone can increase the risk of hypokalaemia.'], 'Fluphenazine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with fluphenazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluvoxamine': ['Severe', 'Fluvoxamine moderately to markedly increases the exposure to aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Formoterol': ['NotSet', 'Both aminophylline and formoterol can increase the risk of hypokalaemia.'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Furosemide': ['NotSet', 'Both aminophylline and furosemide can increase the risk of hypokalaemia.'], 'Haloperidol': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with haloperidol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrochlorothiazide': ['NotSet', 'Both aminophylline and hydrochlorothiazide can increase the risk of hypokalaemia.'], 'Hydrocortisone': ['NotSet', 'Both aminophylline and hydrocortisone can increase the risk of hypokalaemia.'], 'Hydroflumethiazide': ['NotSet', 'Both aminophylline and hydroflumethiazide can increase the risk of hypokalaemia.'], 'Hydroxyzine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with hydroxyzine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indacaterol': ['NotSet', 'Both aminophylline and indacaterol can increase the risk of hypokalaemia.'], 'Indapamide': ['NotSet', 'Both aminophylline and indapamide can increase the risk of hypokalaemia.'], 'Inotuzumab ozogamicin': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with inotuzumab ozogamicin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Interferon alfa': ['Moderate', 'Interferon alfa is predicted to slightly increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Interferon beta': ['Moderate', 'Interferon beta is predicted to slightly increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Isoniazid': ['Severe', 'Isoniazid is predicted to affect the clearance of aminophylline. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Labetalol': ['Severe', 'Labetalol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lapatinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lapatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Leflunomide': ['Moderate', 'Leflunomide decreases the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lenvatinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lenvatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levobunolol': ['Severe', 'Levobunolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levomepromazine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with levomepromazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lithium': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lithium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical Aminophylline is predicted to decrease the concentration of lithium. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lofexidine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lofexidine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with methadone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methotrexate': ['Moderate', 'Methotrexate is predicted to decrease the clearance of aminophylline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Methylprednisolone': ['NotSet', 'Both aminophylline and methylprednisolone can increase the risk of hypokalaemia.'], 'Metolazone': ['NotSet', 'Both aminophylline and metolazone can increase the risk of hypokalaemia.'], 'Metoprolol': ['Severe', 'Metoprolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mexiletine': ['Moderate', 'Mexiletine is predicted to increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with moxifloxacin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nadolol': ['Severe', 'Nadolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nebivolol': ['Severe', 'Nebivolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nilotinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with nilotinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Olodaterol': ['NotSet', 'Both aminophylline and olodaterol can increase the risk of hypokalaemia.'], 'Ondansetron': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ondansetron. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Osimertinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with osimertinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paliperidone': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with paliperidone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with panobinostat. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pasireotide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with pasireotide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pazopanib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with pazopanib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Peginterferon alfa': ['Moderate', 'Peginterferon alfa is predicted to slightly increase the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pentoxifylline': ['Severe', 'Pentoxifylline is predicted to increase the concentration of aminophylline. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to decrease the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Phenytoin': ['Moderate', 'Phenytoin decreases the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with pimozide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pindolol': ['Severe', 'Pindolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prednisolone': ['NotSet', 'Both aminophylline and prednisolone can increase the risk of hypokalaemia.'], 'Primidone': ['Moderate', 'Primidone is predicted to increase the clearance of aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Propranolol': ['Severe', 'Propranolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Quinine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with quinine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ranolazine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ranolazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ribociclib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ribociclib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rifampicin': ['Moderate', 'Rifampicin decreases the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Risperidone': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with risperidone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ritonavir': ['Moderate', 'Ritonavir decreases the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Roflumilast': ['Moderate', 'Aminophylline is predicted to slightly increase the exposure to roflumilast. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Rucaparib': ['Moderate', 'Rucaparib is predicted to increase the exposure to aminophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Salbutamol': ['NotSet', 'Both aminophylline and salbutamol can increase the risk of hypokalaemia.'], 'Salmeterol': ['NotSet', 'Both aminophylline and salmeterol can increase the risk of hypokalaemia.'], 'Saquinavir': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with saquinavir. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sarilumab': ['Moderate', 'Sarilumab potentially affects the exposure to aminophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sildenafil': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sildenafil. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sorafenib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sorafenib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sotalol': ['Severe', 'Sotalol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sotalol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], ""St John's Wort"": ['Severe', ""St John's Wort is predicted to decrease the concentration of aminophylline. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical""], 'Stiripentol': ['Moderate', 'Stiripentol is predicted to increase the exposure to aminophylline. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sulpiride': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sulpiride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sunitinib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sunitinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Telavancin': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with telavancin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Terbutaline': ['NotSet', 'Both aminophylline and terbutaline can increase the risk of hypokalaemia.'], 'Teriflunomide': ['Moderate', 'Teriflunomide decreases the exposure to aminophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tetrabenazine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with tetrabenazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Theophylline': ['NotSet', 'Both aminophylline and theophylline can increase the risk of hypokalaemia.'], 'Timolol': ['Severe', 'Timolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tizanidine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with tizanidine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tocilizumab': ['Moderate', 'Tocilizumab is predicted to decrease the exposure to aminophylline. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tolterodine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with tolterodine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Torasemide': ['NotSet', 'Both aminophylline and torasemide can increase the risk of hypokalaemia.'], 'Toremifene': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with toremifene. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Triamcinolone': ['NotSet', 'Both aminophylline and triamcinolone can increase the risk of hypokalaemia.'], 'Valaciclovir': ['Severe', 'Valaciclovir is predicted to increase the exposure to aminophylline. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Vandetanib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vandetanib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vardenafil': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vardenafil. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vemurafenib': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vemurafenib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venlafaxine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with venlafaxine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vernakalant': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vernakalant. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vilanterol': ['NotSet', 'Both aminophylline and vilanterol can increase the risk of hypokalaemia.'], 'Vinflunine': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vinflunine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with voriconazole. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Xipamide': ['NotSet', 'Both aminophylline and xipamide can increase the risk of hypokalaemia.'], 'Zuclopenthixol': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with zuclopenthixol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical']}","aminosalicylic-acid","{'Dapsone': ['Severe', 'Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with dapsone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prilocaine': ['Severe', 'Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","amiodaro","{'Acebutolol': ['NotSet', 'Both amiodarone and acebutolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with acebutolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Acenocoumarol': ['Severe', 'Amiodarone increases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Afatinib': ['Moderate', 'Amiodarone is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Agalsidase alfa': ['Moderate', 'Amiodarone is predicted to decrease the effects of agalsidase alfa. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Agalsidase beta': ['Moderate', 'Amiodarone is predicted to decrease the effects of agalsidase beta. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Alectinib': ['NotSet', 'Both amiodarone and alectinib can increase the risk of bradycardia.'], 'Alfentanil': ['NotSet', 'Both amiodarone and alfentanil can increase the risk of bradycardia.'], 'Aliskiren': ['Severe', 'Amiodarone is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Alitretinoin': ['Moderate', 'Amiodarone is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amifampridine': ['Severe', 'Both amiodarone and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amisulpride': ['Severe', 'Both amiodarone and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both amiodarone and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apalutamide': ['Severe', 'Both amiodarone and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both amiodarone and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apraclonidine': ['NotSet', 'Both amiodarone and apraclonidine can increase the risk of bradycardia.'], 'Arsenic trioxide': ['Severe', 'Both amiodarone and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both amiodarone and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both amiodarone and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Atazanavir': ['Severe', 'Atazanavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Atenolol': ['NotSet', 'Both amiodarone and atenolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Atorvastatin': ['Moderate', 'Amiodarone is predicted to increase the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both amiodarone and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betaxolol': ['NotSet', 'Both amiodarone and betaxolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with betaxolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Bictegravir': ['Moderate', 'Amiodarone is predicted to increase the exposure to bictegravir. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bisoprolol': ['NotSet', 'Both amiodarone and bisoprolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with bisoprolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Bortezomib': ['NotSet', 'Both amiodarone and bortezomib can increase the risk of peripheral neuropathy.'], 'Bosutinib': ['Severe', 'Both amiodarone and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Brentuximab vedotin': ['NotSet', 'Both amiodarone and brentuximab vedotin can increase the risk of peripheral neuropathy.'], 'Brimonidine': ['NotSet', 'Both amiodarone and brimonidine can increase the risk of bradycardia.'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bupivacaine': ['Severe', 'Bupivacaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cabazitaxel': ['NotSet', 'Both amiodarone and cabazitaxel can increase the risk of peripheral neuropathy.'], 'Cabozantinib': ['Severe', 'Both amiodarone and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Carvedilol': ['NotSet', 'Both amiodarone and carvedilol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with carvedilol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Celiprolol': ['NotSet', 'Both amiodarone and celiprolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with celiprolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ceritinib': ['Severe', 'Both amiodarone and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Amiodarone is predicted to increase the exposure to ceritinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both amiodarone and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ciclosporin': ['Severe', 'Amiodarone increases the concentration of ciclosporin. Manufacturer advises monitor concentration and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cimetidine': ['Moderate', 'Cimetidine increases the exposure to amiodarone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cisatracurium': ['NotSet', 'Both amiodarone and cisatracurium can increase the risk of bradycardia.'], 'Cisplatin': ['NotSet', 'Both amiodarone and cisplatin can increase the risk of peripheral neuropathy.'], 'Citalopram': ['Severe', 'Both amiodarone and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clarithromycin': ['Severe', 'Both amiodarone and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clomipramine': ['Severe', 'Both amiodarone and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clonidine': ['NotSet', 'Both amiodarone and clonidine can increase the risk of bradycardia.'], 'Cobicistat': ['Severe', 'Cobicistat potentially increases the concentration of amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Crizotinib': ['NotSet', 'Both amiodarone and crizotinib can increase the risk of bradycardia. Both amiodarone and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dabigatran': ['Moderate', 'Amiodarone increases the exposure to dabigatran. Manufacturer advises adjust dabigatran dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Darunavir': ['Severe', 'Darunavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dasatinib': ['Severe', 'Both amiodarone and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both amiodarone and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Didanosine': ['NotSet', 'Both amiodarone and didanosine can increase the risk of peripheral neuropathy.'], 'Digoxin': ['NotSet', 'Both amiodarone and digoxin can increase the risk of bradycardia. Amiodarone is predicted to moderately increase the exposure to digoxin. Manufacturer advises monitor and adjust digoxin dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Diltiazem': ['NotSet', 'Both amiodarone and diltiazem can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiodepression when given with diltiazem. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Disulfiram': ['NotSet', 'Both amiodarone and disulfiram can increase the risk of peripheral neuropathy.'], 'Docetaxel': ['NotSet', 'Both amiodarone and docetaxel can increase the risk of peripheral neuropathy.'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Donepezil': ['NotSet', 'Both amiodarone and donepezil can increase the risk of bradycardia. Amiodarone increases the risk of bradycardia when given with donepezil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Droperidol': ['Severe', 'Both amiodarone and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Edoxaban': ['Severe', 'Amiodarone slightly increases the exposure to edoxaban. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Efavirenz': ['Severe', 'Both amiodarone and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both amiodarone and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Eplerenone': ['Severe', 'Amiodarone is predicted to increase the exposure to eplerenone. Manufacturer advises adjust eplerenone dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eribulin': ['NotSet', 'Both amiodarone and eribulin can increase the risk of peripheral neuropathy. Both amiodarone and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erlotinib': ['Moderate', 'Amiodarone is predicted to increase the exposure to erlotinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Erythromycin': ['Severe', 'Both amiodarone and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both amiodarone and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Esmolol': ['NotSet', 'Both amiodarone and esmolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with esmolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Fentanyl': ['NotSet', 'Both amiodarone and fentanyl can increase the risk of bradycardia. Amiodarone is predicted to increase the concentration of fentanyl. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fidaxomicin': ['Moderate', 'Amiodarone is predicted to increase the exposure to fidaxomicin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fingolimod': ['NotSet', 'Both amiodarone and fingolimod can increase the risk of bradycardia. Fingolimod increases the risk of QT-prolongation when given with amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Amiodarone increases the concentration of flecainide. Manufacturer advises adjust flecainide dose and monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Fluconazole': ['Severe', 'Both amiodarone and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluphenazine': ['Severe', 'Both amiodarone and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluvastatin': ['Severe', 'Amiodarone is predicted to increase the exposure to fluvastatin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fosamprenavir': ['Severe', 'Fosamprenavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fosphenytoin': ['NotSet', 'Both amiodarone and fosphenytoin can increase the risk of peripheral neuropathy. Amiodarone is predicted to slightly increase the concentration of fosphenytoin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Galantamine': ['NotSet', 'Both amiodarone and galantamine can increase the risk of bradycardia. Amiodarone increases the risk of bradycardia when given with galantamine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Glibenclamide': ['Moderate', 'Amiodarone is predicted to increase the exposure to glibenclamide. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Gliclazide': ['Moderate', 'Amiodarone is predicted to increase the exposure to gliclazide. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Glimepiride': ['Moderate', 'Amiodarone is predicted to increase the exposure to glimepiride. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Glipizide': ['Moderate', 'Amiodarone is predicted to increase the exposure to glipizide. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with amiodarone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Grapefruit juice': ['Moderate', 'Grapefruit juice increases the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Haloperidol': ['Severe', 'Both amiodarone and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both amiodarone and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ibrutinib': ['Severe', 'Amiodarone is predicted to increase the exposure to ibrutinib. Manufacturer advises adjust ibrutinib dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Idelalisib': ['Moderate', 'Idelalisib is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both amiodarone and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Isoniazid': ['NotSet', 'Both amiodarone and isoniazid can increase the risk of peripheral neuropathy.'], 'Ivabradine': ['NotSet', 'Both amiodarone and ivabradine can increase the risk of bradycardia. Ivabradine is predicted to increase the risk of torsade de pointes when given with amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Labetalol': ['NotSet', 'Both amiodarone and labetalol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with labetalol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Lamivudine': ['NotSet', 'Both amiodarone and lamivudine can increase the risk of peripheral neuropathy.'], 'Lapatinib': ['Severe', 'Both amiodarone and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Larotrectinib': ['Mild', 'Amiodarone is predicted to increase the exposure to larotrectinib. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Ledipasvir': ['Severe', 'Ledipasvir increases the risk of severe bradycardia or heart block when given with amiodarone. Refer to specialist literature. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Lenvatinib': ['Severe', 'Both amiodarone and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Letermovir': ['Moderate', 'Letermovir is predicted to increase the concentration of amiodarone. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levobunolol': ['NotSet', 'Both amiodarone and levobunolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with levobunolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Levobupivacaine': ['Severe', 'Levobupivacaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levomepromazine': ['Severe', 'Both amiodarone and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levothyroxine': ['Moderate', 'Amiodarone is predicted to increase the risk of thyroid dysfunction when given with levothyroxine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Liothyronine': ['Moderate', 'Amiodarone is predicted to increase the risk of thyroid dysfunction when given with liothyronine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lithium': ['Severe', 'Both amiodarone and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both amiodarone and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lomitapide': ['Moderate', 'Amiodarone is predicted to increase the exposure to lomitapide. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lopinavir': ['Severe', 'Lopinavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mepivacaine': ['Severe', 'Mepivacaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['NotSet', 'Both amiodarone and methadone can increase the risk of bradycardia. Both amiodarone and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metoprolol': ['NotSet', 'Both amiodarone and metoprolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with metoprolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Metronidazole': ['NotSet', 'Both amiodarone and metronidazole can increase the risk of peripheral neuropathy.'], 'Mexiletine': ['Severe', 'Mexiletine increases the risk of torsade de pointes when given with amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both amiodarone and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nadolol': ['NotSet', 'Both amiodarone and nadolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with nadolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Nebivolol': ['NotSet', 'Both amiodarone and nebivolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with nebivolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Neostigmine': ['NotSet', 'Both amiodarone and neostigmine can increase the risk of bradycardia.'], 'Nilotinib': ['Severe', 'Both amiodarone and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nintedanib': ['Moderate', 'Amiodarone is predicted to increase the exposure to nintedanib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nitrofurantoin': ['NotSet', 'Both amiodarone and nitrofurantoin can increase the risk of peripheral neuropathy.'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both amiodarone and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both amiodarone and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Oxybuprocaine': ['Severe', 'Oxybuprocaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paclitaxel': ['NotSet', 'Both amiodarone and paclitaxel can increase the risk of peripheral neuropathy.'], 'Paliperidone': ['Severe', 'Both amiodarone and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with amiodarone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both amiodarone and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Amiodarone is predicted to increase the exposure to panobinostat. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pasireotide': ['NotSet', 'Both amiodarone and pasireotide can increase the risk of bradycardia. Both amiodarone and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both amiodarone and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with amiodarone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Phenytoin': ['NotSet', 'Both amiodarone and phenytoin can increase the risk of peripheral neuropathy. Amiodarone is predicted to slightly increase the concentration of phenytoin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Pibrentasvir': ['Moderate', 'Amiodarone is predicted to increase the exposure to pibrentasvir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pimozide': ['Severe', 'Both amiodarone and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pindolol': ['NotSet', 'Both amiodarone and pindolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with pindolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prilocaine': ['Severe', 'Prilocaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Propafenone': ['Severe', 'Propafenone is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Propranolol': ['NotSet', 'Both amiodarone and propranolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with propranolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Proxymetacaine': ['Severe', 'Proxymetacaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pyridostigmine': ['NotSet', 'Both amiodarone and pyridostigmine can increase the risk of bradycardia.'], 'Quinine': ['Severe', 'Both amiodarone and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ranolazine': ['Severe', 'Both amiodarone and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Remifentanil': ['NotSet', 'Both amiodarone and remifentanil can increase the risk of bradycardia.'], 'Ribociclib': ['Severe', 'Both amiodarone and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Ribociclib (high-dose) is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Risperidone': ['Severe', 'Both amiodarone and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ritonavir': ['Severe', 'Ritonavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rivastigmine': ['NotSet', 'Both amiodarone and rivastigmine can increase the risk of bradycardia. Amiodarone increases the risk of bradycardia when given with rivastigmine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ropivacaine': ['Severe', 'Ropivacaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both amiodarone and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Saquinavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Selegiline': ['NotSet', 'Both amiodarone and selegiline can increase the risk of bradycardia.'], 'Sildenafil': ['Severe', 'Both amiodarone and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Simvastatin': ['Severe', 'Amiodarone increases the risk of rhabdomyolysis when given with simvastatin. Manufacturer advises adjust simvastatin dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Sirolimus': ['Severe', 'Amiodarone is predicted to increase the concentration of sirolimus. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Sofosbuvir': ['Severe', 'Sofosbuvir is predicted to increase the risk of severe bradycardia or heart block when given with amiodarone. Refer to specialist literature. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Sorafenib': ['Severe', 'Both amiodarone and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['NotSet', 'Both amiodarone and sotalol can increase the risk of bradycardia. Both amiodarone and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with sotalol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Stavudine': ['NotSet', 'Both amiodarone and stavudine can increase the risk of peripheral neuropathy.'], 'Sufentanil': ['NotSet', 'Both amiodarone and sufentanil can increase the risk of bradycardia.'], 'Sulpiride': ['Severe', 'Both amiodarone and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['Severe', 'Both amiodarone and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tacrolimus': ['Severe', 'Amiodarone is predicted to increase the concentration of tacrolimus. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Talazoparib': ['Severe', 'Amiodarone is predicted to slightly increase the exposure to talazoparib. Manufacturer advises avoid or adjust talazoparib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Telavancin': ['Severe', 'Both amiodarone and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both amiodarone and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tetracaine': ['Severe', 'Tetracaine is predicted to increase the risk of cardiodepression when given with amiodarone. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Thalidomide': ['NotSet', 'Both amiodarone and thalidomide can increase the risk of bradycardia. Both amiodarone and thalidomide can increase the risk of peripheral neuropathy.'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticagrelor': ['Severe', 'Amiodarone is predicted to increase the exposure to ticagrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Timolol': ['NotSet', 'Both amiodarone and timolol can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with timolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Tipranavir': ['Severe', 'Tipranavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tizanidine': ['NotSet', 'Both amiodarone and tizanidine can increase the risk of bradycardia. Both amiodarone and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolbutamide': ['Moderate', 'Amiodarone is predicted to increase the exposure to tolbutamide. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tolterodine': ['Severe', 'Both amiodarone and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Topotecan': ['Severe', 'Amiodarone is predicted to increase the exposure to topotecan. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both amiodarone and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Trametinib': ['Moderate', 'Amiodarone is predicted to increase the concentration of trametinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vandetanib': ['Severe', 'Both amiodarone and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both amiodarone and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Velpatasvir': ['Moderate', 'Amiodarone is predicted to increase the concentration of velpatasvir. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Vemurafenib': ['Severe', 'Both amiodarone and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venetoclax': ['Severe', 'Amiodarone is predicted to increase the exposure to venetoclax. Manufacturer advises avoid or monitor for toxicity. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venlafaxine': ['Severe', 'Both amiodarone and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Verapamil': ['NotSet', 'Both amiodarone and verapamil can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiodepression when given with verapamil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both amiodarone and vinblastine can increase the risk of peripheral neuropathy.'], 'Vincristine': ['NotSet', 'Both amiodarone and vincristine can increase the risk of peripheral neuropathy.'], 'Vindesine': ['NotSet', 'Both amiodarone and vindesine can increase the risk of peripheral neuropathy.'], 'Vinflunine': ['NotSet', 'Both amiodarone and vinflunine can increase the risk of peripheral neuropathy. Both amiodarone and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vinorelbine': ['NotSet', 'Both amiodarone and vinorelbine can increase the risk of peripheral neuropathy.'], 'Voriconazole': ['Severe', 'Both amiodarone and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Warfarin': ['Severe', 'Amiodarone increases the anticoagulant effect of warfarin. Manufacturer advises monitor INR. Severity of interaction: Severe Evidence for interaction: Study'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['Severe', 'Both amiodarone and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","amisulpride","{'Agomelatine': ['NotSet', ""Both amisulpride and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both amisulpride and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both amisulpride and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alimemazine': ['NotSet', ""Both amisulpride and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprazolam': ['NotSet', ""Both amisulpride and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amantadine': ['Moderate', 'Amisulpride is predicted to decrease the effects of amantadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amifampridine': ['Severe', 'Both amisulpride and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both amisulpride and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amitriptyline': ['NotSet', ""Both amisulpride and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both amisulpride and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apalutamide': ['Severe', 'Both amisulpride and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both amisulpride and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Amisulpride is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Apraclonidine': ['NotSet', ""Both amisulpride and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both amisulpride and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Arsenic trioxide': ['Severe', 'Both amisulpride and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both amisulpride and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both amisulpride and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Articaine': ['NotSet', ""Both amisulpride and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both amisulpride and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Baclofen': ['NotSet', ""Both amisulpride and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both amisulpride and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Benperidol': ['NotSet', ""Both amisulpride and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Both amisulpride and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Brimonidine': ['NotSet', ""Both amisulpride and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bromocriptine': ['Moderate', 'Amisulpride is predicted to decrease the effects of bromocriptine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Buclizine': ['NotSet', ""Both amisulpride and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bupivacaine': ['NotSet', ""Both amisulpride and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both amisulpride and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cabergoline': ['Moderate', 'Amisulpride is predicted to decrease the effects of cabergoline. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Cabozantinib': ['Severe', 'Both amisulpride and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Cannabidiol': ['NotSet', ""Both amisulpride and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cariprazine': ['NotSet', ""Both amisulpride and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ceritinib': ['Severe', 'Both amisulpride and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chloral hydrate': ['NotSet', ""Both amisulpride and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both amisulpride and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorphenamine': ['NotSet', ""Both amisulpride and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['Severe', ""Both amisulpride and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cinnarizine': ['NotSet', ""Both amisulpride and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Citalopram': ['Severe', 'Both amisulpride and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clarithromycin': ['Severe', 'Both amisulpride and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clemastine': ['NotSet', ""Both amisulpride and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both amisulpride and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both amisulpride and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['Severe', ""Both amisulpride and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both amisulpride and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both amisulpride and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both amisulpride and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both amisulpride and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Crizotinib': ['Severe', 'Both amisulpride and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Cyclizine': ['NotSet', ""Both amisulpride and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both amisulpride and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dasatinib': ['Severe', 'Both amisulpride and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both amisulpride and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Desflurane': ['NotSet', ""Both amisulpride and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexmedetomidine': ['NotSet', ""Both amisulpride and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both amisulpride and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both amisulpride and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dihydrocodeine': ['NotSet', ""Both amisulpride and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipipanone': ['NotSet', ""Both amisulpride and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Disopyramide': ['Severe', 'Both amisulpride and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with amisulpride. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dosulepin': ['NotSet', ""Both amisulpride and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxepin': ['NotSet', ""Both amisulpride and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both amisulpride and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronedarone': ['Severe', 'Both amisulpride and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', ""Both amisulpride and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Efavirenz': ['Severe', 'Both amisulpride and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both amisulpride and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Eribulin': ['Severe', 'Both amisulpride and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both amisulpride and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both amisulpride and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Esketamine': ['NotSet', ""Both amisulpride and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Etomidate': ['NotSet', ""Both amisulpride and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fentanyl': ['NotSet', ""Both amisulpride and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with amisulpride. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both amisulpride and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both amisulpride and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flupentixol': ['NotSet', ""Both amisulpride and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['Severe', ""Both amisulpride and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both amisulpride and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Gabapentin': ['NotSet', ""Both amisulpride and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with amisulpride. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Guanfacine': ['NotSet', ""Both amisulpride and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['Severe', ""Both amisulpride and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydromorphone': ['NotSet', ""Both amisulpride and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['Severe', ""Both amisulpride and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imipramine': ['NotSet', ""Both amisulpride and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both amisulpride and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Isoflurane': ['NotSet', ""Both amisulpride and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with amisulpride. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketamine': ['NotSet', ""Both amisulpride and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketotifen': ['NotSet', ""Both amisulpride and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lamotrigine': ['NotSet', ""Both amisulpride and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lapatinib': ['Severe', 'Both amisulpride and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both amisulpride and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levetiracetam': ['NotSet', ""Both amisulpride and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levodopa': ['Severe', 'Amisulpride is predicted to decrease the effects of levodopa. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levomepromazine': ['Severe', ""Both amisulpride and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both amisulpride and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lithium': ['Severe', 'Both amisulpride and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofepramine': ['NotSet', ""Both amisulpride and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['Severe', ""Both amisulpride and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both amisulpride and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both amisulpride and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both amisulpride and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loxapine': ['NotSet', ""Both amisulpride and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both amisulpride and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Melatonin': ['NotSet', ""Both amisulpride and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both amisulpride and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both amisulpride and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both amisulpride and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['Severe', ""Both amisulpride and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both amisulpride and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both amisulpride and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mianserin': ['NotSet', ""Both amisulpride and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both amisulpride and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mirtazapine': ['NotSet', ""Both amisulpride and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with amisulpride. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Morphine': ['NotSet', ""Both amisulpride and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxifloxacin': ['Severe', 'Both amisulpride and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Moxonidine': ['NotSet', ""Both amisulpride and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both amisulpride and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nilotinib': ['Severe', 'Both amisulpride and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nitrazepam': ['NotSet', ""Both amisulpride and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrous oxide': ['NotSet', ""Both amisulpride and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both amisulpride and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both amisulpride and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both amisulpride and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both amisulpride and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Oxazepam': ['NotSet', ""Both amisulpride and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both amisulpride and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['Severe', ""Both amisulpride and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with amisulpride. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both amisulpride and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both amisulpride and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both amisulpride and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with amisulpride. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pentazocine': ['NotSet', ""Both amisulpride and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both amisulpride and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pergolide': ['Moderate', 'Amisulpride is predicted to decrease the effects of pergolide. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pericyazine': ['NotSet', ""Both amisulpride and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pethidine': ['NotSet', ""Both amisulpride and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenobarbital': ['NotSet', ""Both amisulpride and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pimozide': ['Severe', ""Both amisulpride and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pizotifen': ['NotSet', ""Both amisulpride and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pramipexole': ['Moderate', 'Amisulpride is predicted to decrease the effects of pramipexole. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pregabalin': ['NotSet', ""Both amisulpride and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both amisulpride and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both amisulpride and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prochlorperazine': ['NotSet', ""Both amisulpride and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both amisulpride and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both amisulpride and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both amisulpride and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quetiapine': ['NotSet', ""Both amisulpride and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quinagolide': ['Moderate', 'Amisulpride is predicted to decrease the effects of quinagolide. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quinine': ['Severe', 'Both amisulpride and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ranolazine': ['Severe', 'Both amisulpride and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Remifentanil': ['NotSet', ""Both amisulpride and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ribociclib': ['Severe', 'Both amisulpride and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Risperidone': ['Severe', ""Both amisulpride and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ropinirole': ['Moderate', 'Amisulpride is predicted to decrease the effects of ropinirole. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ropivacaine': ['NotSet', ""Both amisulpride and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rotigotine': ['Moderate', 'Amisulpride is predicted to decrease the effects of rotigotine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both amisulpride and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sevoflurane': ['NotSet', ""Both amisulpride and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sildenafil': ['Severe', 'Both amisulpride and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sodium oxybate': ['NotSet', ""Both amisulpride and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sorafenib': ['Severe', 'Both amisulpride and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both amisulpride and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sufentanil': ['NotSet', ""Both amisulpride and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['Severe', ""Both amisulpride and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sunitinib': ['Severe', 'Both amisulpride and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tapentadol': ['NotSet', ""Both amisulpride and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Telavancin': ['Severe', 'Both amisulpride and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Temazepam': ['NotSet', ""Both amisulpride and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both amisulpride and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tetracaine': ['NotSet', ""Both amisulpride and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both amisulpride and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Thiopental': ['NotSet', ""Both amisulpride and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tizanidine': ['Severe', ""Both amisulpride and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tolterodine': ['Severe', 'Both amisulpride and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both amisulpride and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tramadol': ['NotSet', ""Both amisulpride and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trazodone': ['NotSet', ""Both amisulpride and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trifluoperazine': ['NotSet', ""Both amisulpride and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both amisulpride and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Vandetanib': ['Severe', 'Both amisulpride and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both amisulpride and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both amisulpride and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', ""Both amisulpride and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Vernakalant': ['Severe', 'Both amisulpride and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both amisulpride and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Voriconazole': ['Severe', 'Both amisulpride and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zolpidem': ['NotSet', ""Both amisulpride and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['Severe', ""Both amisulpride and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both amisulpride and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","amitriptyli","{'Acebutolol': ['NotSet', 'Both amitriptyline and acebutolol can increase the risk of hypotension.'], 'Aceclofenac': ['NotSet', 'Both amitriptyline and aceclofenac can increase the risk of hyponatraemia.'], 'Aclidinium': ['NotSet', 'Both amitriptyline and aclidinium can cause antimuscarinic effects.'], 'Adrenaline/epinephrine': ['Severe', 'Amitriptyline increases the effects of adrenaline/epinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Agomelatine': ['NotSet', ""Both amitriptyline and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both amitriptyline and alcohol (beverage) can increase the risk of hypotension. Both amitriptyline and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both amitriptyline and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfuzosin': ['NotSet', 'Both amitriptyline and alfuzosin can increase the risk of hypotension.'], 'Alimemazine': ['NotSet', ""Both amitriptyline and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aliskiren': ['NotSet', 'Both amitriptyline and aliskiren can increase the risk of hypotension.'], 'Alprazolam': ['NotSet', ""Both amitriptyline and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprostadil': ['NotSet', 'Both amitriptyline and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both amitriptyline and amantadine can increase the risk of hypotension. Both amitriptyline and amantadine can cause antimuscarinic effects.'], 'Amiloride': ['NotSet', 'Both amitriptyline and amiloride can increase the risk of hyponatraemia.'], 'Amisulpride': ['NotSet', ""Both amitriptyline and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amlodipine': ['NotSet', 'Both amitriptyline and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both amitriptyline and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', ""Both amitriptyline and apraclonidine can increase the risk of hypotension. Both amitriptyline and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both amitriptyline and aripiprazole can increase the risk of hypotension. Both amitriptyline and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both amitriptyline and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both amitriptyline and asenapine can increase the risk of hypotension. Both amitriptyline and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Atenolol': ['NotSet', 'Both amitriptyline and atenolol can increase the risk of hypotension.'], 'Atropine': ['NotSet', 'Both amitriptyline and atropine can cause antimuscarinic effects.'], 'Avanafil': ['NotSet', 'Both amitriptyline and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both amitriptyline and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', ""Both amitriptyline and baclofen can increase the risk of hypotension. Both amitriptyline and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and baclofen can cause antimuscarinic effects.""], 'Bendroflumethiazide': ['NotSet', 'Both amitriptyline and bendroflumethiazide can increase the risk of hyponatraemia. Both amitriptyline and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', ""Both amitriptyline and benperidol can increase the risk of hypotension. Both amitriptyline and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betaxolol': ['NotSet', 'Both amitriptyline and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both amitriptyline and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both amitriptyline and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', ""Both amitriptyline and brimonidine can increase the risk of hypotension. Both amitriptyline and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bromocriptine': ['NotSet', 'Both amitriptyline and bromocriptine can increase the risk of hypotension.'], 'Buclizine': ['NotSet', ""Both amitriptyline and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bumetanide': ['NotSet', 'Both amitriptyline and bumetanide can increase the risk of hyponatraemia. Both amitriptyline and bumetanide can increase the risk of hypotension.'], 'Bupivacaine': ['NotSet', ""Both amitriptyline and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both amitriptyline and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupropion': ['Severe', 'Bupropion is predicted to increase the exposure to amitriptyline. Manufacturer advises monitor for toxicity and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cabergoline': ['NotSet', 'Both amitriptyline and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both amitriptyline and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both amitriptyline and candesartan can increase the risk of hypotension.'], 'Cannabidiol': ['NotSet', ""Both amitriptyline and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Captopril': ['NotSet', 'Both amitriptyline and captopril can increase the risk of hypotension.'], 'Carbamazepine': ['NotSet', 'Both amitriptyline and carbamazepine can increase the risk of hyponatraemia. Carbamazepine decreases the exposure to amitriptyline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cariprazine': ['NotSet', ""Both amitriptyline and cariprazine can increase the risk of hypotension. Both amitriptyline and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carvedilol': ['NotSet', 'Both amitriptyline and carvedilol can increase the risk of hypotension.'], 'Celecoxib': ['NotSet', 'Both amitriptyline and celecoxib can increase the risk of hyponatraemia.'], 'Celiprolol': ['NotSet', 'Both amitriptyline and celiprolol can increase the risk of hypotension.'], 'Chloral hydrate': ['NotSet', ""Both amitriptyline and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both amitriptyline and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorothiazide': ['NotSet', 'Both amitriptyline and chlorothiazide can increase the risk of hyponatraemia. Both amitriptyline and chlorothiazide can increase the risk of hypotension.'], 'Chlorphenamine': ['NotSet', ""Both amitriptyline and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and chlorphenamine can cause antimuscarinic effects.""], 'Chlorpromazine': ['NotSet', ""Both amitriptyline and chlorpromazine can increase the risk of hypotension. Both amitriptyline and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and chlorpromazine can cause antimuscarinic effects.""], 'Chlortalidone': ['NotSet', 'Both amitriptyline and chlortalidone can increase the risk of hyponatraemia. Both amitriptyline and chlortalidone can increase the risk of hypotension.'], 'Cimetidine': ['Moderate', 'Cimetidine increases the exposure to amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cinacalcet': ['Severe', 'Cinacalcet is predicted to increase the exposure to amitriptyline. Manufacturer advises monitor for toxicity and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cinnarizine': ['NotSet', ""Both amitriptyline and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Citalopram': ['NotSet', 'Both amitriptyline and citalopram can increase the risk of hyponatraemia.'], 'Clemastine': ['NotSet', ""Both amitriptyline and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and clemastine can cause antimuscarinic effects.""], 'Clobazam': ['NotSet', ""Both amitriptyline and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both amitriptyline and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both amitriptyline and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both amitriptyline and clonidine can increase the risk of hypotension. Both amitriptyline and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Amitriptyline decreases the antihypertensive effects of clonidine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Anecdotal""], 'Clozapine': ['NotSet', ""Both amitriptyline and clozapine can increase the risk of hypotension. Both amitriptyline and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and clozapine can cause antimuscarinic effects.""], 'Cobicistat': ['Mild', 'Cobicistat is predicted to slightly increase the exposure to amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Codeine': ['NotSet', ""Both amitriptyline and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyclizine': ['NotSet', ""Both amitriptyline and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and cyclizine can cause antimuscarinic effects.""], 'Cyclopentolate': ['NotSet', 'Both amitriptyline and cyclopentolate can cause antimuscarinic effects.'], 'Cyproheptadine': ['NotSet', ""Both amitriptyline and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and cyproheptadine can cause antimuscarinic effects.""], 'Dapagliflozin': ['NotSet', 'Both amitriptyline and dapagliflozin can increase the risk of hypotension.'], 'Dapoxetine': ['NotSet', 'Both amitriptyline and dapoxetine can increase the risk of hyponatraemia.'], 'Darifenacin': ['NotSet', 'Both amitriptyline and darifenacin can cause antimuscarinic effects. Darifenacin is predicted to increase the exposure to amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Desflurane': ['NotSet', ""Both amitriptyline and desflurane can increase the risk of hypotension. Both amitriptyline and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Desmopressin': ['NotSet', 'Both amitriptyline and desmopressin can increase the risk of hyponatraemia.'], 'Dexibuprofen': ['NotSet', 'Both amitriptyline and dexibuprofen can increase the risk of hyponatraemia.'], 'Dexketoprofen': ['NotSet', 'Both amitriptyline and dexketoprofen can increase the risk of hyponatraemia.'], 'Dexmedetomidine': ['NotSet', ""Both amitriptyline and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both amitriptyline and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both amitriptyline and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazoxide': ['NotSet', 'Both amitriptyline and diazoxide can increase the risk of hypotension.'], 'Diclofenac': ['NotSet', 'Both amitriptyline and diclofenac can increase the risk of hyponatraemia.'], 'Dicycloverine': ['NotSet', 'Both amitriptyline and dicycloverine can cause antimuscarinic effects.'], 'Dihydrocodeine': ['NotSet', ""Both amitriptyline and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diltiazem': ['NotSet', 'Both amitriptyline and diltiazem can increase the risk of hypotension.'], 'Dimenhydrinate': ['NotSet', 'Both amitriptyline and dimenhydrinate can cause antimuscarinic effects.'], 'Dipipanone': ['NotSet', ""Both amitriptyline and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipyridamole': ['NotSet', 'Both amitriptyline and dipyridamole can increase the risk of hypotension.'], 'Disopyramide': ['NotSet', 'Both amitriptyline and disopyramide can cause antimuscarinic effects.'], 'Doxazosin': ['NotSet', 'Both amitriptyline and doxazosin can increase the risk of hypotension.'], 'Dronabinol': ['NotSet', ""Both amitriptyline and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronedarone': ['Severe', 'Dronedarone is predicted to increase the exposure to amitriptyline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Droperidol': ['NotSet', ""Both amitriptyline and droperidol can increase the risk of hypotension. Both amitriptyline and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Duloxetine': ['NotSet', 'Both amitriptyline and duloxetine can increase the risk of hyponatraemia.'], 'Empagliflozin': ['NotSet', 'Both amitriptyline and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both amitriptyline and enalapril can increase the risk of hypotension.'], 'Ephedrine': ['Severe', 'Amitriptyline is predicted to decrease the effects of ephedrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Eplerenone': ['NotSet', 'Both amitriptyline and eplerenone can increase the risk of hyponatraemia. Both amitriptyline and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both amitriptyline and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both amitriptyline and ertugliflozin can increase the risk of hypotension.'], 'Escitalopram': ['NotSet', 'Both amitriptyline and escitalopram can increase the risk of hyponatraemia.'], 'Esketamine': ['NotSet', ""Both amitriptyline and esketamine can increase the risk of hypotension. Both amitriptyline and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esmolol': ['NotSet', 'Both amitriptyline and esmolol can increase the risk of hypotension.'], 'Etodolac': ['NotSet', 'Both amitriptyline and etodolac can increase the risk of hyponatraemia.'], 'Etomidate': ['NotSet', ""Both amitriptyline and etomidate can increase the risk of hypotension. Both amitriptyline and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Etoricoxib': ['NotSet', 'Both amitriptyline and etoricoxib can increase the risk of hyponatraemia.'], 'Felodipine': ['NotSet', 'Both amitriptyline and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', ""Both amitriptyline and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fesoterodine': ['NotSet', 'Both amitriptyline and fesoterodine can cause antimuscarinic effects.'], 'Flavoxate': ['NotSet', 'Both amitriptyline and flavoxate can cause antimuscarinic effects.'], 'Fluoxetine': ['NotSet', 'Both amitriptyline and fluoxetine can increase the risk of hyponatraemia. Fluoxetine is predicted to increase the exposure to amitriptyline. Manufacturer advises monitor for toxicity and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Flupentixol': ['NotSet', ""Both amitriptyline and flupentixol can increase the risk of hypotension. Both amitriptyline and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both amitriptyline and fluphenazine can increase the risk of hypotension. Both amitriptyline and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both amitriptyline and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurbiprofen': ['NotSet', 'Both amitriptyline and flurbiprofen can increase the risk of hyponatraemia.'], 'Fluvoxamine': ['NotSet', 'Both amitriptyline and fluvoxamine can increase the risk of hyponatraemia. Fluvoxamine increases the exposure to amitriptyline. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosinopril': ['NotSet', 'Both amitriptyline and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both amitriptyline and furosemide can increase the risk of hyponatraemia. Both amitriptyline and furosemide can increase the risk of hypotension.'], 'Gabapentin': ['NotSet', ""Both amitriptyline and gabapentin can increase the risk of hyponatraemia. Both amitriptyline and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Glyceryl trinitrate': ['NotSet', 'Both amitriptyline and glyceryl trinitrate can increase the risk of hypotension.'], 'Glycopyrronium': ['NotSet', 'Both amitriptyline and glycopyrronium can cause antimuscarinic effects.'], 'Guanethidine': ['NotSet', 'Both amitriptyline and guanethidine can increase the risk of hypotension. Amitriptyline is predicted to decrease the antihypertensive effects of guanethidine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Guanfacine': ['NotSet', ""Both amitriptyline and guanfacine can increase the risk of hypotension. Both amitriptyline and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both amitriptyline and haloperidol can increase the risk of hypotension. Both amitriptyline and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and haloperidol can cause antimuscarinic effects.""], 'Homatropine': ['NotSet', 'Both amitriptyline and homatropine can cause antimuscarinic effects.'], 'Hydralazine': ['NotSet', 'Both amitriptyline and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both amitriptyline and hydrochlorothiazide can increase the risk of hyponatraemia. Both amitriptyline and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both amitriptyline and hydroflumethiazide can increase the risk of hyponatraemia. Both amitriptyline and hydroflumethiazide can increase the risk of hypotension.'], 'Hydromorphone': ['NotSet', ""Both amitriptyline and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both amitriptyline and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and hydroxyzine can cause antimuscarinic effects.""], 'Hyoscine': ['NotSet', 'Both amitriptyline and hyoscine can cause antimuscarinic effects.'], 'Ibuprofen': ['NotSet', 'Both amitriptyline and ibuprofen can increase the risk of hyponatraemia.'], 'Imidapril': ['NotSet', 'Both amitriptyline and imidapril can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both amitriptyline and indapamide can increase the risk of hyponatraemia. Both amitriptyline and indapamide can increase the risk of hypotension.'], 'Indometacin': ['NotSet', 'Both amitriptyline and indometacin can increase the risk of hyponatraemia.'], 'Indoramin': ['NotSet', 'Both amitriptyline and indoramin can increase the risk of hypotension.'], 'Ipratropium': ['NotSet', 'Both amitriptyline and ipratropium can cause antimuscarinic effects.'], 'Irbesartan': ['NotSet', 'Both amitriptyline and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both amitriptyline and isocarboxazid can increase the risk of hypotension. Amitriptyline is predicted to increase the risk of severe toxic reaction when given with isocarboxazid. Manufacturer advises avoid and for 14 days after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Isoflurane': ['NotSet', ""Both amitriptyline and isoflurane can increase the risk of hypotension. Both amitriptyline and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isosorbide dinitrate': ['NotSet', 'Both amitriptyline and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both amitriptyline and isosorbide mononitrate can increase the risk of hypotension.'], 'Ketamine': ['NotSet', ""Both amitriptyline and ketamine can increase the risk of hypotension. Both amitriptyline and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketoprofen': ['NotSet', 'Both amitriptyline and ketoprofen can increase the risk of hyponatraemia.'], 'Ketorolac': ['NotSet', 'Both amitriptyline and ketorolac can increase the risk of hyponatraemia.'], 'Ketotifen': ['NotSet', ""Both amitriptyline and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Labetalol': ['NotSet', 'Both amitriptyline and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both amitriptyline and lacidipine can increase the risk of hypotension.'], 'Lamotrigine': ['NotSet', ""Both amitriptyline and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lercanidipine': ['NotSet', 'Both amitriptyline and lercanidipine can increase the risk of hypotension.'], 'Levetiracetam': ['NotSet', ""Both amitriptyline and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levobunolol': ['NotSet', 'Both amitriptyline and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both amitriptyline and levodopa can increase the risk of hypotension. Amitriptyline decreases the absorption of levodopa. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levomepromazine': ['NotSet', ""Both amitriptyline and levomepromazine can increase the risk of hypotension. Both amitriptyline and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and levomepromazine can cause antimuscarinic effects.""], 'Lidocaine': ['NotSet', ""Both amitriptyline and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lisinopril': ['NotSet', 'Both amitriptyline and lisinopril can increase the risk of hypotension.'], 'Lithium': ['Severe', 'Amitriptyline potentially increases the risk of neurotoxicity when given with lithium. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Lofexidine': ['NotSet', ""Both amitriptyline and lofexidine can increase the risk of hypotension. Both amitriptyline and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both amitriptyline and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both amitriptyline and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both amitriptyline and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Losartan': ['NotSet', 'Both amitriptyline and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', ""Both amitriptyline and loxapine can increase the risk of hypotension. Both amitriptyline and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and loxapine can cause antimuscarinic effects.""], 'Lurasidone': ['NotSet', ""Both amitriptyline and lurasidone can increase the risk of hypotension. Both amitriptyline and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mefenamic acid': ['NotSet', 'Both amitriptyline and mefenamic acid can increase the risk of hyponatraemia.'], 'Melatonin': ['NotSet', ""Both amitriptyline and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meloxicam': ['NotSet', 'Both amitriptyline and meloxicam can increase the risk of hyponatraemia.'], 'Mepivacaine': ['NotSet', ""Both amitriptyline and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both amitriptyline and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both amitriptyline and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both amitriptyline and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both amitriptyline and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both amitriptyline and methoxyflurane can increase the risk of hypotension. Both amitriptyline and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methyldopa': ['NotSet', 'Both amitriptyline and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both amitriptyline and metolazone can increase the risk of hyponatraemia. Both amitriptyline and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both amitriptyline and metoprolol can increase the risk of hypotension.'], 'Metyrapone': ['Moderate', 'Amitriptyline decreases the effects of metyrapone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Mianserin': ['NotSet', ""Both amitriptyline and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both amitriptyline and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Minoxidil': ['NotSet', 'Both amitriptyline and minoxidil can increase the risk of hypotension.'], 'Mirtazapine': ['NotSet', ""Both amitriptyline and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moclobemide': ['Severe', 'Amitriptyline is predicted to increase the risk of severe toxic reaction when given with moclobemide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Morphine': ['NotSet', ""Both amitriptyline and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxisylyte': ['NotSet', 'Both amitriptyline and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', ""Both amitriptyline and moxonidine can increase the risk of hypotension. Both amitriptyline and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Amitriptyline is predicted to decrease the effects of moxonidine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Nabilone': ['NotSet', ""Both amitriptyline and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabumetone': ['NotSet', 'Both amitriptyline and nabumetone can increase the risk of hyponatraemia.'], 'Nadolol': ['NotSet', 'Both amitriptyline and nadolol can increase the risk of hypotension.'], 'Naproxen': ['NotSet', 'Both amitriptyline and naproxen can increase the risk of hyponatraemia.'], 'Nebivolol': ['NotSet', 'Both amitriptyline and nebivolol can increase the risk of hypotension.'], 'Nefopam': ['NotSet', 'Both amitriptyline and nefopam can cause antimuscarinic effects.'], 'Nicardipine': ['NotSet', 'Both amitriptyline and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both amitriptyline and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both amitriptyline and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both amitriptyline and nimodipine can increase the risk of hypotension.'], 'Nitrazepam': ['NotSet', ""Both amitriptyline and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitroprusside': ['NotSet', 'Both amitriptyline and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', ""Both amitriptyline and nitrous oxide can increase the risk of hypotension. Both amitriptyline and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Noradrenaline/norepinephrine': ['Severe', 'Amitriptyline increases the effects of noradrenaline/norepinephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Olanzapine': ['NotSet', ""Both amitriptyline and olanzapine can increase the risk of hypotension. Both amitriptyline and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olmesartan': ['NotSet', 'Both amitriptyline and olmesartan can increase the risk of hypotension.'], 'Orphenadrine': ['NotSet', 'Both amitriptyline and orphenadrine can cause antimuscarinic effects.'], 'Oxazepam': ['NotSet', ""Both amitriptyline and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxybutynin': ['NotSet', 'Both amitriptyline and oxybutynin can cause antimuscarinic effects.'], 'Oxycodone': ['NotSet', ""Both amitriptyline and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both amitriptyline and paliperidone can increase the risk of hypotension. Both amitriptyline and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Parecoxib': ['NotSet', 'Both amitriptyline and parecoxib can increase the risk of hyponatraemia.'], 'Paroxetine': ['NotSet', 'Both amitriptyline and paroxetine can increase the risk of hyponatraemia. Paroxetine is predicted to increase the exposure to amitriptyline. Manufacturer advises monitor for toxicity and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Pentazocine': ['NotSet', ""Both amitriptyline and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both amitriptyline and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pergolide': ['NotSet', 'Both amitriptyline and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', ""Both amitriptyline and pericyazine can increase the risk of hypotension. Both amitriptyline and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perindopril': ['NotSet', 'Both amitriptyline and perindopril can increase the risk of hypotension.'], 'Pethidine': ['NotSet', ""Both amitriptyline and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['NotSet', 'Both amitriptyline and phenelzine can increase the risk of hypotension. Amitriptyline is predicted to increase the risk of severe toxic reaction when given with phenelzine. Manufacturer advises avoid and for 14 days after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenobarbital': ['NotSet', ""Both amitriptyline and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Phenobarbital is predicted to decrease the exposure to amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Phenylephrine': ['Severe', 'Amitriptyline increases the effects of phenylephrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Pimozide': ['NotSet', ""Both amitriptyline and pimozide can increase the risk of hypotension. Both amitriptyline and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and pimozide can cause antimuscarinic effects.""], 'Pindolol': ['NotSet', 'Both amitriptyline and pindolol can increase the risk of hypotension.'], 'Piroxicam': ['NotSet', 'Both amitriptyline and piroxicam can increase the risk of hyponatraemia.'], 'Pitolisant': ['Mild', 'Amitriptyline is predicted to decrease the efficacy of pitolisant. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Pizotifen': ['NotSet', ""Both amitriptyline and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pramipexole': ['NotSet', 'Both amitriptyline and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both amitriptyline and prazosin can increase the risk of hypotension.'], 'Pregabalin': ['NotSet', ""Both amitriptyline and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both amitriptyline and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both amitriptyline and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Primidone is predicted to decrease the exposure to amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Prochlorperazine': ['NotSet', ""Both amitriptyline and prochlorperazine can increase the risk of hypotension. Both amitriptyline and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and prochlorperazine can cause antimuscarinic effects.""], 'Procyclidine': ['NotSet', 'Both amitriptyline and procyclidine can cause antimuscarinic effects.'], 'Promazine': ['NotSet', ""Both amitriptyline and promazine can increase the risk of hypotension. Both amitriptyline and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both amitriptyline and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and promethazine can cause antimuscarinic effects.""], 'Propafenone': ['NotSet', 'Both amitriptyline and propafenone can cause antimuscarinic effects. Propafenone is predicted to increase the concentration of amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Propantheline': ['NotSet', 'Both amitriptyline and propantheline can cause antimuscarinic effects.'], 'Propiverine': ['NotSet', 'Both amitriptyline and propiverine can cause antimuscarinic effects.'], 'Propofol': ['NotSet', ""Both amitriptyline and propofol can increase the risk of hypotension. Both amitriptyline and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propranolol': ['NotSet', 'Both amitriptyline and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', ""Both amitriptyline and quetiapine can increase the risk of hypotension. Both amitriptyline and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quinagolide': ['NotSet', 'Both amitriptyline and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both amitriptyline and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both amitriptyline and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', ""Both amitriptyline and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Riociguat': ['NotSet', 'Both amitriptyline and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', ""Both amitriptyline and risperidone can increase the risk of hypotension. Both amitriptyline and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to increase the exposure to amitriptyline. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ropinirole': ['NotSet', 'Both amitriptyline and ropinirole can increase the risk of hypotension.'], 'Ropivacaine': ['NotSet', ""Both amitriptyline and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rotigotine': ['NotSet', 'Both amitriptyline and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both amitriptyline and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both amitriptyline and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both amitriptyline and selegiline can increase the risk of hypotension.'], 'Sertraline': ['NotSet', 'Both amitriptyline and sertraline can increase the risk of hyponatraemia.'], 'Sevoflurane': ['NotSet', ""Both amitriptyline and sevoflurane can increase the risk of hypotension. Both amitriptyline and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sildenafil': ['NotSet', 'Both amitriptyline and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', ""Both amitriptyline and sodium oxybate can increase the risk of hypotension. Both amitriptyline and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sodium picosulfate': ['NotSet', 'Both amitriptyline and sodium picosulfate can increase the risk of hyponatraemia.'], 'Solifenacin': ['NotSet', 'Both amitriptyline and solifenacin can cause antimuscarinic effects.'], 'Sotalol': ['NotSet', 'Both amitriptyline and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both amitriptyline and spironolactone can increase the risk of hyponatraemia. Both amitriptyline and spironolactone can increase the risk of hypotension.'], 'Sucralfate': ['Moderate', 'Sucralfate is predicted to decrease the absorption of amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sufentanil': ['NotSet', ""Both amitriptyline and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulindac': ['NotSet', 'Both amitriptyline and sulindac can increase the risk of hyponatraemia.'], 'Sulpiride': ['NotSet', ""Both amitriptyline and sulpiride can increase the risk of hypotension. Both amitriptyline and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tadalafil': ['NotSet', 'Both amitriptyline and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both amitriptyline and tamsulosin can increase the risk of hypotension.'], 'Tapentadol': ['NotSet', ""Both amitriptyline and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Telmisartan': ['NotSet', 'Both amitriptyline and telmisartan can increase the risk of hypotension.'], 'Temazepam': ['NotSet', ""Both amitriptyline and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tenoxicam': ['NotSet', 'Both amitriptyline and tenoxicam can increase the risk of hyponatraemia.'], 'Terazosin': ['NotSet', 'Both amitriptyline and terazosin can increase the risk of hypotension.'], 'Terbinafine': ['Severe', 'Terbinafine is predicted to increase the exposure to amitriptyline. Manufacturer advises monitor for toxicity and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Tetracaine': ['NotSet', ""Both amitriptyline and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both amitriptyline and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both amitriptyline and thiopental can increase the risk of hypotension. Both amitriptyline and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Amitriptyline increases the risk of cardiac arrhythmias and hypotension when given with thiopental. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study""], 'Tiaprofenic acid': ['NotSet', 'Both amitriptyline and tiaprofenic acid can increase the risk of hyponatraemia.'], 'Timolol': ['NotSet', 'Both amitriptyline and timolol can increase the risk of hypotension.'], 'Tiotropium': ['NotSet', 'Both amitriptyline and tiotropium can cause antimuscarinic effects.'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to increase the exposure to amitriptyline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tizanidine': ['NotSet', ""Both amitriptyline and tizanidine can increase the risk of hypotension. Both amitriptyline and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tolfenamic acid': ['NotSet', 'Both amitriptyline and tolfenamic acid can increase the risk of hyponatraemia.'], 'Tolterodine': ['NotSet', 'Both amitriptyline and tolterodine can cause antimuscarinic effects.'], 'Torasemide': ['NotSet', 'Both amitriptyline and torasemide can increase the risk of hyponatraemia. Both amitriptyline and torasemide can increase the risk of hypotension.'], 'Tramadol': ['NotSet', ""Both amitriptyline and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trandolapril': ['NotSet', 'Both amitriptyline and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both amitriptyline and tranylcypromine can increase the risk of hypotension. Amitriptyline is predicted to increase the risk of severe toxic reaction when given with tranylcypromine. Manufacturer advises avoid and for 14 days after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trazodone': ['NotSet', ""Both amitriptyline and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Triamterene': ['NotSet', 'Both amitriptyline and triamterene can increase the risk of hyponatraemia.'], 'Trifluoperazine': ['NotSet', ""Both amitriptyline and trifluoperazine can increase the risk of hypotension. Both amitriptyline and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Both amitriptyline and trifluoperazine can cause antimuscarinic effects.""], 'Trihexyphenidyl': ['NotSet', 'Both amitriptyline and trihexyphenidyl can cause antimuscarinic effects.'], 'Trimethoprim': ['NotSet', 'Both amitriptyline and trimethoprim can increase the risk of hyponatraemia.'], 'Tropicamide': ['NotSet', 'Both amitriptyline and tropicamide can cause antimuscarinic effects.'], 'Trospium': ['NotSet', 'Both amitriptyline and trospium can cause antimuscarinic effects.'], 'Umeclidinium': ['NotSet', 'Both amitriptyline and umeclidinium can cause antimuscarinic effects.'], 'Valsartan': ['NotSet', 'Both amitriptyline and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both amitriptyline and vardenafil can increase the risk of hypotension.'], 'Venlafaxine': ['NotSet', ""Both amitriptyline and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['NotSet', 'Both amitriptyline and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both amitriptyline and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both amitriptyline and xipamide can increase the risk of hyponatraemia. Both amitriptyline and xipamide can increase the risk of hypotension.'], 'Zolpidem': ['NotSet', ""Both amitriptyline and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both amitriptyline and zuclopenthixol can increase the risk of hypotension. Both amitriptyline and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","amlodipine","{'Acebutolol': ['NotSet', 'Both amlodipine and acebutolol can increase the risk of hypotension.'], 'Alcohol (beverage)': ['NotSet', 'Both amlodipine and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both amlodipine and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both amlodipine and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both amlodipine and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both amlodipine and amantadine can increase the risk of hypotension.'], 'Amitriptyline': ['NotSet', 'Both amlodipine and amitriptyline can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both amlodipine and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both amlodipine and apraclonidine can increase the risk of hypotension.'], 'Aprepitant': ['Moderate', 'Aprepitant is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aripiprazole': ['NotSet', 'Both amlodipine and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both amlodipine and asenapine can increase the risk of hypotension.'], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atenolol': ['NotSet', 'Both amlodipine and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both amlodipine and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both amlodipine and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both amlodipine and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both amlodipine and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both amlodipine and benperidol can increase the risk of hypotension.'], 'Betaxolol': ['NotSet', 'Both amlodipine and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both amlodipine and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both amlodipine and bortezomib can increase the risk of hypotension.'], 'Bosentan': ['Moderate', 'Bosentan is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Brimonidine': ['NotSet', 'Both amlodipine and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both amlodipine and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both amlodipine and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both amlodipine and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both amlodipine and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both amlodipine and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both amlodipine and captopril can increase the risk of hypotension.'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cariprazine': ['NotSet', 'Both amlodipine and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both amlodipine and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both amlodipine and celiprolol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both amlodipine and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both amlodipine and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both amlodipine and chlortalidone can increase the risk of hypotension.'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clomipramine': ['NotSet', 'Both amlodipine and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both amlodipine and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both amlodipine and clozapine can increase the risk of hypotension.'], 'Cobicistat': ['Moderate', 'Cobicistat is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Crizotinib': ['Moderate', 'Crizotinib is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dapagliflozin': ['NotSet', 'Both amlodipine and dapagliflozin can increase the risk of hypotension.'], 'Darunavir': ['Moderate', 'Darunavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Desflurane': ['NotSet', 'Both amlodipine and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both amlodipine and diazoxide can increase the risk of hypotension.'], 'Diltiazem': ['Moderate', 'Diltiazem is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dipyridamole': ['NotSet', 'Both amlodipine and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', 'Both amlodipine and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both amlodipine and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both amlodipine and doxepin can increase the risk of hypotension.'], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Droperidol': ['NotSet', 'Both amlodipine and droperidol can increase the risk of hypotension.'], 'Efavirenz': ['Moderate', 'Efavirenz is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Empagliflozin': ['NotSet', 'Both amlodipine and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both amlodipine and enalapril can increase the risk of hypotension.'], 'Enzalutamide': ['Moderate', 'Enzalutamide is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eplerenone': ['NotSet', 'Both amlodipine and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both amlodipine and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both amlodipine and ertugliflozin can increase the risk of hypotension.'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Esketamine': ['NotSet', 'Both amlodipine and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both amlodipine and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both amlodipine and etomidate can increase the risk of hypotension.'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Flupentixol': ['NotSet', 'Both amlodipine and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both amlodipine and fluphenazine can increase the risk of hypotension.'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosinopril': ['NotSet', 'Both amlodipine and fosinopril can increase the risk of hypotension.'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Furosemide': ['NotSet', 'Both amlodipine and furosemide can increase the risk of hypotension.'], 'Glyceryl trinitrate': ['NotSet', 'Both amlodipine and glyceryl trinitrate can increase the risk of hypotension.'], 'Grapefruit juice': ['Mild', 'Grapefruit juice very slightly increases the exposure to amlodipine. Manufacturer advises avoid. Severity of interaction: Mild Evidence for interaction: Study'], 'Grazoprevir': ['Moderate', 'Grazoprevir is predicted to increase the concentration of amlodipine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Guanethidine': ['NotSet', 'Both amlodipine and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both amlodipine and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both amlodipine and haloperidol can increase the risk of hypotension.'], 'Hydralazine': ['NotSet', 'Both amlodipine and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both amlodipine and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both amlodipine and hydroflumethiazide can increase the risk of hypotension.'], 'Idelalisib': ['Moderate', 'Idelalisib is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imatinib': ['Moderate', 'Imatinib is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imidapril': ['NotSet', 'Both amlodipine and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both amlodipine and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both amlodipine and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both amlodipine and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both amlodipine and irbesartan can increase the risk of hypotension.'], 'Isavuconazole': ['Moderate', 'Isavuconazole is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Isocarboxazid': ['NotSet', 'Both amlodipine and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both amlodipine and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both amlodipine and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both amlodipine and isosorbide mononitrate can increase the risk of hypotension.'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketamine': ['NotSet', 'Both amlodipine and ketamine can increase the risk of hypotension.'], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Labetalol': ['NotSet', 'Both amlodipine and labetalol can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both amlodipine and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both amlodipine and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both amlodipine and levomepromazine can increase the risk of hypotension.'], 'Lisinopril': ['NotSet', 'Both amlodipine and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both amlodipine and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both amlodipine and lofexidine can increase the risk of hypotension.'], 'Lomitapide': ['Moderate', 'Amlodipine is predicted to increase the exposure to lomitapide. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Losartan': ['NotSet', 'Both amlodipine and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both amlodipine and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both amlodipine and lurasidone can increase the risk of hypotension.'], 'Magnesium': ['Severe', 'Intravenous magnesium potentially increases the risk of hypotension when given with amlodipine (in pregnant women). Manufacturer advises monitor blood pressure. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of bradycardia when given with amlodipine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methoxyflurane': ['NotSet', 'Both amlodipine and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both amlodipine and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both amlodipine and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both amlodipine and metoprolol can increase the risk of hypotension.'], 'Miconazole': ['Moderate', 'Miconazole is predicted to increase the exposure to amlodipine. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Minoxidil': ['NotSet', 'Both amlodipine and minoxidil can increase the risk of hypotension.'], 'Mitotane': ['Moderate', 'Mitotane is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Moxisylyte': ['NotSet', 'Both amlodipine and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both amlodipine and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both amlodipine and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both amlodipine and nebivolol can increase the risk of hypotension.'], 'Netupitant': ['Moderate', 'Netupitant is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nevirapine': ['Moderate', 'Nevirapine is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nicorandil': ['NotSet', 'Both amlodipine and nicorandil can increase the risk of hypotension.'], 'Nilotinib': ['Moderate', 'Nilotinib is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nitroprusside': ['NotSet', 'Both amlodipine and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both amlodipine and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both amlodipine and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both amlodipine and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both amlodipine and olmesartan can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both amlodipine and paliperidone can increase the risk of hypotension.'], 'Pergolide': ['NotSet', 'Both amlodipine and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both amlodipine and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both amlodipine and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both amlodipine and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['NotSet', 'Both amlodipine and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both amlodipine and pindolol can increase the risk of hypotension.'], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pramipexole': ['NotSet', 'Both amlodipine and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both amlodipine and prazosin can increase the risk of hypotension.'], 'Primidone': ['Moderate', 'Primidone is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Prochlorperazine': ['NotSet', 'Both amlodipine and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both amlodipine and promazine can increase the risk of hypotension.'], 'Propofol': ['NotSet', 'Both amlodipine and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both amlodipine and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both amlodipine and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both amlodipine and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both amlodipine and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both amlodipine and ramipril can increase the risk of hypotension.'], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Riociguat': ['NotSet', 'Both amlodipine and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both amlodipine and risperidone can increase the risk of hypotension.'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ropinirole': ['NotSet', 'Both amlodipine and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both amlodipine and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both amlodipine and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both amlodipine and sapropterin can increase the risk of hypotension.'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Selegiline': ['NotSet', 'Both amlodipine and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both amlodipine and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both amlodipine and sildenafil can increase the risk of hypotension.'], 'Simvastatin': ['Mild', 'Amlodipine slightly increases the exposure to simvastatin. Manufacturer advises adjust simvastatin dose. Severity of interaction: Mild Evidence for interaction: Study'], 'Sodium oxybate': ['NotSet', 'Both amlodipine and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both amlodipine and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both amlodipine and spironolactone can increase the risk of hypotension.'], ""St John's Wort"": ['Moderate', ""St John's Wort is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Sulpiride': ['NotSet', 'Both amlodipine and sulpiride can increase the risk of hypotension.'], 'Tadalafil': ['NotSet', 'Both amlodipine and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both amlodipine and tamsulosin can increase the risk of hypotension.'], 'Telmisartan': ['NotSet', 'Both amlodipine and telmisartan can increase the risk of hypotension.'], 'Temsirolimus': ['Moderate', 'Temsirolimus is predicted to increase the risk of angioedema when given with amlodipine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Terazosin': ['NotSet', 'Both amlodipine and terazosin can increase the risk of hypotension.'], 'Thiopental': ['NotSet', 'Both amlodipine and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both amlodipine and timolol can increase the risk of hypotension.'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tizanidine': ['NotSet', 'Both amlodipine and tizanidine can increase the risk of hypotension.'], 'Tocilizumab': ['Moderate', 'Tocilizumab is predicted to decrease the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Torasemide': ['NotSet', 'Both amlodipine and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both amlodipine and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both amlodipine and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both amlodipine and trifluoperazine can increase the risk of hypotension.'], 'Trimipramine': ['NotSet', 'Both amlodipine and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both amlodipine and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both amlodipine and vardenafil can increase the risk of hypotension.'], 'Verapamil': ['Moderate', 'Verapamil is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Vernakalant': ['NotSet', 'Both amlodipine and vernakalant can increase the risk of hypotension.'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Xipamide': ['NotSet', 'Both amlodipine and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both amlodipine and zuclopenthixol can increase the risk of hypotension.']}","amoxicillin","{'Acenocoumarol': ['Severe', 'Amoxicillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Allopurinol': ['Moderate', 'Allopurinol increases the risk of skin rash when given with amoxicillin. Manufacturer advises consider alternatives. Severity of interaction: Moderate Evidence for interaction: Study'], 'Methotrexate': ['Severe', 'Amoxicillin is predicted to increase the risk of toxicity when given with methotrexate. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Phenindione': ['Severe', 'Amoxicillin is predicted to increase the risk of bleeding events when given with phenindione. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Warfarin': ['Severe', 'Amoxicillin potentially alters the anticoagulant effect of warfarin. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal']}","amphotericin","{'Aceclofenac': ['NotSet', 'Both amphotericin and aceclofenac can increase the risk of nephrotoxicity.'], 'Aciclovir': ['NotSet', 'Both amphotericin and aciclovir can increase the risk of nephrotoxicity.'], 'Adefovir': ['NotSet', 'Both amphotericin and adefovir can increase the risk of nephrotoxicity.'], 'Amifampridine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amifampridine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amikacin': ['NotSet', 'Both amphotericin and amikacin can increase the risk of nephrotoxicity.'], 'Aminophylline': ['NotSet', 'Both amphotericin and aminophylline can increase the risk of hypokalaemia.'], 'Amiodarone': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amiodarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amisulpride': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with amisulpride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apalutamide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apomorphine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Arsenic trioxide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Artemether': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Artenimol': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bacitracin': ['NotSet', 'Both amphotericin and bacitracin can increase the risk of nephrotoxicity.'], 'Bambuterol': ['NotSet', 'Both amphotericin and bambuterol can increase the risk of hypokalaemia.'], 'Beclometasone': ['NotSet', 'Both amphotericin and beclometasone can increase the risk of hypokalaemia.'], 'Bedaquiline': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with bedaquiline. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bendroflumethiazide': ['NotSet', 'Both amphotericin and bendroflumethiazide can increase the risk of hypokalaemia.'], 'Betamethasone': ['NotSet', 'Both amphotericin and betamethasone can increase the risk of hypokalaemia.'], 'Bosutinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with bosutinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Budesonide': ['NotSet', 'Both amphotericin and budesonide can increase the risk of hypokalaemia.'], 'Bumetanide': ['NotSet', 'Both amphotericin and bumetanide can increase the risk of hypokalaemia.'], 'Cabozantinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with cabozantinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Capreomycin': ['NotSet', 'Both amphotericin and capreomycin can increase the risk of nephrotoxicity.'], 'Carboplatin': ['NotSet', 'Both amphotericin and carboplatin can increase the risk of nephrotoxicity.'], 'Cefaclor': ['NotSet', 'Both amphotericin and cefaclor can increase the risk of nephrotoxicity.'], 'Cefadroxil': ['NotSet', 'Both amphotericin and cefadroxil can increase the risk of nephrotoxicity.'], 'Cefalexin': ['NotSet', 'Both amphotericin and cefalexin can increase the risk of nephrotoxicity.'], 'Cefepime': ['NotSet', 'Both amphotericin and cefepime can increase the risk of nephrotoxicity.'], 'Cefixime': ['NotSet', 'Both amphotericin and cefixime can increase the risk of nephrotoxicity.'], 'Cefotaxime': ['NotSet', 'Both amphotericin and cefotaxime can increase the risk of nephrotoxicity.'], 'Cefoxitin': ['NotSet', 'Both amphotericin and cefoxitin can increase the risk of nephrotoxicity.'], 'Cefradine': ['NotSet', 'Both amphotericin and cefradine can increase the risk of nephrotoxicity.'], 'Ceftaroline': ['NotSet', 'Both amphotericin and ceftaroline can increase the risk of nephrotoxicity.'], 'Ceftazidime': ['NotSet', 'Both amphotericin and ceftazidime can increase the risk of nephrotoxicity.'], 'Ceftobiprole': ['NotSet', 'Both amphotericin and ceftobiprole can increase the risk of nephrotoxicity.'], 'Ceftolozane': ['NotSet', 'Both amphotericin and ceftolozane can increase the risk of nephrotoxicity.'], 'Ceftriaxone': ['NotSet', 'Both amphotericin and ceftriaxone can increase the risk of nephrotoxicity.'], 'Cefuroxime': ['NotSet', 'Both amphotericin and cefuroxime can increase the risk of nephrotoxicity.'], 'Celecoxib': ['NotSet', 'Both amphotericin and celecoxib can increase the risk of nephrotoxicity.'], 'Ceritinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ceritinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorothiazide': ['NotSet', 'Both amphotericin and chlorothiazide can increase the risk of hypokalaemia.'], 'Chlorpromazine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with chlorpromazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlortalidone': ['NotSet', 'Both amphotericin and chlortalidone can increase the risk of hypokalaemia.'], 'Ciclosporin': ['NotSet', 'Both amphotericin and ciclosporin can increase the risk of nephrotoxicity.'], 'Cidofovir': ['NotSet', 'Both amphotericin and cidofovir can increase the risk of nephrotoxicity.'], 'Cisplatin': ['NotSet', 'Both amphotericin and cisplatin can increase the risk of nephrotoxicity.'], 'Citalopram': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with citalopram. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clarithromycin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clomipramine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clomipramine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Colistimethate': ['Severe', 'Colistimethate (particularly intravenous) potentially increases the risk of nephrotoxicity when given with amphotericin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Crizotinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with crizotinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dasatinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with dasatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Deflazacort': ['NotSet', 'Both amphotericin and deflazacort can increase the risk of hypokalaemia.'], 'Delamanid': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with delamanid. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexamethasone': ['NotSet', 'Both amphotericin and dexamethasone can increase the risk of hypokalaemia.'], 'Dexibuprofen': ['NotSet', 'Both amphotericin and dexibuprofen can increase the risk of nephrotoxicity.'], 'Dexketoprofen': ['NotSet', 'Both amphotericin and dexketoprofen can increase the risk of nephrotoxicity.'], 'Diclofenac': ['NotSet', 'Both amphotericin and diclofenac can increase the risk of nephrotoxicity.'], 'Digoxin': ['Severe', 'Amphotericin is predicted to increase the risk of digoxin toxicity when given with digoxin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Disopyramide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with disopyramide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with dronedarone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Droperidol': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with droperidol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Efavirenz': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with efavirenz. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Encorafenib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with encorafenib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eribulin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with eribulin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erythromycin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with erythromycin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Escitalopram': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with escitalopram. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etodolac': ['NotSet', 'Both amphotericin and etodolac can increase the risk of nephrotoxicity.'], 'Etoricoxib': ['NotSet', 'Both amphotericin and etoricoxib can increase the risk of nephrotoxicity.'], 'Flecainide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with flecainide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluconazole': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with fluconazole. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flucytosine': ['Severe', 'Amphotericin increases the risk of toxicity when given with flucytosine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Fludrocortisone': ['NotSet', 'Both amphotericin and fludrocortisone can increase the risk of hypokalaemia.'], 'Fluphenazine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with fluphenazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flurbiprofen': ['NotSet', 'Both amphotericin and flurbiprofen can increase the risk of nephrotoxicity.'], 'Formoterol': ['NotSet', 'Both amphotericin and formoterol can increase the risk of hypokalaemia.'], 'Foscarnet': ['NotSet', 'Both amphotericin and foscarnet can increase the risk of nephrotoxicity.'], 'Furosemide': ['NotSet', 'Both amphotericin and furosemide can increase the risk of hypokalaemia.'], 'Ganciclovir': ['NotSet', 'Both amphotericin and ganciclovir can increase the risk of nephrotoxicity.'], 'Gentamicin': ['NotSet', 'Both amphotericin and gentamicin can increase the risk of nephrotoxicity.'], 'Haloperidol': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with haloperidol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrochlorothiazide': ['NotSet', 'Both amphotericin and hydrochlorothiazide can increase the risk of hypokalaemia.'], 'Hydrocortisone': ['NotSet', 'Both amphotericin and hydrocortisone can increase the risk of hypokalaemia.'], 'Hydroflumethiazide': ['NotSet', 'Both amphotericin and hydroflumethiazide can increase the risk of hypokalaemia.'], 'Hydroxyzine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with hydroxyzine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibuprofen': ['NotSet', 'Both amphotericin and ibuprofen can increase the risk of nephrotoxicity.'], 'Ifosfamide': ['NotSet', 'Both amphotericin and ifosfamide can increase the risk of nephrotoxicity.'], 'Indacaterol': ['NotSet', 'Both amphotericin and indacaterol can increase the risk of hypokalaemia.'], 'Indapamide': ['NotSet', 'Both amphotericin and indapamide can increase the risk of hypokalaemia.'], 'Indometacin': ['NotSet', 'Both amphotericin and indometacin can increase the risk of nephrotoxicity.'], 'Inotuzumab ozogamicin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with inotuzumab ozogamicin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketoprofen': ['NotSet', 'Both amphotericin and ketoprofen can increase the risk of nephrotoxicity.'], 'Ketorolac': ['NotSet', 'Both amphotericin and ketorolac can increase the risk of nephrotoxicity.'], 'Lapatinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lapatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lenvatinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lenvatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levomepromazine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with levomepromazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lithium': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lithium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lofexidine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with lofexidine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mefenamic acid': ['NotSet', 'Both amphotericin and mefenamic acid can increase the risk of nephrotoxicity.'], 'Meloxicam': ['NotSet', 'Both amphotericin and meloxicam can increase the risk of nephrotoxicity.'], 'Methadone': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with methadone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methotrexate': ['NotSet', 'Both amphotericin and methotrexate can increase the risk of nephrotoxicity.'], 'Methylprednisolone': ['NotSet', 'Both amphotericin and methylprednisolone can increase the risk of hypokalaemia.'], 'Metolazone': ['NotSet', 'Both amphotericin and metolazone can increase the risk of hypokalaemia.'], 'Micafungin': ['Moderate', 'Micafungin slightly increases the exposure to amphotericin. Manufacturer advises avoid or monitor toxicity. Severity of interaction: Moderate Evidence for interaction: Study'], 'Moxifloxacin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with moxifloxacin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nabumetone': ['NotSet', 'Both amphotericin and nabumetone can increase the risk of nephrotoxicity.'], 'Naproxen': ['NotSet', 'Both amphotericin and naproxen can increase the risk of nephrotoxicity.'], 'Neomycin': ['NotSet', 'Both amphotericin and neomycin can increase the risk of nephrotoxicity.'], 'Nilotinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with nilotinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Olodaterol': ['NotSet', 'Both amphotericin and olodaterol can increase the risk of hypokalaemia.'], 'Ondansetron': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ondansetron. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Osimertinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with osimertinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Oxaliplatin': ['NotSet', 'Both amphotericin and oxaliplatin can increase the risk of nephrotoxicity.'], 'Paliperidone': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with paliperidone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with panobinostat. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Parecoxib': ['NotSet', 'Both amphotericin and parecoxib can increase the risk of nephrotoxicity.'], 'Pasireotide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with pasireotide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pazopanib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with pazopanib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pemetrexed': ['NotSet', 'Both amphotericin and pemetrexed can increase the risk of nephrotoxicity.'], 'Penicillamine': ['NotSet', 'Both amphotericin and penicillamine can increase the risk of nephrotoxicity.'], 'Pentamidine': ['NotSet', 'Both amphotericin and pentamidine can increase the risk of nephrotoxicity.'], 'Pimozide': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with pimozide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Piroxicam': ['NotSet', 'Both amphotericin and piroxicam can increase the risk of nephrotoxicity.'], 'Polymyxin b': ['NotSet', 'Both amphotericin and polymyxin b can increase the risk of nephrotoxicity.'], 'Prednisolone': ['NotSet', 'Both amphotericin and prednisolone can increase the risk of hypokalaemia.'], 'Quinine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with quinine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ranolazine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ranolazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ribociclib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with ribociclib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Risperidone': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with risperidone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salbutamol': ['NotSet', 'Both amphotericin and salbutamol can increase the risk of hypokalaemia.'], 'Salmeterol': ['NotSet', 'Both amphotericin and salmeterol can increase the risk of hypokalaemia.'], 'Saquinavir': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with saquinavir. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sildenafil': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sildenafil. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sodium stibogluconate': ['Severe', 'Sodium stibogluconate increases the risk of cardiovascular side-effects when given with amphotericin. Manufacturer advises separate administration by 14 days. Severity of interaction: Severe Evidence for interaction: Study'], 'Sorafenib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sorafenib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sotalol': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sotalol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Streptomycin': ['NotSet', 'Both amphotericin and streptomycin can increase the risk of nephrotoxicity.'], 'Streptozocin': ['NotSet', 'Both amphotericin and streptozocin can increase the risk of nephrotoxicity.'], 'Sulindac': ['NotSet', 'Both amphotericin and sulindac can increase the risk of nephrotoxicity.'], 'Sulpiride': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sulpiride. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sunitinib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with sunitinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tacrolimus': ['NotSet', 'Both amphotericin and tacrolimus can increase the risk of nephrotoxicity.'], 'Telavancin': ['NotSet', 'Both amphotericin and telavancin can increase the risk of nephrotoxicity. Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with telavancin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenofovir disoproxil': ['NotSet', 'Both amphotericin and tenofovir disoproxil can increase the risk of nephrotoxicity.'], 'Tenoxicam': ['NotSet', 'Both amphotericin and tenoxicam can increase the risk of nephrotoxicity.'], 'Terbutaline': ['NotSet', 'Both amphotericin and terbutaline can increase the risk of hypokalaemia.'], 'Tetrabenazine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with tetrabenazine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Theophylline': ['NotSet', 'Both amphotericin and theophylline can increase the risk of hypokalaemia.'], 'Tiaprofenic acid': ['NotSet', 'Both amphotericin and tiaprofenic acid can increase the risk of nephrotoxicity.'], 'Tizanidine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with tizanidine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tobramycin': ['NotSet', 'Both amphotericin and tobramycin can increase the risk of nephrotoxicity.'], 'Tolfenamic acid': ['NotSet', 'Both amphotericin and tolfenamic acid can increase the risk of nephrotoxicity.'], 'Tolterodine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with tolterodine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Torasemide': ['NotSet', 'Both amphotericin and torasemide can increase the risk of hypokalaemia.'], 'Toremifene': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with toremifene. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Triamcinolone': ['NotSet', 'Both amphotericin and triamcinolone can increase the risk of hypokalaemia.'], 'Trimethoprim': ['NotSet', 'Both amphotericin and trimethoprim can increase the risk of nephrotoxicity.'], 'Valaciclovir': ['NotSet', 'Both amphotericin and valaciclovir can increase the risk of nephrotoxicity.'], 'Valganciclovir': ['NotSet', 'Both amphotericin and valganciclovir can increase the risk of nephrotoxicity.'], 'Vancomycin': ['NotSet', 'Both amphotericin and vancomycin can increase the risk of nephrotoxicity.'], 'Vandetanib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vandetanib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vardenafil': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vardenafil. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vemurafenib': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vemurafenib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venlafaxine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with venlafaxine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vernakalant': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vernakalant. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vilanterol': ['NotSet', 'Both amphotericin and vilanterol can increase the risk of hypokalaemia.'], 'Vinflunine': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with vinflunine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with voriconazole. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Xipamide': ['NotSet', 'Both amphotericin and xipamide can increase the risk of hypokalaemia.'], 'Zidovudine': ['NotSet', 'Both amphotericin and zidovudine can increase the risk of nephrotoxicity.'], 'Zoledronate': ['NotSet', 'Both amphotericin and zoledronate can increase the risk of nephrotoxicity.'], 'Zuclopenthixol': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with zuclopenthixol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical']}","ampicillin","{'Acenocoumarol': ['Severe', 'Ampicillin potentially alters the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Allopurinol': ['Moderate', 'Allopurinol increases the risk of skin rash when given with ampicillin. Manufacturer advises consider alternatives. Severity of interaction: Moderate Evidence for interaction: Study'], 'Methotrexate': ['Severe', 'Ampicillin is predicted to increase the risk of toxicity when given with methotrexate. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Phenindione': ['Severe', 'Ampicillin is predicted to increase the risk of bleeding events when given with phenindione. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Warfarin': ['Severe', 'Ampicillin potentially alters the anticoagulant effect of warfarin. Manufacturer advises monitor INR and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal']}","amsacrine","{'Afatinib': ['NotSet', 'Both amsacrine and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both amsacrine and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both amsacrine and alemtuzumab can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both amsacrine and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both amsacrine and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both amsacrine and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both amsacrine and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both amsacrine and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both amsacrine and azathioprine can increase the risk of myelosuppression.'], 'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Balsalazide': ['NotSet', 'Both amsacrine and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both amsacrine and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both amsacrine and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both amsacrine and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both amsacrine and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both amsacrine and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both amsacrine and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both amsacrine and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both amsacrine and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both amsacrine and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both amsacrine and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both amsacrine and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both amsacrine and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both amsacrine and capecitabine can increase the risk of myelosuppression.'], 'Carbimazole': ['NotSet', 'Both amsacrine and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both amsacrine and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both amsacrine and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both amsacrine and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both amsacrine and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both amsacrine and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both amsacrine and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both amsacrine and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both amsacrine and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both amsacrine and cladribine can increase the risk of myelosuppression.'], 'Clofarabine': ['NotSet', 'Both amsacrine and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both amsacrine and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both amsacrine and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both amsacrine and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both amsacrine and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both amsacrine and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both amsacrine and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both amsacrine and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both amsacrine and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both amsacrine and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both amsacrine and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both amsacrine and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both amsacrine and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both amsacrine and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both amsacrine and doxorubicin can increase the risk of myelosuppression.'], 'Epirubicin': ['NotSet', 'Both amsacrine and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both amsacrine and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both amsacrine and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both amsacrine and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both amsacrine and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both amsacrine and everolimus can increase the risk of myelosuppression.'], 'Fludarabine': ['NotSet', 'Both amsacrine and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both amsacrine and fluorouracil can increase the risk of myelosuppression.'], 'Ganciclovir': ['NotSet', 'Both amsacrine and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both amsacrine and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both amsacrine and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both amsacrine and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both amsacrine and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both amsacrine and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both amsacrine and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both amsacrine and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both amsacrine and imatinib can increase the risk of myelosuppression.'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Interferon alfa': ['NotSet', 'Both amsacrine and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both amsacrine and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both amsacrine and irinotecan can increase the risk of myelosuppression.'], 'Leflunomide': ['NotSet', 'Both amsacrine and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both amsacrine and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both amsacrine and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both amsacrine and lomustine can increase the risk of myelosuppression.'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Melphalan': ['NotSet', 'Both amsacrine and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both amsacrine and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both amsacrine and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both amsacrine and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both amsacrine and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both amsacrine and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both amsacrine and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both amsacrine and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both amsacrine and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both amsacrine and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both amsacrine and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both amsacrine and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both amsacrine and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both amsacrine and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both amsacrine and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both amsacrine and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both amsacrine and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both amsacrine and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both amsacrine and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both amsacrine and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both amsacrine and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both amsacrine and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both amsacrine and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both amsacrine and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both amsacrine and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both amsacrine and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both amsacrine and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both amsacrine and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both amsacrine and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both amsacrine and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both amsacrine and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both amsacrine and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both amsacrine and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both amsacrine and regorafenib can increase the risk of myelosuppression.'], 'Rituximab': ['NotSet', 'Both amsacrine and rituximab can increase the risk of myelosuppression.'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ruxolitinib': ['NotSet', 'Both amsacrine and ruxolitinib can increase the risk of myelosuppression.'], 'Siltuximab': ['NotSet', 'Both amsacrine and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both amsacrine and sorafenib can increase the risk of myelosuppression.'], 'Sulfadiazine': ['NotSet', 'Both amsacrine and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both amsacrine and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both amsacrine and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both amsacrine and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both amsacrine and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both amsacrine and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both amsacrine and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both amsacrine and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both amsacrine and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both amsacrine and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both amsacrine and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both amsacrine and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both amsacrine and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both amsacrine and trimethoprim can increase the risk of myelosuppression.'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Valganciclovir': ['NotSet', 'Both amsacrine and valganciclovir can increase the risk of myelosuppression.'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both amsacrine and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both amsacrine and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both amsacrine and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both amsacrine and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both amsacrine and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both amsacrine and vismodegib can increase the risk of myelosuppression.'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both amsacrine and zidovudine can increase the risk of myelosuppression.']}","anagrelide","{'Aceclofenac': ['NotSet', 'Both anagrelide and aceclofenac can increase the risk of bleeding.'], 'Acenocoumarol': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Alteplase': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amifampridine': ['Severe', 'Both anagrelide and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both anagrelide and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both anagrelide and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apalutamide': ['Severe', 'Both anagrelide and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apixaban': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apomorphine': ['Severe', 'Both anagrelide and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Argatroban': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Arsenic trioxide': ['Severe', 'Both anagrelide and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both anagrelide and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both anagrelide and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aspirin': ['NotSet', 'Both anagrelide and aspirin can increase the risk of bleeding.'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both anagrelide and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bevacizumab': ['NotSet', 'Both anagrelide and bevacizumab can increase the risk of bleeding.'], 'Bivalirudin': ['Severe', 'Bivalirudin is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Both anagrelide and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cabozantinib': ['Severe', 'Both anagrelide and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Cangrelor': ['NotSet', 'Both anagrelide and cangrelor can increase the risk of bleeding.'], 'Celecoxib': ['NotSet', 'Both anagrelide and celecoxib can increase the risk of bleeding.'], 'Ceritinib': ['Severe', 'Both anagrelide and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both anagrelide and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cilostazol': ['NotSet', 'Both anagrelide and cilostazol can increase the risk of bleeding.'], 'Ciprofloxacin': ['Moderate', 'Ciprofloxacin is predicted to increase the exposure to anagrelide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Both anagrelide and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both anagrelide and citalopram can increase the risk of bleeding.'], 'Clarithromycin': ['Severe', 'Both anagrelide and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clomipramine': ['Severe', 'Both anagrelide and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clopidogrel': ['NotSet', 'Both anagrelide and clopidogrel can increase the risk of bleeding.'], 'Combined hormonal contraceptives': ['Moderate', 'Combined hormonal contraceptives are predicted to increase the exposure to anagrelide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Crizotinib': ['Severe', 'Both anagrelide and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dabigatran': ['Severe', 'Dabigatran is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dalteparin': ['Severe', 'Dalteparin is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Danaparoid': ['Severe', 'Danaparoid is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dapoxetine': ['NotSet', 'Both anagrelide and dapoxetine can increase the risk of bleeding.'], 'Dasatinib': ['Severe', 'Both anagrelide and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both anagrelide and dasatinib can increase the risk of bleeding.'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both anagrelide and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['NotSet', 'Both anagrelide and dexibuprofen can increase the risk of bleeding.'], 'Dexketoprofen': ['NotSet', 'Both anagrelide and dexketoprofen can increase the risk of bleeding.'], 'Diclofenac': ['NotSet', 'Both anagrelide and diclofenac can increase the risk of bleeding.'], 'Dipyridamole': ['NotSet', 'Both anagrelide and dipyridamole can increase the risk of bleeding.'], 'Disopyramide': ['Severe', 'Both anagrelide and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with anagrelide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Severe', 'Both anagrelide and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', 'Both anagrelide and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Duloxetine': ['NotSet', 'Both anagrelide and duloxetine can increase the risk of bleeding.'], 'Edoxaban': ['Severe', 'Edoxaban is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Efavirenz': ['Severe', 'Both anagrelide and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both anagrelide and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Enoxaparin': ['Severe', 'Enoxaparin is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Epoprostenol': ['NotSet', 'Both anagrelide and epoprostenol can increase the risk of bleeding.'], 'Eptifibatide': ['NotSet', 'Both anagrelide and eptifibatide can increase the risk of bleeding.'], 'Eribulin': ['Severe', 'Both anagrelide and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both anagrelide and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both anagrelide and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both anagrelide and escitalopram can increase the risk of bleeding.'], 'Etodolac': ['NotSet', 'Both anagrelide and etodolac can increase the risk of bleeding.'], 'Etoricoxib': ['NotSet', 'Both anagrelide and etoricoxib can increase the risk of bleeding.'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with anagrelide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both anagrelide and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both anagrelide and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluoxetine': ['NotSet', 'Both anagrelide and fluoxetine can increase the risk of bleeding.'], 'Fluphenazine': ['Severe', 'Both anagrelide and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Flurbiprofen': ['NotSet', 'Both anagrelide and flurbiprofen can increase the risk of bleeding.'], 'Fluvoxamine': ['NotSet', 'Both anagrelide and fluvoxamine can increase the risk of bleeding. Fluvoxamine is predicted to increase the exposure to anagrelide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fondaparinux': ['Severe', 'Fondaparinux is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with anagrelide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Haloperidol': ['Severe', 'Both anagrelide and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Heparin (unfractionated)': ['Severe', 'Heparin (unfractionated) is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both anagrelide and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ibrutinib': ['NotSet', 'Both anagrelide and ibrutinib can increase the risk of bleeding.'], 'Ibuprofen': ['NotSet', 'Both anagrelide and ibuprofen can increase the risk of bleeding.'], 'Iloprost': ['NotSet', 'Both anagrelide and iloprost can increase the risk of bleeding.'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indometacin': ['NotSet', 'Both anagrelide and indometacin can increase the risk of bleeding.'], 'Inotersen': ['NotSet', 'Both anagrelide and inotersen can increase the risk of bleeding.'], 'Inotuzumab ozogamicin': ['Severe', 'Both anagrelide and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with anagrelide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketoprofen': ['NotSet', 'Both anagrelide and ketoprofen can increase the risk of bleeding.'], 'Ketorolac': ['NotSet', 'Both anagrelide and ketorolac can increase the risk of bleeding.'], 'Lapatinib': ['Severe', 'Both anagrelide and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both anagrelide and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levomepromazine': ['Severe', 'Both anagrelide and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lithium': ['Severe', 'Both anagrelide and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both anagrelide and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Mefenamic acid': ['NotSet', 'Both anagrelide and mefenamic acid can increase the risk of bleeding.'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Meloxicam': ['NotSet', 'Both anagrelide and meloxicam can increase the risk of bleeding.'], 'Methadone': ['Severe', 'Both anagrelide and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mexiletine': ['Moderate', 'Mexiletine is predicted to increase the exposure to anagrelide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with anagrelide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both anagrelide and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nabumetone': ['NotSet', 'Both anagrelide and nabumetone can increase the risk of bleeding.'], 'Naproxen': ['NotSet', 'Both anagrelide and naproxen can increase the risk of bleeding.'], 'Nicotinic acid': ['Severe', 'Nicotinic acid is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nilotinib': ['Severe', 'Both anagrelide and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Omega-3-acid ethyl esters': ['Severe', 'Omega-3-acid ethyl esters is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both anagrelide and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both anagrelide and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Paliperidone': ['Severe', 'Both anagrelide and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with anagrelide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both anagrelide and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Parecoxib': ['NotSet', 'Both anagrelide and parecoxib can increase the risk of bleeding.'], 'Paroxetine': ['NotSet', 'Both anagrelide and paroxetine can increase the risk of bleeding.'], 'Pasireotide': ['Severe', 'Both anagrelide and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both anagrelide and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with anagrelide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Phenindione': ['Severe', 'Phenindione is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pimozide': ['Severe', 'Both anagrelide and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Piroxicam': ['NotSet', 'Both anagrelide and piroxicam can increase the risk of bleeding.'], 'Prasugrel': ['NotSet', 'Both anagrelide and prasugrel can increase the risk of bleeding.'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Quinine': ['Severe', 'Both anagrelide and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ranolazine': ['Severe', 'Both anagrelide and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Regorafenib': ['NotSet', 'Both anagrelide and regorafenib can increase the risk of bleeding.'], 'Ribociclib': ['Severe', 'Both anagrelide and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Risperidone': ['Severe', 'Both anagrelide and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Rivaroxaban': ['Severe', 'Rivaroxaban is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both anagrelide and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sertraline': ['NotSet', 'Both anagrelide and sertraline can increase the risk of bleeding.'], 'Sildenafil': ['Severe', 'Both anagrelide and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sorafenib': ['Severe', 'Both anagrelide and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both anagrelide and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Streptokinase': ['Severe', 'Streptokinase is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sulindac': ['NotSet', 'Both anagrelide and sulindac can increase the risk of bleeding.'], 'Sulpiride': ['Severe', 'Both anagrelide and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['Severe', 'Both anagrelide and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telavancin': ['Severe', 'Both anagrelide and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tenecteplase': ['Severe', 'Tenecteplase is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenoxicam': ['NotSet', 'Both anagrelide and tenoxicam can increase the risk of bleeding.'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both anagrelide and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tiaprofenic acid': ['NotSet', 'Both anagrelide and tiaprofenic acid can increase the risk of bleeding.'], 'Ticagrelor': ['NotSet', 'Both anagrelide and ticagrelor can increase the risk of bleeding.'], 'Tinzaparin': ['Severe', 'Tinzaparin is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tirofiban': ['NotSet', 'Both anagrelide and tirofiban can increase the risk of bleeding.'], 'Tizanidine': ['Severe', 'Both anagrelide and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolfenamic acid': ['NotSet', 'Both anagrelide and tolfenamic acid can increase the risk of bleeding.'], 'Tolterodine': ['Severe', 'Both anagrelide and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both anagrelide and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Trastuzumab emtansine': ['NotSet', 'Both anagrelide and trastuzumab emtansine can increase the risk of bleeding.'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Urokinase': ['Severe', 'Urokinase is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vandetanib': ['Severe', 'Both anagrelide and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both anagrelide and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both anagrelide and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both anagrelide and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Both anagrelide and venlafaxine can increase the risk of bleeding.'], 'Vernakalant': ['Severe', 'Both anagrelide and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both anagrelide and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with anagrelide. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Severe', 'Both anagrelide and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vortioxetine': ['NotSet', 'Both anagrelide and vortioxetine can increase the risk of bleeding.'], 'Warfarin': ['Severe', 'Warfarin is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with anagrelide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['Severe', 'Both anagrelide and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","anakinra","{'Afatinib': ['NotSet', 'Both anakinra and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both anakinra and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both anakinra and alemtuzumab can increase the risk of myelosuppression.'], 'Amsacrine': ['NotSet', 'Both anakinra and amsacrine can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both anakinra and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both anakinra and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both anakinra and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both anakinra and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both anakinra and azathioprine can increase the risk of myelosuppression.'], 'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Balsalazide': ['NotSet', 'Both anakinra and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both anakinra and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both anakinra and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both anakinra and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both anakinra and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both anakinra and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both anakinra and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both anakinra and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both anakinra and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both anakinra and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both anakinra and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both anakinra and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both anakinra and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both anakinra and capecitabine can increase the risk of myelosuppression.'], 'Carbimazole': ['NotSet', 'Both anakinra and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both anakinra and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both anakinra and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both anakinra and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both anakinra and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both anakinra and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both anakinra and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both anakinra and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both anakinra and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both anakinra and cladribine can increase the risk of myelosuppression.'], 'Clofarabine': ['NotSet', 'Both anakinra and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both anakinra and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both anakinra and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both anakinra and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both anakinra and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both anakinra and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both anakinra and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both anakinra and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both anakinra and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both anakinra and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both anakinra and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both anakinra and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both anakinra and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both anakinra and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both anakinra and doxorubicin can increase the risk of myelosuppression.'], 'Epirubicin': ['NotSet', 'Both anakinra and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both anakinra and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both anakinra and estramustine can increase the risk of myelosuppression.'], 'Etanercept': ['Severe', 'Anakinra is predicted to increase the risk of generalised infection (possibly life-threatening) when given with etanercept. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ethosuximide': ['NotSet', 'Both anakinra and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both anakinra and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both anakinra and everolimus can increase the risk of myelosuppression.'], 'Fludarabine': ['NotSet', 'Both anakinra and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both anakinra and fluorouracil can increase the risk of myelosuppression.'], 'Ganciclovir': ['NotSet', 'Both anakinra and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both anakinra and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both anakinra and gemcitabine can increase the risk of myelosuppression.'], 'Golimumab': ['Severe', 'Anakinra is predicted to increase the risk of generalised infection (possibly life-threatening) when given with golimumab. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxycarbamide': ['NotSet', 'Both anakinra and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both anakinra and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both anakinra and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both anakinra and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both anakinra and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both anakinra and imatinib can increase the risk of myelosuppression.'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Interferon alfa': ['NotSet', 'Both anakinra and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both anakinra and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both anakinra and irinotecan can increase the risk of myelosuppression.'], 'Leflunomide': ['NotSet', 'Both anakinra and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both anakinra and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both anakinra and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both anakinra and lomustine can increase the risk of myelosuppression.'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Melphalan': ['NotSet', 'Both anakinra and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both anakinra and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both anakinra and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both anakinra and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both anakinra and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both anakinra and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both anakinra and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both anakinra and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both anakinra and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both anakinra and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both anakinra and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both anakinra and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both anakinra and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both anakinra and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both anakinra and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both anakinra and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both anakinra and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both anakinra and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both anakinra and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both anakinra and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both anakinra and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both anakinra and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both anakinra and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both anakinra and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both anakinra and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both anakinra and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both anakinra and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both anakinra and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both anakinra and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both anakinra and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both anakinra and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both anakinra and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both anakinra and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both anakinra and regorafenib can increase the risk of myelosuppression.'], 'Rituximab': ['NotSet', 'Both anakinra and rituximab can increase the risk of myelosuppression.'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ruxolitinib': ['NotSet', 'Both anakinra and ruxolitinib can increase the risk of myelosuppression.'], 'Siltuximab': ['NotSet', 'Both anakinra and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both anakinra and sorafenib can increase the risk of myelosuppression.'], 'Sulfadiazine': ['NotSet', 'Both anakinra and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both anakinra and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both anakinra and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both anakinra and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both anakinra and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both anakinra and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both anakinra and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both anakinra and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both anakinra and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both anakinra and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both anakinra and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both anakinra and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both anakinra and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both anakinra and trimethoprim can increase the risk of myelosuppression.'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Valganciclovir': ['NotSet', 'Both anakinra and valganciclovir can increase the risk of myelosuppression.'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both anakinra and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both anakinra and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both anakinra and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both anakinra and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both anakinra and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both anakinra and vismodegib can increase the risk of myelosuppression.'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both anakinra and zidovudine can increase the risk of myelosuppression.']}","antazoli","{'Betahistine': ['Moderate', 'Antazoline is predicted to decrease the effects of betahistine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Isocarboxazid': ['Severe', 'Isocarboxazid is predicted to increase the risk of antimuscarinic side-effects when given with antazoline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenelzine': ['Severe', 'Phenelzine is predicted to increase the risk of antimuscarinic side-effects when given with antazoline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pitolisant': ['Moderate', 'Antazoline is predicted to decrease the efficacy of pitolisant. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tranylcypromine': ['Severe', 'Tranylcypromine is predicted to increase the risk of antimuscarinic side-effects when given with antazoline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","anti-d-rh0-immunoglobulin","{'Dinutuximab': ['Severe', 'Anti-D (Rh0) immunoglobulin is predicted to alter the effects of dinutuximab. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","antithymocyte-immunoglobulin-rabbit","{'Dinutuximab': ['Severe', 'Antithymocyte immunoglobulin (rabbit) is predicted to alter the effects of dinutuximab. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","apalutamide","{'Acenocoumarol': ['Mild', 'Apalutamide is predicted to decrease the exposure to acenocoumarol. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Alfentanil': ['Moderate', 'Apalutamide is predicted to decrease the exposure to alfentanil. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Amifampridine': ['Severe', 'Both apalutamide and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both apalutamide and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both apalutamide and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both apalutamide and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both apalutamide and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Arsenic trioxide': ['Severe', 'Both apalutamide and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both apalutamide and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both apalutamide and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Atazanavir': ['Mild', 'Atazanavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Avanafil': ['Moderate', 'Apalutamide is predicted to decrease the exposure to avanafil. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both apalutamide and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Both apalutamide and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Apalutamide is predicted to decrease the exposure to bosutinib. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical Apalutamide is predicted to decrease the exposure to budesonide. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Buspirone': ['Moderate', 'Apalutamide is predicted to decrease the exposure to buspirone. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cabozantinib': ['Severe', 'Both apalutamide and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ceritinib': ['Severe', 'Both apalutamide and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both apalutamide and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Both apalutamide and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Apalutamide is predicted to decrease the exposure to citalopram. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Clarithromycin': ['Severe', 'Both apalutamide and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Clarithromycin is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Clomipramine': ['Severe', 'Both apalutamide and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clopidogrel': ['Mild', 'Clopidogrel is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Cobicistat': ['Mild', 'Cobicistat is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Colchicine': ['Mild', 'Apalutamide is predicted to decrease the exposure to colchicine. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Crizotinib': ['Severe', 'Both apalutamide and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dabigatran': ['Mild', 'Apalutamide is predicted to decrease the exposure to dabigatran. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Darifenacin': ['Moderate', 'Apalutamide is predicted to decrease the exposure to darifenacin. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Darunavir': ['Mild', 'Darunavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Dasatinib': ['Severe', 'Both apalutamide and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Apalutamide is predicted to decrease the exposure to dasatinib. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both apalutamide and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Diazepam': ['Mild', 'Apalutamide is predicted to decrease the exposure to diazepam. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Digoxin': ['Mild', 'Apalutamide is predicted to decrease the exposure to digoxin. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Disopyramide': ['Severe', 'Both apalutamide and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with apalutamide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Severe', 'Both apalutamide and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', 'Both apalutamide and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Efavirenz': ['Severe', 'Both apalutamide and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both apalutamide and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Eplerenone': ['Moderate', 'Apalutamide is predicted to decrease the exposure to eplerenone. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eribulin': ['Severe', 'Both apalutamide and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both apalutamide and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both apalutamide and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Everolimus': ['Moderate', 'Apalutamide is predicted to decrease the exposure to everolimus. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Felodipine': ['Moderate', 'Apalutamide is predicted to decrease the exposure to felodipine. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fexofenadine': ['Mild', 'Apalutamide slightly decreases the exposure to fexofenadine. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with apalutamide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both apalutamide and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both apalutamide and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluphenazine': ['Severe', 'Both apalutamide and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluticasone': ['Moderate', 'Apalutamide is predicted to decrease the exposure to fluticasone. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fosamprenavir': ['Mild', 'Fosamprenavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Gemfibrozil': ['Mild', 'Gemfibrozil is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with apalutamide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Haloperidol': ['Severe', 'Both apalutamide and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both apalutamide and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Idelalisib': ['Mild', 'Idelalisib is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both apalutamide and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Itraconazole': ['Mild', 'Itraconazole is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with apalutamide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ivacaftor': ['Moderate', 'Apalutamide is predicted to decrease the exposure to ivacaftor. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketoconazole': ['Mild', 'Ketoconazole is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Lansoprazole': ['Mild', 'Apalutamide is predicted to decrease the exposure to lansoprazole. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Lapatinib': ['Severe', 'Both apalutamide and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both apalutamide and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lercanidipine': ['Moderate', 'Apalutamide is predicted to decrease the exposure to lercanidipine. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Levomepromazine': ['Severe', 'Both apalutamide and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levothyroxine': ['Mild', 'Apalutamide potentially decreases the exposure to levothyroxine. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Lithium': ['Severe', 'Both apalutamide and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both apalutamide and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lomitapide': ['Moderate', 'Apalutamide is predicted to decrease the exposure to lomitapide. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lopinavir': ['Mild', 'Lopinavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Lurasidone': ['Moderate', 'Apalutamide is predicted to decrease the exposure to lurasidone. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Maraviroc': ['Moderate', 'Apalutamide is predicted to decrease the exposure to maraviroc. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['Severe', 'Both apalutamide and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methotrexate': ['Mild', 'Apalutamide is predicted to decrease the exposure to methotrexate. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Midazolam': ['Severe', 'Apalutamide markedly decreases the exposure to midazolam. Manufacturer advises avoid or monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with apalutamide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moclobemide': ['Mild', 'Apalutamide is predicted to decrease the exposure to moclobemide. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Moxifloxacin': ['Severe', 'Both apalutamide and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Naloxegol': ['Moderate', 'Apalutamide is predicted to decrease the exposure to naloxegol. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nilotinib': ['Severe', 'Both apalutamide and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Omeprazole': ['Moderate', 'Apalutamide markedly decreases the exposure to omeprazole. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ondansetron': ['Severe', 'Both apalutamide and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both apalutamide and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Paliperidone': ['Severe', 'Both apalutamide and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with apalutamide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both apalutamide and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both apalutamide and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both apalutamide and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with apalutamide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pimozide': ['Severe', 'Both apalutamide and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Quetiapine': ['Moderate', 'Apalutamide is predicted to decrease the exposure to quetiapine. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Quinine': ['Severe', 'Both apalutamide and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Rabeprazole': ['Mild', 'Apalutamide is predicted to decrease the exposure to rabeprazole. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Ranolazine': ['Severe', 'Both apalutamide and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ribociclib': ['Severe', 'Both apalutamide and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Risperidone': ['Severe', 'Both apalutamide and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ritonavir': ['Mild', 'Ritonavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Rosuvastatin': ['Mild', 'Apalutamide slightly decreases the exposure to rosuvastatin. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical Apalutamide is predicted to decrease the exposure to salmeterol. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Saquinavir': ['Severe', 'Both apalutamide and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Saquinavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Sildenafil': ['Severe', 'Both apalutamide and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Apalutamide is predicted to decrease the exposure to sildenafil. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Simvastatin': ['Moderate', 'Apalutamide is predicted to decrease the exposure to simvastatin. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sirolimus': ['Moderate', 'Apalutamide is predicted to decrease the exposure to sirolimus. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sorafenib': ['Severe', 'Both apalutamide and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both apalutamide and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sulpiride': ['Severe', 'Both apalutamide and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['Severe', 'Both apalutamide and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telavancin': ['Severe', 'Both apalutamide and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Temsirolimus': ['Moderate', 'Apalutamide is predicted to decrease the exposure to temsirolimus. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both apalutamide and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticagrelor': ['Moderate', 'Apalutamide is predicted to decrease the exposure to ticagrelor. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tipranavir': ['Mild', 'Tipranavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Tizanidine': ['Severe', 'Both apalutamide and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolterodine': ['Severe', 'Both apalutamide and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolvaptan': ['Moderate', 'Apalutamide is predicted to decrease the exposure to tolvaptan. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both apalutamide and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Valproate': ['Mild', 'Apalutamide potentially decreases the exposure to valproate. Manufacturer advises monitor. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Vandetanib': ['Severe', 'Both apalutamide and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both apalutamide and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Apalutamide is predicted to decrease the exposure to vardenafil. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Vemurafenib': ['Severe', 'Both apalutamide and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both apalutamide and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vernakalant': ['Severe', 'Both apalutamide and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both apalutamide and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Voriconazole': ['Severe', 'Both apalutamide and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Voriconazole is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Warfarin': ['Mild', 'Apalutamide is predicted to decrease the exposure to warfarin. Manufacturer advises avoid or monitor. Severity of interaction: Mild Evidence for interaction: Study'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apalutamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['Severe', 'Both apalutamide and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","apixaban","{'Aceclofenac': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Acenocoumarol': ['NotSet', 'Both apixaban and acenocoumarol can increase the risk of bleeding.'], 'Alteplase': ['NotSet', 'Both apixaban and alteplase can increase the risk of bleeding.'], 'Anagrelide': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Argatroban': ['NotSet', 'Both apixaban and argatroban can increase the risk of bleeding.'], 'Aspirin': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bevacizumab': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with bevacizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bivalirudin': ['NotSet', 'Both apixaban and bivalirudin can increase the risk of bleeding.'], 'Cangrelor': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with cangrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Carbamazepine': ['Severe', 'Carbamazepine is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Celecoxib': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with celecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cilostazol': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with cilostazol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with citalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clopidogrel': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with clopidogrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cobicistat': ['Severe', 'Cobicistat is predicted to increase the exposure to apixaban. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dabigatran': ['NotSet', 'Both apixaban and dabigatran can increase the risk of bleeding.'], 'Dalteparin': ['NotSet', 'Both apixaban and dalteparin can increase the risk of bleeding.'], 'Danaparoid': ['NotSet', 'Both apixaban and danaparoid can increase the risk of bleeding.'], 'Dapoxetine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with dapoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dasatinib': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with dasatinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with dexibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexketoprofen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with dexketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Diclofenac': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with diclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dipyridamole': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with dipyridamole. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to apixaban. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Duloxetine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with duloxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Edoxaban': ['NotSet', 'Both apixaban and edoxaban can increase the risk of bleeding.'], 'Enoxaparin': ['NotSet', 'Both apixaban and enoxaparin can increase the risk of bleeding.'], 'Enzalutamide': ['Severe', 'Enzalutamide is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Epoprostenol': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with epoprostenol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eptifibatide': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with eptifibatide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to apixaban. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Escitalopram': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with escitalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etodolac': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with etodolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etoricoxib': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with etoricoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluoxetine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with fluoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flurbiprofen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with flurbiprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluvoxamine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with fluvoxamine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fondaparinux': ['NotSet', 'Both apixaban and fondaparinux can increase the risk of bleeding.'], 'Fosphenytoin': ['Severe', 'Fosphenytoin is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Heparin (unfractionated)': ['NotSet', 'Both apixaban and heparin (unfractionated) can increase the risk of bleeding.'], 'Ibrutinib': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with ibrutinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibuprofen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with ibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Iloprost': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with iloprost. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indometacin': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with indometacin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotersen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with inotersen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Itraconazole': ['Severe', 'Itraconazole is predicted to increase the exposure to apixaban. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketoconazole': ['Severe', 'Ketoconazole slightly to moderately increases the exposure to apixaban. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketoprofen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with ketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketorolac': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with ketorolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mefenamic acid': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with mefenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Meloxicam': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with meloxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mitotane': ['Severe', 'Mitotane is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Nabumetone': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with nabumetone. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Naproxen': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with naproxen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nicotinic acid': ['NotSet', 'Both apixaban and nicotinic acid can increase the risk of bleeding.'], 'Omega-3-acid ethyl esters': ['NotSet', 'Both apixaban and omega-3-acid ethyl esters can increase the risk of bleeding.'], 'Parecoxib': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with parecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paroxetine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with paroxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenindione': ['NotSet', 'Both apixaban and phenindione can increase the risk of bleeding.'], 'Phenobarbital': ['Severe', 'Phenobarbital is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenytoin': ['Severe', 'Phenytoin is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Piroxicam': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with piroxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prasugrel': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with prasugrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Primidone': ['Severe', 'Primidone is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Regorafenib': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with regorafenib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rifampicin': ['Severe', 'Rifampicin is predicted to moderately decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ritonavir': ['Severe', 'Ritonavir is predicted to increase the exposure to apixaban. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rivaroxaban': ['NotSet', 'Both apixaban and rivaroxaban can increase the risk of bleeding.'], 'Sertraline': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with sertraline. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], ""St John's Wort"": ['Moderate', ""St John's Wort is predicted to decrease the exposure to apixaban. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Streptokinase': ['NotSet', 'Both apixaban and streptokinase can increase the risk of bleeding.'], 'Sulindac': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with sulindac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenecteplase': ['NotSet', 'Both apixaban and tenecteplase can increase the risk of bleeding.'], 'Tenoxicam': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with tenoxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tiaprofenic acid': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with tiaprofenic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticagrelor': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with ticagrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tinzaparin': ['NotSet', 'Both apixaban and tinzaparin can increase the risk of bleeding.'], 'Tirofiban': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with tirofiban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tolfenamic acid': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with tolfenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trastuzumab emtansine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with trastuzumab emtansine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Urokinase': ['NotSet', 'Both apixaban and urokinase can increase the risk of bleeding.'], 'Venlafaxine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with venlafaxine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Verapamil': ['Moderate', 'Verapamil is predicted to increase the exposure to apixaban. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with apixaban. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to increase the exposure to apixaban. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Vortioxetine': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with vortioxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Warfarin': ['NotSet', 'Both apixaban and warfarin can increase the risk of bleeding.']}","apomorphi","{'Acebutolol': ['NotSet', 'Both apomorphine and acebutolol can increase the risk of hypotension.'], 'Alcohol (beverage)': ['NotSet', 'Both apomorphine and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both apomorphine and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both apomorphine and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both apomorphine and alprostadil can increase the risk of hypotension.'], 'Amifampridine': ['Severe', 'Both apomorphine and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both apomorphine and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both apomorphine and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Amisulpride is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amitriptyline': ['NotSet', 'Both apomorphine and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both apomorphine and amlodipine can increase the risk of hypotension.'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both apomorphine and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apalutamide': ['Severe', 'Both apomorphine and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apraclonidine': ['NotSet', 'Both apomorphine and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both apomorphine and aripiprazole can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of apomorphine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Arsenic trioxide': ['Severe', 'Both apomorphine and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both apomorphine and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both apomorphine and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Asenapine': ['NotSet', 'Both apomorphine and asenapine can increase the risk of hypotension. Asenapine is predicted to decrease the effects of apomorphine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Atenolol': ['NotSet', 'Both apomorphine and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both apomorphine and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both apomorphine and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both apomorphine and baclofen can increase the risk of hypotension.'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both apomorphine and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['NotSet', 'Both apomorphine and bendroflumethiazide can increase the risk of hypotension. Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Benperidol': ['NotSet', 'Both apomorphine and benperidol can increase the risk of hypotension. Benperidol is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betaxolol': ['NotSet', 'Both apomorphine and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both apomorphine and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both apomorphine and bortezomib can increase the risk of hypotension.'], 'Bosutinib': ['Severe', 'Both apomorphine and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Brimonidine': ['NotSet', 'Both apomorphine and brimonidine can increase the risk of hypotension.'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['NotSet', 'Both apomorphine and bumetanide can increase the risk of hypotension. Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cabozantinib': ['Severe', 'Both apomorphine and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Canagliflozin': ['NotSet', 'Both apomorphine and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both apomorphine and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both apomorphine and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', 'Both apomorphine and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both apomorphine and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both apomorphine and celiprolol can increase the risk of hypotension.'], 'Ceritinib': ['Severe', 'Both apomorphine and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlorothiazide': ['NotSet', 'Both apomorphine and chlorothiazide can increase the risk of hypotension. Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['NotSet', 'Both apomorphine and chlorpromazine can increase the risk of hypotension. Both apomorphine and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Chlorpromazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Chlortalidone': ['NotSet', 'Both apomorphine and chlortalidone can increase the risk of hypotension. Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Both apomorphine and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clarithromycin': ['Severe', 'Both apomorphine and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clomipramine': ['NotSet', 'Both apomorphine and clomipramine can increase the risk of hypotension. Both apomorphine and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clonidine': ['NotSet', 'Both apomorphine and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both apomorphine and clozapine can increase the risk of hypotension. Clozapine is predicted to decrease the effects of apomorphine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Crizotinib': ['Severe', 'Both apomorphine and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dapagliflozin': ['NotSet', 'Both apomorphine and dapagliflozin can increase the risk of hypotension.'], 'Dasatinib': ['Severe', 'Both apomorphine and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both apomorphine and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Desflurane': ['NotSet', 'Both apomorphine and desflurane can increase the risk of hypotension.'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Diazoxide': ['NotSet', 'Both apomorphine and diazoxide can increase the risk of hypotension.'], 'Diltiazem': ['NotSet', 'Both apomorphine and diltiazem can increase the risk of hypotension.'], 'Dipyridamole': ['NotSet', 'Both apomorphine and dipyridamole can increase the risk of hypotension.'], 'Disopyramide': ['Severe', 'Both apomorphine and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with apomorphine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dosulepin': ['NotSet', 'Both apomorphine and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both apomorphine and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both apomorphine and doxepin can increase the risk of hypotension.'], 'Dronedarone': ['Severe', 'Both apomorphine and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['NotSet', 'Both apomorphine and droperidol can increase the risk of hypotension. Both apomorphine and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Droperidol is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Efavirenz': ['Severe', 'Both apomorphine and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Empagliflozin': ['NotSet', 'Both apomorphine and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both apomorphine and enalapril can increase the risk of hypotension.'], 'Encorafenib': ['Severe', 'Both apomorphine and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Eplerenone': ['NotSet', 'Both apomorphine and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both apomorphine and eprosartan can increase the risk of hypotension.'], 'Eribulin': ['Severe', 'Both apomorphine and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ertugliflozin': ['NotSet', 'Both apomorphine and ertugliflozin can increase the risk of hypotension.'], 'Erythromycin': ['Severe', 'Both apomorphine and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both apomorphine and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Esketamine': ['NotSet', 'Both apomorphine and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both apomorphine and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both apomorphine and etomidate can increase the risk of hypotension.'], 'Felodipine': ['NotSet', 'Both apomorphine and felodipine can increase the risk of hypotension.'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with apomorphine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both apomorphine and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both apomorphine and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flupentixol': ['NotSet', 'Both apomorphine and flupentixol can increase the risk of hypotension. Flupentixol is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fluphenazine': ['NotSet', 'Both apomorphine and fluphenazine can increase the risk of hypotension. Both apomorphine and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Fluphenazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fosinopril': ['NotSet', 'Both apomorphine and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both apomorphine and furosemide can increase the risk of hypotension. Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Glyceryl trinitrate': ['NotSet', 'Both apomorphine and glyceryl trinitrate can increase the risk of hypotension.'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with apomorphine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical Apomorphine is predicted to increase the risk of severe hypotension when given with granisetron. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Guanethidine': ['NotSet', 'Both apomorphine and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both apomorphine and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both apomorphine and haloperidol can increase the risk of hypotension. Both apomorphine and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Haloperidol is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Hydralazine': ['NotSet', 'Both apomorphine and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both apomorphine and hydrochlorothiazide can increase the risk of hypotension. Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['NotSet', 'Both apomorphine and hydroflumethiazide can increase the risk of hypotension. Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both apomorphine and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Imidapril': ['NotSet', 'Both apomorphine and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both apomorphine and imipramine can increase the risk of hypotension.'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['NotSet', 'Both apomorphine and indapamide can increase the risk of hypotension. Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indoramin': ['NotSet', 'Both apomorphine and indoramin can increase the risk of hypotension.'], 'Inotuzumab ozogamicin': ['Severe', 'Both apomorphine and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Irbesartan': ['NotSet', 'Both apomorphine and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both apomorphine and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both apomorphine and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both apomorphine and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both apomorphine and isosorbide mononitrate can increase the risk of hypotension.'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with apomorphine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketamine': ['NotSet', 'Both apomorphine and ketamine can increase the risk of hypotension.'], 'Labetalol': ['NotSet', 'Both apomorphine and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both apomorphine and lacidipine can increase the risk of hypotension.'], 'Lapatinib': ['Severe', 'Both apomorphine and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both apomorphine and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lercanidipine': ['NotSet', 'Both apomorphine and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both apomorphine and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both apomorphine and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both apomorphine and levomepromazine can increase the risk of hypotension. Both apomorphine and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Levomepromazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lisinopril': ['NotSet', 'Both apomorphine and lisinopril can increase the risk of hypotension.'], 'Lithium': ['Severe', 'Both apomorphine and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofepramine': ['NotSet', 'Both apomorphine and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both apomorphine and lofexidine can increase the risk of hypotension. Both apomorphine and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Losartan': ['NotSet', 'Both apomorphine and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both apomorphine and loxapine can increase the risk of hypotension. Loxapine is predicted to decrease the effects of apomorphine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lurasidone': ['NotSet', 'Both apomorphine and lurasidone can increase the risk of hypotension.'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Memantine': ['Moderate', 'Memantine is predicted to increase the effects of apomorphine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Methadone': ['Severe', 'Both apomorphine and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methoxyflurane': ['NotSet', 'Both apomorphine and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both apomorphine and methyldopa can increase the risk of hypotension.'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metoclopramide': ['Moderate', 'Metoclopramide is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Metolazone': ['NotSet', 'Both apomorphine and metolazone can increase the risk of hypotension. Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metoprolol': ['NotSet', 'Both apomorphine and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both apomorphine and minoxidil can increase the risk of hypotension.'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with apomorphine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both apomorphine and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Moxisylyte': ['NotSet', 'Both apomorphine and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both apomorphine and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both apomorphine and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both apomorphine and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both apomorphine and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both apomorphine and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both apomorphine and nifedipine can increase the risk of hypotension.'], 'Nilotinib': ['Severe', 'Both apomorphine and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nimodipine': ['NotSet', 'Both apomorphine and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both apomorphine and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both apomorphine and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both apomorphine and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both apomorphine and olanzapine can increase the risk of hypotension. Olanzapine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Olmesartan': ['NotSet', 'Both apomorphine and olmesartan can increase the risk of hypotension.'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both apomorphine and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Apomorphine increases the risk of severe hypotension when given with ondansetron. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Osimertinib': ['Severe', 'Both apomorphine and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Paliperidone': ['NotSet', 'Both apomorphine and paliperidone can increase the risk of hypotension. Both apomorphine and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Paliperidone is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Palonosetron': ['Severe', 'Apomorphine is predicted to increase the risk of severe hypotension when given with palonosetron. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical Palonosetron is predicted to increase the risk of QT-prolongation when given with apomorphine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both apomorphine and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both apomorphine and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both apomorphine and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with apomorphine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pericyazine': ['NotSet', 'Both apomorphine and pericyazine can increase the risk of hypotension. Pericyazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Perindopril': ['NotSet', 'Both apomorphine and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both apomorphine and phenelzine can increase the risk of hypotension.'], 'Pimozide': ['NotSet', 'Both apomorphine and pimozide can increase the risk of hypotension. Both apomorphine and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Pimozide is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pindolol': ['NotSet', 'Both apomorphine and pindolol can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both apomorphine and prazosin can increase the risk of hypotension.'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prochlorperazine': ['NotSet', 'Both apomorphine and prochlorperazine can increase the risk of hypotension. Prochlorperazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Promazine': ['NotSet', 'Both apomorphine and promazine can increase the risk of hypotension. Promazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Propofol': ['NotSet', 'Both apomorphine and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both apomorphine and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both apomorphine and quetiapine can increase the risk of hypotension. Quetiapine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quinapril': ['NotSet', 'Both apomorphine and quinapril can increase the risk of hypotension.'], 'Quinine': ['Severe', 'Both apomorphine and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ramipril': ['NotSet', 'Both apomorphine and ramipril can increase the risk of hypotension.'], 'Ranolazine': ['Severe', 'Both apomorphine and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ribociclib': ['Severe', 'Both apomorphine and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Riociguat': ['NotSet', 'Both apomorphine and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both apomorphine and risperidone can increase the risk of hypotension. Both apomorphine and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Risperidone is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sacubitril': ['NotSet', 'Both apomorphine and sacubitril can increase the risk of hypotension.'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sapropterin': ['NotSet', 'Both apomorphine and sapropterin can increase the risk of hypotension.'], 'Saquinavir': ['Severe', 'Both apomorphine and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Selegiline': ['NotSet', 'Both apomorphine and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both apomorphine and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both apomorphine and sildenafil can increase the risk of hypotension. Both apomorphine and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sodium oxybate': ['NotSet', 'Both apomorphine and sodium oxybate can increase the risk of hypotension.'], 'Sorafenib': ['Severe', 'Both apomorphine and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['NotSet', 'Both apomorphine and sotalol can increase the risk of hypotension. Both apomorphine and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Spironolactone': ['NotSet', 'Both apomorphine and spironolactone can increase the risk of hypotension.'], 'Sulpiride': ['NotSet', 'Both apomorphine and sulpiride can increase the risk of hypotension. Both apomorphine and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Sulpiride is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sunitinib': ['Severe', 'Both apomorphine and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tadalafil': ['NotSet', 'Both apomorphine and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both apomorphine and tamsulosin can increase the risk of hypotension.'], 'Telavancin': ['Severe', 'Both apomorphine and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telmisartan': ['NotSet', 'Both apomorphine and telmisartan can increase the risk of hypotension.'], 'Terazosin': ['NotSet', 'Both apomorphine and terazosin can increase the risk of hypotension.'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both apomorphine and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Thiopental': ['NotSet', 'Both apomorphine and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both apomorphine and timolol can increase the risk of hypotension.'], 'Tizanidine': ['NotSet', 'Both apomorphine and tizanidine can increase the risk of hypotension. Both apomorphine and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolterodine': ['Severe', 'Both apomorphine and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Torasemide': ['NotSet', 'Both apomorphine and torasemide can increase the risk of hypotension. Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both apomorphine and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Trandolapril': ['NotSet', 'Both apomorphine and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both apomorphine and tranylcypromine can increase the risk of hypotension.'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trifluoperazine': ['NotSet', 'Both apomorphine and trifluoperazine can increase the risk of hypotension. Trifluoperazine is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Trimipramine': ['NotSet', 'Both apomorphine and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both apomorphine and valsartan can increase the risk of hypotension.'], 'Vandetanib': ['Severe', 'Both apomorphine and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['NotSet', 'Both apomorphine and vardenafil can increase the risk of hypotension. Both apomorphine and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both apomorphine and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both apomorphine and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Verapamil': ['NotSet', 'Both apomorphine and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both apomorphine and vernakalant can increase the risk of hypotension. Both apomorphine and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both apomorphine and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Voriconazole': ['Severe', 'Both apomorphine and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Xipamide': ['NotSet', 'Both apomorphine and xipamide can increase the risk of hypotension. Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with apomorphine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['NotSet', 'Both apomorphine and zuclopenthixol can increase the risk of hypotension. Both apomorphine and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Zuclopenthixol is predicted to decrease the effects of apomorphine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","apraclonidine","{'Acebutolol': ['NotSet', 'Both apraclonidine and acebutolol can increase the risk of bradycardia. Both apraclonidine and acebutolol can increase the risk of hypotension.'], 'Adrenaline/epinephrine': ['Severe', 'Adrenaline/epinephrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Agomelatine': ['NotSet', ""Both apraclonidine and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both apraclonidine and alcohol (beverage) can increase the risk of hypotension. Both apraclonidine and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alectinib': ['NotSet', 'Both apraclonidine and alectinib can increase the risk of bradycardia.'], 'Alfentanil': ['NotSet', ""Both apraclonidine and alfentanil can increase the risk of bradycardia. Both apraclonidine and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfuzosin': ['NotSet', 'Both apraclonidine and alfuzosin can increase the risk of hypotension.'], 'Alimemazine': ['NotSet', ""Both apraclonidine and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aliskiren': ['NotSet', 'Both apraclonidine and aliskiren can increase the risk of hypotension.'], 'Alprazolam': ['NotSet', ""Both apraclonidine and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprostadil': ['NotSet', 'Both apraclonidine and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both apraclonidine and amantadine can increase the risk of hypotension.'], 'Amiodarone': ['NotSet', 'Both apraclonidine and amiodarone can increase the risk of bradycardia.'], 'Amisulpride': ['NotSet', ""Both apraclonidine and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both apraclonidine and amitriptyline can increase the risk of hypotension. Both apraclonidine and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amlodipine': ['NotSet', 'Both apraclonidine and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both apraclonidine and apomorphine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', ""Both apraclonidine and aripiprazole can increase the risk of hypotension. Both apraclonidine and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both apraclonidine and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both apraclonidine and asenapine can increase the risk of hypotension. Both apraclonidine and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Atenolol': ['NotSet', 'Both apraclonidine and atenolol can increase the risk of bradycardia. Both apraclonidine and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both apraclonidine and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both apraclonidine and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', ""Both apraclonidine and baclofen can increase the risk of hypotension. Both apraclonidine and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bendroflumethiazide': ['NotSet', 'Both apraclonidine and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', ""Both apraclonidine and benperidol can increase the risk of hypotension. Both apraclonidine and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betaxolol': ['NotSet', 'Both apraclonidine and betaxolol can increase the risk of bradycardia. Both apraclonidine and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both apraclonidine and bisoprolol can increase the risk of bradycardia. Both apraclonidine and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both apraclonidine and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', ""Both apraclonidine and brimonidine can increase the risk of bradycardia. Both apraclonidine and brimonidine can increase the risk of hypotension. Both apraclonidine and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bromocriptine': ['NotSet', 'Both apraclonidine and bromocriptine can increase the risk of hypotension.'], 'Buclizine': ['NotSet', ""Both apraclonidine and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bumetanide': ['NotSet', 'Both apraclonidine and bumetanide can increase the risk of hypotension.'], 'Bupivacaine': ['NotSet', ""Both apraclonidine and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both apraclonidine and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cabergoline': ['NotSet', 'Both apraclonidine and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both apraclonidine and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both apraclonidine and candesartan can increase the risk of hypotension.'], 'Cannabidiol': ['NotSet', ""Both apraclonidine and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Captopril': ['NotSet', 'Both apraclonidine and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', ""Both apraclonidine and cariprazine can increase the risk of hypotension. Both apraclonidine and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carvedilol': ['NotSet', 'Both apraclonidine and carvedilol can increase the risk of bradycardia. Both apraclonidine and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both apraclonidine and celiprolol can increase the risk of bradycardia. Both apraclonidine and celiprolol can increase the risk of hypotension.'], 'Chloral hydrate': ['NotSet', ""Both apraclonidine and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both apraclonidine and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorothiazide': ['NotSet', 'Both apraclonidine and chlorothiazide can increase the risk of hypotension.'], 'Chlorphenamine': ['NotSet', ""Both apraclonidine and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both apraclonidine and chlorpromazine can increase the risk of hypotension. Both apraclonidine and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlortalidone': ['NotSet', 'Both apraclonidine and chlortalidone can increase the risk of hypotension.'], 'Cinnarizine': ['NotSet', ""Both apraclonidine and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cisatracurium': ['NotSet', 'Both apraclonidine and cisatracurium can increase the risk of bradycardia.'], 'Clemastine': ['NotSet', ""Both apraclonidine and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both apraclonidine and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both apraclonidine and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both apraclonidine and clomipramine can increase the risk of hypotension. Both apraclonidine and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both apraclonidine and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both apraclonidine and clonidine can increase the risk of bradycardia. Both apraclonidine and clonidine can increase the risk of hypotension. Both apraclonidine and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both apraclonidine and clozapine can increase the risk of hypotension. Both apraclonidine and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both apraclonidine and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Crizotinib': ['NotSet', 'Both apraclonidine and crizotinib can increase the risk of bradycardia.'], 'Cyclizine': ['NotSet', ""Both apraclonidine and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both apraclonidine and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dapagliflozin': ['NotSet', 'Both apraclonidine and dapagliflozin can increase the risk of hypotension.'], 'Desflurane': ['NotSet', ""Both apraclonidine and desflurane can increase the risk of hypotension. Both apraclonidine and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexamfetamine': ['Severe', 'Dexamfetamine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexmedetomidine': ['NotSet', ""Both apraclonidine and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both apraclonidine and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both apraclonidine and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazoxide': ['NotSet', 'Both apraclonidine and diazoxide can increase the risk of hypotension.'], 'Digoxin': ['NotSet', 'Both apraclonidine and digoxin can increase the risk of bradycardia.'], 'Dihydrocodeine': ['NotSet', ""Both apraclonidine and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diltiazem': ['NotSet', 'Both apraclonidine and diltiazem can increase the risk of bradycardia. Both apraclonidine and diltiazem can increase the risk of hypotension.'], 'Dipipanone': ['NotSet', ""Both apraclonidine and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipyridamole': ['NotSet', 'Both apraclonidine and dipyridamole can increase the risk of hypotension.'], 'Dobutamine': ['Severe', 'Dobutamine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Donepezil': ['NotSet', 'Both apraclonidine and donepezil can increase the risk of bradycardia.'], 'Dopamine': ['Severe', 'Dopamine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dosulepin': ['NotSet', ""Both apraclonidine and dosulepin can increase the risk of hypotension. Both apraclonidine and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxazosin': ['NotSet', 'Both apraclonidine and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', ""Both apraclonidine and doxepin can increase the risk of hypotension. Both apraclonidine and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both apraclonidine and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both apraclonidine and droperidol can increase the risk of hypotension. Both apraclonidine and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Empagliflozin': ['NotSet', 'Both apraclonidine and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both apraclonidine and enalapril can increase the risk of hypotension.'], 'Ephedrine': ['Severe', 'Ephedrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eplerenone': ['NotSet', 'Both apraclonidine and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both apraclonidine and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both apraclonidine and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', ""Both apraclonidine and esketamine can increase the risk of hypotension. Both apraclonidine and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esmolol': ['NotSet', 'Both apraclonidine and esmolol can increase the risk of bradycardia. Both apraclonidine and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', ""Both apraclonidine and etomidate can increase the risk of hypotension. Both apraclonidine and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Felodipine': ['NotSet', 'Both apraclonidine and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', ""Both apraclonidine and fentanyl can increase the risk of bradycardia. Both apraclonidine and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fingolimod': ['NotSet', 'Both apraclonidine and fingolimod can increase the risk of bradycardia.'], 'Flecainide': ['NotSet', 'Both apraclonidine and flecainide can increase the risk of bradycardia.'], 'Flupentixol': ['NotSet', ""Both apraclonidine and flupentixol can increase the risk of hypotension. Both apraclonidine and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both apraclonidine and fluphenazine can increase the risk of hypotension. Both apraclonidine and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both apraclonidine and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fosinopril': ['NotSet', 'Both apraclonidine and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both apraclonidine and furosemide can increase the risk of hypotension.'], 'Gabapentin': ['NotSet', ""Both apraclonidine and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Galantamine': ['NotSet', 'Both apraclonidine and galantamine can increase the risk of bradycardia.'], 'Glyceryl trinitrate': ['NotSet', 'Both apraclonidine and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both apraclonidine and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', ""Both apraclonidine and guanfacine can increase the risk of hypotension. Both apraclonidine and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both apraclonidine and haloperidol can increase the risk of hypotension. Both apraclonidine and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydralazine': ['NotSet', 'Both apraclonidine and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both apraclonidine and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both apraclonidine and hydroflumethiazide can increase the risk of hypotension.'], 'Hydromorphone': ['NotSet', ""Both apraclonidine and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both apraclonidine and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imidapril': ['NotSet', 'Both apraclonidine and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', ""Both apraclonidine and imipramine can increase the risk of hypotension. Both apraclonidine and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Indapamide': ['NotSet', 'Both apraclonidine and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both apraclonidine and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both apraclonidine and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both apraclonidine and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', ""Both apraclonidine and isoflurane can increase the risk of hypotension. Both apraclonidine and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isometheptene': ['Severe', 'Isometheptene is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Isosorbide dinitrate': ['NotSet', 'Both apraclonidine and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both apraclonidine and isosorbide mononitrate can increase the risk of hypotension.'], 'Ivabradine': ['NotSet', 'Both apraclonidine and ivabradine can increase the risk of bradycardia.'], 'Ketamine': ['NotSet', ""Both apraclonidine and ketamine can increase the risk of hypotension. Both apraclonidine and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketotifen': ['NotSet', ""Both apraclonidine and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Labetalol': ['NotSet', 'Both apraclonidine and labetalol can increase the risk of bradycardia. Both apraclonidine and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both apraclonidine and lacidipine can increase the risk of hypotension.'], 'Lamotrigine': ['NotSet', ""Both apraclonidine and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lercanidipine': ['NotSet', 'Both apraclonidine and lercanidipine can increase the risk of hypotension.'], 'Levetiracetam': ['NotSet', ""Both apraclonidine and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levobunolol': ['NotSet', 'Both apraclonidine and levobunolol can increase the risk of bradycardia. Both apraclonidine and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both apraclonidine and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', ""Both apraclonidine and levomepromazine can increase the risk of hypotension. Both apraclonidine and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both apraclonidine and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lisdexamfetamine': ['Severe', 'Lisdexamfetamine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lisinopril': ['NotSet', 'Both apraclonidine and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', ""Both apraclonidine and lofepramine can increase the risk of hypotension. Both apraclonidine and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both apraclonidine and lofexidine can increase the risk of hypotension. Both apraclonidine and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both apraclonidine and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both apraclonidine and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both apraclonidine and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Losartan': ['NotSet', 'Both apraclonidine and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', ""Both apraclonidine and loxapine can increase the risk of hypotension. Both apraclonidine and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both apraclonidine and lurasidone can increase the risk of hypotension. Both apraclonidine and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both apraclonidine and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both apraclonidine and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both apraclonidine and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both apraclonidine and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Metaraminol': ['Severe', 'Metaraminol is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['NotSet', ""Both apraclonidine and methadone can increase the risk of bradycardia. Both apraclonidine and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both apraclonidine and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both apraclonidine and methoxyflurane can increase the risk of hypotension. Both apraclonidine and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methyldopa': ['NotSet', 'Both apraclonidine and methyldopa can increase the risk of hypotension.'], 'Methylphenidate': ['Severe', 'Methylphenidate is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['NotSet', 'Both apraclonidine and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both apraclonidine and metoprolol can increase the risk of bradycardia. Both apraclonidine and metoprolol can increase the risk of hypotension.'], 'Mianserin': ['NotSet', ""Both apraclonidine and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both apraclonidine and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midodrine': ['Severe', 'Midodrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Minoxidil': ['NotSet', 'Both apraclonidine and minoxidil can increase the risk of hypotension.'], 'Mirtazapine': ['NotSet', ""Both apraclonidine and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Morphine': ['NotSet', ""Both apraclonidine and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxisylyte': ['NotSet', 'Both apraclonidine and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', ""Both apraclonidine and moxonidine can increase the risk of hypotension. Both apraclonidine and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both apraclonidine and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nadolol': ['NotSet', 'Both apraclonidine and nadolol can increase the risk of bradycardia. Both apraclonidine and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both apraclonidine and nebivolol can increase the risk of bradycardia. Both apraclonidine and nebivolol can increase the risk of hypotension.'], 'Neostigmine': ['NotSet', 'Both apraclonidine and neostigmine can increase the risk of bradycardia.'], 'Nicardipine': ['NotSet', 'Both apraclonidine and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both apraclonidine and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both apraclonidine and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both apraclonidine and nimodipine can increase the risk of hypotension.'], 'Nitrazepam': ['NotSet', ""Both apraclonidine and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitroprusside': ['NotSet', 'Both apraclonidine and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', ""Both apraclonidine and nitrous oxide can increase the risk of hypotension. Both apraclonidine and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Noradrenaline/norepinephrine': ['Severe', 'Noradrenaline/norepinephrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nortriptyline': ['NotSet', ""Both apraclonidine and nortriptyline can increase the risk of hypotension. Both apraclonidine and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both apraclonidine and olanzapine can increase the risk of hypotension. Both apraclonidine and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olmesartan': ['NotSet', 'Both apraclonidine and olmesartan can increase the risk of hypotension.'], 'Oxazepam': ['NotSet', ""Both apraclonidine and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both apraclonidine and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both apraclonidine and paliperidone can increase the risk of hypotension. Both apraclonidine and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pasireotide': ['NotSet', 'Both apraclonidine and pasireotide can increase the risk of bradycardia.'], 'Pentazocine': ['NotSet', ""Both apraclonidine and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both apraclonidine and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pergolide': ['NotSet', 'Both apraclonidine and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', ""Both apraclonidine and pericyazine can increase the risk of hypotension. Both apraclonidine and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perindopril': ['NotSet', 'Both apraclonidine and perindopril can increase the risk of hypotension.'], 'Pethidine': ['NotSet', ""Both apraclonidine and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['NotSet', 'Both apraclonidine and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['NotSet', ""Both apraclonidine and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenylephrine': ['Severe', 'Phenylephrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pimozide': ['NotSet', ""Both apraclonidine and pimozide can increase the risk of hypotension. Both apraclonidine and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pindolol': ['NotSet', 'Both apraclonidine and pindolol can increase the risk of bradycardia. Both apraclonidine and pindolol can increase the risk of hypotension.'], 'Pizotifen': ['NotSet', ""Both apraclonidine and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pramipexole': ['NotSet', 'Both apraclonidine and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both apraclonidine and prazosin can increase the risk of hypotension.'], 'Pregabalin': ['NotSet', ""Both apraclonidine and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both apraclonidine and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both apraclonidine and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prochlorperazine': ['NotSet', ""Both apraclonidine and prochlorperazine can increase the risk of hypotension. Both apraclonidine and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both apraclonidine and promazine can increase the risk of hypotension. Both apraclonidine and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both apraclonidine and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both apraclonidine and propofol can increase the risk of hypotension. Both apraclonidine and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propranolol': ['NotSet', 'Both apraclonidine and propranolol can increase the risk of bradycardia. Both apraclonidine and propranolol can increase the risk of hypotension.'], 'Pseudoephedrine': ['Severe', 'Pseudoephedrine is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pyridostigmine': ['NotSet', 'Both apraclonidine and pyridostigmine can increase the risk of bradycardia.'], 'Quetiapine': ['NotSet', ""Both apraclonidine and quetiapine can increase the risk of hypotension. Both apraclonidine and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quinagolide': ['NotSet', 'Both apraclonidine and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both apraclonidine and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both apraclonidine and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', ""Both apraclonidine and remifentanil can increase the risk of bradycardia. Both apraclonidine and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Riociguat': ['NotSet', 'Both apraclonidine and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', ""Both apraclonidine and risperidone can increase the risk of hypotension. Both apraclonidine and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rivastigmine': ['NotSet', 'Both apraclonidine and rivastigmine can increase the risk of bradycardia.'], 'Ropinirole': ['NotSet', 'Both apraclonidine and ropinirole can increase the risk of hypotension.'], 'Ropivacaine': ['NotSet', ""Both apraclonidine and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rotigotine': ['NotSet', 'Both apraclonidine and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both apraclonidine and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both apraclonidine and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both apraclonidine and selegiline can increase the risk of bradycardia. Both apraclonidine and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', ""Both apraclonidine and sevoflurane can increase the risk of hypotension. Both apraclonidine and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sildenafil': ['NotSet', 'Both apraclonidine and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', ""Both apraclonidine and sodium oxybate can increase the risk of hypotension. Both apraclonidine and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sotalol': ['NotSet', 'Both apraclonidine and sotalol can increase the risk of bradycardia. Both apraclonidine and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both apraclonidine and spironolactone can increase the risk of hypotension.'], 'Sufentanil': ['NotSet', ""Both apraclonidine and sufentanil can increase the risk of bradycardia. Both apraclonidine and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both apraclonidine and sulpiride can increase the risk of hypotension. Both apraclonidine and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tadalafil': ['NotSet', 'Both apraclonidine and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both apraclonidine and tamsulosin can increase the risk of hypotension.'], 'Tapentadol': ['NotSet', ""Both apraclonidine and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Telmisartan': ['NotSet', 'Both apraclonidine and telmisartan can increase the risk of hypotension.'], 'Temazepam': ['NotSet', ""Both apraclonidine and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Terazosin': ['NotSet', 'Both apraclonidine and terazosin can increase the risk of hypotension.'], 'Tetracaine': ['NotSet', ""Both apraclonidine and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both apraclonidine and thalidomide can increase the risk of bradycardia. Both apraclonidine and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both apraclonidine and thiopental can increase the risk of hypotension. Both apraclonidine and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Timolol': ['NotSet', 'Both apraclonidine and timolol can increase the risk of bradycardia. Both apraclonidine and timolol can increase the risk of hypotension.'], 'Tizanidine': ['NotSet', ""Both apraclonidine and tizanidine can increase the risk of bradycardia. Both apraclonidine and tizanidine can increase the risk of hypotension. Both apraclonidine and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Torasemide': ['NotSet', 'Both apraclonidine and torasemide can increase the risk of hypotension.'], 'Tramadol': ['NotSet', ""Both apraclonidine and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trandolapril': ['NotSet', 'Both apraclonidine and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both apraclonidine and tranylcypromine can increase the risk of hypotension.'], 'Trazodone': ['NotSet', ""Both apraclonidine and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both apraclonidine and trifluoperazine can increase the risk of hypotension. Both apraclonidine and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both apraclonidine and trimipramine can increase the risk of hypotension. Both apraclonidine and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Valsartan': ['NotSet', 'Both apraclonidine and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both apraclonidine and vardenafil can increase the risk of hypotension.'], 'Venlafaxine': ['NotSet', ""Both apraclonidine and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['NotSet', 'Both apraclonidine and verapamil can increase the risk of bradycardia. Both apraclonidine and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both apraclonidine and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both apraclonidine and xipamide can increase the risk of hypotension.'], 'Xylometazoline': ['Severe', 'Xylometazoline is predicted to decrease the effects of apraclonidine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zolpidem': ['NotSet', ""Both apraclonidine and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both apraclonidine and zuclopenthixol can increase the risk of hypotension. Both apraclonidine and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","apremilast","{'Carbamazepine': ['Severe', 'Carbamazepine moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Enzalutamide': ['Severe', 'Enzalutamide moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosphenytoin': ['Severe', 'Fosphenytoin moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Mitotane': ['Severe', 'Mitotane moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenobarbital': ['Severe', 'Phenobarbital moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenytoin': ['Severe', 'Phenytoin moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Primidone': ['Severe', 'Primidone moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Rifampicin': ['Severe', 'Rifampicin moderately decreases the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], ""St John's Wort"": ['Severe', ""St John's Wort is predicted to decrease the exposure to apremilast. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical""]}","aprepitant","{'Abemaciclib': ['Moderate', 'Aprepitant is predicted to increase the exposure to abemaciclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Acenocoumarol': ['Moderate', 'Aprepitant decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR during treatment and for 14 days after. Severity of interaction: Moderate Evidence for interaction: Study'], 'Alfentanil': ['Moderate', 'Aprepitant is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Alprazolam': ['Severe', 'Aprepitant is predicted to increase the exposure to alprazolam. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Amlodipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atorvastatin': ['Severe', 'Aprepitant is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Avanafil': ['Moderate', 'Aprepitant is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Axitinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bedaquiline': ['Mild', 'Aprepitant is predicted to increase the exposure to bedaquiline. Manufacturer advises avoid prolonged use. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Bosentan': ['Moderate', 'Bosentan is predicted to decrease the exposure to aprepitant. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bosutinib': ['Severe', 'Aprepitant is predicted to increase the exposure to bosutinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bromocriptine': ['Severe', 'Aprepitant is predicted to increase the exposure to bromocriptine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Budesonide': ['Moderate', 'Aprepitant is predicted to increase the exposure to oral budesonide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Buprenorphine': ['Moderate', 'Aprepitant is predicted to increase the exposure to buprenorphine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Buspirone': ['Moderate', 'Aprepitant is predicted to increase the exposure to buspirone. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cabazitaxel': ['Moderate', 'Aprepitant is predicted to increase the exposure to cabazitaxel. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Cabergoline': ['Moderate', 'Aprepitant is predicted to increase the concentration of cabergoline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Cabozantinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to cabozantinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cariprazine': ['Severe', 'Aprepitant is predicted to increase the exposure to cariprazine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciclosporin': ['Severe', 'Aprepitant is predicted to increase the concentration of ciclosporin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cobicistat': ['Moderate', 'Cobicistat is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cobimetinib': ['Severe', 'Aprepitant is predicted to increase the exposure to cobimetinib. Manufacturer advises caution and monitor for toxicity. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Colchicine': ['Severe', 'Aprepitant is predicted to increase the exposure to colchicine. Manufacturer advises adjust colchicine dose with moderate inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Combined hormonal contraceptives': ['Severe', 'Aprepitant is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions. Severity of interaction: Severe Evidence for interaction: Study'], 'Dapoxetine': ['Moderate', 'Aprepitant is predicted to increase the exposure to dapoxetine. Manufacturer advises adjust dapoxetine dose with moderate inhibitors of CYP3A4. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Darifenacin': ['Moderate', 'Aprepitant is predicted to slightly increase the exposure to darifenacin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Darunavir': ['Moderate', 'Darunavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dasatinib': ['Severe', 'Aprepitant is predicted to increase the exposure to dasatinib. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Desogestrel': ['Severe', 'Aprepitant is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexamethasone': ['Moderate', 'Aprepitant moderately increases the exposure to dexamethasone. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Diltiazem': ['Moderate', 'Diltiazem is predicted to increase the exposure to aprepitant and aprepitant is predicted to increase the exposure to diltiazem. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Domperidone': ['Severe', 'Aprepitant increases the risk of QT-prolongation when given with domperidone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Dronedarone': ['Severe', 'Aprepitant increases the exposure to dronedarone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dutasteride': ['Mild', 'Aprepitant is predicted to moderately increase the exposure to dutasteride. Manufacturer advises monitor side effects. Severity of interaction: Mild Evidence for interaction: Study'], 'Efavirenz': ['Moderate', 'Efavirenz is predicted to decrease the exposure to aprepitant. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eletriptan': ['Moderate', 'Aprepitant is predicted to increase the exposure to eletriptan. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eliglustat': ['Severe', 'Aprepitant is predicted to increase the exposure to eliglustat. Manufacturer advises avoid or adjust dose—consult product literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Encorafenib': ['Moderate', 'Aprepitant is predicted to moderately increase the exposure to encorafenib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Enzalutamide': ['Moderate', 'Enzalutamide is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eplerenone': ['Severe', 'Aprepitant is predicted to increase the exposure to eplerenone. Manufacturer advises adjust eplerenone dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ergometrine': ['Severe', 'Aprepitant is predicted to increase the risk of ergotism when given with ergometrine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ergotamine': ['Severe', 'Aprepitant is predicted to increase the risk of ergotism when given with ergotamine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erlotinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to erlotinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Etonogestrel': ['Severe', 'Aprepitant is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Everolimus': ['Moderate', 'Aprepitant is predicted to increase the concentration of everolimus. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Felodipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to felodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fentanyl': ['Moderate', 'Aprepitant is predicted to increase the exposure to fentanyl. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fesoterodine': ['Mild', 'Aprepitant is predicted to increase the exposure to fesoterodine. Manufacturer advises adjust fesoterodine dose with moderate inhibitors of CYP3A4 in hepatic and renal impairment. Severity of interaction: Mild Evidence for interaction: Study'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fluticasone': ['Moderate', 'Aprepitant is predicted to increase the exposure to fluticasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Gefitinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to gefitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Guanfacine': ['Moderate', 'Aprepitant is predicted to increase the concentration of guanfacine. Manufacturer advises adjust guanfacine dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Hormone replacement therapy': ['Moderate', 'Aprepitant is predicted to decrease the effects of hormone replacement therapy. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ibrutinib': ['Severe', 'Aprepitant is predicted to increase the exposure to ibrutinib. Manufacturer advises adjust ibrutinib dose with moderate inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Idelalisib': ['Moderate', 'Idelalisib is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ifosfamide': ['Severe', 'Aprepitant is predicted to increase the exposure to ifosfamide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Imatinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to imatinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Irinotecan': ['Severe', 'Aprepitant is predicted to increase the exposure to intravenous irinotecan. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Isavuconazole': ['Moderate', 'Aprepitant is predicted to increase the exposure to isavuconazole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ivabradine': ['Severe', 'Aprepitant is predicted to increase the exposure to ivabradine. Manufacturer advises adjust ivabradine dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ivacaftor': ['Severe', 'Aprepitant is predicted to increase the exposure to ivacaftor. Manufacturer advises adjust ivacaftor or tezacaftor with ivacaftor dose with moderate inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lacidipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to lacidipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lapatinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to lapatinib. Manufacturer advises caution and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lercanidipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to lercanidipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Levonorgestrel': ['Severe', 'Aprepitant is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lomitapide': ['Moderate', 'Aprepitant is predicted to increase the exposure to lomitapide. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lurasidone': ['Moderate', 'Aprepitant is predicted to increase the exposure to lurasidone. Manufacturer advises adjust lurasidone dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Maraviroc': ['Moderate', 'Aprepitant is predicted to increase the exposure to maraviroc. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Methadone': ['Moderate', 'Aprepitant is predicted to increase the exposure to methadone. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Methylprednisolone': ['Moderate', 'Aprepitant is predicted to increase the exposure to methylprednisolone. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Midazolam': ['Severe', 'Aprepitant is predicted to increase the exposure to midazolam. Manufacturer advises monitor side effects and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Midostaurin': ['Moderate', 'Aprepitant is predicted to increase the exposure to midostaurin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Mitotane': ['Moderate', 'Mitotane is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mizolastine': ['Severe', 'Aprepitant is predicted to increase the exposure to mizolastine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Naloxegol': ['Moderate', 'Aprepitant is predicted to increase the exposure to naloxegol. Manufacturer advises adjust naloxegol dose and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nevirapine': ['Moderate', 'Nevirapine is predicted to decrease the exposure to aprepitant. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nicardipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to nicardipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nifedipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to nifedipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nilotinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to nilotinib. Manufacturer advises consider alternatives. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nimodipine': ['Moderate', 'Aprepitant is predicted to increase the exposure to nimodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Norethisterone': ['Severe', 'Aprepitant is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Olaparib': ['Moderate', 'Aprepitant is predicted to increase the exposure to olaparib. Manufacturer advises avoid moderate inhibitors of CYP3A4 or adjust olaparib dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Oxybutynin': ['Mild', 'Aprepitant is predicted to increase the exposure to oxybutynin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Oxycodone': ['Moderate', 'Aprepitant is predicted to increase the exposure to oxycodone. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pazopanib': ['Moderate', 'Aprepitant is predicted to increase the exposure to pazopanib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['Severe', 'Aprepitant is predicted to increase the exposure to pimozide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Piperaquine': ['Severe', 'Aprepitant is predicted to increase the concentration of piperaquine. Manufacturer advises caution and monitor ECG. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Primidone': ['Moderate', 'Primidone is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Propafenone': ['Moderate', 'Aprepitant is predicted to increase the exposure to propafenone. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Quetiapine': ['Moderate', 'Aprepitant is predicted to increase the exposure to quetiapine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ranolazine': ['Severe', 'Aprepitant is predicted to increase the exposure to ranolazine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Ribociclib': ['Moderate', 'Aprepitant is predicted to increase the exposure to ribociclib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to markedly decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rupatadine': ['Moderate', 'Aprepitant is predicted to increase the exposure to rupatadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ruxolitinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to ruxolitinib. Manufacturer advises monitor side effects. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Salmeterol': ['Moderate', 'Aprepitant is predicted to increase the exposure to salmeterol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Saxagliptin': ['Mild', 'Aprepitant is predicted to increase the exposure to saxagliptin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Sildenafil': ['Moderate', 'Aprepitant is predicted to increase the exposure to sildenafil. Manufacturer advises monitor or adjust sildenafil dose with moderate inhibitors of CYP3A4. Severity of interaction: Moderate Evidence for interaction: Study'], 'Simvastatin': ['Severe', 'Aprepitant is predicted to increase the exposure to simvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sirolimus': ['Moderate', 'Aprepitant increases the concentration of sirolimus. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], ""St John's Wort"": ['Moderate', ""St John's Wort is predicted to decrease the exposure to aprepitant. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Sufentanil': ['Moderate', 'Aprepitant is predicted to increase the exposure to sufentanil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sunitinib': ['Moderate', 'Aprepitant is predicted to increase the exposure to sunitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tacrolimus': ['Severe', 'Aprepitant is predicted to increase the concentration of tacrolimus. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Tadalafil': ['Severe', 'Aprepitant is predicted to increase the exposure to tadalafil. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tamsulosin': ['Moderate', 'Aprepitant is predicted to increase the exposure to tamsulosin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Temsirolimus': ['Moderate', 'Aprepitant is predicted to increase the concentration of temsirolimus. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Tezacaftor': ['Severe', 'Aprepitant is predicted to increase the exposure to tezacaftor. Manufacturer advises adjust tezacaftor with ivacaftor dose with moderate inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tofacitinib': ['Moderate', 'Aprepitant given with a potent CYP2C19 inhibitor is predicted to increase the exposure to tofacitinib. Manufacturer advises adjust tofacitinib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tolterodine': ['Mild', 'Aprepitant is predicted to increase the exposure to tolterodine. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Tolvaptan': ['Moderate', 'Aprepitant is predicted to increase the exposure to tolvaptan. Manufacturer advises caution or adjust tolvaptan dose with moderate inhibitors of CYP3A4. Severity of interaction: Moderate Evidence for interaction: Study'], 'Trazodone': ['Moderate', 'Aprepitant is predicted to increase the exposure to trazodone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ulipristal': ['Severe', 'Aprepitant decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Vardenafil': ['Severe', 'Aprepitant is predicted to increase the exposure to vardenafil. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venetoclax': ['Severe', 'Aprepitant is predicted to increase the exposure to venetoclax. Manufacturer advises avoid or adjust dose—consult product literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Verapamil': ['Moderate', 'Verapamil is predicted to increase the exposure to aprepitant and aprepitant is predicted to increase the exposure to verapamil. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Vinblastine': ['Severe', 'Aprepitant is predicted to increase the exposure to vinblastine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vincristine': ['Severe', 'Aprepitant is predicted to increase the exposure to vincristine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vindesine': ['Severe', 'Aprepitant is predicted to increase the exposure to vindesine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Aprepitant is predicted to increase the exposure to vinflunine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinorelbine': ['Severe', 'Aprepitant is predicted to increase the exposure to vinorelbine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Warfarin': ['Moderate', 'Aprepitant decreases the anticoagulant effect of warfarin. Manufacturer advises monitor INR during treatment and for 14 days after. Severity of interaction: Moderate Evidence for interaction: Study'], 'Zopiclone': ['Moderate', 'Aprepitant is predicted to increase the exposure to zopiclone. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study']}","argatrob","{'Aceclofenac': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with aceclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Acenocoumarol': ['NotSet', 'Both argatroban and acenocoumarol can increase the risk of bleeding.'], 'Alteplase': ['NotSet', 'Both argatroban and alteplase can increase the risk of bleeding.'], 'Anagrelide': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with anagrelide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Apixaban': ['NotSet', 'Both argatroban and apixaban can increase the risk of bleeding.'], 'Aspirin': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bevacizumab': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with bevacizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bivalirudin': ['NotSet', 'Both argatroban and bivalirudin can increase the risk of bleeding.'], 'Cangrelor': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with cangrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Celecoxib': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with celecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cilostazol': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with cilostazol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with citalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clopidogrel': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with clopidogrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dabigatran': ['NotSet', 'Both argatroban and dabigatran can increase the risk of bleeding.'], 'Dalteparin': ['NotSet', 'Both argatroban and dalteparin can increase the risk of bleeding.'], 'Danaparoid': ['NotSet', 'Both argatroban and danaparoid can increase the risk of bleeding.'], 'Dapoxetine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with dapoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dasatinib': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with dasatinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexibuprofen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with dexibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexketoprofen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with dexketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Diclofenac': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with diclofenac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dipyridamole': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with dipyridamole. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Duloxetine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with duloxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Edoxaban': ['NotSet', 'Both argatroban and edoxaban can increase the risk of bleeding.'], 'Enoxaparin': ['NotSet', 'Both argatroban and enoxaparin can increase the risk of bleeding.'], 'Epoprostenol': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with epoprostenol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eptifibatide': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with eptifibatide. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Escitalopram': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with escitalopram. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etodolac': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with etodolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Etoricoxib': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with etoricoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluoxetine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with fluoxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flurbiprofen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with flurbiprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluvoxamine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with fluvoxamine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fondaparinux': ['NotSet', 'Both argatroban and fondaparinux can increase the risk of bleeding.'], 'Heparin (unfractionated)': ['NotSet', 'Both argatroban and heparin (unfractionated) can increase the risk of bleeding.'], 'Ibrutinib': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with ibrutinib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibuprofen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with ibuprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Iloprost': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with iloprost. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indometacin': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with indometacin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotersen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with inotersen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketoprofen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with ketoprofen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ketorolac': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with ketorolac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mefenamic acid': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with mefenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Meloxicam': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with meloxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nabumetone': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with nabumetone. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Naproxen': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with naproxen. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nicotinic acid': ['NotSet', 'Both argatroban and nicotinic acid can increase the risk of bleeding.'], 'Omega-3-acid ethyl esters': ['NotSet', 'Both argatroban and omega-3-acid ethyl esters can increase the risk of bleeding.'], 'Parecoxib': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with parecoxib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paroxetine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with paroxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenindione': ['NotSet', 'Both argatroban and phenindione can increase the risk of bleeding.'], 'Piroxicam': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with piroxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prasugrel': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with prasugrel. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ranibizumab': ['Severe', 'Ranibizumab is predicted to increase the risk of bleeding events when given with argatroban. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Regorafenib': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with regorafenib. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rivaroxaban': ['NotSet', 'Both argatroban and rivaroxaban can increase the risk of bleeding.'], 'Sertraline': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with sertraline. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Streptokinase': ['NotSet', 'Both argatroban and streptokinase can increase the risk of bleeding.'], 'Sulindac': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with sulindac. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenecteplase': ['NotSet', 'Both argatroban and tenecteplase can increase the risk of bleeding.'], 'Tenoxicam': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with tenoxicam. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tiaprofenic acid': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with tiaprofenic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ticagrelor': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with ticagrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tinzaparin': ['NotSet', 'Both argatroban and tinzaparin can increase the risk of bleeding.'], 'Tirofiban': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with tirofiban. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tolfenamic acid': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with tolfenamic acid. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trastuzumab emtansine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with trastuzumab emtansine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Urokinase': ['NotSet', 'Both argatroban and urokinase can increase the risk of bleeding.'], 'Venlafaxine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with venlafaxine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with argatroban. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vortioxetine': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with vortioxetine. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Warfarin': ['NotSet', 'Both argatroban and warfarin can increase the risk of bleeding.']}","aripiprazole","{'Acebutolol': ['NotSet', 'Both aripiprazole and acebutolol can increase the risk of hypotension.'], 'Agomelatine': ['NotSet', ""Both aripiprazole and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both aripiprazole and alcohol (beverage) can increase the risk of hypotension. Both aripiprazole and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both aripiprazole and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfuzosin': ['NotSet', 'Both aripiprazole and alfuzosin can increase the risk of hypotension.'], 'Alimemazine': ['NotSet', ""Both aripiprazole and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aliskiren': ['NotSet', 'Both aripiprazole and aliskiren can increase the risk of hypotension.'], 'Alprazolam': ['NotSet', ""Both aripiprazole and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprostadil': ['NotSet', 'Both aripiprazole and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both aripiprazole and amantadine can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of amantadine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amisulpride': ['NotSet', ""Both aripiprazole and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both aripiprazole and amitriptyline can increase the risk of hypotension. Both aripiprazole and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amlodipine': ['NotSet', 'Both aripiprazole and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both aripiprazole and apomorphine can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of apomorphine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Apraclonidine': ['NotSet', ""Both aripiprazole and apraclonidine can increase the risk of hypotension. Both aripiprazole and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both aripiprazole and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both aripiprazole and asenapine can increase the risk of hypotension. Both aripiprazole and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atenolol': ['NotSet', 'Both aripiprazole and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both aripiprazole and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both aripiprazole and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', ""Both aripiprazole and baclofen can increase the risk of hypotension. Both aripiprazole and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bendroflumethiazide': ['NotSet', 'Both aripiprazole and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', ""Both aripiprazole and benperidol can increase the risk of hypotension. Both aripiprazole and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betaxolol': ['NotSet', 'Both aripiprazole and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both aripiprazole and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both aripiprazole and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', ""Both aripiprazole and brimonidine can increase the risk of hypotension. Both aripiprazole and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bromocriptine': ['NotSet', 'Both aripiprazole and bromocriptine can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of bromocriptine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Buclizine': ['NotSet', ""Both aripiprazole and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bumetanide': ['NotSet', 'Both aripiprazole and bumetanide can increase the risk of hypotension.'], 'Bupivacaine': ['NotSet', ""Both aripiprazole and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both aripiprazole and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupropion': ['Moderate', 'Bupropion is predicted to moderately increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cabergoline': ['NotSet', 'Both aripiprazole and cabergoline can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of cabergoline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Canagliflozin': ['NotSet', 'Both aripiprazole and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both aripiprazole and candesartan can increase the risk of hypotension.'], 'Cannabidiol': ['NotSet', ""Both aripiprazole and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Captopril': ['NotSet', 'Both aripiprazole and captopril can increase the risk of hypotension.'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cariprazine': ['NotSet', ""Both aripiprazole and cariprazine can increase the risk of hypotension. Both aripiprazole and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carvedilol': ['NotSet', 'Both aripiprazole and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both aripiprazole and celiprolol can increase the risk of hypotension.'], 'Chloral hydrate': ['NotSet', ""Both aripiprazole and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both aripiprazole and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorothiazide': ['NotSet', 'Both aripiprazole and chlorothiazide can increase the risk of hypotension.'], 'Chlorphenamine': ['NotSet', ""Both aripiprazole and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both aripiprazole and chlorpromazine can increase the risk of hypotension. Both aripiprazole and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlortalidone': ['NotSet', 'Both aripiprazole and chlortalidone can increase the risk of hypotension.'], 'Cinacalcet': ['Moderate', 'Cinacalcet is predicted to moderately increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cinnarizine': ['NotSet', ""Both aripiprazole and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clemastine': ['NotSet', ""Both aripiprazole and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both aripiprazole and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both aripiprazole and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both aripiprazole and clomipramine can increase the risk of hypotension. Both aripiprazole and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both aripiprazole and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both aripiprazole and clonidine can increase the risk of hypotension. Both aripiprazole and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both aripiprazole and clozapine can increase the risk of hypotension. Both aripiprazole and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cobicistat': ['Moderate', 'Cobicistat is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Codeine': ['NotSet', ""Both aripiprazole and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyclizine': ['NotSet', ""Both aripiprazole and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both aripiprazole and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dapagliflozin': ['NotSet', 'Both aripiprazole and dapagliflozin can increase the risk of hypotension.'], 'Darunavir': ['Moderate', 'Darunavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Desflurane': ['NotSet', ""Both aripiprazole and desflurane can increase the risk of hypotension. Both aripiprazole and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both aripiprazole and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both aripiprazole and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both aripiprazole and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazoxide': ['NotSet', 'Both aripiprazole and diazoxide can increase the risk of hypotension.'], 'Dihydrocodeine': ['NotSet', ""Both aripiprazole and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diltiazem': ['NotSet', 'Both aripiprazole and diltiazem can increase the risk of hypotension.'], 'Dipipanone': ['NotSet', ""Both aripiprazole and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipyridamole': ['NotSet', 'Both aripiprazole and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', ""Both aripiprazole and dosulepin can increase the risk of hypotension. Both aripiprazole and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxazosin': ['NotSet', 'Both aripiprazole and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', ""Both aripiprazole and doxepin can increase the risk of hypotension. Both aripiprazole and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both aripiprazole and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both aripiprazole and droperidol can increase the risk of hypotension. Both aripiprazole and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Empagliflozin': ['NotSet', 'Both aripiprazole and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both aripiprazole and enalapril can increase the risk of hypotension.'], 'Enzalutamide': ['Moderate', 'Enzalutamide is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eplerenone': ['NotSet', 'Both aripiprazole and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both aripiprazole and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both aripiprazole and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', ""Both aripiprazole and esketamine can increase the risk of hypotension. Both aripiprazole and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esmolol': ['NotSet', 'Both aripiprazole and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', ""Both aripiprazole and etomidate can increase the risk of hypotension. Both aripiprazole and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Felodipine': ['NotSet', 'Both aripiprazole and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', ""Both aripiprazole and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluoxetine': ['Moderate', 'Fluoxetine is predicted to moderately increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Flupentixol': ['NotSet', ""Both aripiprazole and flupentixol can increase the risk of hypotension. Both aripiprazole and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both aripiprazole and fluphenazine can increase the risk of hypotension. Both aripiprazole and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both aripiprazole and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosinopril': ['NotSet', 'Both aripiprazole and fosinopril can increase the risk of hypotension.'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Furosemide': ['NotSet', 'Both aripiprazole and furosemide can increase the risk of hypotension.'], 'Gabapentin': ['NotSet', ""Both aripiprazole and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Glyceryl trinitrate': ['NotSet', 'Both aripiprazole and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both aripiprazole and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', ""Both aripiprazole and guanfacine can increase the risk of hypotension. Both aripiprazole and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both aripiprazole and haloperidol can increase the risk of hypotension. Both aripiprazole and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydralazine': ['NotSet', 'Both aripiprazole and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both aripiprazole and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both aripiprazole and hydroflumethiazide can increase the risk of hypotension.'], 'Hydromorphone': ['NotSet', ""Both aripiprazole and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both aripiprazole and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Idelalisib': ['Moderate', 'Idelalisib is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Imidapril': ['NotSet', 'Both aripiprazole and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', ""Both aripiprazole and imipramine can increase the risk of hypotension. Both aripiprazole and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Indapamide': ['NotSet', 'Both aripiprazole and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both aripiprazole and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both aripiprazole and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both aripiprazole and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', ""Both aripiprazole and isoflurane can increase the risk of hypotension. Both aripiprazole and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isosorbide dinitrate': ['NotSet', 'Both aripiprazole and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both aripiprazole and isosorbide mononitrate can increase the risk of hypotension.'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketamine': ['NotSet', ""Both aripiprazole and ketamine can increase the risk of hypotension. Both aripiprazole and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketotifen': ['NotSet', ""Both aripiprazole and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Labetalol': ['NotSet', 'Both aripiprazole and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both aripiprazole and lacidipine can increase the risk of hypotension.'], 'Lamotrigine': ['NotSet', ""Both aripiprazole and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lercanidipine': ['NotSet', 'Both aripiprazole and lercanidipine can increase the risk of hypotension.'], 'Levetiracetam': ['NotSet', ""Both aripiprazole and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levobunolol': ['NotSet', 'Both aripiprazole and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both aripiprazole and levodopa can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of levodopa. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levomepromazine': ['NotSet', ""Both aripiprazole and levomepromazine can increase the risk of hypotension. Both aripiprazole and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both aripiprazole and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lisinopril': ['NotSet', 'Both aripiprazole and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', ""Both aripiprazole and lofepramine can increase the risk of hypotension. Both aripiprazole and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both aripiprazole and lofexidine can increase the risk of hypotension. Both aripiprazole and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Loprazolam': ['NotSet', ""Both aripiprazole and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both aripiprazole and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both aripiprazole and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Losartan': ['NotSet', 'Both aripiprazole and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', ""Both aripiprazole and loxapine can increase the risk of hypotension. Both aripiprazole and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both aripiprazole and lurasidone can increase the risk of hypotension. Both aripiprazole and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both aripiprazole and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both aripiprazole and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both aripiprazole and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both aripiprazole and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both aripiprazole and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both aripiprazole and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both aripiprazole and methoxyflurane can increase the risk of hypotension. Both aripiprazole and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methyldopa': ['NotSet', 'Both aripiprazole and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both aripiprazole and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both aripiprazole and metoprolol can increase the risk of hypotension.'], 'Mianserin': ['NotSet', ""Both aripiprazole and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both aripiprazole and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Minoxidil': ['NotSet', 'Both aripiprazole and minoxidil can increase the risk of hypotension.'], 'Mirtazapine': ['NotSet', ""Both aripiprazole and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mitotane': ['Moderate', 'Mitotane is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Morphine': ['NotSet', ""Both aripiprazole and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxisylyte': ['NotSet', 'Both aripiprazole and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', ""Both aripiprazole and moxonidine can increase the risk of hypotension. Both aripiprazole and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both aripiprazole and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nadolol': ['NotSet', 'Both aripiprazole and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both aripiprazole and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both aripiprazole and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both aripiprazole and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both aripiprazole and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both aripiprazole and nimodipine can increase the risk of hypotension.'], 'Nitrazepam': ['NotSet', ""Both aripiprazole and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitroprusside': ['NotSet', 'Both aripiprazole and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', ""Both aripiprazole and nitrous oxide can increase the risk of hypotension. Both aripiprazole and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both aripiprazole and nortriptyline can increase the risk of hypotension. Both aripiprazole and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both aripiprazole and olanzapine can increase the risk of hypotension. Both aripiprazole and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olmesartan': ['NotSet', 'Both aripiprazole and olmesartan can increase the risk of hypotension.'], 'Oxazepam': ['NotSet', ""Both aripiprazole and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both aripiprazole and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both aripiprazole and paliperidone can increase the risk of hypotension. Both aripiprazole and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paroxetine': ['Moderate', 'Paroxetine is predicted to moderately increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pentazocine': ['NotSet', ""Both aripiprazole and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both aripiprazole and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pergolide': ['NotSet', 'Both aripiprazole and pergolide can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of pergolide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pericyazine': ['NotSet', ""Both aripiprazole and pericyazine can increase the risk of hypotension. Both aripiprazole and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perindopril': ['NotSet', 'Both aripiprazole and perindopril can increase the risk of hypotension.'], 'Pethidine': ['NotSet', ""Both aripiprazole and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['NotSet', 'Both aripiprazole and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['NotSet', ""Both aripiprazole and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Phenobarbital is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study""], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pimozide': ['NotSet', ""Both aripiprazole and pimozide can increase the risk of hypotension. Both aripiprazole and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pindolol': ['NotSet', 'Both aripiprazole and pindolol can increase the risk of hypotension.'], 'Pizotifen': ['NotSet', ""Both aripiprazole and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pramipexole': ['NotSet', 'Both aripiprazole and pramipexole can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of pramipexole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Prazosin': ['NotSet', 'Both aripiprazole and prazosin can increase the risk of hypotension.'], 'Pregabalin': ['NotSet', ""Both aripiprazole and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both aripiprazole and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both aripiprazole and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing). Primidone is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study""], 'Prochlorperazine': ['NotSet', ""Both aripiprazole and prochlorperazine can increase the risk of hypotension. Both aripiprazole and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both aripiprazole and promazine can increase the risk of hypotension. Both aripiprazole and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both aripiprazole and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both aripiprazole and propofol can increase the risk of hypotension. Both aripiprazole and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propranolol': ['NotSet', 'Both aripiprazole and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', ""Both aripiprazole and quetiapine can increase the risk of hypotension. Both aripiprazole and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quinagolide': ['NotSet', 'Both aripiprazole and quinagolide can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of quinagolide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quinapril': ['NotSet', 'Both aripiprazole and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both aripiprazole and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', ""Both aripiprazole and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to moderately decrease the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Riociguat': ['NotSet', 'Both aripiprazole and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', ""Both aripiprazole and risperidone can increase the risk of hypotension. Both aripiprazole and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ropinirole': ['NotSet', 'Both aripiprazole and ropinirole can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of ropinirole. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ropivacaine': ['NotSet', ""Both aripiprazole and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rotigotine': ['NotSet', 'Both aripiprazole and rotigotine can increase the risk of hypotension. Aripiprazole is predicted to decrease the effects of rotigotine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sacubitril': ['NotSet', 'Both aripiprazole and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both aripiprazole and sapropterin can increase the risk of hypotension.'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Selegiline': ['NotSet', 'Both aripiprazole and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', ""Both aripiprazole and sevoflurane can increase the risk of hypotension. Both aripiprazole and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sildenafil': ['NotSet', 'Both aripiprazole and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', ""Both aripiprazole and sodium oxybate can increase the risk of hypotension. Both aripiprazole and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sotalol': ['NotSet', 'Both aripiprazole and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both aripiprazole and spironolactone can increase the risk of hypotension.'], 'Sufentanil': ['NotSet', ""Both aripiprazole and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both aripiprazole and sulpiride can increase the risk of hypotension. Both aripiprazole and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tadalafil': ['NotSet', 'Both aripiprazole and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both aripiprazole and tamsulosin can increase the risk of hypotension.'], 'Tapentadol': ['NotSet', ""Both aripiprazole and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Telmisartan': ['NotSet', 'Both aripiprazole and telmisartan can increase the risk of hypotension.'], 'Temazepam': ['NotSet', ""Both aripiprazole and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Terazosin': ['NotSet', 'Both aripiprazole and terazosin can increase the risk of hypotension.'], 'Terbinafine': ['Moderate', 'Terbinafine is predicted to moderately increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tetracaine': ['NotSet', ""Both aripiprazole and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both aripiprazole and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both aripiprazole and thiopental can increase the risk of hypotension. Both aripiprazole and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Timolol': ['NotSet', 'Both aripiprazole and timolol can increase the risk of hypotension.'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tizanidine': ['NotSet', ""Both aripiprazole and tizanidine can increase the risk of hypotension. Both aripiprazole and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Torasemide': ['NotSet', 'Both aripiprazole and torasemide can increase the risk of hypotension.'], 'Tramadol': ['NotSet', ""Both aripiprazole and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trandolapril': ['NotSet', 'Both aripiprazole and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both aripiprazole and tranylcypromine can increase the risk of hypotension.'], 'Trazodone': ['NotSet', ""Both aripiprazole and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both aripiprazole and trifluoperazine can increase the risk of hypotension. Both aripiprazole and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both aripiprazole and trimipramine can increase the risk of hypotension. Both aripiprazole and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Valsartan': ['NotSet', 'Both aripiprazole and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both aripiprazole and vardenafil can increase the risk of hypotension.'], 'Venlafaxine': ['NotSet', ""Both aripiprazole and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['NotSet', 'Both aripiprazole and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both aripiprazole and vernakalant can increase the risk of hypotension.'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Xipamide': ['NotSet', 'Both aripiprazole and xipamide can increase the risk of hypotension.'], 'Zolpidem': ['NotSet', ""Both aripiprazole and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both aripiprazole and zuclopenthixol can increase the risk of hypotension. Both aripiprazole and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","arsenic-trioxide","{'Afatinib': ['NotSet', 'Both arsenic trioxide and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both arsenic trioxide and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both arsenic trioxide and alemtuzumab can increase the risk of myelosuppression.'], 'Amifampridine': ['Severe', 'Both arsenic trioxide and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both arsenic trioxide and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both arsenic trioxide and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amsacrine': ['NotSet', 'Both arsenic trioxide and amsacrine can increase the risk of myelosuppression.'], 'Anagrelide': ['Severe', 'Both arsenic trioxide and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Anakinra': ['NotSet', 'Both arsenic trioxide and anakinra can increase the risk of myelosuppression.'], 'Apalutamide': ['Severe', 'Both arsenic trioxide and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both arsenic trioxide and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artemether': ['Severe', 'Both arsenic trioxide and artemether prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Artenimol': ['Severe', 'Both arsenic trioxide and artenimol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Asparaginase': ['NotSet', 'Both arsenic trioxide and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both arsenic trioxide and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both arsenic trioxide and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both arsenic trioxide and azathioprine can increase the risk of myelosuppression.'], 'Balsalazide': ['NotSet', 'Both arsenic trioxide and balsalazide can increase the risk of myelosuppression.'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both arsenic trioxide and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Belimumab': ['NotSet', 'Both arsenic trioxide and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both arsenic trioxide and bendamustine can increase the risk of myelosuppression.'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bevacizumab': ['NotSet', 'Both arsenic trioxide and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both arsenic trioxide and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both arsenic trioxide and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both arsenic trioxide and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both arsenic trioxide and bosutinib can increase the risk of myelosuppression. Both arsenic trioxide and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Brentuximab vedotin': ['NotSet', 'Both arsenic trioxide and brentuximab vedotin can increase the risk of myelosuppression.'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Busulfan': ['NotSet', 'Both arsenic trioxide and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both arsenic trioxide and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both arsenic trioxide and cabozantinib can increase the risk of myelosuppression. Both arsenic trioxide and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Canakinumab': ['NotSet', 'Both arsenic trioxide and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both arsenic trioxide and capecitabine can increase the risk of myelosuppression.'], 'Carbimazole': ['NotSet', 'Both arsenic trioxide and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both arsenic trioxide and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both arsenic trioxide and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both arsenic trioxide and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both arsenic trioxide and ceritinib can increase the risk of myelosuppression. Both arsenic trioxide and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Cetuximab': ['NotSet', 'Both arsenic trioxide and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both arsenic trioxide and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both arsenic trioxide and chlormethine can increase the risk of myelosuppression.'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both arsenic trioxide and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cisplatin': ['NotSet', 'Both arsenic trioxide and cisplatin can increase the risk of myelosuppression.'], 'Citalopram': ['Severe', 'Both arsenic trioxide and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Cladribine': ['NotSet', 'Both arsenic trioxide and cladribine can increase the risk of myelosuppression.'], 'Clarithromycin': ['Severe', 'Both arsenic trioxide and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clofarabine': ['NotSet', 'Both arsenic trioxide and clofarabine can increase the risk of myelosuppression.'], 'Clomipramine': ['Severe', 'Both arsenic trioxide and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clozapine': ['NotSet', 'Both arsenic trioxide and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both arsenic trioxide and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both arsenic trioxide and crizotinib can increase the risk of myelosuppression. Both arsenic trioxide and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Cyclophosphamide': ['NotSet', 'Both arsenic trioxide and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both arsenic trioxide and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both arsenic trioxide and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both arsenic trioxide and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both arsenic trioxide and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both arsenic trioxide and dasatinib can increase the risk of myelosuppression. Both arsenic trioxide and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Daunorubicin': ['NotSet', 'Both arsenic trioxide and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both arsenic trioxide and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both arsenic trioxide and deferiprone can increase the risk of myelosuppression.'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both arsenic trioxide and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Disopyramide': ['Severe', 'Both arsenic trioxide and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Docetaxel': ['NotSet', 'Both arsenic trioxide and docetaxel can increase the risk of myelosuppression.'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with arsenic trioxide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Doxorubicin': ['NotSet', 'Both arsenic trioxide and doxorubicin can increase the risk of myelosuppression.'], 'Dronedarone': ['Severe', 'Both arsenic trioxide and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', 'Both arsenic trioxide and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Efavirenz': ['Severe', 'Both arsenic trioxide and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both arsenic trioxide and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Epirubicin': ['NotSet', 'Both arsenic trioxide and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both arsenic trioxide and eribulin can increase the risk of myelosuppression. Both arsenic trioxide and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both arsenic trioxide and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both arsenic trioxide and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Estramustine': ['NotSet', 'Both arsenic trioxide and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both arsenic trioxide and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both arsenic trioxide and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both arsenic trioxide and everolimus can increase the risk of myelosuppression.'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with arsenic trioxide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both arsenic trioxide and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both arsenic trioxide and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludarabine': ['NotSet', 'Both arsenic trioxide and fludarabine can increase the risk of myelosuppression.'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluorouracil': ['NotSet', 'Both arsenic trioxide and fluorouracil can increase the risk of myelosuppression.'], 'Fluphenazine': ['Severe', 'Both arsenic trioxide and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ganciclovir': ['NotSet', 'Both arsenic trioxide and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both arsenic trioxide and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both arsenic trioxide and gemcitabine can increase the risk of myelosuppression.'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with arsenic trioxide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Haloperidol': ['Severe', 'Both arsenic trioxide and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxycarbamide': ['NotSet', 'Both arsenic trioxide and hydroxycarbamide can increase the risk of myelosuppression.'], 'Hydroxyzine': ['Severe', 'Both arsenic trioxide and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ibrutinib': ['NotSet', 'Both arsenic trioxide and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both arsenic trioxide and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both arsenic trioxide and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both arsenic trioxide and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both arsenic trioxide and imatinib can increase the risk of myelosuppression.'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both arsenic trioxide and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Interferon alfa': ['NotSet', 'Both arsenic trioxide and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both arsenic trioxide and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both arsenic trioxide and irinotecan can increase the risk of myelosuppression.'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with arsenic trioxide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lapatinib': ['Severe', 'Both arsenic trioxide and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Leflunomide': ['NotSet', 'Both arsenic trioxide and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both arsenic trioxide and lenalidomide can increase the risk of myelosuppression.'], 'Lenvatinib': ['Severe', 'Both arsenic trioxide and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levomepromazine': ['Severe', 'Both arsenic trioxide and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Linezolid': ['NotSet', 'Both arsenic trioxide and linezolid can increase the risk of myelosuppression.'], 'Lithium': ['Severe', 'Both arsenic trioxide and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both arsenic trioxide and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lomustine': ['NotSet', 'Both arsenic trioxide and lomustine can increase the risk of myelosuppression.'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Melphalan': ['NotSet', 'Both arsenic trioxide and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both arsenic trioxide and mercaptopurine can increase the risk of myelosuppression.'], 'Methadone': ['Severe', 'Both arsenic trioxide and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methotrexate': ['NotSet', 'Both arsenic trioxide and methotrexate can increase the risk of myelosuppression.'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mitomycin': ['NotSet', 'Both arsenic trioxide and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both arsenic trioxide and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both arsenic trioxide and mitoxantrone can increase the risk of myelosuppression.'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with arsenic trioxide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both arsenic trioxide and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Mycophenolate': ['NotSet', 'Both arsenic trioxide and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both arsenic trioxide and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both arsenic trioxide and nilotinib can increase the risk of myelosuppression. Both arsenic trioxide and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nivolumab': ['NotSet', 'Both arsenic trioxide and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both arsenic trioxide and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both arsenic trioxide and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both arsenic trioxide and olaparib can increase the risk of myelosuppression.'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Olsalazine': ['NotSet', 'Both arsenic trioxide and olsalazine can increase the risk of myelosuppression.'], 'Ondansetron': ['Severe', 'Both arsenic trioxide and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both arsenic trioxide and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Oxaliplatin': ['NotSet', 'Both arsenic trioxide and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both arsenic trioxide and paclitaxel can increase the risk of myelosuppression.'], 'Paliperidone': ['Severe', 'Both arsenic trioxide and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with arsenic trioxide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panitumumab': ['NotSet', 'Both arsenic trioxide and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both arsenic trioxide and panobinostat can increase the risk of myelosuppression. Both arsenic trioxide and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both arsenic trioxide and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['NotSet', 'Both arsenic trioxide and pazopanib can increase the risk of myelosuppression. Both arsenic trioxide and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pegaspargase': ['NotSet', 'Both arsenic trioxide and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both arsenic trioxide and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both arsenic trioxide and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both arsenic trioxide and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both arsenic trioxide and pentamidine can increase the risk of myelosuppression. Intravenous pentamidine potentially increases the risk of QT-prolongation when given with arsenic trioxide. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pentostatin': ['NotSet', 'Both arsenic trioxide and pentostatin can increase the risk of myelosuppression.'], 'Pimozide': ['Severe', 'Both arsenic trioxide and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pixantrone': ['NotSet', 'Both arsenic trioxide and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both arsenic trioxide and pomalidomide can increase the risk of myelosuppression.'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Primaquine': ['NotSet', 'Both arsenic trioxide and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both arsenic trioxide and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both arsenic trioxide and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both arsenic trioxide and pyrimethamine can increase the risk of myelosuppression.'], 'Quinine': ['Severe', 'Both arsenic trioxide and quinine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Raltitrexed': ['NotSet', 'Both arsenic trioxide and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both arsenic trioxide and ramucirumab can increase the risk of myelosuppression.'], 'Ranolazine': ['Severe', 'Both arsenic trioxide and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Regorafenib': ['NotSet', 'Both arsenic trioxide and regorafenib can increase the risk of myelosuppression.'], 'Ribociclib': ['Severe', 'Both arsenic trioxide and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Risperidone': ['Severe', 'Both arsenic trioxide and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Rituximab': ['NotSet', 'Both arsenic trioxide and rituximab can increase the risk of myelosuppression.'], 'Ruxolitinib': ['NotSet', 'Both arsenic trioxide and ruxolitinib can increase the risk of myelosuppression.'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both arsenic trioxide and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sildenafil': ['Severe', 'Both arsenic trioxide and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Siltuximab': ['NotSet', 'Both arsenic trioxide and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both arsenic trioxide and sorafenib can increase the risk of myelosuppression. Both arsenic trioxide and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both arsenic trioxide and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sulfadiazine': ['NotSet', 'Both arsenic trioxide and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both arsenic trioxide and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both arsenic trioxide and sulfasalazine can increase the risk of myelosuppression.'], 'Sulpiride': ['Severe', 'Both arsenic trioxide and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['NotSet', 'Both arsenic trioxide and sunitinib can increase the risk of myelosuppression. Both arsenic trioxide and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telavancin': ['Severe', 'Both arsenic trioxide and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Temozolomide': ['NotSet', 'Both arsenic trioxide and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both arsenic trioxide and temsirolimus can increase the risk of myelosuppression.'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both arsenic trioxide and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Thalidomide': ['NotSet', 'Both arsenic trioxide and thalidomide can increase the risk of myelosuppression.'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Thiotepa': ['NotSet', 'Both arsenic trioxide and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both arsenic trioxide and tioguanine can increase the risk of myelosuppression.'], 'Tizanidine': ['Severe', 'Both arsenic trioxide and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolterodine': ['Severe', 'Both arsenic trioxide and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Topotecan': ['NotSet', 'Both arsenic trioxide and topotecan can increase the risk of myelosuppression.'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both arsenic trioxide and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Trabectedin': ['NotSet', 'Both arsenic trioxide and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both arsenic trioxide and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both arsenic trioxide and treosulfan can increase the risk of myelosuppression.'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trimethoprim': ['NotSet', 'Both arsenic trioxide and trimethoprim can increase the risk of myelosuppression.'], 'Valganciclovir': ['NotSet', 'Both arsenic trioxide and valganciclovir can increase the risk of myelosuppression.'], 'Vandetanib': ['Severe', 'Both arsenic trioxide and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both arsenic trioxide and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both arsenic trioxide and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both arsenic trioxide and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vernakalant': ['Severe', 'Both arsenic trioxide and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both arsenic trioxide and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both arsenic trioxide and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both arsenic trioxide and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both arsenic trioxide and vinflunine can increase the risk of myelosuppression. Both arsenic trioxide and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vinorelbine': ['NotSet', 'Both arsenic trioxide and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both arsenic trioxide and vismodegib can increase the risk of myelosuppression.'], 'Voriconazole': ['Severe', 'Both arsenic trioxide and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with arsenic trioxide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both arsenic trioxide and zidovudine can increase the risk of myelosuppression.'], 'Zuclopenthixol': ['Severe', 'Both arsenic trioxide and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","artemeth","{'Amifampridine': ['Severe', 'Both artemether and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both artemether and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both artemether and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both artemether and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apalutamide': ['Severe', 'Both artemether and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both artemether and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Arsenic trioxide': ['Severe', 'Both artemether and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both artemether and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Both artemether and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cabozantinib': ['Severe', 'Both artemether and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Carbamazepine': ['Severe', 'Carbamazepine is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ceritinib': ['Severe', 'Both artemether and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both artemether and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Both artemether and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clarithromycin': ['Severe', 'Both artemether and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clomipramine': ['Severe', 'Both artemether and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Crizotinib': ['Severe', 'Both artemether and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dasatinib': ['Severe', 'Both artemether and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both artemether and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Disopyramide': ['Severe', 'Both artemether and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with artemether. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Severe', 'Both artemether and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', 'Both artemether and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Efavirenz': ['Severe', 'Both artemether and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe Efavirenz decreases the concentration of artemether. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Encorafenib': ['Severe', 'Both artemether and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Enzalutamide': ['Severe', 'Enzalutamide is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Eribulin': ['Severe', 'Both artemether and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both artemether and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both artemether and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Etravirine': ['Moderate', 'Etravirine decreases the exposure to artemether. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with artemether. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both artemether and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both artemether and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluphenazine': ['Severe', 'Both artemether and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fosphenytoin': ['Severe', 'Fosphenytoin is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with artemether. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Grapefruit juice': ['Unknown', 'Grapefruit juice increases the exposure to artemether. Manufacturer advises caution. Severity of interaction: Unknown Evidence for interaction: Study'], 'Haloperidol': ['Severe', 'Both artemether and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both artemether and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both artemether and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with artemether. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lapatinib': ['Severe', 'Both artemether and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both artemether and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levomepromazine': ['Severe', 'Both artemether and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lithium': ['Severe', 'Both artemether and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both artemether and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['Severe', 'Both artemether and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mitotane': ['Severe', 'Mitotane is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with artemether. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both artemether and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nilotinib': ['Severe', 'Both artemether and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both artemether and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both artemether and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Paliperidone': ['Severe', 'Both artemether and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with artemether. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both artemether and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both artemether and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both artemether and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with artemether. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Phenobarbital': ['Severe', 'Phenobarbital is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenytoin': ['Severe', 'Phenytoin is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Pimozide': ['Severe', 'Both artemether and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Primidone': ['Severe', 'Primidone is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ranolazine': ['Severe', 'Both artemether and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ribociclib': ['Severe', 'Both artemether and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Rifampicin': ['Severe', 'Rifampicin is predicted to decrease the exposure to artemether (with lumefantrine). Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Risperidone': ['Severe', 'Both artemether and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both artemether and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sildenafil': ['Severe', 'Both artemether and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sorafenib': ['Severe', 'Both artemether and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both artemether and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sulpiride': ['Severe', 'Both artemether and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['Severe', 'Both artemether and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telavancin': ['Severe', 'Both artemether and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both artemether and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tizanidine': ['Severe', 'Both artemether and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolterodine': ['Severe', 'Both artemether and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both artemether and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vandetanib': ['Severe', 'Both artemether and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both artemether and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both artemether and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both artemether and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vernakalant': ['Severe', 'Both artemether and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both artemether and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Voriconazole': ['Severe', 'Both artemether and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artemether. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['Severe', 'Both artemether and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","artenim","{'Amifampridine': ['Severe', 'Both artenimol and amifampridine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Aminophylline': ['Severe', 'Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Both artenimol and amiodarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amisulpride': ['Severe', 'Both artenimol and amisulpride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Amphotericin': ['Severe', 'Amphotericin is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Anagrelide': ['Severe', 'Both artenimol and anagrelide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apalutamide': ['Severe', 'Both artenimol and apalutamide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Apomorphine': ['Severe', 'Both artenimol and apomorphine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Arsenic trioxide': ['Severe', 'Both artenimol and arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bambuterol': ['Severe', 'Bambuterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bedaquiline': ['Severe', 'Both artenimol and bedaquiline prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Bendroflumethiazide': ['Severe', 'Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bosutinib': ['Severe', 'Both artenimol and bosutinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Budesonide': ['Severe', 'Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Bumetanide': ['Severe', 'Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cabozantinib': ['Severe', 'Both artenimol and cabozantinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ceritinib': ['Severe', 'Both artenimol and ceritinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlorothiazide': ['Severe', 'Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlorpromazine': ['Severe', 'Both artenimol and chlorpromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Chlortalidone': ['Severe', 'Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Citalopram': ['Severe', 'Both artenimol and citalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clarithromycin': ['Severe', 'Both artenimol and clarithromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Clomipramine': ['Severe', 'Both artenimol and clomipramine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Crizotinib': ['Severe', 'Both artenimol and crizotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dasatinib': ['Severe', 'Both artenimol and dasatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Delamanid': ['Severe', 'Both artenimol and delamanid prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Disopyramide': ['Severe', 'Both artenimol and disopyramide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Domperidone': ['Severe', 'Domperidone increases the risk of QT-prolongation when given with artenimol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dronedarone': ['Severe', 'Both artenimol and dronedarone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Droperidol': ['Severe', 'Both artenimol and droperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Efavirenz': ['Severe', 'Both artenimol and efavirenz prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Encorafenib': ['Severe', 'Both artenimol and encorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Eribulin': ['Severe', 'Both artenimol and eribulin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Erythromycin': ['Severe', 'Both artenimol and erythromycin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Escitalopram': ['Severe', 'Both artenimol and escitalopram prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fingolimod': ['Severe', 'Fingolimod increases the risk of QT-prolongation when given with artenimol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Flecainide': ['Severe', 'Both artenimol and flecainide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fluconazole': ['Severe', 'Both artenimol and fluconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fluphenazine': ['Severe', 'Both artenimol and fluphenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Formoterol': ['Severe', 'Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Furosemide': ['Severe', 'Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Granisetron': ['Severe', 'Granisetron is predicted to increase the risk of QT-prolongation when given with artenimol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Haloperidol': ['Severe', 'Both artenimol and haloperidol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Hydrochlorothiazide': ['Severe', 'Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroflumethiazide': ['Severe', 'Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydroxyzine': ['Severe', 'Both artenimol and hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Indacaterol': ['Severe', 'Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indapamide': ['Severe', 'Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Inotuzumab ozogamicin': ['Severe', 'Both artenimol and inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ivabradine': ['Severe', 'Ivabradine is predicted to increase the risk of torsade de pointes when given with artenimol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lapatinib': ['Severe', 'Both artenimol and lapatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lenvatinib': ['Severe', 'Both artenimol and lenvatinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Levomepromazine': ['Severe', 'Both artenimol and levomepromazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lithium': ['Severe', 'Both artenimol and lithium prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Lofexidine': ['Severe', 'Both artenimol and lofexidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of QT-prolongation when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['Severe', 'Both artenimol and methadone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Metolazone': ['Severe', 'Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mizolastine': ['Severe', 'Mizolastine is predicted to increase the risk of QT-prolongation when given with artenimol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Moxifloxacin': ['Severe', 'Both artenimol and moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Nilotinib': ['Severe', 'Both artenimol and nilotinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Olodaterol': ['Severe', 'Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ondansetron': ['Severe', 'Both artenimol and ondansetron prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Osimertinib': ['Severe', 'Both artenimol and osimertinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Paliperidone': ['Severe', 'Both artenimol and paliperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Palonosetron': ['Severe', 'Palonosetron is predicted to increase the risk of QT-prolongation when given with artenimol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Panobinostat': ['Severe', 'Both artenimol and panobinostat prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pasireotide': ['Severe', 'Both artenimol and pasireotide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pazopanib': ['Severe', 'Both artenimol and pazopanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Pentamidine': ['Severe', 'Intravenous pentamidine potentially increases the risk of QT-prolongation when given with artenimol. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pimozide': ['Severe', 'Both artenimol and pimozide prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ranolazine': ['Severe', 'Both artenimol and ranolazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Ribociclib': ['Severe', 'Both artenimol and ribociclib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Risperidone': ['Severe', 'Both artenimol and risperidone prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Salbutamol': ['Severe', 'Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salmeterol': ['Severe', 'Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Both artenimol and saquinavir prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sildenafil': ['Severe', 'Both artenimol and sildenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sorafenib': ['Severe', 'Both artenimol and sorafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sotalol': ['Severe', 'Both artenimol and sotalol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sulpiride': ['Severe', 'Both artenimol and sulpiride prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Sunitinib': ['Severe', 'Both artenimol and sunitinib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Telavancin': ['Severe', 'Both artenimol and telavancin prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Terbutaline': ['Severe', 'Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tetrabenazine': ['Severe', 'Both artenimol and tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Theophylline': ['Severe', 'Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tizanidine': ['Severe', 'Both artenimol and tizanidine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Tolterodine': ['Severe', 'Both artenimol and tolterodine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Torasemide': ['Severe', 'Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Toremifene': ['Severe', 'Both artenimol and toremifene prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vandetanib': ['Severe', 'Both artenimol and vandetanib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vardenafil': ['Severe', 'Both artenimol and vardenafil prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vemurafenib': ['Severe', 'Both artenimol and vemurafenib prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Venlafaxine': ['Severe', 'Both artenimol and venlafaxine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vernakalant': ['Severe', 'Both artenimol and vernakalant prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Vilanterol': ['Severe', 'Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Both artenimol and vinflunine prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Voriconazole': ['Severe', 'Both artenimol and voriconazole prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe'], 'Xipamide': ['Severe', 'Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with artenimol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zuclopenthixol': ['Severe', 'Both artenimol and zuclopenthixol prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. Severity of interaction: Severe']}","articai","{'Agomelatine': ['NotSet', ""Both articaine and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both articaine and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both articaine and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alimemazine': ['NotSet', ""Both articaine and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprazolam': ['NotSet', ""Both articaine and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amisulpride': ['NotSet', ""Both articaine and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both articaine and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Apraclonidine': ['NotSet', ""Both articaine and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both articaine and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Asenapine': ['NotSet', ""Both articaine and asenapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Baclofen': ['NotSet', ""Both articaine and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Benperidol': ['NotSet', ""Both articaine and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Brimonidine': ['NotSet', ""Both articaine and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buclizine': ['NotSet', ""Both articaine and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bupivacaine': ['NotSet', ""Both articaine and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both articaine and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cannabidiol': ['NotSet', ""Both articaine and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cariprazine': ['NotSet', ""Both articaine and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chloral hydrate': ['NotSet', ""Both articaine and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both articaine and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorphenamine': ['NotSet', ""Both articaine and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both articaine and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cinnarizine': ['NotSet', ""Both articaine and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clemastine': ['NotSet', ""Both articaine and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both articaine and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both articaine and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both articaine and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both articaine and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both articaine and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both articaine and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both articaine and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyclizine': ['NotSet', ""Both articaine and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both articaine and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Desflurane': ['NotSet', ""Both articaine and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both articaine and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both articaine and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both articaine and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dihydrocodeine': ['NotSet', ""Both articaine and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipipanone': ['NotSet', ""Both articaine and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dosulepin': ['NotSet', ""Both articaine and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxepin': ['NotSet', ""Both articaine and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both articaine and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both articaine and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esketamine': ['NotSet', ""Both articaine and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Etomidate': ['NotSet', ""Both articaine and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fentanyl': ['NotSet', ""Both articaine and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flupentixol': ['NotSet', ""Both articaine and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both articaine and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both articaine and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Gabapentin': ['NotSet', ""Both articaine and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Guanfacine': ['NotSet', ""Both articaine and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both articaine and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydromorphone': ['NotSet', ""Both articaine and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both articaine and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imipramine': ['NotSet', ""Both articaine and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isoflurane': ['NotSet', ""Both articaine and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketamine': ['NotSet', ""Both articaine and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketotifen': ['NotSet', ""Both articaine and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lamotrigine': ['NotSet', ""Both articaine and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levetiracetam': ['NotSet', ""Both articaine and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levomepromazine': ['NotSet', ""Both articaine and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both articaine and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofepramine': ['NotSet', ""Both articaine and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both articaine and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both articaine and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both articaine and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both articaine and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loxapine': ['NotSet', ""Both articaine and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both articaine and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both articaine and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both articaine and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both articaine and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both articaine and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both articaine and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both articaine and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both articaine and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mianserin': ['NotSet', ""Both articaine and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both articaine and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mirtazapine': ['NotSet', ""Both articaine and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Morphine': ['NotSet', ""Both articaine and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxonidine': ['NotSet', ""Both articaine and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both articaine and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrazepam': ['NotSet', ""Both articaine and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitrous oxide': ['NotSet', ""Both articaine and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both articaine and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both articaine and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxazepam': ['NotSet', ""Both articaine and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both articaine and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both articaine and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pentazocine': ['NotSet', ""Both articaine and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both articaine and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pericyazine': ['NotSet', ""Both articaine and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pethidine': ['NotSet', ""Both articaine and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenobarbital': ['NotSet', ""Both articaine and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pimozide': ['NotSet', ""Both articaine and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pizotifen': ['NotSet', ""Both articaine and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pregabalin': ['NotSet', ""Both articaine and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both articaine and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both articaine and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prochlorperazine': ['NotSet', ""Both articaine and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both articaine and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both articaine and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both articaine and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quetiapine': ['NotSet', ""Both articaine and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Remifentanil': ['NotSet', ""Both articaine and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Risperidone': ['NotSet', ""Both articaine and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ropivacaine': ['NotSet', ""Both articaine and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sevoflurane': ['NotSet', ""Both articaine and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sodium oxybate': ['NotSet', ""Both articaine and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sufentanil': ['NotSet', ""Both articaine and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both articaine and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tapentadol': ['NotSet', ""Both articaine and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Temazepam': ['NotSet', ""Both articaine and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tetracaine': ['NotSet', ""Both articaine and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both articaine and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both articaine and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tizanidine': ['NotSet', ""Both articaine and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tramadol': ['NotSet', ""Both articaine and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trazodone': ['NotSet', ""Both articaine and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both articaine and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both articaine and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Venlafaxine': ['NotSet', ""Both articaine and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zolpidem': ['NotSet', ""Both articaine and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both articaine and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","ascorbic-acid","{'Deferiprone': ['Severe', 'Ascorbic acid is predicted to increase the risk of cardiovascular side-effects when given with deferiprone. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Desferrioxamine': ['Severe', 'Ascorbic acid is predicted to increase the risk of cardiovascular side-effects when given with desferrioxamine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical']}","asenapine","{'Acebutolol': ['NotSet', 'Both asenapine and acebutolol can increase the risk of hypotension.'], 'Agomelatine': ['NotSet', ""Both asenapine and agomelatine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alcohol (beverage)': ['NotSet', ""Both asenapine and alcohol (beverage) can increase the risk of hypotension. Both asenapine and alcohol (beverage) can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfentanil': ['NotSet', ""Both asenapine and alfentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alfuzosin': ['NotSet', 'Both asenapine and alfuzosin can increase the risk of hypotension.'], 'Alimemazine': ['NotSet', ""Both asenapine and alimemazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aliskiren': ['NotSet', 'Both asenapine and aliskiren can increase the risk of hypotension.'], 'Alprazolam': ['NotSet', ""Both asenapine and alprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Alprostadil': ['NotSet', 'Both asenapine and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both asenapine and amantadine can increase the risk of hypotension. Asenapine is predicted to decrease the effects of amantadine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Amisulpride': ['NotSet', ""Both asenapine and amisulpride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amitriptyline': ['NotSet', ""Both asenapine and amitriptyline can increase the risk of hypotension. Both asenapine and amitriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Amlodipine': ['NotSet', 'Both asenapine and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both asenapine and apomorphine can increase the risk of hypotension. Asenapine is predicted to decrease the effects of apomorphine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Apraclonidine': ['NotSet', ""Both asenapine and apraclonidine can increase the risk of hypotension. Both asenapine and apraclonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Aripiprazole': ['NotSet', ""Both asenapine and aripiprazole can increase the risk of hypotension. Both asenapine and aripiprazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Articaine': ['NotSet', ""Both asenapine and articaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Atenolol': ['NotSet', 'Both asenapine and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both asenapine and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both asenapine and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', ""Both asenapine and baclofen can increase the risk of hypotension. Both asenapine and baclofen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bendroflumethiazide': ['NotSet', 'Both asenapine and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', ""Both asenapine and benperidol can increase the risk of hypotension. Both asenapine and benperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Betaxolol': ['NotSet', 'Both asenapine and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both asenapine and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both asenapine and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', ""Both asenapine and brimonidine can increase the risk of hypotension. Both asenapine and brimonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bromocriptine': ['NotSet', 'Both asenapine and bromocriptine can increase the risk of hypotension. Asenapine is predicted to decrease the effects of bromocriptine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Buclizine': ['NotSet', ""Both asenapine and buclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Bumetanide': ['NotSet', 'Both asenapine and bumetanide can increase the risk of hypotension.'], 'Bupivacaine': ['NotSet', ""Both asenapine and bupivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Buprenorphine': ['NotSet', ""Both asenapine and buprenorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cabergoline': ['NotSet', 'Both asenapine and cabergoline can increase the risk of hypotension. Asenapine is predicted to decrease the effects of cabergoline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Canagliflozin': ['NotSet', 'Both asenapine and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both asenapine and candesartan can increase the risk of hypotension.'], 'Cannabidiol': ['NotSet', ""Both asenapine and cannabidiol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Captopril': ['NotSet', 'Both asenapine and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', ""Both asenapine and cariprazine can increase the risk of hypotension. Both asenapine and cariprazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Carvedilol': ['NotSet', 'Both asenapine and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both asenapine and celiprolol can increase the risk of hypotension.'], 'Chloral hydrate': ['NotSet', ""Both asenapine and chloral hydrate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlordiazepoxide': ['NotSet', ""Both asenapine and chlordiazepoxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorothiazide': ['NotSet', 'Both asenapine and chlorothiazide can increase the risk of hypotension.'], 'Chlorphenamine': ['NotSet', ""Both asenapine and chlorphenamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlorpromazine': ['NotSet', ""Both asenapine and chlorpromazine can increase the risk of hypotension. Both asenapine and chlorpromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Chlortalidone': ['NotSet', 'Both asenapine and chlortalidone can increase the risk of hypotension.'], 'Cinnarizine': ['NotSet', ""Both asenapine and cinnarizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clemastine': ['NotSet', ""Both asenapine and clemastine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clobazam': ['NotSet', ""Both asenapine and clobazam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomethiazole': ['NotSet', ""Both asenapine and clomethiazole can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clomipramine': ['NotSet', ""Both asenapine and clomipramine can increase the risk of hypotension. Both asenapine and clomipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonazepam': ['NotSet', ""Both asenapine and clonazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clonidine': ['NotSet', ""Both asenapine and clonidine can increase the risk of hypotension. Both asenapine and clonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Clozapine': ['NotSet', ""Both asenapine and clozapine can increase the risk of hypotension. Both asenapine and clozapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Codeine': ['NotSet', ""Both asenapine and codeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyclizine': ['NotSet', ""Both asenapine and cyclizine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Cyproheptadine': ['NotSet', ""Both asenapine and cyproheptadine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dapagliflozin': ['NotSet', 'Both asenapine and dapagliflozin can increase the risk of hypotension.'], 'Desflurane': ['NotSet', ""Both asenapine and desflurane can increase the risk of hypotension. Both asenapine and desflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dexmedetomidine': ['NotSet', ""Both asenapine and dexmedetomidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diamorphine': ['NotSet', ""Both asenapine and diamorphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazepam': ['NotSet', ""Both asenapine and diazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diazoxide': ['NotSet', 'Both asenapine and diazoxide can increase the risk of hypotension.'], 'Dihydrocodeine': ['NotSet', ""Both asenapine and dihydrocodeine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Diltiazem': ['NotSet', 'Both asenapine and diltiazem can increase the risk of hypotension.'], 'Dipipanone': ['NotSet', ""Both asenapine and dipipanone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dipyridamole': ['NotSet', 'Both asenapine and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', ""Both asenapine and dosulepin can increase the risk of hypotension. Both asenapine and dosulepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Doxazosin': ['NotSet', 'Both asenapine and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', ""Both asenapine and doxepin can increase the risk of hypotension. Both asenapine and doxepin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Dronabinol': ['NotSet', ""Both asenapine and dronabinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Droperidol': ['NotSet', ""Both asenapine and droperidol can increase the risk of hypotension. Both asenapine and droperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Empagliflozin': ['NotSet', 'Both asenapine and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both asenapine and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both asenapine and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both asenapine and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both asenapine and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', ""Both asenapine and esketamine can increase the risk of hypotension. Both asenapine and esketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Esmolol': ['NotSet', 'Both asenapine and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', ""Both asenapine and etomidate can increase the risk of hypotension. Both asenapine and etomidate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Felodipine': ['NotSet', 'Both asenapine and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', ""Both asenapine and fentanyl can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flupentixol': ['NotSet', ""Both asenapine and flupentixol can increase the risk of hypotension. Both asenapine and flupentixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluphenazine': ['NotSet', ""Both asenapine and fluphenazine can increase the risk of hypotension. Both asenapine and fluphenazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Flurazepam': ['NotSet', ""Both asenapine and flurazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Fluvoxamine': ['Moderate', 'Fluvoxamine increases the exposure to asenapine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosinopril': ['NotSet', 'Both asenapine and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both asenapine and furosemide can increase the risk of hypotension.'], 'Gabapentin': ['NotSet', ""Both asenapine and gabapentin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Glyceryl trinitrate': ['NotSet', 'Both asenapine and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both asenapine and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', ""Both asenapine and guanfacine can increase the risk of hypotension. Both asenapine and guanfacine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Haloperidol': ['NotSet', ""Both asenapine and haloperidol can increase the risk of hypotension. Both asenapine and haloperidol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydralazine': ['NotSet', 'Both asenapine and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both asenapine and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both asenapine and hydroflumethiazide can increase the risk of hypotension.'], 'Hydromorphone': ['NotSet', ""Both asenapine and hydromorphone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Hydroxyzine': ['NotSet', ""Both asenapine and hydroxyzine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Imidapril': ['NotSet', 'Both asenapine and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', ""Both asenapine and imipramine can increase the risk of hypotension. Both asenapine and imipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Indapamide': ['NotSet', 'Both asenapine and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both asenapine and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both asenapine and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both asenapine and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', ""Both asenapine and isoflurane can increase the risk of hypotension. Both asenapine and isoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Isosorbide dinitrate': ['NotSet', 'Both asenapine and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both asenapine and isosorbide mononitrate can increase the risk of hypotension.'], 'Ketamine': ['NotSet', ""Both asenapine and ketamine can increase the risk of hypotension. Both asenapine and ketamine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ketotifen': ['NotSet', ""Both asenapine and ketotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Labetalol': ['NotSet', 'Both asenapine and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both asenapine and lacidipine can increase the risk of hypotension.'], 'Lamotrigine': ['NotSet', ""Both asenapine and lamotrigine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lercanidipine': ['NotSet', 'Both asenapine and lercanidipine can increase the risk of hypotension.'], 'Levetiracetam': ['NotSet', ""Both asenapine and levetiracetam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Levobunolol': ['NotSet', 'Both asenapine and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both asenapine and levodopa can increase the risk of hypotension. Asenapine is predicted to decrease the effects of levodopa. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Levomepromazine': ['NotSet', ""Both asenapine and levomepromazine can increase the risk of hypotension. Both asenapine and levomepromazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lidocaine': ['NotSet', ""Both asenapine and lidocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lisinopril': ['NotSet', 'Both asenapine and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', ""Both asenapine and lofepramine can increase the risk of hypotension. Both asenapine and lofepramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lofexidine': ['NotSet', ""Both asenapine and lofexidine can increase the risk of hypotension. Both asenapine and lofexidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Loprazolam': ['NotSet', ""Both asenapine and loprazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lorazepam': ['NotSet', ""Both asenapine and lorazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lormetazepam': ['NotSet', ""Both asenapine and lormetazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Losartan': ['NotSet', 'Both asenapine and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', ""Both asenapine and loxapine can increase the risk of hypotension. Both asenapine and loxapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Lurasidone': ['NotSet', ""Both asenapine and lurasidone can increase the risk of hypotension. Both asenapine and lurasidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Melatonin': ['NotSet', ""Both asenapine and melatonin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Mepivacaine': ['NotSet', ""Both asenapine and mepivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meprobamate': ['NotSet', ""Both asenapine and meprobamate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Meptazinol': ['NotSet', ""Both asenapine and meptazinol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methadone': ['NotSet', ""Both asenapine and methadone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methocarbamol': ['NotSet', ""Both asenapine and methocarbamol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methoxyflurane': ['NotSet', ""Both asenapine and methoxyflurane can increase the risk of hypotension. Both asenapine and methoxyflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Methyldopa': ['NotSet', 'Both asenapine and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both asenapine and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both asenapine and metoprolol can increase the risk of hypotension.'], 'Mianserin': ['NotSet', ""Both asenapine and mianserin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Midazolam': ['NotSet', ""Both asenapine and midazolam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Minoxidil': ['NotSet', 'Both asenapine and minoxidil can increase the risk of hypotension.'], 'Mirtazapine': ['NotSet', ""Both asenapine and mirtazapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Morphine': ['NotSet', ""Both asenapine and morphine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Moxisylyte': ['NotSet', 'Both asenapine and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', ""Both asenapine and moxonidine can increase the risk of hypotension. Both asenapine and moxonidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nabilone': ['NotSet', ""Both asenapine and nabilone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nadolol': ['NotSet', 'Both asenapine and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both asenapine and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both asenapine and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both asenapine and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both asenapine and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both asenapine and nimodipine can increase the risk of hypotension.'], 'Nitrazepam': ['NotSet', ""Both asenapine and nitrazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nitroprusside': ['NotSet', 'Both asenapine and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', ""Both asenapine and nitrous oxide can increase the risk of hypotension. Both asenapine and nitrous oxide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Nortriptyline': ['NotSet', ""Both asenapine and nortriptyline can increase the risk of hypotension. Both asenapine and nortriptyline can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olanzapine': ['NotSet', ""Both asenapine and olanzapine can increase the risk of hypotension. Both asenapine and olanzapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Olmesartan': ['NotSet', 'Both asenapine and olmesartan can increase the risk of hypotension.'], 'Oxazepam': ['NotSet', ""Both asenapine and oxazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Oxycodone': ['NotSet', ""Both asenapine and oxycodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paliperidone': ['NotSet', ""Both asenapine and paliperidone can increase the risk of hypotension. Both asenapine and paliperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Paroxetine': ['Moderate', 'Paroxetine moderately increases the exposure to asenapine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pentazocine': ['NotSet', ""Both asenapine and pentazocine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perampanel': ['NotSet', ""Both asenapine and perampanel can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pergolide': ['NotSet', 'Both asenapine and pergolide can increase the risk of hypotension. Asenapine is predicted to decrease the effects of pergolide. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pericyazine': ['NotSet', ""Both asenapine and pericyazine can increase the risk of hypotension. Both asenapine and pericyazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Perindopril': ['NotSet', 'Both asenapine and perindopril can increase the risk of hypotension.'], 'Pethidine': ['NotSet', ""Both asenapine and pethidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Phenelzine': ['NotSet', 'Both asenapine and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['NotSet', ""Both asenapine and phenobarbital can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pimozide': ['NotSet', ""Both asenapine and pimozide can increase the risk of hypotension. Both asenapine and pimozide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pindolol': ['NotSet', 'Both asenapine and pindolol can increase the risk of hypotension.'], 'Pizotifen': ['NotSet', ""Both asenapine and pizotifen can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Pramipexole': ['NotSet', 'Both asenapine and pramipexole can increase the risk of hypotension. Asenapine is predicted to decrease the effects of pramipexole. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Prazosin': ['NotSet', 'Both asenapine and prazosin can increase the risk of hypotension.'], 'Pregabalin': ['NotSet', ""Both asenapine and pregabalin can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prilocaine': ['NotSet', ""Both asenapine and prilocaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Primidone': ['NotSet', ""Both asenapine and primidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Prochlorperazine': ['NotSet', ""Both asenapine and prochlorperazine can increase the risk of hypotension. Both asenapine and prochlorperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promazine': ['NotSet', ""Both asenapine and promazine can increase the risk of hypotension. Both asenapine and promazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Promethazine': ['NotSet', ""Both asenapine and promethazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propofol': ['NotSet', ""Both asenapine and propofol can increase the risk of hypotension. Both asenapine and propofol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Propranolol': ['NotSet', 'Both asenapine and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', ""Both asenapine and quetiapine can increase the risk of hypotension. Both asenapine and quetiapine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Quinagolide': ['NotSet', 'Both asenapine and quinagolide can increase the risk of hypotension. Asenapine is predicted to decrease the effects of quinagolide. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quinapril': ['NotSet', 'Both asenapine and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both asenapine and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', ""Both asenapine and remifentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Riociguat': ['NotSet', 'Both asenapine and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', ""Both asenapine and risperidone can increase the risk of hypotension. Both asenapine and risperidone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Ropinirole': ['NotSet', 'Both asenapine and ropinirole can increase the risk of hypotension. Asenapine is predicted to decrease the effects of ropinirole. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ropivacaine': ['NotSet', ""Both asenapine and ropivacaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Rotigotine': ['NotSet', 'Both asenapine and rotigotine can increase the risk of hypotension. Asenapine is predicted to decrease the effects of rotigotine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Sacubitril': ['NotSet', 'Both asenapine and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both asenapine and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both asenapine and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', ""Both asenapine and sevoflurane can increase the risk of hypotension. Both asenapine and sevoflurane can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sildenafil': ['NotSet', 'Both asenapine and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', ""Both asenapine and sodium oxybate can increase the risk of hypotension. Both asenapine and sodium oxybate can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sotalol': ['NotSet', 'Both asenapine and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both asenapine and spironolactone can increase the risk of hypotension.'], 'Sufentanil': ['NotSet', ""Both asenapine and sufentanil can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Sulpiride': ['NotSet', ""Both asenapine and sulpiride can increase the risk of hypotension. Both asenapine and sulpiride can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Tadalafil': ['NotSet', 'Both asenapine and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both asenapine and tamsulosin can increase the risk of hypotension.'], 'Tapentadol': ['NotSet', ""Both asenapine and tapentadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Telmisartan': ['NotSet', 'Both asenapine and telmisartan can increase the risk of hypotension.'], 'Temazepam': ['NotSet', ""Both asenapine and temazepam can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Terazosin': ['NotSet', 'Both asenapine and terazosin can increase the risk of hypotension.'], 'Tetracaine': ['NotSet', ""Both asenapine and tetracaine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thalidomide': ['NotSet', ""Both asenapine and thalidomide can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Thiopental': ['NotSet', ""Both asenapine and thiopental can increase the risk of hypotension. Both asenapine and thiopental can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Timolol': ['NotSet', 'Both asenapine and timolol can increase the risk of hypotension.'], 'Tizanidine': ['NotSet', ""Both asenapine and tizanidine can increase the risk of hypotension. Both asenapine and tizanidine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Torasemide': ['NotSet', 'Both asenapine and torasemide can increase the risk of hypotension.'], 'Tramadol': ['NotSet', ""Both asenapine and tramadol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trandolapril': ['NotSet', 'Both asenapine and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both asenapine and tranylcypromine can increase the risk of hypotension.'], 'Trazodone': ['NotSet', ""Both asenapine and trazodone can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trifluoperazine': ['NotSet', ""Both asenapine and trifluoperazine can increase the risk of hypotension. Both asenapine and trifluoperazine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Trimipramine': ['NotSet', ""Both asenapine and trimipramine can increase the risk of hypotension. Both asenapine and trimipramine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Valsartan': ['NotSet', 'Both asenapine and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both asenapine and vardenafil can increase the risk of hypotension.'], 'Venlafaxine': ['NotSet', ""Both asenapine and venlafaxine can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Verapamil': ['NotSet', 'Both asenapine and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both asenapine and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both asenapine and xipamide can increase the risk of hypotension.'], 'Zolpidem': ['NotSet', ""Both asenapine and zolpidem can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""], 'Zuclopenthixol': ['NotSet', ""Both asenapine and zuclopenthixol can increase the risk of hypotension. Both asenapine and zuclopenthixol can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in Guidance on Prescribing).""]}","asparaginase","{'Afatinib': ['NotSet', 'Both asparaginase and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both asparaginase and aflibercept can increase the risk of myelosuppression.'], 'Alcohol (beverage)': ['NotSet', 'Both asparaginase and alcohol (beverage) can increase the risk of hepatotoxicity.'], 'Alectinib': ['NotSet', 'Both asparaginase and alectinib can increase the risk of hepatotoxicity.'], 'Alemtuzumab': ['NotSet', 'Both asparaginase and alemtuzumab can increase the risk of myelosuppression.'], 'Amsacrine': ['NotSet', 'Both asparaginase and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both asparaginase and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both asparaginase and arsenic trioxide can increase the risk of myelosuppression.'], 'Atorvastatin': ['NotSet', 'Both asparaginase and atorvastatin can increase the risk of hepatotoxicity.'], 'Axitinib': ['NotSet', 'Both asparaginase and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both asparaginase and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both asparaginase and azathioprine can increase the risk of myelosuppression.'], 'Balsalazide': ['NotSet', 'Both asparaginase and balsalazide can increase the risk of myelosuppression.'], 'Bedaquiline': ['NotSet', 'Both asparaginase and bedaquiline can increase the risk of hepatotoxicity.'], 'Belimumab': ['NotSet', 'Both asparaginase and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both asparaginase and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both asparaginase and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both asparaginase and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both asparaginase and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both asparaginase and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both asparaginase and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both asparaginase and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both asparaginase and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both asparaginase and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both asparaginase and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both asparaginase and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both asparaginase and capecitabine can increase the risk of myelosuppression.'], 'Carbamazepine': ['NotSet', 'Both asparaginase and carbamazepine can increase the risk of hepatotoxicity.'], 'Carbimazole': ['NotSet', 'Both asparaginase and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both asparaginase and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both asparaginase and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both asparaginase and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both asparaginase and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both asparaginase and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both asparaginase and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both asparaginase and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both asparaginase and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both asparaginase and cladribine can increase the risk of myelosuppression.'], 'Clavulanate': ['NotSet', 'Both asparaginase and clavulanate can increase the risk of hepatotoxicity.'], 'Clofarabine': ['NotSet', 'Both asparaginase and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both asparaginase and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both asparaginase and crisantaspase can increase the risk of hepatotoxicity. Both asparaginase and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both asparaginase and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both asparaginase and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both asparaginase and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both asparaginase and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both asparaginase and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both asparaginase and dactinomycin can increase the risk of hepatotoxicity. Both asparaginase and dactinomycin can increase the risk of myelosuppression.'], 'Dantrolene': ['NotSet', 'Both asparaginase and dantrolene can increase the risk of hepatotoxicity.'], 'Dasatinib': ['NotSet', 'Both asparaginase and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both asparaginase and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both asparaginase and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both asparaginase and deferiprone can increase the risk of myelosuppression.'], 'Demeclocycline': ['NotSet', 'Both asparaginase and demeclocycline can increase the risk of hepatotoxicity.'], 'Didanosine': ['NotSet', 'Both asparaginase and didanosine can increase the risk of hepatotoxicity.'], 'Docetaxel': ['NotSet', 'Both asparaginase and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both asparaginase and doxorubicin can increase the risk of myelosuppression.'], 'Doxycycline': ['NotSet', 'Both asparaginase and doxycycline can increase the risk of hepatotoxicity.'], 'Epirubicin': ['NotSet', 'Both asparaginase and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both asparaginase and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both asparaginase and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both asparaginase and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both asparaginase and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both asparaginase and everolimus can increase the risk of myelosuppression.'], 'Flucloxacillin': ['NotSet', 'Both asparaginase and flucloxacillin can increase the risk of hepatotoxicity.'], 'Fluconazole': ['NotSet', 'Both asparaginase and fluconazole can increase the risk of hepatotoxicity.'], 'Fludarabine': ['NotSet', 'Both asparaginase and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both asparaginase and fluorouracil can increase the risk of myelosuppression.'], 'Fluvastatin': ['NotSet', 'Both asparaginase and fluvastatin can increase the risk of hepatotoxicity.'], 'Ganciclovir': ['NotSet', 'Both asparaginase and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both asparaginase and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both asparaginase and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both asparaginase and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both asparaginase and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both asparaginase and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both asparaginase and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both asparaginase and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both asparaginase and imatinib can increase the risk of myelosuppression. Asparaginase is predicted to increase the risk of hepatotoxicity when given with imatinib. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Interferon alfa': ['NotSet', 'Both asparaginase and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both asparaginase and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both asparaginase and irinotecan can increase the risk of myelosuppression.'], 'Isoniazid': ['NotSet', 'Both asparaginase and isoniazid can increase the risk of hepatotoxicity.'], 'Itraconazole': ['NotSet', 'Both asparaginase and itraconazole can increase the risk of hepatotoxicity.'], 'Leflunomide': ['NotSet', 'Both asparaginase and leflunomide can increase the risk of hepatotoxicity. Both asparaginase and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both asparaginase and lenalidomide can increase the risk of hepatotoxicity. Both asparaginase and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both asparaginase and linezolid can increase the risk of myelosuppression.'], 'Lomitapide': ['NotSet', 'Both asparaginase and lomitapide can increase the risk of hepatotoxicity.'], 'Lomustine': ['NotSet', 'Both asparaginase and lomustine can increase the risk of myelosuppression.'], 'Lymecycline': ['NotSet', 'Both asparaginase and lymecycline can increase the risk of hepatotoxicity.'], 'Melphalan': ['NotSet', 'Both asparaginase and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both asparaginase and mercaptopurine can increase the risk of hepatotoxicity. Both asparaginase and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both asparaginase and methotrexate can increase the risk of hepatotoxicity. Both asparaginase and methotrexate can increase the risk of myelosuppression. Asparaginase affects the efficacy of methotrexate. Manufacturer advises separating administration. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Micafungin': ['NotSet', 'Both asparaginase and micafungin can increase the risk of hepatotoxicity.'], 'Minocycline': ['NotSet', 'Both asparaginase and minocycline can increase the risk of hepatotoxicity.'], 'Mitomycin': ['NotSet', 'Both asparaginase and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both asparaginase and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both asparaginase and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both asparaginase and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both asparaginase and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both asparaginase and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both asparaginase and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both asparaginase and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both asparaginase and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both asparaginase and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both asparaginase and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both asparaginase and oxaliplatin can increase the risk of myelosuppression.'], 'Oxytetracycline': ['NotSet', 'Both asparaginase and oxytetracycline can increase the risk of hepatotoxicity.'], 'Paclitaxel': ['NotSet', 'Both asparaginase and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both asparaginase and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both asparaginase and panobinostat can increase the risk of myelosuppression.'], 'Paracetamol': ['NotSet', 'Both asparaginase and paracetamol can increase the risk of hepatotoxicity.'], 'Pazopanib': ['NotSet', 'Both asparaginase and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both asparaginase and pegaspargase can increase the risk of hepatotoxicity. Both asparaginase and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both asparaginase and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both asparaginase and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both asparaginase and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both asparaginase and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both asparaginase and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both asparaginase and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both asparaginase and pomalidomide can increase the risk of myelosuppression.'], 'Pravastatin': ['NotSet', 'Both asparaginase and pravastatin can increase the risk of hepatotoxicity.'], 'Primaquine': ['NotSet', 'Both asparaginase and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both asparaginase and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both asparaginase and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both asparaginase and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both asparaginase and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both asparaginase and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both asparaginase and regorafenib can increase the risk of myelosuppression.'], 'Rituximab': ['NotSet', 'Both asparaginase and rituximab can increase the risk of myelosuppression.'], 'Rosuvastatin': ['NotSet', 'Both asparaginase and rosuvastatin can increase the risk of hepatotoxicity.'], 'Ruxolitinib': ['NotSet', 'Both asparaginase and ruxolitinib can increase the risk of myelosuppression.'], 'Siltuximab': ['NotSet', 'Both asparaginase and siltuximab can increase the risk of myelosuppression.'], 'Simvastatin': ['NotSet', 'Both asparaginase and simvastatin can increase the risk of hepatotoxicity.'], 'Sorafenib': ['NotSet', 'Both asparaginase and sorafenib can increase the risk of myelosuppression.'], 'Streptozocin': ['NotSet', 'Both asparaginase and streptozocin can increase the risk of hepatotoxicity.'], 'Sulfadiazine': ['NotSet', 'Both asparaginase and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both asparaginase and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both asparaginase and sulfasalazine can increase the risk of hepatotoxicity. Both asparaginase and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both asparaginase and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both asparaginase and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both asparaginase and temsirolimus can increase the risk of myelosuppression.'], 'Tetracycline': ['NotSet', 'Both asparaginase and tetracycline can increase the risk of hepatotoxicity.'], 'Thalidomide': ['NotSet', 'Both asparaginase and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both asparaginase and thiotepa can increase the risk of myelosuppression.'], 'Tigecycline': ['NotSet', 'Both asparaginase and tigecycline can increase the risk of hepatotoxicity.'], 'Tioguanine': ['NotSet', 'Both asparaginase and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both asparaginase and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both asparaginase and trabectedin can increase the risk of hepatotoxicity. Both asparaginase and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both asparaginase and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both asparaginase and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both asparaginase and trimethoprim can increase the risk of myelosuppression.'], 'Valganciclovir': ['NotSet', 'Both asparaginase and valganciclovir can increase the risk of myelosuppression.'], 'Valproate': ['NotSet', 'Both asparaginase and valproate can increase the risk of hepatotoxicity.'], 'Vinblastine': ['NotSet', 'Both asparaginase and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both asparaginase and vincristine can increase the risk of hepatotoxicity. Both asparaginase and vincristine can increase the risk of myelosuppression. Asparaginase potentially increases the risk of neurotoxicity when given with vincristine. Manufacturer advises vincristine should be taken 3 to 24 hours before asparaginase. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Vindesine': ['NotSet', 'Both asparaginase and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both asparaginase and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both asparaginase and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both asparaginase and vismodegib can increase the risk of myelosuppression.'], 'Zidovudine': ['NotSet', 'Both asparaginase and zidovudine can increase the risk of myelosuppression.']}","aspirin","{'Aceclofenac': ['NotSet', 'Both aspirin and aceclofenac can increase the risk of bleeding.'], 'Acenocoumarol': ['Severe', 'Acenocoumarol is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Acetazolamide': ['Severe', 'Acetazolamide increases the risk of severe toxic reaction when given with aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Alendronate': ['Moderate', 'Aspirin (high-dose) is predicted to increase the risk of gastrointestinal irritation when given with alendronate. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Alteplase': ['Severe', 'Alteplase is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Aluminium hydroxide': ['Moderate', 'Aluminium hydroxide decreases the absorption of aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Anagrelide': ['NotSet', 'Both aspirin and anagrelide can increase the risk of bleeding.'], 'Apixaban': ['Severe', 'Apixaban is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Argatroban': ['Severe', 'Argatroban is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Beclometasone': ['Moderate', 'Beclometasone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with beclometasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bendroflumethiazide': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with bendroflumethiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Moderate', 'Betamethasone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with betamethasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bevacizumab': ['NotSet', 'Both aspirin and bevacizumab can increase the risk of bleeding.'], 'Bivalirudin': ['Severe', 'Bivalirudin is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Budesonide': ['Moderate', 'Budesonide is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with budesonide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cangrelor': ['NotSet', 'Both aspirin and cangrelor can increase the risk of bleeding.'], 'Celecoxib': ['NotSet', 'Both aspirin and celecoxib can increase the risk of bleeding.'], 'Chlorothiazide': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with chlorothiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Chlortalidone': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with chlortalidone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ciclesonide': ['Moderate', 'Ciclesonide is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with ciclesonide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cilostazol': ['NotSet', 'Both aspirin and cilostazol can increase the risk of bleeding.'], 'Citalopram': ['NotSet', 'Both aspirin and citalopram can increase the risk of bleeding.'], 'Clodronate': ['Severe', 'Aspirin (high-dose) is predicted to increase the risk of renal impairment when given with clodronate. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Clopidogrel': ['NotSet', 'Both aspirin and clopidogrel can increase the risk of bleeding.'], 'Dabigatran': ['Severe', 'Dabigatran is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dalteparin': ['Severe', 'Dalteparin is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Danaparoid': ['Severe', 'Danaparoid is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dapoxetine': ['NotSet', 'Both aspirin and dapoxetine can increase the risk of bleeding.'], 'Daptomycin': ['Moderate', 'Aspirin (high-dose) increases the risk of renal impairment when given with daptomycin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Dasatinib': ['NotSet', 'Both aspirin and dasatinib can increase the risk of bleeding.'], 'Deferasirox': ['Severe', 'Aspirin (high-dose) is predicted to increase the risk of gastrointestinal bleeds when given with deferasirox. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Deflazacort': ['Moderate', 'Deflazacort is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with deflazacort. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dexamethasone': ['Moderate', 'Dexamethasone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with dexamethasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dexibuprofen': ['NotSet', 'Both aspirin and dexibuprofen can increase the risk of bleeding.'], 'Dexketoprofen': ['NotSet', 'Both aspirin and dexketoprofen can increase the risk of bleeding.'], 'Diclofenac': ['NotSet', 'Both aspirin and diclofenac can increase the risk of bleeding.'], 'Dipyridamole': ['NotSet', 'Both aspirin and dipyridamole can increase the risk of bleeding.'], 'Duloxetine': ['NotSet', 'Both aspirin and duloxetine can increase the risk of bleeding.'], 'Edoxaban': ['Severe', 'Edoxaban is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Enoxaparin': ['Severe', 'Enoxaparin is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Epoprostenol': ['NotSet', 'Both aspirin and epoprostenol can increase the risk of bleeding.'], 'Eptifibatide': ['NotSet', 'Both aspirin and eptifibatide can increase the risk of bleeding.'], 'Erlotinib': ['Severe', 'Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with aspirin (high-dose). Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Escitalopram': ['NotSet', 'Both aspirin and escitalopram can increase the risk of bleeding.'], 'Etodolac': ['NotSet', 'Both aspirin and etodolac can increase the risk of bleeding.'], 'Etoricoxib': ['NotSet', 'Both aspirin and etoricoxib can increase the risk of bleeding.'], 'Fludrocortisone': ['Moderate', 'Fludrocortisone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with fludrocortisone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fluoxetine': ['NotSet', 'Both aspirin and fluoxetine can increase the risk of bleeding.'], 'Flurbiprofen': ['NotSet', 'Both aspirin and flurbiprofen can increase the risk of bleeding.'], 'Fluticasone': ['Moderate', 'Fluticasone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with fluticasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fluvoxamine': ['NotSet', 'Both aspirin and fluvoxamine can increase the risk of bleeding.'], 'Fondaparinux': ['Severe', 'Fondaparinux is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Heparin (unfractionated)': ['Severe', 'Heparin (unfractionated) is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrochlorothiazide': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with hydrochlorothiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Moderate', 'Hydrocortisone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with hydrocortisone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Hydroflumethiazide': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with hydroflumethiazide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ibandronate': ['Moderate', 'Aspirin (high-dose) is predicted to increase the risk of gastrointestinal irritation when given with ibandronate. Manufacturer advises caution and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ibrutinib': ['NotSet', 'Both aspirin and ibrutinib can increase the risk of bleeding.'], 'Ibuprofen': ['NotSet', 'Both aspirin and ibuprofen can increase the risk of bleeding.'], 'Iloprost': ['NotSet', 'Both aspirin and iloprost can increase the risk of bleeding.'], 'Indapamide': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with indapamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Indometacin': ['NotSet', 'Both aspirin and indometacin can increase the risk of bleeding.'], 'Inotersen': ['NotSet', 'Both aspirin and inotersen can increase the risk of bleeding.'], 'Ketoprofen': ['NotSet', 'Both aspirin and ketoprofen can increase the risk of bleeding.'], 'Ketorolac': ['NotSet', 'Both aspirin and ketorolac can increase the risk of bleeding.'], 'Magnesium carbonate': ['Moderate', 'Magnesium carbonate decreases the absorption of aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Magnesium trisilicate': ['Moderate', 'Magnesium trisilicate decreases the absorption of aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mefenamic acid': ['NotSet', 'Both aspirin and mefenamic acid can increase the risk of bleeding.'], 'Meloxicam': ['NotSet', 'Both aspirin and meloxicam can increase the risk of bleeding.'], 'Methotrexate': ['Severe', 'Aspirin (high-dose) is predicted to increase the risk of toxicity when given with methotrexate. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Methylprednisolone': ['Moderate', 'Methylprednisolone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with methylprednisolone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Metolazone': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with metolazone. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Mometasone': ['Moderate', 'Mometasone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with mometasone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nabumetone': ['NotSet', 'Both aspirin and nabumetone can increase the risk of bleeding.'], 'Naproxen': ['NotSet', 'Both aspirin and naproxen can increase the risk of bleeding.'], 'Nicorandil': ['Severe', 'Aspirin is predicted to increase the risk of gastrointestinal perforation when given with nicorandil. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nicotinic acid': ['Severe', 'Nicotinic acid is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Omega-3-acid ethyl esters': ['Severe', 'Omega-3-acid ethyl esters is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Parecoxib': ['NotSet', 'Both aspirin and parecoxib can increase the risk of bleeding.'], 'Paroxetine': ['NotSet', 'Both aspirin and paroxetine can increase the risk of bleeding.'], 'Pemetrexed': ['Severe', 'Aspirin (high-dose) potentially increases the exposure to pemetrexed. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenindione': ['Severe', 'Phenindione is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Piroxicam': ['NotSet', 'Both aspirin and piroxicam can increase the risk of bleeding.'], 'Prasugrel': ['NotSet', 'Both aspirin and prasugrel can increase the risk of bleeding.'], 'Prednisolone': ['Moderate', 'Prednisolone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with prednisolone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Regorafenib': ['NotSet', 'Both aspirin and regorafenib can increase the risk of bleeding.'], 'Rivaroxaban': ['Severe', 'Rivaroxaban is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sertraline': ['NotSet', 'Both aspirin and sertraline can increase the risk of bleeding.'], 'Streptokinase': ['Severe', 'Streptokinase is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Sulindac': ['NotSet', 'Both aspirin and sulindac can increase the risk of bleeding.'], 'Tenecteplase': ['Severe', 'Tenecteplase is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenoxicam': ['NotSet', 'Both aspirin and tenoxicam can increase the risk of bleeding.'], 'Tiaprofenic acid': ['NotSet', 'Both aspirin and tiaprofenic acid can increase the risk of bleeding.'], 'Ticagrelor': ['NotSet', 'Both aspirin and ticagrelor can increase the risk of bleeding.'], 'Tinzaparin': ['Severe', 'Tinzaparin is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tirofiban': ['NotSet', 'Both aspirin and tirofiban can increase the risk of bleeding.'], 'Tolfenamic acid': ['NotSet', 'Both aspirin and tolfenamic acid can increase the risk of bleeding.'], 'Trastuzumab emtansine': ['NotSet', 'Both aspirin and trastuzumab emtansine can increase the risk of bleeding.'], 'Triamcinolone': ['Moderate', 'Triamcinolone is predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with triamcinolone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Urokinase': ['Severe', 'Urokinase is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venlafaxine': ['NotSet', 'Both aspirin and venlafaxine can increase the risk of bleeding.'], 'Volanesorsen': ['Severe', 'Volanesorsen potentially increases the risk of bleeding events when given with aspirin. Manufacturer advises avoid depending on platelet count—consult product literature. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vortioxetine': ['NotSet', 'Both aspirin and vortioxetine can increase the risk of bleeding.'], 'Warfarin': ['Severe', 'Warfarin is predicted to increase the risk of bleeding events when given with aspirin. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Xipamide': ['Severe', 'Aspirin (high-dose) increases the risk of acute renal failure when given with xipamide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['Severe', 'Zidovudine increases the risk of haematological toxicity when given with aspirin (high-dose). Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study']}","ataluren","{'Amikacin': ['Severe', 'Ataluren is predicted to increase the risk of nephrotoxicity when given with intravenous amikacin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Gentamicin': ['Severe', 'Ataluren is predicted to increase the risk of nephrotoxicity when given with intravenous gentamicin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Rifampicin': ['Moderate', 'Rifampicin decreases the exposure to ataluren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Streptomycin': ['Severe', 'Ataluren is predicted to increase the risk of nephrotoxicity when given with intravenous streptomycin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Tobramycin': ['Severe', 'Ataluren is predicted to increase the risk of nephrotoxicity when given with intravenous tobramycin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study']}","atazanavir","{'Abemaciclib': ['Severe', 'Atazanavir is predicted to increase the exposure to abemaciclib. Manufacturer advises avoid or adjust abemaciclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Acenocoumarol': ['Moderate', 'Atazanavir is predicted to affect the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Alfentanil': ['Severe', 'Atazanavir is predicted to increase the exposure to alfentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Alfuzosin': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to alfuzosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Alitretinoin': ['Moderate', 'Atazanavir is predicted to increase the exposure to alitretinoin. Manufacturer advises adjust alitretinoin dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Almotriptan': ['Mild', 'Atazanavir increases the exposure to almotriptan. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Alprazolam': ['Moderate', 'Atazanavir moderately increases the exposure to alprazolam. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aluminium hydroxide': ['Severe', 'Aluminium hydroxide is predicted to decrease the absorption of atazanavir. Manufacturer advises atazanavir should be taken 2 hours before or 1 hour after antacids. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['Severe', 'Atazanavir is predicted to increase the exposure to amiodarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amlodipine': ['Moderate', 'Atazanavir is predicted to increase the exposure to amlodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Apalutamide': ['Mild', 'Atazanavir is predicted to increase the exposure to apalutamide. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Aprepitant': ['Moderate', 'Atazanavir is predicted to markedly increase the exposure to aprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aripiprazole': ['Moderate', 'Atazanavir is predicted to slightly increase the exposure to aripiprazole. Manufacturer advises adjust aripiprazole dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Atorvastatin': ['Severe', 'Atazanavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Atovaquone': ['Moderate', 'Atazanavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Avanafil': ['Severe', 'Atazanavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Axitinib': ['Moderate', 'Atazanavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Beclometasone': ['Moderate', 'Atazanavir is predicted to increase the exposure to beclometasone (risk with beclometasone is likely to be lower than with other corticosteroids). Manufacturer advises caution and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bedaquiline': ['Mild', 'Atazanavir is predicted to increase the exposure to bedaquiline. Manufacturer advises avoid prolonged use. Severity of interaction: Mild Evidence for interaction: Study'], 'Betamethasone': ['Severe', 'Atazanavir is predicted to increase the exposure to betamethasone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Bictegravir': ['Severe', 'Atazanavir moderately increases the exposure to bictegravir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Bortezomib': ['Moderate', 'Atazanavir slightly increases the exposure to bortezomib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bosentan': ['Severe', 'Atazanavir is predicted to increase the exposure to bosentan. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Bosutinib': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to bosutinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Brigatinib': ['Severe', 'Atazanavir is predicted to increase the exposure to brigatinib. Manufacturer advises adjust brigatinib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Bromocriptine': ['Severe', 'Atazanavir increases the exposure to bromocriptine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Budesonide': ['Severe', 'Atazanavir is predicted to increase the exposure to budesonide. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Buprenorphine': ['Severe', 'Atazanavir is predicted to increase the exposure to buprenorphine. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Buspirone': ['Severe', 'Atazanavir is predicted to increase the exposure to buspirone. Manufacturer advises adjust buspirone dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cabazitaxel': ['Severe', 'Atazanavir is predicted to increase the exposure to cabazitaxel. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Cabergoline': ['Moderate', 'Atazanavir is predicted to increase the concentration of cabergoline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Cabozantinib': ['Moderate', 'Atazanavir slightly increases the exposure to cabozantinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cannabidiol': ['Mild', 'Atazanavir is predicted to increase the exposure to cannabidiol. Manufacturer advises avoid or adjust dose. Severity of interaction: Mild Evidence for interaction: Study'], 'Carbamazepine': ['Severe', 'Atazanavir is predicted to increase the exposure to carbamazepine and carbamazepine is predicted to decrease the exposure to atazanavir. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Cariprazine': ['Severe', 'Atazanavir is predicted to moderately increase the exposure to cariprazine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ceritinib': ['Severe', 'Atazanavir is predicted to increase the exposure to ceritinib. Manufacturer advises avoid or adjust ceritinib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciclesonide': ['Severe', 'Atazanavir is predicted to increase the exposure to ciclesonide. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciclosporin': ['Severe', 'Atazanavir increases the concentration of ciclosporin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Cilostazol': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to cilostazol. Manufacturer advises adjust cilostazol dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cimetidine': ['Moderate', 'Cimetidine decreases the exposure to atazanavir. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Cinacalcet': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to cinacalcet. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clarithromycin': ['Severe', 'Atazanavir is predicted to increase the exposure to clarithromycin. Manufacturer advises adjust dose in renal impairment. Severity of interaction: Severe Evidence for interaction: Study'], 'Cobimetinib': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to cobimetinib. Manufacturer advises avoid or monitor for toxicity. Severity of interaction: Severe Evidence for interaction: Study'], 'Colchicine': ['Severe', 'Atazanavir is predicted to increase the exposure to colchicine. Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust colchicine dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Combined hormonal contraceptives': ['Severe', 'Atazanavir (unboosted) increases the exposure to combined hormonal contraceptives. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Crizotinib': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to crizotinib. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dabrafenib': ['Moderate', 'Atazanavir is predicted to increase the exposure to dabrafenib. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dapoxetine': ['Severe', 'Atazanavir is predicted to moderately increase the exposure to dapoxetine. Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust dapoxetine dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Darifenacin': ['Severe', 'Atazanavir is predicted to markedly to very markedly increase the exposure to darifenacin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Dasatinib': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to dasatinib. Manufacturer advises avoid or adjust dose—consult product literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Deflazacort': ['Severe', 'Atazanavir is predicted to increase the exposure to deflazacort. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Delamanid': ['Severe', 'Atazanavir very slightly increases the exposure to delamanid. Manufacturer advises caution and monitor ECG. Severity of interaction: Severe Evidence for interaction: Study'], 'Dexamethasone': ['Severe', 'Atazanavir is predicted to increase the exposure to dexamethasone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Didanosine': ['Severe', 'Didanosine (buffered) decreases the exposure to atazanavir. Manufacturer advises didanosine should be taken 2 hours after atazanavir. Severity of interaction: Severe Evidence for interaction: Study'], 'Diltiazem': ['Severe', 'Atazanavir is predicted to increase the exposure to diltiazem. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Disopyramide': ['Severe', 'Atazanavir is predicted to increase the exposure to disopyramide. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Docetaxel': ['Severe', 'Atazanavir is predicted to moderately increase the exposure to docetaxel. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Domperidone': ['Severe', 'Atazanavir increases the risk of QT-prolongation when given with domperidone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Doravirine': ['Mild', 'Atazanavir is predicted to increase the exposure to doravirine. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Doxazosin': ['Moderate', 'Atazanavir is predicted to increase the exposure to doxazosin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dronabinol': ['Mild', 'Atazanavir is predicted to increase the exposure to dronabinol. Manufacturer advises adjust dose. Severity of interaction: Mild Evidence for interaction: Study'], 'Dronedarone': ['Severe', 'Atazanavir very markedly increases the exposure to dronedarone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Dutasteride': ['Moderate', 'Atazanavir is predicted to increase the exposure to dutasteride. Manufacturer advises monitor side effects and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Efavirenz': ['Severe', 'Efavirenz decreases the exposure to atazanavir. Refer to specialist literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Eletriptan': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to eletriptan. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Eliglustat': ['Severe', 'Atazanavir is predicted to increase the exposure to eliglustat. Manufacturer advises avoid or adjust dose—consult product literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Elvitegravir': ['Moderate', 'Atazanavir boosted with ritonavir increases the concentration of elvitegravir. Refer to specialist literature. Severity of interaction: Moderate Evidence for interaction: Study'], 'Encorafenib': ['Severe', 'Atazanavir is predicted to increase the exposure to encorafenib. Manufacturer advises avoid or monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Eplerenone': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to eplerenone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ergometrine': ['Severe', 'Atazanavir is predicted to increase the risk of ergotism when given with ergometrine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ergotamine': ['Severe', 'Atazanavir is predicted to increase the risk of ergotism when given with ergotamine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erlotinib': ['Moderate', 'Atazanavir is predicted to slightly increase the exposure to erlotinib. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Erythromycin': ['Severe', 'Atazanavir is predicted to increase the exposure to erythromycin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Esketamine': ['Moderate', 'Atazanavir is predicted to increase the exposure to esketamine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Esomeprazole': ['Severe', 'Esomeprazole decreases the exposure to atazanavir. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Everolimus': ['Severe', 'Atazanavir is predicted to increase the concentration of everolimus. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Famotidine': ['Moderate', 'Famotidine decreases the exposure to atazanavir. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Felodipine': ['Moderate', 'Atazanavir is predicted to increase the exposure to felodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fentanyl': ['Severe', 'Atazanavir is predicted to increase the exposure to fentanyl. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Fesoterodine': ['Severe', 'Atazanavir is predicted to moderately increase the exposure to fesoterodine. Manufacturer advises adjust fesoterodine dose with potent inhibitors of CYP3A4; avoid in hepatic and renal impairment. Severity of interaction: Severe Evidence for interaction: Study'], 'Fludrocortisone': ['Severe', 'Atazanavir is predicted to increase the exposure to fludrocortisone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Fluticasone': ['Severe', 'Atazanavir is predicted to increase the exposure to fluticasone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosaprepitant': ['Moderate', 'Atazanavir is predicted to increase the exposure to fosaprepitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fosphenytoin': ['Severe', 'Atazanavir is predicted to affect the exposure to fosphenytoin and fosphenytoin decreases the concentration of atazanavir. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Galantamine': ['Moderate', 'Atazanavir is predicted to increase the exposure to galantamine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Gefitinib': ['Moderate', 'Atazanavir is predicted to increase the exposure to gefitinib. Manufacturer advises monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Glecaprevir': ['Severe', 'Atazanavir boosted with ritonavir increases the exposure to glecaprevir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Grazoprevir': ['Severe', 'Atazanavir is predicted to moderately to markedly increase the exposure to grazoprevir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Guanfacine': ['Moderate', 'Atazanavir is predicted to increase the exposure to guanfacine. Manufacturer advises adjust guanfacine dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Hydrocortisone': ['Severe', 'Atazanavir is predicted to increase the exposure to hydrocortisone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Ibrutinib': ['Severe', 'Atazanavir is predicted to very markedly increase the exposure to ibrutinib. Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust ibrutinib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Imatinib': ['Moderate', 'Atazanavir is predicted to increase the exposure to imatinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Irinotecan': ['Moderate', 'Atazanavir is predicted to increase the risk of toxicity when given with irinotecan. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Isavuconazole': ['Severe', 'Atazanavir is predicted to increase the exposure to isavuconazole. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Itraconazole': ['Severe', 'Atazanavir is predicted to increase the exposure to itraconazole. Manufacturer advises use with caution and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ivabradine': ['Severe', 'Atazanavir is predicted to increase the exposure to ivabradine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ivacaftor': ['Severe', 'Atazanavir is predicted to increase the exposure to ivacaftor. Manufacturer advises adjust ivacaftor or lumacaftor with ivacaftor or tezacaftor with ivacaftor dose with potent inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketoconazole': ['Moderate', 'Atazanavir is predicted to increase the exposure to ketoconazole. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lacidipine': ['Moderate', 'Atazanavir is predicted to increase the exposure to lacidipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lansoprazole': ['Severe', 'Lansoprazole decreases the exposure to atazanavir. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Lapatinib': ['Moderate', 'Atazanavir is predicted to increase the exposure to lapatinib. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Larotrectinib': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to larotrectinib. Manufacturer advises avoid or adjust larotrectinib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lercanidipine': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to lercanidipine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Letermovir': ['Moderate', 'Atazanavir boosted with ritonavir is predicted to increase the concentration of letermovir. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lidocaine': ['Severe', 'Atazanavir is predicted to increase the exposure to lidocaine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Lomitapide': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to lomitapide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Lorlatinib': ['Severe', 'Atazanavir is predicted to increase the exposure to lorlatinib. Manufacturer advises avoid or adjust lorlatinib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Lurasidone': ['Severe', 'Atazanavir is predicted to increase the exposure to lurasidone. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Macitentan': ['Moderate', 'Atazanavir is predicted to increase the exposure to macitentan. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Magnesium carbonate': ['Severe', 'Magnesium carbonate is predicted to decrease the absorption of atazanavir. Manufacturer advises atazanavir should be taken 2 hours before or 1 hour after antacids. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Magnesium trisilicate': ['Severe', 'Magnesium trisilicate is predicted to decrease the absorption of atazanavir. Manufacturer advises atazanavir should be taken 2 hours before or 1 hour after antacids. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Maraviroc': ['Severe', 'Atazanavir moderately to markedly increases the exposure to maraviroc. Refer to specialist literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Methadone': ['Moderate', 'Atazanavir boosted with ritonavir is predicted to decrease the exposure to methadone. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Methylprednisolone': ['Severe', 'Atazanavir is predicted to increase the exposure to methylprednisolone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Miconazole': ['Moderate', 'Miconazole is predicted to increase the concentration of atazanavir. Manufacturer advises use with caution and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Midazolam': ['Severe', 'Atazanavir is predicted to markedly to very markedly increase the exposure to midazolam. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Midostaurin': ['Severe', 'Atazanavir is predicted to very markedly increase the exposure to midostaurin. Manufacturer advises avoid or monitor for toxicity. Severity of interaction: Severe Evidence for interaction: Study'], 'Mirabegron': ['Moderate', 'Atazanavir is predicted to increase the exposure to mirabegron. Manufacturer advises adjust mirabegron dose in hepatic and renal impairment. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mirtazapine': ['Moderate', 'Atazanavir is predicted to increase the exposure to mirtazapine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mizolastine': ['Severe', 'Atazanavir is predicted to increase the exposure to mizolastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Modafinil': ['Mild', 'Atazanavir is predicted to increase the exposure to modafinil. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Mometasone': ['Severe', 'Atazanavir is predicted to increase the exposure to mometasone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Naloxegol': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to naloxegol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Netupitant': ['Moderate', 'Atazanavir is predicted to increase the exposure to netupitant. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nevirapine': ['Moderate', 'Nevirapine decreases the exposure to atazanavir. Refer to specialist literature. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nicardipine': ['Moderate', 'Atazanavir is predicted to increase the exposure to nicardipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nifedipine': ['Moderate', 'Atazanavir is predicted to increase the exposure to nifedipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nilotinib': ['Severe', 'Atazanavir is predicted to moderately increase the exposure to nilotinib. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Nimodipine': ['Moderate', 'Atazanavir is predicted to increase the exposure to nimodipine. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nitisinone': ['Moderate', 'Atazanavir is predicted to increase the exposure to nitisinone. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nizatidine': ['Moderate', 'Nizatidine decreases the exposure to atazanavir. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Olaparib': ['Moderate', 'Atazanavir is predicted to increase the exposure to olaparib. Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust olaparib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Omeprazole': ['Severe', 'Omeprazole decreases the exposure to atazanavir. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ospemifene': ['Moderate', 'Atazanavir is predicted to increase the exposure to ospemifene. Manufacturer advises avoid in poor CYP2C9 metabolisers. Severity of interaction: Moderate Evidence for interaction: Study'], 'Oxybutynin': ['Mild', 'Atazanavir is predicted to increase the exposure to oxybutynin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Oxycodone': ['Severe', 'Atazanavir is predicted to increase the exposure to oxycodone. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Paclitaxel': ['Severe', 'Atazanavir is predicted to increase the exposure to paclitaxel. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Palbociclib': ['Severe', 'Atazanavir is predicted to increase the exposure to palbociclib. Manufacturer advises avoid or adjust palbociclib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Panobinostat': ['Moderate', 'Atazanavir is predicted to increase the exposure to panobinostat. Manufacturer advises adjust panobinostat dose; in hepatic impairment avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pantoprazole': ['Severe', 'Pantoprazole decreases the exposure to atazanavir. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Paricalcitol': ['Moderate', 'Atazanavir is predicted to increase the exposure to paricalcitol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Paritaprevir': ['Moderate', 'Atazanavir boosted with ritonavir markedly increases the exposure to paritaprevir. Manufacturer advises avoid or give unboosted. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pazopanib': ['Moderate', 'Atazanavir is predicted to increase the exposure to pazopanib. Manufacturer advises avoid or adjust pazopanib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Perampanel': ['Mild', 'Atazanavir is predicted to very slightly increase the exposure to perampanel. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Phenobarbital': ['Severe', 'Atazanavir is predicted to affect the concentration of phenobarbital and phenobarbital is predicted to decrease the concentration of atazanavir. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenytoin': ['Severe', 'Atazanavir is predicted to affect the exposure to phenytoin and phenytoin decreases the concentration of atazanavir. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pibrentasvir': ['Severe', 'Atazanavir boosted with ritonavir increases the exposure to pibrentasvir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Pimozide': ['Severe', 'Atazanavir is predicted to increase the exposure to pimozide. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Piperaquine': ['Severe', 'Atazanavir is predicted to increase the concentration of piperaquine. Manufacturer advises caution and monitor ECG. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ponatinib': ['Moderate', 'Atazanavir is predicted to slightly increase the exposure to ponatinib. Manufacturer advises monitor and adjust ponatinib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to atazanavir. Manufacturer advises monitor toxicity. Severity of interaction: Moderate Evidence for interaction: Study'], 'Praziquantel': ['Mild', 'Atazanavir is predicted to moderately increase the exposure to praziquantel. Manufacturer advises caution. Severity of interaction: Mild Evidence for interaction: Study'], 'Prednisolone': ['Severe', 'Atazanavir is predicted to increase the exposure to prednisolone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Primidone': ['Severe', 'Atazanavir is predicted to affect the concentration of primidone and primidone is predicted to decrease the concentration of atazanavir. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Proguanil': ['Moderate', 'Atazanavir is predicted to decrease the exposure to proguanil. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Propafenone': ['Severe', 'Atazanavir is predicted to increase the exposure to propafenone. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Propiverine': ['Moderate', 'Atazanavir given with carbimazole is predicted to increase the exposure to propiverine. Manufacturer advises adjust starting dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Quetiapine': ['Severe', 'Atazanavir is predicted to increase the exposure to quetiapine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Quinine': ['Severe', 'Atazanavir is predicted to affect the exposure to quinine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Rabeprazole': ['Severe', 'Rabeprazole decreases the exposure to atazanavir. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Raltegravir': ['Moderate', 'Atazanavir increases the exposure to raltegravir (high-dose). Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ranitidine': ['Moderate', 'Ranitidine decreases the exposure to atazanavir. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ranolazine': ['Severe', 'Atazanavir is predicted to increase the exposure to ranolazine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Reboxetine': ['Moderate', 'Atazanavir is predicted to increase the exposure to reboxetine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Regorafenib': ['Moderate', 'Atazanavir is predicted to increase the exposure to regorafenib. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Repaglinide': ['Moderate', 'Atazanavir is predicted to increase the exposure to repaglinide. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ribociclib': ['Moderate', 'Atazanavir is predicted to increase the exposure to ribociclib. Manufacturer advises avoid or adjust ribociclib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifabutin': ['Severe', 'Atazanavir boosted with ritonavir increases the exposure to rifabutin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Rifampicin': ['Severe', 'Rifampicin is predicted to moderately to markedly decrease the exposure to atazanavir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Risperidone': ['Moderate', 'Atazanavir is predicted to increase the exposure to risperidone. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rosuvastatin': ['Severe', 'Atazanavir slightly to moderately increases the exposure to rosuvastatin. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Rupatadine': ['Moderate', 'Atazanavir is predicted to increase the exposure to rupatadine. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ruxolitinib': ['Moderate', 'Atazanavir is predicted to increase the exposure to ruxolitinib. Manufacturer advises adjust dose and monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Salmeterol': ['Severe', 'Atazanavir is predicted to increase the exposure to salmeterol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Saxagliptin': ['Moderate', 'Atazanavir is predicted to increase the exposure to saxagliptin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Sildenafil': ['Severe', 'Atazanavir is predicted to increase the exposure to sildenafil. Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust sildenafil dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Simvastatin': ['Severe', 'Atazanavir is predicted to increase the exposure to simvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Sirolimus': ['Severe', 'Atazanavir is predicted to increase the concentration of sirolimus. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Sodium zirconium cyclosilicate': ['Moderate', 'Sodium zirconium cyclosilicate is predicted to decrease the exposure to atazanavir. Manufacturer advises separate administration by at least 2 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Solifenacin': ['Severe', 'Atazanavir is predicted to increase the exposure to solifenacin. Manufacturer advises adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment. Severity of interaction: Severe Evidence for interaction: Study'], ""St John's Wort"": ['Severe', ""St John's Wort is predicted to decrease the exposure to atazanavir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study""], 'Sufentanil': ['Severe', 'Atazanavir is predicted to increase the exposure to sufentanil. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Sunitinib': ['Moderate', 'Atazanavir is predicted to slightly increase the exposure to sunitinib. Manufacturer advises avoid or adjust sunitinib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tacrolimus': ['Severe', 'Atazanavir is predicted to increase the concentration of tacrolimus. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Tadalafil': ['Severe', 'Atazanavir is predicted to increase the exposure to tadalafil. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Tamsulosin': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to tamsulosin. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Temsirolimus': ['Severe', 'Atazanavir is predicted to increase the concentration of temsirolimus. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tenofovir alafenamide': ['Moderate', 'Atazanavir increases the exposure to tenofovir alafenamide. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tenofovir disoproxil': ['Severe', 'Atazanavir is predicted to increase the risk of renal impairment when given with tenofovir disoproxil. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Tezacaftor': ['Severe', 'Atazanavir is predicted to increase the exposure to tezacaftor. Manufacturer advises adjust tezacaftor with ivacaftor dose with potent inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Ticagrelor': ['Severe', 'Atazanavir is predicted to markedly increase the exposure to ticagrelor. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Tofacitinib': ['Moderate', 'Atazanavir is predicted to increase the exposure to tofacitinib. Manufacturer advises adjust tofacitinib dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tolterodine': ['Severe', 'Atazanavir is predicted to increase the exposure to tolterodine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Tolvaptan': ['Severe', 'Atazanavir is predicted to increase the exposure to tolvaptan. Manufacturer advises caution or adjust tolvaptan dose with potent inhibitors of CYP3A4. Severity of interaction: Severe Evidence for interaction: Study'], 'Toremifene': ['Moderate', 'Atazanavir is predicted to increase the exposure to toremifene. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Trabectedin': ['Severe', 'Atazanavir is predicted to increase the exposure to trabectedin. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trastuzumab emtansine': ['Severe', 'Atazanavir is predicted to increase the exposure to trastuzumab emtansine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Trazodone': ['Moderate', 'Atazanavir is predicted to moderately increase the exposure to trazodone. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Triamcinolone': ['Severe', 'Atazanavir is predicted to increase the exposure to triamcinolone. Manufacturer advises avoid or monitor side effects. Severity of interaction: Severe Evidence for interaction: Study'], 'Ulipristal': ['Severe', 'Atazanavir is predicted to increase the exposure to ulipristal. Manufacturer advises avoid if used for uterine fibroids. Severity of interaction: Severe Evidence for interaction: Study'], 'Vardenafil': ['Severe', 'Atazanavir is predicted to increase the exposure to vardenafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Vemurafenib': ['Severe', 'Atazanavir is predicted to increase the exposure to vemurafenib. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Venetoclax': ['Severe', 'Atazanavir is predicted to increase the exposure to venetoclax. Manufacturer advises avoid or adjust dose—consult product literature. Severity of interaction: Severe Evidence for interaction: Study'], 'Venlafaxine': ['Moderate', 'Atazanavir is predicted to increase the exposure to venlafaxine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Verapamil': ['Severe', 'Atazanavir is predicted to increase the exposure to verapamil. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Vinblastine': ['Severe', 'Atazanavir is predicted to increase the exposure to vinblastine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vincristine': ['Severe', 'Atazanavir is predicted to increase the exposure to vincristine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vindesine': ['Severe', 'Atazanavir is predicted to increase the exposure to vindesine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinflunine': ['Severe', 'Atazanavir is predicted to increase the exposure to vinflunine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinorelbine': ['Severe', 'Atazanavir is predicted to increase the exposure to vinorelbine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Voriconazole': ['Severe', 'Atazanavir is predicted to affect the exposure to voriconazole and voriconazole potentially affects the exposure to atazanavir. Manufacturer advises monitor efficacy and toxicity. Severity of interaction: Severe Evidence for interaction: Study'], 'Voxilaprevir': ['Severe', 'Atazanavir boosted with ritonavir increases the concentration of voxilaprevir. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Warfarin': ['Moderate', 'Atazanavir is predicted to affect the anticoagulant effect of warfarin. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Zopiclone': ['Moderate', 'Atazanavir is predicted to increase the exposure to zopiclone. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","atenolol","{'Adrenaline/epinephrine': ['Severe', 'Atenolol is predicted to increase the risk of hypertension and bradycardia when given with adrenaline/epinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Alcohol (beverage)': ['NotSet', 'Both atenolol and alcohol (beverage) can increase the risk of hypotension.'], 'Alectinib': ['NotSet', 'Both atenolol and alectinib can increase the risk of bradycardia.'], 'Alfentanil': ['NotSet', 'Both atenolol and alfentanil can increase the risk of bradycardia.'], 'Alfuzosin': ['NotSet', 'Both atenolol and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both atenolol and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both atenolol and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both atenolol and amantadine can increase the risk of hypotension.'], 'Aminophylline': ['Severe', 'Atenolol is predicted to increase the risk of bronchospasm when given with aminophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Amiodarone': ['NotSet', 'Both atenolol and amiodarone can increase the risk of bradycardia. Amiodarone is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Amitriptyline': ['NotSet', 'Both atenolol and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both atenolol and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both atenolol and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both atenolol and apraclonidine can increase the risk of bradycardia. Both atenolol and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both atenolol and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both atenolol and asenapine can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both atenolol and avanafil can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both atenolol and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both atenolol and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both atenolol and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both atenolol and benperidol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both atenolol and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both atenolol and brimonidine can increase the risk of bradycardia. Both atenolol and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both atenolol and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both atenolol and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both atenolol and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both atenolol and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both atenolol and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both atenolol and captopril can increase the risk of hypotension.'], 'Cariprazine': ['NotSet', 'Both atenolol and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both atenolol and carvedilol can increase the risk of bradycardia. Both atenolol and carvedilol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both atenolol and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both atenolol and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both atenolol and chlortalidone can increase the risk of hypotension.'], 'Cisatracurium': ['NotSet', 'Both atenolol and cisatracurium can increase the risk of bradycardia.'], 'Clomipramine': ['NotSet', 'Both atenolol and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both atenolol and clonidine can increase the risk of bradycardia. Both atenolol and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both atenolol and clozapine can increase the risk of hypotension.'], 'Crizotinib': ['NotSet', 'Both atenolol and crizotinib can increase the risk of bradycardia.'], 'Dapagliflozin': ['NotSet', 'Both atenolol and dapagliflozin can increase the risk of hypotension.'], 'Desflurane': ['NotSet', 'Both atenolol and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both atenolol and diazoxide can increase the risk of hypotension.'], 'Digoxin': ['NotSet', 'Both atenolol and digoxin can increase the risk of bradycardia.'], 'Diltiazem': ['NotSet', 'Both atenolol and diltiazem can increase the risk of bradycardia. Both atenolol and diltiazem can increase the risk of hypotension. Diltiazem is predicted to increase the risk of cardiodepression when given with atenolol. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Dipyridamole': ['NotSet', 'Both atenolol and dipyridamole can increase the risk of hypotension.'], 'Disopyramide': ['Severe', 'Disopyramide is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Dobutamine': ['Moderate', 'Atenolol increases the risk of hypertension and bradycardia when given with dobutamine. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Donepezil': ['NotSet', 'Both atenolol and donepezil can increase the risk of bradycardia. Donepezil is predicted to increase the risk of bradycardia when given with atenolol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Dosulepin': ['NotSet', 'Both atenolol and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both atenolol and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both atenolol and doxepin can increase the risk of hypotension.'], 'Dronedarone': ['Severe', 'Dronedarone is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Droperidol': ['NotSet', 'Both atenolol and droperidol can increase the risk of hypotension.'], 'Empagliflozin': ['NotSet', 'Both atenolol and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both atenolol and enalapril can increase the risk of hypotension.'], 'Eplerenone': ['NotSet', 'Both atenolol and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both atenolol and eprosartan can increase the risk of hypotension.'], 'Ergometrine': ['Severe', 'Atenolol is predicted to increase the risk of peripheral vasoconstriction when given with ergometrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Ergotamine': ['Severe', 'Atenolol is predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Ertugliflozin': ['NotSet', 'Both atenolol and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', 'Both atenolol and esketamine can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both atenolol and etomidate can increase the risk of hypotension.'], 'Felodipine': ['NotSet', 'Both atenolol and felodipine can increase the risk of hypotension.'], 'Fentanyl': ['NotSet', 'Both atenolol and fentanyl can increase the risk of bradycardia.'], 'Fingolimod': ['NotSet', 'Both atenolol and fingolimod can increase the risk of bradycardia.'], 'Flecainide': ['NotSet', 'Both atenolol and flecainide can increase the risk of bradycardia. Flecainide is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Flupentixol': ['NotSet', 'Both atenolol and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both atenolol and fluphenazine can increase the risk of hypotension.'], 'Fosinopril': ['NotSet', 'Both atenolol and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both atenolol and furosemide can increase the risk of hypotension.'], 'Galantamine': ['NotSet', 'Both atenolol and galantamine can increase the risk of bradycardia. Galantamine is predicted to increase the risk of bradycardia when given with atenolol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Glyceryl trinitrate': ['NotSet', 'Both atenolol and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both atenolol and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both atenolol and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both atenolol and haloperidol can increase the risk of hypotension.'], 'Hydralazine': ['NotSet', 'Both atenolol and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both atenolol and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both atenolol and hydroflumethiazide can increase the risk of hypotension.'], 'Imidapril': ['NotSet', 'Both atenolol and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both atenolol and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both atenolol and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both atenolol and indoramin can increase the risk of hypotension.'], 'Irbesartan': ['NotSet', 'Both atenolol and irbesartan can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both atenolol and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both atenolol and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both atenolol and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both atenolol and isosorbide mononitrate can increase the risk of hypotension.'], 'Ivabradine': ['NotSet', 'Both atenolol and ivabradine can increase the risk of bradycardia.'], 'Ketamine': ['NotSet', 'Both atenolol and ketamine can increase the risk of hypotension.'], 'Labetalol': ['NotSet', 'Both atenolol and labetalol can increase the risk of bradycardia. Both atenolol and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both atenolol and lacidipine can increase the risk of hypotension.'], 'Lanreotide': ['Moderate', 'Atenolol is predicted to increase the risk of bradycardia when given with lanreotide. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Lercanidipine': ['NotSet', 'Both atenolol and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both atenolol and levobunolol can increase the risk of bradycardia. Both atenolol and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both atenolol and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both atenolol and levomepromazine can increase the risk of hypotension.'], 'Lidocaine': ['Severe', 'Lidocaine is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Lisinopril': ['NotSet', 'Both atenolol and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both atenolol and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both atenolol and lofexidine can increase the risk of hypotension.'], 'Losartan': ['NotSet', 'Both atenolol and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both atenolol and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both atenolol and lurasidone can increase the risk of hypotension.'], 'Mefloquine': ['Severe', 'Mefloquine is predicted to increase the risk of bradycardia when given with atenolol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methadone': ['NotSet', 'Both atenolol and methadone can increase the risk of bradycardia.'], 'Methoxyflurane': ['NotSet', 'Both atenolol and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both atenolol and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both atenolol and metolazone can increase the risk of hypotension.'], 'Mexiletine': ['Severe', 'Mexiletine potentially increases the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises avoid or monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Minoxidil': ['NotSet', 'Both atenolol and minoxidil can increase the risk of hypotension.'], 'Moxisylyte': ['NotSet', 'Both atenolol and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both atenolol and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both atenolol and nadolol can increase the risk of bradycardia. Both atenolol and nadolol can increase the risk of hypotension.'], 'Neostigmine': ['NotSet', 'Both atenolol and neostigmine can increase the risk of bradycardia.'], 'Nicardipine': ['NotSet', 'Both atenolol and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both atenolol and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both atenolol and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both atenolol and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both atenolol and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both atenolol and nitrous oxide can increase the risk of hypotension.'], 'Noradrenaline/norepinephrine': ['Severe', 'Atenolol is predicted to increase the risk of hypertension and bradycardia when given with noradrenaline/norepinephrine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Nortriptyline': ['NotSet', 'Both atenolol and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both atenolol and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both atenolol and olmesartan can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both atenolol and paliperidone can increase the risk of hypotension.'], 'Pasireotide': ['NotSet', 'Both atenolol and pasireotide can increase the risk of bradycardia.'], 'Pergolide': ['NotSet', 'Both atenolol and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both atenolol and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both atenolol and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both atenolol and phenelzine can increase the risk of hypotension.'], 'Pimozide': ['NotSet', 'Both atenolol and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both atenolol and pindolol can increase the risk of bradycardia. Both atenolol and pindolol can increase the risk of hypotension.'], 'Pramipexole': ['NotSet', 'Both atenolol and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both atenolol and prazosin can increase the risk of hypotension.'], 'Prochlorperazine': ['NotSet', 'Both atenolol and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both atenolol and promazine can increase the risk of hypotension.'], 'Propafenone': ['Severe', 'Propafenone is predicted to increase the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Propofol': ['NotSet', 'Both atenolol and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both atenolol and propranolol can increase the risk of bradycardia. Both atenolol and propranolol can increase the risk of hypotension.'], 'Pyridostigmine': ['NotSet', 'Both atenolol and pyridostigmine can increase the risk of bradycardia.'], 'Quetiapine': ['NotSet', 'Both atenolol and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both atenolol and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both atenolol and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both atenolol and ramipril can increase the risk of hypotension.'], 'Remifentanil': ['NotSet', 'Both atenolol and remifentanil can increase the risk of bradycardia.'], 'Riociguat': ['NotSet', 'Both atenolol and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both atenolol and risperidone can increase the risk of hypotension.'], 'Rivastigmine': ['NotSet', 'Both atenolol and rivastigmine can increase the risk of bradycardia. Rivastigmine is predicted to increase the risk of bradycardia when given with atenolol. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ropinirole': ['NotSet', 'Both atenolol and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both atenolol and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both atenolol and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both atenolol and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both atenolol and selegiline can increase the risk of bradycardia. Both atenolol and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both atenolol and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both atenolol and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both atenolol and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both atenolol and sotalol can increase the risk of bradycardia. Both atenolol and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both atenolol and spironolactone can increase the risk of hypotension.'], 'Sufentanil': ['NotSet', 'Both atenolol and sufentanil can increase the risk of bradycardia.'], 'Sulpiride': ['NotSet', 'Both atenolol and sulpiride can increase the risk of hypotension.'], 'Tadalafil': ['NotSet', 'Both atenolol and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both atenolol and tamsulosin can increase the risk of hypotension.'], 'Telmisartan': ['NotSet', 'Both atenolol and telmisartan can increase the risk of hypotension.'], 'Terazosin': ['NotSet', 'Both atenolol and terazosin can increase the risk of hypotension.'], 'Thalidomide': ['NotSet', 'Both atenolol and thalidomide can increase the risk of bradycardia.'], 'Theophylline': ['Severe', 'Atenolol is predicted to increase the risk of bronchospasm when given with theophylline. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Thiopental': ['NotSet', 'Both atenolol and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both atenolol and timolol can increase the risk of bradycardia. Both atenolol and timolol can increase the risk of hypotension.'], 'Tizanidine': ['NotSet', 'Both atenolol and tizanidine can increase the risk of bradycardia. Both atenolol and tizanidine can increase the risk of hypotension.'], 'Torasemide': ['NotSet', 'Both atenolol and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both atenolol and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both atenolol and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both atenolol and trifluoperazine can increase the risk of hypotension.'], 'Trimipramine': ['NotSet', 'Both atenolol and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both atenolol and valsartan can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both atenolol and vardenafil can increase the risk of hypotension.'], 'Verapamil': ['NotSet', 'Both atenolol and verapamil can increase the risk of bradycardia. Both atenolol and verapamil can increase the risk of hypotension. Intravenous verapamil increases the risk of cardiovascular side-effects when given with atenolol. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study Oral verapamil increases the risk of cardiovascular side-effects when given with atenolol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Vernakalant': ['NotSet', 'Both atenolol and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both atenolol and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both atenolol and zuclopenthixol can increase the risk of hypotension.']}","atezolizumab","{'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to decrease the efficacy of atezolizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to decrease the efficacy of atezolizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to decrease the efficacy of atezolizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to decrease the efficacy of atezolizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to decrease the efficacy of atezolizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to decrease the efficacy of atezolizumab. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with atezolizumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical']}","atomoxetine","{'Bambuterol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with bambuterol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Bupropion': ['Severe', 'Bupropion is predicted to markedly increase the exposure to atomoxetine. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Cinacalcet': ['Severe', 'Cinacalcet is predicted to markedly increase the exposure to atomoxetine. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Dacomitinib': ['Severe', 'Dacomitinib is predicted to markedly increase the exposure to atomoxetine. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Dexamfetamine': ['Severe', 'Dexamfetamine is predicted to increase the risk of side-effects when given with atomoxetine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Eliglustat': ['Moderate', 'Eliglustat is predicted to increase the exposure to atomoxetine. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fluoxetine': ['Severe', 'Fluoxetine is predicted to markedly increase the exposure to atomoxetine. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Formoterol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with formoterol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Indacaterol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with indacaterol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Isocarboxazid': ['Severe', 'Isocarboxazid is predicted to increase the risk of side-effects when given with atomoxetine. Manufacturer advises avoid and for 2 weeks after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Lisdexamfetamine': ['Severe', 'Lisdexamfetamine is predicted to increase the risk of side-effects when given with atomoxetine. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Olodaterol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with olodaterol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Panobinostat': ['Severe', 'Panobinostat is predicted to increase the exposure to atomoxetine. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Paroxetine': ['Severe', 'Paroxetine is predicted to markedly increase the exposure to atomoxetine. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenelzine': ['Severe', 'Phenelzine is predicted to increase the risk of side-effects when given with atomoxetine. Manufacturer advises avoid and for 2 weeks after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Salbutamol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with salbutamol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Salmeterol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with salmeterol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Terbinafine': ['Severe', 'Terbinafine is predicted to markedly increase the exposure to atomoxetine. Manufacturer advises adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Terbutaline': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with terbutaline (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tranylcypromine': ['Severe', 'Tranylcypromine is predicted to increase the risk of side-effects when given with atomoxetine. Manufacturer advises avoid and for 2 weeks after stopping the MAOI. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vilanterol': ['Moderate', 'Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with vilanterol (high-dose). Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study']}","atorvastatin","{'Alcohol (beverage)': ['NotSet', 'Both atorvastatin and alcohol (beverage) can increase the risk of hepatotoxicity.'], 'Alectinib': ['NotSet', 'Both atorvastatin and alectinib can increase the risk of hepatotoxicity.'], 'Aliskiren': ['Moderate', 'Atorvastatin slightly to moderately increases the exposure to aliskiren. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Amiodarone': ['Moderate', 'Amiodarone is predicted to increase the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Aprepitant': ['Severe', 'Aprepitant is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Asparaginase': ['NotSet', 'Both atorvastatin and asparaginase can increase the risk of hepatotoxicity.'], 'Atazanavir': ['Severe', 'Atazanavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Bedaquiline': ['NotSet', 'Both atorvastatin and bedaquiline can increase the risk of hepatotoxicity.'], 'Bezafibrate': ['Severe', 'Bezafibrate increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Bosentan': ['Mild', 'Bosentan slightly decreases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Carbamazepine': ['NotSet', 'Both atorvastatin and carbamazepine can increase the risk of hepatotoxicity. Carbamazepine is predicted to decrease the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ceftobiprole': ['Moderate', 'Ceftobiprole is predicted to increase the concentration of atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ciclosporin': ['Severe', 'Ciclosporin very markedly increases the exposure to atorvastatin. Manufacturer advises avoid or adjust atorvastatin dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Ciprofibrate': ['Severe', 'Ciprofibrate increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises avoid or adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Clarithromycin': ['Severe', 'Clarithromycin is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Clavulanate': ['NotSet', 'Both atorvastatin and clavulanate can increase the risk of hepatotoxicity.'], 'Cobicistat': ['Severe', 'Cobicistat is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Colchicine': ['Severe', 'Colchicine increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Crisantaspase': ['NotSet', 'Both atorvastatin and crisantaspase can increase the risk of hepatotoxicity.'], 'Crizotinib': ['Severe', 'Crizotinib is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dactinomycin': ['NotSet', 'Both atorvastatin and dactinomycin can increase the risk of hepatotoxicity.'], 'Danazol': ['Severe', 'Danazol is predicted to increase the risk of rhabdomyolysis when given with atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dantrolene': ['NotSet', 'Both atorvastatin and dantrolene can increase the risk of hepatotoxicity.'], 'Daptomycin': ['Severe', 'Atorvastatin is predicted to increase the risk of rhabdomyolysis when given with daptomycin. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Darunavir': ['Severe', 'Darunavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Demeclocycline': ['NotSet', 'Both atorvastatin and demeclocycline can increase the risk of hepatotoxicity.'], 'Didanosine': ['NotSet', 'Both atorvastatin and didanosine can increase the risk of hepatotoxicity.'], 'Diltiazem': ['Severe', 'Diltiazem slightly to moderately increases the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Doxycycline': ['NotSet', 'Both atorvastatin and doxycycline can increase the risk of hepatotoxicity.'], 'Dronedarone': ['Severe', 'Dronedarone slightly increases the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Efavirenz': ['Mild', 'Efavirenz slightly decreases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Elbasvir': ['Moderate', 'Elbasvir increases the exposure to atorvastatin. Manufacturer advises adjust atorvastatin dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Eltrombopag': ['Moderate', 'Eltrombopag is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Erythromycin': ['Severe', 'Erythromycin slightly increases the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Eslicarbazepine': ['Moderate', 'Eslicarbazepine is predicted to decrease the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ezetimibe': ['Severe', 'Ezetimibe potentially increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fenofibrate': ['Severe', 'Fenofibrate increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises adjust fenofibrate dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Flucloxacillin': ['NotSet', 'Both atorvastatin and flucloxacillin can increase the risk of hepatotoxicity.'], 'Fluconazole': ['NotSet', 'Both atorvastatin and fluconazole can increase the risk of hepatotoxicity. Fluconazole potentially increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fosamprenavir': ['Severe', 'Fosamprenavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin potentially decreases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Fusidate': ['Severe', 'Fusidate increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Gemfibrozil': ['Severe', 'Gemfibrozil increases the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Glecaprevir': ['Severe', 'Glecaprevir (with pibrentasvir) markedly increases the exposure to atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Grapefruit juice': ['Mild', 'Grapefruit juice increases the exposure to atorvastatin. Manufacturer advises caution. Severity of interaction: Mild Evidence for interaction: Study'], 'Grazoprevir': ['Moderate', 'Grazoprevir increases the exposure to atorvastatin. Manufacturer advises adjust atorvastatin dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Idelalisib': ['Severe', 'Idelalisib is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Imatinib': ['Severe', 'Imatinib is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Isavuconazole': ['Moderate', 'Isavuconazole slightly increases the exposure to atorvastatin. Manufacturer advises monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Isoniazid': ['NotSet', 'Both atorvastatin and isoniazid can increase the risk of hepatotoxicity.'], 'Itraconazole': ['NotSet', 'Both atorvastatin and itraconazole can increase the risk of hepatotoxicity. Itraconazole is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketoconazole': ['Severe', 'Ketoconazole is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Ledipasvir': ['Moderate', 'Ledipasvir is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Leflunomide': ['NotSet', 'Both atorvastatin and leflunomide can increase the risk of hepatotoxicity. Leflunomide is predicted to increase the exposure to atorvastatin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lenalidomide': ['NotSet', 'Both atorvastatin and lenalidomide can increase the risk of hepatotoxicity.'], 'Letermovir': ['Severe', 'Letermovir moderately increases the exposure to atorvastatin. Manufacturer advises avoid or adjust atorvastatin dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Lomitapide': ['NotSet', 'Both atorvastatin and lomitapide can increase the risk of hepatotoxicity. Lomitapide increases the exposure to atorvastatin. Manufacturer advises adjust lomitapide dose or separate administration by 12 hours. Severity of interaction: Mild Evidence for interaction: Study'], 'Lopinavir': ['Severe', 'Lopinavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Lymecycline': ['NotSet', 'Both atorvastatin and lymecycline can increase the risk of hepatotoxicity.'], 'Mercaptopurine': ['NotSet', 'Both atorvastatin and mercaptopurine can increase the risk of hepatotoxicity.'], 'Methotrexate': ['NotSet', 'Both atorvastatin and methotrexate can increase the risk of hepatotoxicity.'], 'Micafungin': ['NotSet', 'Both atorvastatin and micafungin can increase the risk of hepatotoxicity.'], 'Miconazole': ['Severe', 'Miconazole potentially increases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Minocycline': ['NotSet', 'Both atorvastatin and minocycline can increase the risk of hepatotoxicity.'], 'Netupitant': ['Severe', 'Netupitant is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nevirapine': ['Mild', 'Nevirapine slightly decreases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study'], 'Nicotinic acid': ['Severe', 'Nicotinic acid is predicted to increase the risk of rhabdomyolysis when given with atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nilotinib': ['Severe', 'Nilotinib is predicted to slightly increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Oxytetracycline': ['NotSet', 'Both atorvastatin and oxytetracycline can increase the risk of hepatotoxicity.'], 'Paracetamol': ['NotSet', 'Both atorvastatin and paracetamol can increase the risk of hepatotoxicity.'], 'Paritaprevir': ['Severe', 'Paritaprevir (in fixed-dose combination) is predicted to increase the risk of rhabdomyolysis when given with atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Pazopanib': ['Moderate', 'Pazopanib is predicted to affect the exposure to atorvastatin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Pegaspargase': ['NotSet', 'Both atorvastatin and pegaspargase can increase the risk of hepatotoxicity.'], 'Phenytoin': ['Moderate', 'Phenytoin potentially decreases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Pibrentasvir': ['Severe', 'Pibrentasvir (with glecaprevir) markedly increases the exposure to atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Posaconazole': ['Severe', 'Posaconazole is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ranolazine': ['Moderate', 'Ranolazine is predicted to increase the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Regorafenib': ['Moderate', 'Regorafenib is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor side effects. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifampicin': ['Moderate', 'Rifampicin markedly decreases the exposure to atorvastatin. Manufacturer advises atorvastatin should be taken at the same time as rifampicin. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ritonavir': ['Severe', 'Ritonavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Sacubitril': ['Severe', 'Sacubitril is predicted to increase the exposure to atorvastatin. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Study'], 'Saquinavir': ['Severe', 'Saquinavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Sarilumab': ['Moderate', 'Sarilumab is predicted to decrease the exposure to atorvastatin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], ""St John's Wort"": ['Mild', ""St John's Wort slightly decreases the exposure to atorvastatin. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Study""], 'Streptozocin': ['NotSet', 'Both atorvastatin and streptozocin can increase the risk of hepatotoxicity.'], 'Sulfasalazine': ['NotSet', 'Both atorvastatin and sulfasalazine can increase the risk of hepatotoxicity.'], 'Tedizolid': ['Moderate', 'Tedizolid is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Teriflunomide': ['Moderate', 'Teriflunomide is predicted to increase the exposure to atorvastatin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tetracycline': ['NotSet', 'Both atorvastatin and tetracycline can increase the risk of hepatotoxicity.'], 'Tigecycline': ['NotSet', 'Both atorvastatin and tigecycline can increase the risk of hepatotoxicity.'], 'Tipranavir': ['Severe', 'Tipranavir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Tocilizumab': ['Moderate', 'Tocilizumab is predicted to decrease the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Trabectedin': ['NotSet', 'Both atorvastatin and trabectedin can increase the risk of hepatotoxicity.'], 'Valproate': ['NotSet', 'Both atorvastatin and valproate can increase the risk of hepatotoxicity.'], 'Velpatasvir': ['Severe', 'Velpatasvir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Venetoclax': ['Moderate', 'Venetoclax is predicted to increase the exposure to atorvastatin. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Verapamil': ['Severe', 'Verapamil is predicted to slightly to moderately increase the exposure to atorvastatin. Manufacturer advises monitor and adjust dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vincristine': ['NotSet', 'Both atorvastatin and vincristine can increase the risk of hepatotoxicity.'], 'Voriconazole': ['Severe', 'Voriconazole is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid or adjust dose and monitor rhabdomyolysis. Severity of interaction: Severe Evidence for interaction: Study'], 'Voxilaprevir': ['Moderate', 'Voxilaprevir is predicted to increase the exposure to atorvastatin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical']}","atovaquone","{'Atazanavir': ['Moderate', 'Atazanavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Darunavir': ['Moderate', 'Darunavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Efavirenz': ['Moderate', 'Efavirenz moderately decreases the exposure to atovaquone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Lopinavir': ['Moderate', 'Lopinavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Metoclopramide': ['Moderate', 'Metoclopramide decreases the concentration of atovaquone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifabutin': ['Moderate', 'Rifabutin slightly decreases the exposure to atovaquone. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rifampicin': ['Moderate', 'Rifampicin moderately decreases the exposure to atovaquone and atovaquone slightly increases the exposure to rifampicin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ritonavir': ['Moderate', 'Ritonavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Saquinavir': ['Moderate', 'Saquinavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tetracycline': ['Moderate', 'Tetracycline decreases the concentration of atovaquone. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Tipranavir': ['Moderate', 'Tipranavir decreases the exposure to atovaquone. Manufacturer advises avoid if boosted with ritonavir. Severity of interaction: Moderate Evidence for interaction: Study']}","atracuri","{'Amikacin': ['NotSet', 'Both atracurium and amikacin have neuromuscular blocking effects.'], 'Beclometasone': ['Severe', 'Beclometasone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Betamethasone': ['Severe', 'Betamethasone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Botulinum toxin type A': ['NotSet', 'Both atracurium and botulinum toxin type A have neuromuscular blocking effects.'], 'Botulinum toxin type B': ['NotSet', 'Both atracurium and botulinum toxin type B have neuromuscular blocking effects.'], 'Budesonide': ['Severe', 'Budesonide is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the effects of (but acute use increases the effects of) atracurium. Manufacturer advises monitor and adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ciclesonide': ['Severe', 'Ciclesonide is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Clindamycin': ['Severe', 'Clindamycin increases the effects of atracurium. Manufacturer advises caution. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Colistimethate': ['NotSet', 'Both atracurium and colistimethate have neuromuscular blocking effects.'], 'Deflazacort': ['Severe', 'Deflazacort is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Dexamethasone': ['Severe', 'Dexamethasone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Donepezil': ['Moderate', 'Donepezil is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fludrocortisone': ['Severe', 'Fludrocortisone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fluticasone': ['Severe', 'Fluticasone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin decreases the effects of (but acute use increases the effects of) atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Galantamine': ['Moderate', 'Galantamine is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Gentamicin': ['NotSet', 'Both atracurium and gentamicin have neuromuscular blocking effects.'], 'Hydrocortisone': ['Severe', 'Hydrocortisone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Irinotecan': ['Moderate', 'Irinotecan is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Magnesium': ['Moderate', 'Intravenous magnesium increases the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Methylprednisolone': ['Severe', 'Methylprednisolone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Metoclopramide': ['Moderate', 'Metoclopramide is predicted to increase the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Mometasone': ['Severe', 'Mometasone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Neomycin': ['NotSet', 'Both atracurium and neomycin have neuromuscular blocking effects.'], 'Phenytoin': ['Moderate', 'Phenytoin decreases the effects of (but acute use increases the effects of) atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Piperacillin': ['Moderate', 'Piperacillin increases the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Polymyxin b': ['NotSet', 'Both atracurium and polymyxin b have neuromuscular blocking effects.'], 'Prednisolone': ['Severe', 'Prednisolone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Rivastigmine': ['Moderate', 'Rivastigmine is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Streptomycin': ['NotSet', 'Both atracurium and streptomycin have neuromuscular blocking effects.'], 'Suxamethonium': ['NotSet', 'Both atracurium and suxamethonium have neuromuscular blocking effects.'], 'Tobramycin': ['NotSet', 'Both atracurium and tobramycin have neuromuscular blocking effects.'], 'Triamcinolone': ['Severe', 'Triamcinolone is predicted to decrease the effects of atracurium. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Anecdotal']}","atropi","{'Aclidinium': ['NotSet', 'Both atropine and aclidinium can cause antimuscarinic effects.'], 'Amantadine': ['NotSet', 'Both atropine and amantadine can cause antimuscarinic effects.'], 'Amitriptyline': ['NotSet', 'Both atropine and amitriptyline can cause antimuscarinic effects.'], 'Baclofen': ['NotSet', 'Both atropine and baclofen can cause antimuscarinic effects.'], 'Chlorphenamine': ['NotSet', 'Both atropine and chlorphenamine can cause antimuscarinic effects.'], 'Chlorpromazine': ['NotSet', 'Both atropine and chlorpromazine can cause antimuscarinic effects.'], 'Clemastine': ['NotSet', 'Both atropine and clemastine can cause antimuscarinic effects.'], 'Clomipramine': ['NotSet', 'Both atropine and clomipramine can cause antimuscarinic effects.'], 'Clozapine': ['NotSet', 'Both atropine and clozapine can cause antimuscarinic effects.'], 'Cyclizine': ['NotSet', 'Both atropine and cyclizine can cause antimuscarinic effects.'], 'Cyclopentolate': ['NotSet', 'Both atropine and cyclopentolate can cause antimuscarinic effects.'], 'Cyproheptadine': ['NotSet', 'Both atropine and cyproheptadine can cause antimuscarinic effects.'], 'Darifenacin': ['NotSet', 'Both atropine and darifenacin can cause antimuscarinic effects.'], 'Dicycloverine': ['NotSet', 'Both atropine and dicycloverine can cause antimuscarinic effects.'], 'Dimenhydrinate': ['NotSet', 'Both atropine and dimenhydrinate can cause antimuscarinic effects.'], 'Disopyramide': ['NotSet', 'Both atropine and disopyramide can cause antimuscarinic effects.'], 'Dosulepin': ['NotSet', 'Both atropine and dosulepin can cause antimuscarinic effects.'], 'Doxepin': ['NotSet', 'Both atropine and doxepin can cause antimuscarinic effects.'], 'Fesoterodine': ['NotSet', 'Both atropine and fesoterodine can cause antimuscarinic effects.'], 'Flavoxate': ['NotSet', 'Both atropine and flavoxate can cause antimuscarinic effects.'], 'Glycopyrronium': ['NotSet', 'Both atropine and glycopyrronium can cause antimuscarinic effects.'], 'Haloperidol': ['NotSet', 'Both atropine and haloperidol can cause antimuscarinic effects.'], 'Homatropine': ['NotSet', 'Both atropine and homatropine can cause antimuscarinic effects.'], 'Hydroxyzine': ['NotSet', 'Both atropine and hydroxyzine can cause antimuscarinic effects.'], 'Hyoscine': ['NotSet', 'Both atropine and hyoscine can cause antimuscarinic effects.'], 'Imipramine': ['NotSet', 'Both atropine and imipramine can cause antimuscarinic effects.'], 'Ipratropium': ['NotSet', 'Both atropine and ipratropium can cause antimuscarinic effects.'], 'Levodopa': ['Moderate', 'Atropine decreases the absorption of levodopa. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Levomepromazine': ['NotSet', 'Both atropine and levomepromazine can cause antimuscarinic effects.'], 'Lofepramine': ['NotSet', 'Both atropine and lofepramine can cause antimuscarinic effects.'], 'Loxapine': ['NotSet', 'Both atropine and loxapine can cause antimuscarinic effects.'], 'Nefopam': ['NotSet', 'Both atropine and nefopam can cause antimuscarinic effects.'], 'Nortriptyline': ['NotSet', 'Both atropine and nortriptyline can cause antimuscarinic effects.'], 'Orphenadrine': ['NotSet', 'Both atropine and orphenadrine can cause antimuscarinic effects.'], 'Oxybutynin': ['NotSet', 'Both atropine and oxybutynin can cause antimuscarinic effects.'], 'Phenylephrine': ['Severe', 'Atropine increases the risk of severe hypertension when given with phenylephrine. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Pimozide': ['NotSet', 'Both atropine and pimozide can cause antimuscarinic effects.'], 'Prochlorperazine': ['NotSet', 'Both atropine and prochlorperazine can cause antimuscarinic effects.'], 'Procyclidine': ['NotSet', 'Both atropine and procyclidine can cause antimuscarinic effects.'], 'Promethazine': ['NotSet', 'Both atropine and promethazine can cause antimuscarinic effects.'], 'Propafenone': ['NotSet', 'Both atropine and propafenone can cause antimuscarinic effects.'], 'Propantheline': ['NotSet', 'Both atropine and propantheline can cause antimuscarinic effects.'], 'Propiverine': ['NotSet', 'Both atropine and propiverine can cause antimuscarinic effects.'], 'Solifenacin': ['NotSet', 'Both atropine and solifenacin can cause antimuscarinic effects.'], 'Tiotropium': ['NotSet', 'Both atropine and tiotropium can cause antimuscarinic effects.'], 'Tolterodine': ['NotSet', 'Both atropine and tolterodine can cause antimuscarinic effects.'], 'Trifluoperazine': ['NotSet', 'Both atropine and trifluoperazine can cause antimuscarinic effects.'], 'Trihexyphenidyl': ['NotSet', 'Both atropine and trihexyphenidyl can cause antimuscarinic effects.'], 'Trimipramine': ['NotSet', 'Both atropine and trimipramine can cause antimuscarinic effects.'], 'Tropicamide': ['NotSet', 'Both atropine and tropicamide can cause antimuscarinic effects.'], 'Trospium': ['NotSet', 'Both atropine and trospium can cause antimuscarinic effects.'], 'Umeclidinium': ['NotSet', 'Both atropine and umeclidinium can cause antimuscarinic effects.']}","avanafil","{'Acebutolol': ['NotSet', 'Both avanafil and acebutolol can increase the risk of hypotension.'], 'Alcohol (beverage)': ['NotSet', 'Both avanafil and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both avanafil and alfuzosin can increase the risk of hypotension. Alfuzosin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Aliskiren': ['NotSet', 'Both avanafil and aliskiren can increase the risk of hypotension.'], 'Alprostadil': ['NotSet', 'Both avanafil and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both avanafil and amantadine can increase the risk of hypotension.'], 'Amitriptyline': ['NotSet', 'Both avanafil and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both avanafil and amlodipine can increase the risk of hypotension.'], 'Apalutamide': ['Moderate', 'Apalutamide is predicted to decrease the exposure to avanafil. Manufacturer advises avoid or monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Apomorphine': ['NotSet', 'Both avanafil and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both avanafil and apraclonidine can increase the risk of hypotension.'], 'Aprepitant': ['Moderate', 'Aprepitant is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Aripiprazole': ['NotSet', 'Both avanafil and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both avanafil and asenapine can increase the risk of hypotension.'], 'Atazanavir': ['Severe', 'Atazanavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Atenolol': ['NotSet', 'Both avanafil and atenolol can increase the risk of hypotension.'], 'Azilsartan': ['NotSet', 'Both avanafil and azilsartan can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both avanafil and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both avanafil and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both avanafil and benperidol can increase the risk of hypotension.'], 'Betaxolol': ['NotSet', 'Both avanafil and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both avanafil and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both avanafil and bortezomib can increase the risk of hypotension.'], 'Bosentan': ['Moderate', 'Bosentan decreases the exposure to avanafil. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Study'], 'Brimonidine': ['NotSet', 'Both avanafil and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both avanafil and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both avanafil and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both avanafil and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both avanafil and canagliflozin can increase the risk of hypotension.'], 'Candesartan': ['NotSet', 'Both avanafil and candesartan can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both avanafil and captopril can increase the risk of hypotension.'], 'Carbamazepine': ['Severe', 'Carbamazepine is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Cariprazine': ['NotSet', 'Both avanafil and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both avanafil and carvedilol can increase the risk of hypotension.'], 'Celiprolol': ['NotSet', 'Both avanafil and celiprolol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both avanafil and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both avanafil and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both avanafil and chlortalidone can increase the risk of hypotension.'], 'Clarithromycin': ['Severe', 'Clarithromycin is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Clomipramine': ['NotSet', 'Both avanafil and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both avanafil and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both avanafil and clozapine can increase the risk of hypotension.'], 'Cobicistat': ['Severe', 'Cobicistat is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Crizotinib': ['Moderate', 'Crizotinib is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Dapagliflozin': ['NotSet', 'Both avanafil and dapagliflozin can increase the risk of hypotension.'], 'Darunavir': ['Severe', 'Darunavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Desflurane': ['NotSet', 'Both avanafil and desflurane can increase the risk of hypotension.'], 'Diazoxide': ['NotSet', 'Both avanafil and diazoxide can increase the risk of hypotension.'], 'Diltiazem': ['NotSet', 'Both avanafil and diltiazem can increase the risk of hypotension. Diltiazem is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Dipyridamole': ['NotSet', 'Both avanafil and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', 'Both avanafil and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both avanafil and doxazosin can increase the risk of hypotension. Doxazosin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Doxepin': ['NotSet', 'Both avanafil and doxepin can increase the risk of hypotension.'], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Droperidol': ['NotSet', 'Both avanafil and droperidol can increase the risk of hypotension.'], 'Efavirenz': ['Moderate', 'Efavirenz is predicted to decrease the exposure to avanafil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Empagliflozin': ['NotSet', 'Both avanafil and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both avanafil and enalapril can increase the risk of hypotension.'], 'Enzalutamide': ['Severe', 'Enzalutamide is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Eplerenone': ['NotSet', 'Both avanafil and eplerenone can increase the risk of hypotension.'], 'Eprosartan': ['NotSet', 'Both avanafil and eprosartan can increase the risk of hypotension.'], 'Ertugliflozin': ['NotSet', 'Both avanafil and ertugliflozin can increase the risk of hypotension.'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Esketamine': ['NotSet', 'Both avanafil and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both avanafil and esmolol can increase the risk of hypotension.'], 'Etomidate': ['NotSet', 'Both avanafil and etomidate can increase the risk of hypotension.'], 'Etravirine': ['Moderate', 'Etravirine moderately decreases the exposure to avanafil. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Felodipine': ['NotSet', 'Both avanafil and felodipine can increase the risk of hypotension.'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Flupentixol': ['NotSet', 'Both avanafil and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both avanafil and fluphenazine can increase the risk of hypotension.'], 'Fosamprenavir': ['Severe', 'Fosamprenavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Fosinopril': ['NotSet', 'Both avanafil and fosinopril can increase the risk of hypotension.'], 'Fosphenytoin': ['Severe', 'Fosphenytoin is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Furosemide': ['NotSet', 'Both avanafil and furosemide can increase the risk of hypotension.'], 'Glyceryl trinitrate': ['NotSet', 'Both avanafil and glyceryl trinitrate can increase the risk of hypotension. Glyceryl trinitrate potentially increases the risk of hypotension when given with avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Grapefruit juice': ['Moderate', 'Grapefruit juice is predicted to increase the exposure to avanafil. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Guanethidine': ['NotSet', 'Both avanafil and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both avanafil and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both avanafil and haloperidol can increase the risk of hypotension.'], 'Hydralazine': ['NotSet', 'Both avanafil and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both avanafil and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both avanafil and hydroflumethiazide can increase the risk of hypotension.'], 'Idelalisib': ['Severe', 'Idelalisib is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Imatinib': ['Moderate', 'Imatinib is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Imidapril': ['NotSet', 'Both avanafil and imidapril can increase the risk of hypotension.'], 'Imipramine': ['NotSet', 'Both avanafil and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both avanafil and indapamide can increase the risk of hypotension.'], 'Indoramin': ['NotSet', 'Both avanafil and indoramin can increase the risk of hypotension. Indoramin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Irbesartan': ['NotSet', 'Both avanafil and irbesartan can increase the risk of hypotension.'], 'Isavuconazole': ['Moderate', 'Isavuconazole is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Isocarboxazid': ['NotSet', 'Both avanafil and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both avanafil and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both avanafil and isosorbide dinitrate can increase the risk of hypotension. Isosorbide dinitrate potentially increases the risk of hypotension when given with avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Isosorbide mononitrate': ['NotSet', 'Both avanafil and isosorbide mononitrate can increase the risk of hypotension. Isosorbide mononitrate potentially increases the risk of hypotension when given with avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Itraconazole': ['Severe', 'Itraconazole is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ketamine': ['NotSet', 'Both avanafil and ketamine can increase the risk of hypotension.'], 'Ketoconazole': ['Severe', 'Ketoconazole is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Labetalol': ['NotSet', 'Both avanafil and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both avanafil and lacidipine can increase the risk of hypotension.'], 'Lercanidipine': ['NotSet', 'Both avanafil and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both avanafil and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both avanafil and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both avanafil and levomepromazine can increase the risk of hypotension.'], 'Lisinopril': ['NotSet', 'Both avanafil and lisinopril can increase the risk of hypotension.'], 'Lofepramine': ['NotSet', 'Both avanafil and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both avanafil and lofexidine can increase the risk of hypotension.'], 'Lopinavir': ['Severe', 'Lopinavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Losartan': ['NotSet', 'Both avanafil and losartan can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both avanafil and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both avanafil and lurasidone can increase the risk of hypotension.'], 'Methoxyflurane': ['NotSet', 'Both avanafil and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both avanafil and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both avanafil and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both avanafil and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both avanafil and minoxidil can increase the risk of hypotension.'], 'Mitotane': ['Severe', 'Mitotane is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Moxisylyte': ['NotSet', 'Both avanafil and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both avanafil and moxonidine can increase the risk of hypotension.'], 'Nadolol': ['NotSet', 'Both avanafil and nadolol can increase the risk of hypotension.'], 'Nebivolol': ['NotSet', 'Both avanafil and nebivolol can increase the risk of hypotension.'], 'Netupitant': ['Moderate', 'Netupitant is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nevirapine': ['Moderate', 'Nevirapine is predicted to decrease the exposure to avanafil. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nicardipine': ['NotSet', 'Both avanafil and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both avanafil and nicorandil can increase the risk of hypotension. Nicorandil is predicted to increase the risk of hypotension when given with avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Nifedipine': ['NotSet', 'Both avanafil and nifedipine can increase the risk of hypotension.'], 'Nilotinib': ['Moderate', 'Nilotinib is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nimodipine': ['NotSet', 'Both avanafil and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both avanafil and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both avanafil and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both avanafil and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both avanafil and olanzapine can increase the risk of hypotension.'], 'Olmesartan': ['NotSet', 'Both avanafil and olmesartan can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both avanafil and paliperidone can increase the risk of hypotension.'], 'Pergolide': ['NotSet', 'Both avanafil and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both avanafil and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both avanafil and perindopril can increase the risk of hypotension.'], 'Phenelzine': ['NotSet', 'Both avanafil and phenelzine can increase the risk of hypotension.'], 'Phenobarbital': ['Severe', 'Phenobarbital is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Phenytoin': ['Severe', 'Phenytoin is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Pimozide': ['NotSet', 'Both avanafil and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both avanafil and pindolol can increase the risk of hypotension.'], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pramipexole': ['NotSet', 'Both avanafil and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both avanafil and prazosin can increase the risk of hypotension. Prazosin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Primidone': ['Severe', 'Primidone is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Prochlorperazine': ['NotSet', 'Both avanafil and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both avanafil and promazine can increase the risk of hypotension.'], 'Propofol': ['NotSet', 'Both avanafil and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both avanafil and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both avanafil and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both avanafil and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both avanafil and quinapril can increase the risk of hypotension.'], 'Ramipril': ['NotSet', 'Both avanafil and ramipril can increase the risk of hypotension.'], 'Rifampicin': ['Severe', 'Rifampicin is predicted to decrease the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Riociguat': ['NotSet', 'Both avanafil and riociguat can increase the risk of hypotension. Riociguat is predicted to increase the risk of hypotension when given with avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Risperidone': ['NotSet', 'Both avanafil and risperidone can increase the risk of hypotension.'], 'Ritonavir': ['Severe', 'Ritonavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Ropinirole': ['NotSet', 'Both avanafil and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both avanafil and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both avanafil and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both avanafil and sapropterin can increase the risk of hypotension. Avanafil is predicted to increase the risk of hypotension when given with sapropterin. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Saquinavir': ['Severe', 'Saquinavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Selegiline': ['NotSet', 'Both avanafil and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both avanafil and sevoflurane can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both avanafil and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both avanafil and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both avanafil and spironolactone can increase the risk of hypotension.'], ""St John's Wort"": ['Moderate', ""St John's Wort is predicted to decrease the exposure to avanafil. Manufacturer advises monitor efficacy. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Sulpiride': ['NotSet', 'Both avanafil and sulpiride can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both avanafil and tamsulosin can increase the risk of hypotension. Tamsulosin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Telmisartan': ['NotSet', 'Both avanafil and telmisartan can increase the risk of hypotension.'], 'Terazosin': ['NotSet', 'Both avanafil and terazosin can increase the risk of hypotension. Terazosin causes significant hypotensive effects when given with avanafil. Manufacturer advises patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Thiopental': ['NotSet', 'Both avanafil and thiopental can increase the risk of hypotension.'], 'Timolol': ['NotSet', 'Both avanafil and timolol can increase the risk of hypotension.'], 'Tipranavir': ['Severe', 'Tipranavir is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Tizanidine': ['NotSet', 'Both avanafil and tizanidine can increase the risk of hypotension.'], 'Torasemide': ['NotSet', 'Both avanafil and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both avanafil and trandolapril can increase the risk of hypotension.'], 'Tranylcypromine': ['NotSet', 'Both avanafil and tranylcypromine can increase the risk of hypotension.'], 'Trifluoperazine': ['NotSet', 'Both avanafil and trifluoperazine can increase the risk of hypotension.'], 'Trimipramine': ['NotSet', 'Both avanafil and trimipramine can increase the risk of hypotension.'], 'Valsartan': ['NotSet', 'Both avanafil and valsartan can increase the risk of hypotension.'], 'Verapamil': ['NotSet', 'Both avanafil and verapamil can increase the risk of hypotension. Verapamil is predicted to increase the exposure to avanafil. Manufacturer advises adjust avanafil dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Vernakalant': ['NotSet', 'Both avanafil and vernakalant can increase the risk of hypotension.'], 'Voriconazole': ['Severe', 'Voriconazole is predicted to increase the exposure to avanafil. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Xipamide': ['NotSet', 'Both avanafil and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both avanafil and zuclopenthixol can increase the risk of hypotension.']}","avelumab","{'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with avelumab. Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical']}","axitinib","{'Acenocoumarol': ['Severe', 'Axitinib is predicted to increase the risk of bleeding events when given with acenocoumarol. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Afatinib': ['NotSet', 'Both axitinib and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both axitinib and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both axitinib and alemtuzumab can increase the risk of myelosuppression.'], 'Amsacrine': ['NotSet', 'Both axitinib and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both axitinib and anakinra can increase the risk of myelosuppression.'], 'Aprepitant': ['Moderate', 'Aprepitant is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Arsenic trioxide': ['NotSet', 'Both axitinib and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both axitinib and asparaginase can increase the risk of myelosuppression.'], 'Atazanavir': ['Moderate', 'Atazanavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Azacitidine': ['NotSet', 'Both axitinib and azacitidine can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both axitinib and azathioprine can increase the risk of myelosuppression.'], 'Balsalazide': ['NotSet', 'Both axitinib and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both axitinib and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both axitinib and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both axitinib and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both axitinib and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both axitinib and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both axitinib and bortezomib can increase the risk of myelosuppression.'], 'Bosentan': ['Moderate', 'Bosentan is predicted to decrease the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bosutinib': ['NotSet', 'Both axitinib and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both axitinib and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both axitinib and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both axitinib and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both axitinib and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both axitinib and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both axitinib and capecitabine can increase the risk of myelosuppression.'], 'Carbamazepine': ['Moderate', 'Carbamazepine is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Carbimazole': ['NotSet', 'Both axitinib and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both axitinib and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both axitinib and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both axitinib and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both axitinib and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both axitinib and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both axitinib and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both axitinib and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both axitinib and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both axitinib and cladribine can increase the risk of myelosuppression.'], 'Clarithromycin': ['Moderate', 'Clarithromycin is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Clofarabine': ['NotSet', 'Both axitinib and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both axitinib and clozapine can increase the risk of myelosuppression.'], 'Cobicistat': ['Moderate', 'Cobicistat is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Crisantaspase': ['NotSet', 'Both axitinib and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both axitinib and crizotinib can increase the risk of myelosuppression. Crizotinib is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Cyclophosphamide': ['NotSet', 'Both axitinib and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both axitinib and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both axitinib and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both axitinib and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both axitinib and dactinomycin can increase the risk of myelosuppression.'], 'Darunavir': ['Moderate', 'Darunavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Dasatinib': ['NotSet', 'Both axitinib and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both axitinib and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both axitinib and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both axitinib and deferiprone can increase the risk of myelosuppression.'], 'Diltiazem': ['Moderate', 'Diltiazem is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Docetaxel': ['NotSet', 'Both axitinib and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both axitinib and doxorubicin can increase the risk of myelosuppression.'], 'Dronedarone': ['Moderate', 'Dronedarone is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Efavirenz': ['Moderate', 'Efavirenz is predicted to decrease the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Enzalutamide': ['Moderate', 'Enzalutamide is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Epirubicin': ['NotSet', 'Both axitinib and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both axitinib and eribulin can increase the risk of myelosuppression.'], 'Erythromycin': ['Moderate', 'Erythromycin is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Estramustine': ['NotSet', 'Both axitinib and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both axitinib and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both axitinib and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both axitinib and everolimus can increase the risk of myelosuppression.'], 'Fluconazole': ['Moderate', 'Fluconazole is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fludarabine': ['NotSet', 'Both axitinib and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both axitinib and fluorouracil can increase the risk of myelosuppression.'], 'Fosamprenavir': ['Moderate', 'Fosamprenavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Fosphenytoin': ['Moderate', 'Fosphenytoin is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ganciclovir': ['NotSet', 'Both axitinib and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both axitinib and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both axitinib and gemcitabine can increase the risk of myelosuppression.'], 'Grapefruit juice': ['Moderate', 'Grapefruit juice is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Hydroxycarbamide': ['NotSet', 'Both axitinib and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both axitinib and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both axitinib and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both axitinib and idelalisib can increase the risk of myelosuppression. Idelalisib is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ifosfamide': ['NotSet', 'Both axitinib and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both axitinib and imatinib can increase the risk of myelosuppression. Imatinib is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Interferon alfa': ['NotSet', 'Both axitinib and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both axitinib and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both axitinib and irinotecan can increase the risk of myelosuppression.'], 'Isavuconazole': ['Moderate', 'Isavuconazole is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Itraconazole': ['Moderate', 'Itraconazole is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ketoconazole': ['Moderate', 'Ketoconazole is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Leflunomide': ['NotSet', 'Both axitinib and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both axitinib and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both axitinib and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both axitinib and lomustine can increase the risk of myelosuppression.'], 'Lopinavir': ['Moderate', 'Lopinavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Melphalan': ['NotSet', 'Both axitinib and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both axitinib and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both axitinib and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both axitinib and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both axitinib and mitotane can increase the risk of myelosuppression. Mitotane is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Mitoxantrone': ['NotSet', 'Both axitinib and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both axitinib and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both axitinib and nelarabine can increase the risk of myelosuppression.'], 'Netupitant': ['Moderate', 'Netupitant is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nevirapine': ['Moderate', 'Nevirapine is predicted to decrease the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nilotinib': ['NotSet', 'Both axitinib and nilotinib can increase the risk of myelosuppression. Nilotinib is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nivolumab': ['NotSet', 'Both axitinib and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both axitinib and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both axitinib and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both axitinib and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both axitinib and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both axitinib and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both axitinib and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both axitinib and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both axitinib and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both axitinib and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both axitinib and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both axitinib and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both axitinib and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both axitinib and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both axitinib and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both axitinib and pentostatin can increase the risk of myelosuppression.'], 'Phenindione': ['Severe', 'Axitinib is predicted to increase the risk of bleeding events when given with phenindione. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenobarbital': ['Moderate', 'Phenobarbital is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Phenytoin': ['Moderate', 'Phenytoin is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Pixantrone': ['NotSet', 'Both axitinib and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both axitinib and pomalidomide can increase the risk of myelosuppression.'], 'Posaconazole': ['Moderate', 'Posaconazole is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Primaquine': ['NotSet', 'Both axitinib and primaquine can increase the risk of myelosuppression.'], 'Primidone': ['Moderate', 'Primidone is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Procarbazine': ['NotSet', 'Both axitinib and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both axitinib and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both axitinib and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both axitinib and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both axitinib and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both axitinib and regorafenib can increase the risk of myelosuppression.'], 'Rifampicin': ['Moderate', 'Rifampicin is predicted to decrease the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Ritonavir': ['Moderate', 'Ritonavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Rituximab': ['NotSet', 'Both axitinib and rituximab can increase the risk of myelosuppression.'], 'Ruxolitinib': ['NotSet', 'Both axitinib and ruxolitinib can increase the risk of myelosuppression.'], 'Saquinavir': ['Moderate', 'Saquinavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Siltuximab': ['NotSet', 'Both axitinib and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both axitinib and sorafenib can increase the risk of myelosuppression.'], ""St John's Wort"": ['Moderate', ""St John's Wort is predicted to decrease the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical""], 'Sulfadiazine': ['NotSet', 'Both axitinib and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both axitinib and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both axitinib and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both axitinib and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both axitinib and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both axitinib and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both axitinib and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both axitinib and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both axitinib and tioguanine can increase the risk of myelosuppression.'], 'Tipranavir': ['Moderate', 'Tipranavir is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Topotecan': ['NotSet', 'Both axitinib and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both axitinib and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both axitinib and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both axitinib and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both axitinib and trimethoprim can increase the risk of myelosuppression.'], 'Valganciclovir': ['NotSet', 'Both axitinib and valganciclovir can increase the risk of myelosuppression.'], 'Verapamil': ['Moderate', 'Verapamil is predicted to increase the exposure to axitinib. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both axitinib and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both axitinib and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both axitinib and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both axitinib and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both axitinib and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both axitinib and vismodegib can increase the risk of myelosuppression.'], 'Voriconazole': ['Moderate', 'Voriconazole is predicted to increase the exposure to axitinib. Manufacturer advises avoid or adjust dose. Severity of interaction: Moderate Evidence for interaction: Study'], 'Warfarin': ['Severe', 'Axitinib is predicted to increase the risk of bleeding events when given with warfarin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both axitinib and zidovudine can increase the risk of myelosuppression.']}","azacitidine","{'Afatinib': ['NotSet', 'Both azacitidine and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both azacitidine and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both azacitidine and alemtuzumab can increase the risk of myelosuppression.'], 'Amsacrine': ['NotSet', 'Both azacitidine and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both azacitidine and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both azacitidine and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both azacitidine and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both azacitidine and axitinib can increase the risk of myelosuppression.'], 'Azathioprine': ['NotSet', 'Both azacitidine and azathioprine can increase the risk of myelosuppression.'], 'Balsalazide': ['NotSet', 'Both azacitidine and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both azacitidine and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both azacitidine and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both azacitidine and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both azacitidine and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both azacitidine and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both azacitidine and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both azacitidine and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both azacitidine and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both azacitidine and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both azacitidine and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both azacitidine and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both azacitidine and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both azacitidine and capecitabine can increase the risk of myelosuppression.'], 'Carbimazole': ['NotSet', 'Both azacitidine and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both azacitidine and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both azacitidine and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both azacitidine and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both azacitidine and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both azacitidine and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both azacitidine and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both azacitidine and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both azacitidine and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both azacitidine and cladribine can increase the risk of myelosuppression.'], 'Clofarabine': ['NotSet', 'Both azacitidine and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both azacitidine and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both azacitidine and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both azacitidine and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both azacitidine and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both azacitidine and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both azacitidine and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both azacitidine and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both azacitidine and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both azacitidine and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both azacitidine and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both azacitidine and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both azacitidine and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both azacitidine and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both azacitidine and doxorubicin can increase the risk of myelosuppression.'], 'Epirubicin': ['NotSet', 'Both azacitidine and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both azacitidine and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both azacitidine and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both azacitidine and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both azacitidine and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both azacitidine and everolimus can increase the risk of myelosuppression.'], 'Fludarabine': ['NotSet', 'Both azacitidine and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both azacitidine and fluorouracil can increase the risk of myelosuppression.'], 'Ganciclovir': ['NotSet', 'Both azacitidine and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both azacitidine and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both azacitidine and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both azacitidine and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both azacitidine and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both azacitidine and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both azacitidine and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both azacitidine and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both azacitidine and imatinib can increase the risk of myelosuppression.'], 'Interferon alfa': ['NotSet', 'Both azacitidine and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both azacitidine and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both azacitidine and irinotecan can increase the risk of myelosuppression.'], 'Leflunomide': ['NotSet', 'Both azacitidine and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both azacitidine and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both azacitidine and linezolid can increase the risk of myelosuppression.'], 'Lomustine': ['NotSet', 'Both azacitidine and lomustine can increase the risk of myelosuppression.'], 'Melphalan': ['NotSet', 'Both azacitidine and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both azacitidine and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both azacitidine and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both azacitidine and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both azacitidine and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both azacitidine and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both azacitidine and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both azacitidine and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both azacitidine and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both azacitidine and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both azacitidine and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both azacitidine and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both azacitidine and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both azacitidine and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both azacitidine and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both azacitidine and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both azacitidine and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both azacitidine and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both azacitidine and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both azacitidine and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both azacitidine and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both azacitidine and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both azacitidine and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both azacitidine and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both azacitidine and pentostatin can increase the risk of myelosuppression.'], 'Pixantrone': ['NotSet', 'Both azacitidine and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both azacitidine and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both azacitidine and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both azacitidine and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both azacitidine and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both azacitidine and pyrimethamine can increase the risk of myelosuppression.'], 'Raltitrexed': ['NotSet', 'Both azacitidine and raltitrexed can increase the risk of myelosuppression.'], 'Ramucirumab': ['NotSet', 'Both azacitidine and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both azacitidine and regorafenib can increase the risk of myelosuppression.'], 'Rituximab': ['NotSet', 'Both azacitidine and rituximab can increase the risk of myelosuppression.'], 'Ruxolitinib': ['NotSet', 'Both azacitidine and ruxolitinib can increase the risk of myelosuppression.'], 'Siltuximab': ['NotSet', 'Both azacitidine and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both azacitidine and sorafenib can increase the risk of myelosuppression.'], 'Sulfadiazine': ['NotSet', 'Both azacitidine and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both azacitidine and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both azacitidine and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both azacitidine and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both azacitidine and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both azacitidine and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both azacitidine and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both azacitidine and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both azacitidine and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both azacitidine and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both azacitidine and trabectedin can increase the risk of myelosuppression.'], 'Trastuzumab emtansine': ['NotSet', 'Both azacitidine and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both azacitidine and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both azacitidine and trimethoprim can increase the risk of myelosuppression.'], 'Valganciclovir': ['NotSet', 'Both azacitidine and valganciclovir can increase the risk of myelosuppression.'], 'Vinblastine': ['NotSet', 'Both azacitidine and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both azacitidine and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both azacitidine and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both azacitidine and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both azacitidine and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both azacitidine and vismodegib can increase the risk of myelosuppression.'], 'Zidovudine': ['NotSet', 'Both azacitidine and zidovudine can increase the risk of myelosuppression.']}","azathioprine","{'Acenocoumarol': ['Moderate', 'Azathioprine decreases the anticoagulant effect of acenocoumarol. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Afatinib': ['NotSet', 'Both azathioprine and afatinib can increase the risk of myelosuppression.'], 'Aflibercept': ['NotSet', 'Both azathioprine and aflibercept can increase the risk of myelosuppression.'], 'Alemtuzumab': ['NotSet', 'Both azathioprine and alemtuzumab can increase the risk of myelosuppression.'], 'Allopurinol': ['Severe', 'Allopurinol potentially increases the risk of haematological toxicity when given with azathioprine. Manufacturer advises adjust azathioprine dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Amsacrine': ['NotSet', 'Both azathioprine and amsacrine can increase the risk of myelosuppression.'], 'Anakinra': ['NotSet', 'Both azathioprine and anakinra can increase the risk of myelosuppression.'], 'Arsenic trioxide': ['NotSet', 'Both azathioprine and arsenic trioxide can increase the risk of myelosuppression.'], 'Asparaginase': ['NotSet', 'Both azathioprine and asparaginase can increase the risk of myelosuppression.'], 'Axitinib': ['NotSet', 'Both azathioprine and axitinib can increase the risk of myelosuppression.'], 'Azacitidine': ['NotSet', 'Both azathioprine and azacitidine can increase the risk of myelosuppression.'], 'Bacillus Calmette-Guérin vaccine': ['Severe', 'Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Balsalazide': ['NotSet', 'Both azathioprine and balsalazide can increase the risk of myelosuppression.'], 'Belimumab': ['NotSet', 'Both azathioprine and belimumab can increase the risk of myelosuppression.'], 'Bendamustine': ['NotSet', 'Both azathioprine and bendamustine can increase the risk of myelosuppression.'], 'Bevacizumab': ['NotSet', 'Both azathioprine and bevacizumab can increase the risk of myelosuppression.'], 'Bleomycin': ['NotSet', 'Both azathioprine and bleomycin can increase the risk of myelosuppression.'], 'Blinatumomab': ['NotSet', 'Both azathioprine and blinatumomab can increase the risk of myelosuppression.'], 'Bortezomib': ['NotSet', 'Both azathioprine and bortezomib can increase the risk of myelosuppression.'], 'Bosutinib': ['NotSet', 'Both azathioprine and bosutinib can increase the risk of myelosuppression.'], 'Brentuximab vedotin': ['NotSet', 'Both azathioprine and brentuximab vedotin can increase the risk of myelosuppression.'], 'Busulfan': ['NotSet', 'Both azathioprine and busulfan can increase the risk of myelosuppression.'], 'Cabazitaxel': ['NotSet', 'Both azathioprine and cabazitaxel can increase the risk of myelosuppression.'], 'Cabozantinib': ['NotSet', 'Both azathioprine and cabozantinib can increase the risk of myelosuppression.'], 'Canakinumab': ['NotSet', 'Both azathioprine and canakinumab can increase the risk of myelosuppression.'], 'Capecitabine': ['NotSet', 'Both azathioprine and capecitabine can increase the risk of myelosuppression.'], 'Captopril': ['Severe', 'Captopril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Carbimazole': ['NotSet', 'Both azathioprine and carbimazole can increase the risk of myelosuppression.'], 'Carboplatin': ['NotSet', 'Both azathioprine and carboplatin can increase the risk of myelosuppression.'], 'Carfilzomib': ['NotSet', 'Both azathioprine and carfilzomib can increase the risk of myelosuppression.'], 'Carmustine': ['NotSet', 'Both azathioprine and carmustine can increase the risk of myelosuppression.'], 'Ceritinib': ['NotSet', 'Both azathioprine and ceritinib can increase the risk of myelosuppression.'], 'Cetuximab': ['NotSet', 'Both azathioprine and cetuximab can increase the risk of myelosuppression.'], 'Chlorambucil': ['NotSet', 'Both azathioprine and chlorambucil can increase the risk of myelosuppression.'], 'Chlormethine': ['NotSet', 'Both azathioprine and chlormethine can increase the risk of myelosuppression.'], 'Cisplatin': ['NotSet', 'Both azathioprine and cisplatin can increase the risk of myelosuppression.'], 'Cladribine': ['NotSet', 'Both azathioprine and cladribine can increase the risk of myelosuppression.'], 'Clofarabine': ['NotSet', 'Both azathioprine and clofarabine can increase the risk of myelosuppression.'], 'Clozapine': ['NotSet', 'Both azathioprine and clozapine can increase the risk of myelosuppression.'], 'Crisantaspase': ['NotSet', 'Both azathioprine and crisantaspase can increase the risk of myelosuppression.'], 'Crizotinib': ['NotSet', 'Both azathioprine and crizotinib can increase the risk of myelosuppression.'], 'Cyclophosphamide': ['NotSet', 'Both azathioprine and cyclophosphamide can increase the risk of myelosuppression.'], 'Cytarabine': ['NotSet', 'Both azathioprine and cytarabine can increase the risk of myelosuppression.'], 'Dabrafenib': ['NotSet', 'Both azathioprine and dabrafenib can increase the risk of myelosuppression.'], 'Dacarbazine': ['NotSet', 'Both azathioprine and dacarbazine can increase the risk of myelosuppression.'], 'Dactinomycin': ['NotSet', 'Both azathioprine and dactinomycin can increase the risk of myelosuppression.'], 'Dasatinib': ['NotSet', 'Both azathioprine and dasatinib can increase the risk of myelosuppression.'], 'Daunorubicin': ['NotSet', 'Both azathioprine and daunorubicin can increase the risk of myelosuppression.'], 'Decitabine': ['NotSet', 'Both azathioprine and decitabine can increase the risk of myelosuppression.'], 'Deferiprone': ['NotSet', 'Both azathioprine and deferiprone can increase the risk of myelosuppression.'], 'Docetaxel': ['NotSet', 'Both azathioprine and docetaxel can increase the risk of myelosuppression.'], 'Doxorubicin': ['NotSet', 'Both azathioprine and doxorubicin can increase the risk of myelosuppression.'], 'Enalapril': ['Severe', 'Enalapril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Epirubicin': ['NotSet', 'Both azathioprine and epirubicin can increase the risk of myelosuppression.'], 'Eribulin': ['NotSet', 'Both azathioprine and eribulin can increase the risk of myelosuppression.'], 'Estramustine': ['NotSet', 'Both azathioprine and estramustine can increase the risk of myelosuppression.'], 'Ethosuximide': ['NotSet', 'Both azathioprine and ethosuximide can increase the risk of myelosuppression.'], 'Etoposide': ['NotSet', 'Both azathioprine and etoposide can increase the risk of myelosuppression.'], 'Everolimus': ['NotSet', 'Both azathioprine and everolimus can increase the risk of myelosuppression.'], 'Febuxostat': ['Severe', 'Febuxostat is predicted to increase the exposure to azathioprine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Fludarabine': ['NotSet', 'Both azathioprine and fludarabine can increase the risk of myelosuppression.'], 'Fluorouracil': ['NotSet', 'Both azathioprine and fluorouracil can increase the risk of myelosuppression.'], 'Fosinopril': ['Severe', 'Fosinopril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ganciclovir': ['NotSet', 'Both azathioprine and ganciclovir can increase the risk of myelosuppression.'], 'Gefitinib': ['NotSet', 'Both azathioprine and gefitinib can increase the risk of myelosuppression.'], 'Gemcitabine': ['NotSet', 'Both azathioprine and gemcitabine can increase the risk of myelosuppression.'], 'Hydroxycarbamide': ['NotSet', 'Both azathioprine and hydroxycarbamide can increase the risk of myelosuppression.'], 'Ibrutinib': ['NotSet', 'Both azathioprine and ibrutinib can increase the risk of myelosuppression.'], 'Idarubicin': ['NotSet', 'Both azathioprine and idarubicin can increase the risk of myelosuppression.'], 'Idelalisib': ['NotSet', 'Both azathioprine and idelalisib can increase the risk of myelosuppression.'], 'Ifosfamide': ['NotSet', 'Both azathioprine and ifosfamide can increase the risk of myelosuppression.'], 'Imatinib': ['NotSet', 'Both azathioprine and imatinib can increase the risk of myelosuppression.'], 'Imidapril': ['Severe', 'Imidapril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Influenza vaccine (live)': ['Severe', 'Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Interferon alfa': ['NotSet', 'Both azathioprine and interferon alfa can increase the risk of myelosuppression.'], 'Interferon beta': ['NotSet', 'Both azathioprine and interferon beta can increase the risk of myelosuppression.'], 'Irinotecan': ['NotSet', 'Both azathioprine and irinotecan can increase the risk of myelosuppression.'], 'Leflunomide': ['NotSet', 'Both azathioprine and leflunomide can increase the risk of myelosuppression.'], 'Lenalidomide': ['NotSet', 'Both azathioprine and lenalidomide can increase the risk of myelosuppression.'], 'Linezolid': ['NotSet', 'Both azathioprine and linezolid can increase the risk of myelosuppression.'], 'Lisinopril': ['Severe', 'Lisinopril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Lomustine': ['NotSet', 'Both azathioprine and lomustine can increase the risk of myelosuppression.'], 'Measles, mumps and rubella vaccine, live': ['Severe', 'Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Melphalan': ['NotSet', 'Both azathioprine and melphalan can increase the risk of myelosuppression.'], 'Mercaptopurine': ['NotSet', 'Both azathioprine and mercaptopurine can increase the risk of myelosuppression.'], 'Methotrexate': ['NotSet', 'Both azathioprine and methotrexate can increase the risk of myelosuppression.'], 'Mitomycin': ['NotSet', 'Both azathioprine and mitomycin can increase the risk of myelosuppression.'], 'Mitotane': ['NotSet', 'Both azathioprine and mitotane can increase the risk of myelosuppression.'], 'Mitoxantrone': ['NotSet', 'Both azathioprine and mitoxantrone can increase the risk of myelosuppression.'], 'Mycophenolate': ['NotSet', 'Both azathioprine and mycophenolate can increase the risk of myelosuppression.'], 'Nelarabine': ['NotSet', 'Both azathioprine and nelarabine can increase the risk of myelosuppression.'], 'Nilotinib': ['NotSet', 'Both azathioprine and nilotinib can increase the risk of myelosuppression.'], 'Nivolumab': ['NotSet', 'Both azathioprine and nivolumab can increase the risk of myelosuppression.'], 'Obinutuzumab': ['NotSet', 'Both azathioprine and obinutuzumab can increase the risk of myelosuppression.'], 'Olanzapine': ['NotSet', 'Both azathioprine and olanzapine can increase the risk of myelosuppression.'], 'Olaparib': ['NotSet', 'Both azathioprine and olaparib can increase the risk of myelosuppression.'], 'Olsalazine': ['NotSet', 'Both azathioprine and olsalazine can increase the risk of myelosuppression.'], 'Oxaliplatin': ['NotSet', 'Both azathioprine and oxaliplatin can increase the risk of myelosuppression.'], 'Paclitaxel': ['NotSet', 'Both azathioprine and paclitaxel can increase the risk of myelosuppression.'], 'Panitumumab': ['NotSet', 'Both azathioprine and panitumumab can increase the risk of myelosuppression.'], 'Panobinostat': ['NotSet', 'Both azathioprine and panobinostat can increase the risk of myelosuppression.'], 'Pazopanib': ['NotSet', 'Both azathioprine and pazopanib can increase the risk of myelosuppression.'], 'Pegaspargase': ['NotSet', 'Both azathioprine and pegaspargase can increase the risk of myelosuppression.'], 'Peginterferon alfa': ['NotSet', 'Both azathioprine and peginterferon alfa can increase the risk of myelosuppression.'], 'Peginterferon beta': ['NotSet', 'Both azathioprine and peginterferon beta can increase the risk of myelosuppression.'], 'Pemetrexed': ['NotSet', 'Both azathioprine and pemetrexed can increase the risk of myelosuppression.'], 'Pentamidine': ['NotSet', 'Both azathioprine and pentamidine can increase the risk of myelosuppression.'], 'Pentostatin': ['NotSet', 'Both azathioprine and pentostatin can increase the risk of myelosuppression.'], 'Perindopril': ['Severe', 'Perindopril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Pixantrone': ['NotSet', 'Both azathioprine and pixantrone can increase the risk of myelosuppression.'], 'Pomalidomide': ['NotSet', 'Both azathioprine and pomalidomide can increase the risk of myelosuppression.'], 'Primaquine': ['NotSet', 'Both azathioprine and primaquine can increase the risk of myelosuppression.'], 'Procarbazine': ['NotSet', 'Both azathioprine and procarbazine can increase the risk of myelosuppression.'], 'Propylthiouracil': ['NotSet', 'Both azathioprine and propylthiouracil can increase the risk of myelosuppression.'], 'Pyrimethamine': ['NotSet', 'Both azathioprine and pyrimethamine can increase the risk of myelosuppression.'], 'Quinapril': ['Severe', 'Quinapril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Raltitrexed': ['NotSet', 'Both azathioprine and raltitrexed can increase the risk of myelosuppression.'], 'Ramipril': ['Severe', 'Ramipril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Ramucirumab': ['NotSet', 'Both azathioprine and ramucirumab can increase the risk of myelosuppression.'], 'Regorafenib': ['NotSet', 'Both azathioprine and regorafenib can increase the risk of myelosuppression.'], 'Rituximab': ['NotSet', 'Both azathioprine and rituximab can increase the risk of myelosuppression.'], 'Rotavirus vaccine': ['Severe', 'Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Ruxolitinib': ['NotSet', 'Both azathioprine and ruxolitinib can increase the risk of myelosuppression.'], 'Siltuximab': ['NotSet', 'Both azathioprine and siltuximab can increase the risk of myelosuppression.'], 'Sorafenib': ['NotSet', 'Both azathioprine and sorafenib can increase the risk of myelosuppression.'], 'Sulfadiazine': ['NotSet', 'Both azathioprine and sulfadiazine can increase the risk of myelosuppression.'], 'Sulfamethoxazole': ['NotSet', 'Both azathioprine and sulfamethoxazole can increase the risk of myelosuppression.'], 'Sulfasalazine': ['NotSet', 'Both azathioprine and sulfasalazine can increase the risk of myelosuppression.'], 'Sunitinib': ['NotSet', 'Both azathioprine and sunitinib can increase the risk of myelosuppression.'], 'Temozolomide': ['NotSet', 'Both azathioprine and temozolomide can increase the risk of myelosuppression.'], 'Temsirolimus': ['NotSet', 'Both azathioprine and temsirolimus can increase the risk of myelosuppression.'], 'Thalidomide': ['NotSet', 'Both azathioprine and thalidomide can increase the risk of myelosuppression.'], 'Thiotepa': ['NotSet', 'Both azathioprine and thiotepa can increase the risk of myelosuppression.'], 'Tioguanine': ['NotSet', 'Both azathioprine and tioguanine can increase the risk of myelosuppression.'], 'Topotecan': ['NotSet', 'Both azathioprine and topotecan can increase the risk of myelosuppression.'], 'Trabectedin': ['NotSet', 'Both azathioprine and trabectedin can increase the risk of myelosuppression.'], 'Trandolapril': ['Severe', 'Trandolapril is predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Trastuzumab emtansine': ['NotSet', 'Both azathioprine and trastuzumab emtansine can increase the risk of myelosuppression.'], 'Treosulfan': ['NotSet', 'Both azathioprine and treosulfan can increase the risk of myelosuppression.'], 'Trimethoprim': ['NotSet', 'Both azathioprine and trimethoprim can increase the risk of myelosuppression.'], 'Typhoid vaccine, oral': ['Severe', 'Typhoid vaccine, oral is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Valganciclovir': ['NotSet', 'Both azathioprine and valganciclovir can increase the risk of myelosuppression.'], 'Varicella-zoster vaccine': ['Severe', 'Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Vinblastine': ['NotSet', 'Both azathioprine and vinblastine can increase the risk of myelosuppression.'], 'Vincristine': ['NotSet', 'Both azathioprine and vincristine can increase the risk of myelosuppression.'], 'Vindesine': ['NotSet', 'Both azathioprine and vindesine can increase the risk of myelosuppression.'], 'Vinflunine': ['NotSet', 'Both azathioprine and vinflunine can increase the risk of myelosuppression.'], 'Vinorelbine': ['NotSet', 'Both azathioprine and vinorelbine can increase the risk of myelosuppression.'], 'Vismodegib': ['NotSet', 'Both azathioprine and vismodegib can increase the risk of myelosuppression.'], 'Warfarin': ['Moderate', 'Azathioprine decreases the anticoagulant effect of warfarin. Manufacturer advises monitor INR. Severity of interaction: Moderate Evidence for interaction: Study'], 'Yellow fever vaccine, live': ['Severe', 'Yellow fever vaccine, live is predicted to increase the risk of generalised infection (possibly life-threatening) when given with azathioprine (high-dose). Public Health England advises avoid (refer to Green Book). Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Zidovudine': ['NotSet', 'Both azathioprine and zidovudine can increase the risk of myelosuppression.']}","azelasti","{'Betahistine': ['Moderate', 'Azelastine is predicted to decrease the effects of betahistine. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Isocarboxazid': ['Severe', 'Isocarboxazid is predicted to increase the risk of antimuscarinic side-effects when given with azelastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Phenelzine': ['Severe', 'Phenelzine is predicted to increase the risk of antimuscarinic side-effects when given with azelastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Tranylcypromine': ['Severe', 'Tranylcypromine is predicted to increase the risk of antimuscarinic side-effects when given with azelastine. Manufacturer advises avoid. Severity of interaction: Severe Evidence for interaction: Theoretical']}","azilsart","{'Acebutolol': ['NotSet', 'Both azilsartan and acebutolol can increase the risk of hypotension.'], 'Aceclofenac': ['NotSet', 'Both azilsartan and aceclofenac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Alcohol (beverage)': ['NotSet', 'Both azilsartan and alcohol (beverage) can increase the risk of hypotension.'], 'Alfuzosin': ['NotSet', 'Both azilsartan and alfuzosin can increase the risk of first-dose hypotension. Both azilsartan and alfuzosin can increase the risk of hypotension.'], 'Aliskiren': ['NotSet', 'Both azilsartan and aliskiren can increase the risk of hypotension. Both azilsartan and aliskiren can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). Azilsartan increases the risk of renal impairment when given with aliskiren. Manufacturer advises use with caution or avoid aliskiren in selected patients. Severity of interaction: Severe Evidence for interaction: Study'], 'Alprostadil': ['NotSet', 'Both azilsartan and alprostadil can increase the risk of hypotension.'], 'Amantadine': ['NotSet', 'Both azilsartan and amantadine can increase the risk of hypotension.'], 'Amiloride': ['NotSet', 'Both azilsartan and amiloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Amitriptyline': ['NotSet', 'Both azilsartan and amitriptyline can increase the risk of hypotension.'], 'Amlodipine': ['NotSet', 'Both azilsartan and amlodipine can increase the risk of hypotension.'], 'Apomorphine': ['NotSet', 'Both azilsartan and apomorphine can increase the risk of hypotension.'], 'Apraclonidine': ['NotSet', 'Both azilsartan and apraclonidine can increase the risk of hypotension.'], 'Aripiprazole': ['NotSet', 'Both azilsartan and aripiprazole can increase the risk of hypotension.'], 'Asenapine': ['NotSet', 'Both azilsartan and asenapine can increase the risk of hypotension.'], 'Atenolol': ['NotSet', 'Both azilsartan and atenolol can increase the risk of hypotension.'], 'Avanafil': ['NotSet', 'Both azilsartan and avanafil can increase the risk of hypotension.'], 'Baclofen': ['NotSet', 'Both azilsartan and baclofen can increase the risk of hypotension.'], 'Bendroflumethiazide': ['NotSet', 'Both azilsartan and bendroflumethiazide can increase the risk of hypotension.'], 'Benperidol': ['NotSet', 'Both azilsartan and benperidol can increase the risk of hypotension.'], 'Betaxolol': ['NotSet', 'Both azilsartan and betaxolol can increase the risk of hypotension.'], 'Bisoprolol': ['NotSet', 'Both azilsartan and bisoprolol can increase the risk of hypotension.'], 'Bortezomib': ['NotSet', 'Both azilsartan and bortezomib can increase the risk of hypotension.'], 'Brimonidine': ['NotSet', 'Both azilsartan and brimonidine can increase the risk of hypotension.'], 'Bromocriptine': ['NotSet', 'Both azilsartan and bromocriptine can increase the risk of hypotension.'], 'Bumetanide': ['NotSet', 'Both azilsartan and bumetanide can increase the risk of hypotension.'], 'Cabergoline': ['NotSet', 'Both azilsartan and cabergoline can increase the risk of hypotension.'], 'Canagliflozin': ['NotSet', 'Both azilsartan and canagliflozin can increase the risk of hypotension.'], 'Captopril': ['NotSet', 'Both azilsartan and captopril can increase the risk of first-dose hypotension. Both azilsartan and captopril can increase the risk of hypotension. Both azilsartan and captopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Cariprazine': ['NotSet', 'Both azilsartan and cariprazine can increase the risk of hypotension.'], 'Carvedilol': ['NotSet', 'Both azilsartan and carvedilol can increase the risk of hypotension.'], 'Celecoxib': ['NotSet', 'Both azilsartan and celecoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Celiprolol': ['NotSet', 'Both azilsartan and celiprolol can increase the risk of hypotension.'], 'Chlorothiazide': ['NotSet', 'Both azilsartan and chlorothiazide can increase the risk of hypotension.'], 'Chlorpromazine': ['NotSet', 'Both azilsartan and chlorpromazine can increase the risk of hypotension.'], 'Chlortalidone': ['NotSet', 'Both azilsartan and chlortalidone can increase the risk of hypotension.'], 'Ciclosporin': ['NotSet', 'Both azilsartan and ciclosporin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Clomipramine': ['NotSet', 'Both azilsartan and clomipramine can increase the risk of hypotension.'], 'Clonidine': ['NotSet', 'Both azilsartan and clonidine can increase the risk of hypotension.'], 'Clozapine': ['NotSet', 'Both azilsartan and clozapine can increase the risk of hypotension.'], 'Dalteparin': ['NotSet', 'Both azilsartan and dalteparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dapagliflozin': ['NotSet', 'Both azilsartan and dapagliflozin can increase the risk of hypotension.'], 'Darbepoetin alfa': ['NotSet', 'Both azilsartan and darbepoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Desflurane': ['NotSet', 'Both azilsartan and desflurane can increase the risk of hypotension.'], 'Dexibuprofen': ['NotSet', 'Both azilsartan and dexibuprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Dexketoprofen': ['NotSet', 'Both azilsartan and dexketoprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Diazoxide': ['NotSet', 'Both azilsartan and diazoxide can increase the risk of hypotension.'], 'Diclofenac': ['NotSet', 'Both azilsartan and diclofenac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Diltiazem': ['NotSet', 'Both azilsartan and diltiazem can increase the risk of hypotension.'], 'Dipyridamole': ['NotSet', 'Both azilsartan and dipyridamole can increase the risk of hypotension.'], 'Dosulepin': ['NotSet', 'Both azilsartan and dosulepin can increase the risk of hypotension.'], 'Doxazosin': ['NotSet', 'Both azilsartan and doxazosin can increase the risk of first-dose hypotension. Both azilsartan and doxazosin can increase the risk of hypotension.'], 'Doxepin': ['NotSet', 'Both azilsartan and doxepin can increase the risk of hypotension.'], 'Droperidol': ['NotSet', 'Both azilsartan and droperidol can increase the risk of hypotension.'], 'Drospirenone': ['NotSet', 'Both azilsartan and drospirenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Empagliflozin': ['NotSet', 'Both azilsartan and empagliflozin can increase the risk of hypotension.'], 'Enalapril': ['NotSet', 'Both azilsartan and enalapril can increase the risk of first-dose hypotension. Both azilsartan and enalapril can increase the risk of hypotension. Both azilsartan and enalapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Enoxaparin': ['NotSet', 'Both azilsartan and enoxaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Eplerenone': ['NotSet', 'Both azilsartan and eplerenone can increase the risk of hypotension. Both azilsartan and eplerenone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin alfa': ['NotSet', 'Both azilsartan and epoetin alfa can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin beta': ['NotSet', 'Both azilsartan and epoetin beta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Epoetin zeta': ['NotSet', 'Both azilsartan and epoetin zeta can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ertugliflozin': ['NotSet', 'Both azilsartan and ertugliflozin can increase the risk of hypotension.'], 'Esketamine': ['NotSet', 'Both azilsartan and esketamine can increase the risk of hypotension.'], 'Esmolol': ['NotSet', 'Both azilsartan and esmolol can increase the risk of hypotension.'], 'Etodolac': ['NotSet', 'Both azilsartan and etodolac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Etomidate': ['NotSet', 'Both azilsartan and etomidate can increase the risk of hypotension.'], 'Etoricoxib': ['NotSet', 'Both azilsartan and etoricoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Felodipine': ['NotSet', 'Both azilsartan and felodipine can increase the risk of hypotension.'], 'Flupentixol': ['NotSet', 'Both azilsartan and flupentixol can increase the risk of hypotension.'], 'Fluphenazine': ['NotSet', 'Both azilsartan and fluphenazine can increase the risk of hypotension.'], 'Flurbiprofen': ['NotSet', 'Both azilsartan and flurbiprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Fosinopril': ['NotSet', 'Both azilsartan and fosinopril can increase the risk of first-dose hypotension. Both azilsartan and fosinopril can increase the risk of hypotension.'], 'Furosemide': ['NotSet', 'Both azilsartan and furosemide can increase the risk of hypotension.'], 'Glyceryl trinitrate': ['NotSet', 'Both azilsartan and glyceryl trinitrate can increase the risk of first-dose hypotension. Both azilsartan and glyceryl trinitrate can increase the risk of hypotension.'], 'Guanethidine': ['NotSet', 'Both azilsartan and guanethidine can increase the risk of hypotension.'], 'Guanfacine': ['NotSet', 'Both azilsartan and guanfacine can increase the risk of hypotension.'], 'Haloperidol': ['NotSet', 'Both azilsartan and haloperidol can increase the risk of hypotension.'], 'Heparin (unfractionated)': ['NotSet', 'Both azilsartan and heparin (unfractionated) can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Hydralazine': ['NotSet', 'Both azilsartan and hydralazine can increase the risk of hypotension.'], 'Hydrochlorothiazide': ['NotSet', 'Both azilsartan and hydrochlorothiazide can increase the risk of hypotension.'], 'Hydroflumethiazide': ['NotSet', 'Both azilsartan and hydroflumethiazide can increase the risk of hypotension.'], 'Ibuprofen': ['NotSet', 'Both azilsartan and ibuprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Imidapril': ['NotSet', 'Both azilsartan and imidapril can increase the risk of first-dose hypotension. Both azilsartan and imidapril can increase the risk of hypotension. Both azilsartan and imidapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Imipramine': ['NotSet', 'Both azilsartan and imipramine can increase the risk of hypotension.'], 'Indapamide': ['NotSet', 'Both azilsartan and indapamide can increase the risk of hypotension.'], 'Indometacin': ['NotSet', 'Both azilsartan and indometacin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Indoramin': ['NotSet', 'Both azilsartan and indoramin can increase the risk of first-dose hypotension. Both azilsartan and indoramin can increase the risk of hypotension.'], 'Isocarboxazid': ['NotSet', 'Both azilsartan and isocarboxazid can increase the risk of hypotension.'], 'Isoflurane': ['NotSet', 'Both azilsartan and isoflurane can increase the risk of hypotension.'], 'Isosorbide dinitrate': ['NotSet', 'Both azilsartan and isosorbide dinitrate can increase the risk of first-dose hypotension. Both azilsartan and isosorbide dinitrate can increase the risk of hypotension.'], 'Isosorbide mononitrate': ['NotSet', 'Both azilsartan and isosorbide mononitrate can increase the risk of first-dose hypotension. Both azilsartan and isosorbide mononitrate can increase the risk of hypotension.'], 'Ketamine': ['NotSet', 'Both azilsartan and ketamine can increase the risk of hypotension.'], 'Ketoprofen': ['NotSet', 'Both azilsartan and ketoprofen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ketorolac': ['NotSet', 'Both azilsartan and ketorolac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Labetalol': ['NotSet', 'Both azilsartan and labetalol can increase the risk of hypotension.'], 'Lacidipine': ['NotSet', 'Both azilsartan and lacidipine can increase the risk of hypotension.'], 'Lercanidipine': ['NotSet', 'Both azilsartan and lercanidipine can increase the risk of hypotension.'], 'Levobunolol': ['NotSet', 'Both azilsartan and levobunolol can increase the risk of hypotension.'], 'Levodopa': ['NotSet', 'Both azilsartan and levodopa can increase the risk of hypotension.'], 'Levomepromazine': ['NotSet', 'Both azilsartan and levomepromazine can increase the risk of hypotension.'], 'Lisinopril': ['NotSet', 'Both azilsartan and lisinopril can increase the risk of first-dose hypotension. Both azilsartan and lisinopril can increase the risk of hypotension. Both azilsartan and lisinopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Lithium': ['Severe', 'Azilsartan potentially increases the concentration of lithium. Manufacturer advises monitor concentration and adjust dose. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Lofepramine': ['NotSet', 'Both azilsartan and lofepramine can increase the risk of hypotension.'], 'Lofexidine': ['NotSet', 'Both azilsartan and lofexidine can increase the risk of hypotension.'], 'Loxapine': ['NotSet', 'Both azilsartan and loxapine can increase the risk of hypotension.'], 'Lurasidone': ['NotSet', 'Both azilsartan and lurasidone can increase the risk of hypotension.'], 'Mefenamic acid': ['NotSet', 'Both azilsartan and mefenamic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Meloxicam': ['NotSet', 'Both azilsartan and meloxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Methoxyflurane': ['NotSet', 'Both azilsartan and methoxyflurane can increase the risk of hypotension.'], 'Methyldopa': ['NotSet', 'Both azilsartan and methyldopa can increase the risk of hypotension.'], 'Metolazone': ['NotSet', 'Both azilsartan and metolazone can increase the risk of hypotension.'], 'Metoprolol': ['NotSet', 'Both azilsartan and metoprolol can increase the risk of hypotension.'], 'Minoxidil': ['NotSet', 'Both azilsartan and minoxidil can increase the risk of hypotension.'], 'Moxisylyte': ['NotSet', 'Both azilsartan and moxisylyte can increase the risk of hypotension.'], 'Moxonidine': ['NotSet', 'Both azilsartan and moxonidine can increase the risk of hypotension.'], 'Nabumetone': ['NotSet', 'Both azilsartan and nabumetone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Nadolol': ['NotSet', 'Both azilsartan and nadolol can increase the risk of hypotension.'], 'Naproxen': ['NotSet', 'Both azilsartan and naproxen can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Nebivolol': ['NotSet', 'Both azilsartan and nebivolol can increase the risk of hypotension.'], 'Nicardipine': ['NotSet', 'Both azilsartan and nicardipine can increase the risk of hypotension.'], 'Nicorandil': ['NotSet', 'Both azilsartan and nicorandil can increase the risk of hypotension.'], 'Nifedipine': ['NotSet', 'Both azilsartan and nifedipine can increase the risk of hypotension.'], 'Nimodipine': ['NotSet', 'Both azilsartan and nimodipine can increase the risk of hypotension.'], 'Nitroprusside': ['NotSet', 'Both azilsartan and nitroprusside can increase the risk of hypotension.'], 'Nitrous oxide': ['NotSet', 'Both azilsartan and nitrous oxide can increase the risk of hypotension.'], 'Nortriptyline': ['NotSet', 'Both azilsartan and nortriptyline can increase the risk of hypotension.'], 'Olanzapine': ['NotSet', 'Both azilsartan and olanzapine can increase the risk of hypotension.'], 'Paliperidone': ['NotSet', 'Both azilsartan and paliperidone can increase the risk of hypotension.'], 'Parecoxib': ['NotSet', 'Both azilsartan and parecoxib can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Pergolide': ['NotSet', 'Both azilsartan and pergolide can increase the risk of hypotension.'], 'Pericyazine': ['NotSet', 'Both azilsartan and pericyazine can increase the risk of hypotension.'], 'Perindopril': ['NotSet', 'Both azilsartan and perindopril can increase the risk of first-dose hypotension. Both azilsartan and perindopril can increase the risk of hypotension. Both azilsartan and perindopril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Phenelzine': ['NotSet', 'Both azilsartan and phenelzine can increase the risk of hypotension.'], 'Pimozide': ['NotSet', 'Both azilsartan and pimozide can increase the risk of hypotension.'], 'Pindolol': ['NotSet', 'Both azilsartan and pindolol can increase the risk of hypotension.'], 'Piroxicam': ['NotSet', 'Both azilsartan and piroxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium aminobenzoate': ['NotSet', 'Both azilsartan and potassium aminobenzoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium canrenoate': ['NotSet', 'Both azilsartan and potassium canrenoate can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Potassium chloride': ['NotSet', 'Both azilsartan and potassium chloride can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Pramipexole': ['NotSet', 'Both azilsartan and pramipexole can increase the risk of hypotension.'], 'Prazosin': ['NotSet', 'Both azilsartan and prazosin can increase the risk of first-dose hypotension. Both azilsartan and prazosin can increase the risk of hypotension.'], 'Prochlorperazine': ['NotSet', 'Both azilsartan and prochlorperazine can increase the risk of hypotension.'], 'Promazine': ['NotSet', 'Both azilsartan and promazine can increase the risk of hypotension.'], 'Propofol': ['NotSet', 'Both azilsartan and propofol can increase the risk of hypotension.'], 'Propranolol': ['NotSet', 'Both azilsartan and propranolol can increase the risk of hypotension.'], 'Quetiapine': ['NotSet', 'Both azilsartan and quetiapine can increase the risk of hypotension.'], 'Quinagolide': ['NotSet', 'Both azilsartan and quinagolide can increase the risk of hypotension.'], 'Quinapril': ['NotSet', 'Both azilsartan and quinapril can increase the risk of first-dose hypotension. Both azilsartan and quinapril can increase the risk of hypotension. Both azilsartan and quinapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Ramipril': ['NotSet', 'Both azilsartan and ramipril can increase the risk of first-dose hypotension. Both azilsartan and ramipril can increase the risk of hypotension. Both azilsartan and ramipril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Riociguat': ['NotSet', 'Both azilsartan and riociguat can increase the risk of hypotension.'], 'Risperidone': ['NotSet', 'Both azilsartan and risperidone can increase the risk of hypotension.'], 'Ropinirole': ['NotSet', 'Both azilsartan and ropinirole can increase the risk of hypotension.'], 'Rotigotine': ['NotSet', 'Both azilsartan and rotigotine can increase the risk of hypotension.'], 'Sacubitril': ['NotSet', 'Both azilsartan and sacubitril can increase the risk of hypotension.'], 'Sapropterin': ['NotSet', 'Both azilsartan and sapropterin can increase the risk of hypotension.'], 'Selegiline': ['NotSet', 'Both azilsartan and selegiline can increase the risk of hypotension.'], 'Sevoflurane': ['NotSet', 'Both azilsartan and sevoflurane can increase the risk of hypotension.'], 'Sildenafil': ['NotSet', 'Both azilsartan and sildenafil can increase the risk of hypotension.'], 'Sodium oxybate': ['NotSet', 'Both azilsartan and sodium oxybate can increase the risk of hypotension.'], 'Sotalol': ['NotSet', 'Both azilsartan and sotalol can increase the risk of hypotension.'], 'Spironolactone': ['NotSet', 'Both azilsartan and spironolactone can increase the risk of hypotension. Both azilsartan and spironolactone can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Sulindac': ['NotSet', 'Both azilsartan and sulindac can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Sulpiride': ['NotSet', 'Both azilsartan and sulpiride can increase the risk of hypotension.'], 'Tacrolimus': ['NotSet', 'Both azilsartan and tacrolimus can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tadalafil': ['NotSet', 'Both azilsartan and tadalafil can increase the risk of hypotension.'], 'Tamsulosin': ['NotSet', 'Both azilsartan and tamsulosin can increase the risk of first-dose hypotension. Both azilsartan and tamsulosin can increase the risk of hypotension.'], 'Tenoxicam': ['NotSet', 'Both azilsartan and tenoxicam can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Terazosin': ['NotSet', 'Both azilsartan and terazosin can increase the risk of first-dose hypotension. Both azilsartan and terazosin can increase the risk of hypotension.'], 'Thiopental': ['NotSet', 'Both azilsartan and thiopental can increase the risk of hypotension.'], 'Tiaprofenic acid': ['NotSet', 'Both azilsartan and tiaprofenic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Timolol': ['NotSet', 'Both azilsartan and timolol can increase the risk of hypotension.'], 'Tinzaparin': ['NotSet', 'Both azilsartan and tinzaparin can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tizanidine': ['NotSet', 'Both azilsartan and tizanidine can increase the risk of hypotension.'], 'Tolfenamic acid': ['NotSet', 'Both azilsartan and tolfenamic acid can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tolvaptan': ['NotSet', 'Both azilsartan and tolvaptan can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Torasemide': ['NotSet', 'Both azilsartan and torasemide can increase the risk of hypotension.'], 'Trandolapril': ['NotSet', 'Both azilsartan and trandolapril can increase the risk of first-dose hypotension. Both azilsartan and trandolapril can increase the risk of hypotension. Both azilsartan and trandolapril can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Tranylcypromine': ['NotSet', 'Both azilsartan and tranylcypromine can increase the risk of hypotension.'], 'Triamterene': ['NotSet', 'Both azilsartan and triamterene can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trifluoperazine': ['NotSet', 'Both azilsartan and trifluoperazine can increase the risk of hypotension.'], 'Trimethoprim': ['NotSet', 'Both azilsartan and trimethoprim can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).'], 'Trimipramine': ['NotSet', 'Both azilsartan and trimipramine can increase the risk of hypotension.'], 'Vardenafil': ['NotSet', 'Both azilsartan and vardenafil can increase the risk of hypotension.'], 'Verapamil': ['NotSet', 'Both azilsartan and verapamil can increase the risk of hypotension.'], 'Vernakalant': ['NotSet', 'Both azilsartan and vernakalant can increase the risk of hypotension.'], 'Xipamide': ['NotSet', 'Both azilsartan and xipamide can increase the risk of hypotension.'], 'Zuclopenthixol': ['NotSet', 'Both azilsartan and zuclopenthixol can increase the risk of hypotension.']}","azithromycin","{'Afatinib': ['Moderate', 'Azithromycin is predicted to increase the exposure to afatinib. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Study'], 'Aliskiren': ['Moderate', 'Azithromycin is predicted to increase the exposure to aliskiren. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Aminophylline': ['Moderate', 'Azithromycin is predicted to increase the exposure to aminophylline. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Bictegravir': ['Moderate', 'Azithromycin is predicted to increase the exposure to bictegravir. Manufacturer advises use with caution or avoid. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Ceritinib': ['Moderate', 'Azithromycin is predicted to increase the exposure to ceritinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Colchicine': ['Severe', 'Azithromycin is predicted to increase the exposure to colchicine. Manufacturer advises avoid or adjust colchicine dose. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Dabigatran': ['Moderate', 'Azithromycin is predicted to increase the exposure to dabigatran. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Digoxin': ['Severe', 'Azithromycin increases the concentration of digoxin. Manufacturer advises monitor digoxin concentration. Severity of interaction: Severe Evidence for interaction: Anecdotal'], 'Edoxaban': ['Severe', 'Azithromycin is predicted to slightly increase the exposure to edoxaban. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Theoretical'], 'Erlotinib': ['Moderate', 'Azithromycin is predicted to increase the exposure to erlotinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Fidaxomicin': ['Moderate', 'Azithromycin is predicted to increase the exposure to fidaxomicin. Manufacturer advises avoid. Severity of interaction: Moderate Evidence for interaction: Study'], 'Larotrectinib': ['Mild', 'Azithromycin is predicted to increase the exposure to larotrectinib. Manufacturer makes no recommendation. Severity of interaction: Mild Evidence for interaction: Theoretical'], 'Lomitapide': ['Moderate', 'Azithromycin is predicted to increase the exposure to lomitapide. Manufacturer advises separate administration by 12 hours. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Nadolol': ['Moderate', 'Azithromycin is predicted to increase the exposure to nadolol. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Study'], 'Nintedanib': ['Moderate', 'Azithromycin is predicted to increase the exposure to nintedanib. Manufacturer advises monitor. Severity of interaction: Moderate Evidence for interaction: Study'], 'Panobinostat': ['Moderate', 'Azithromycin is predicted to increase the exposure to panobinostat. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Pibrentasvir': ['Moderate', 'Azithromycin is predicted to increase the exposure to pibrentasvir. Manufacturer makes no recommendation. Severity of interaction: Moderate Evidence for interaction: Theoretical'], 'Rifabutin': ['Severe', 'Azithromycin increases the risk of neutropenia when given with rifabutin. Manufacturer makes no recommendation. Severity of interaction: Severe Evidence for interaction: Study'], 'Talazoparib': ['Severe', 'Azithromycin is predicted to slightly increase the exposure to talazoparib. Manufacturer advises avoid or adjust talazoparib dose. Severity of interaction: Severe Evidence for interaction: Study'], 'Theophylline': ['Moderate', 'Azithromycin is predicted to increase the exposure to theophylline. Manufacturer advises adjust dose. Severity of interaction: Moderate Evidence for interaction: Anecdotal'], 'Ticagrelor': ['Severe', 'Azithromycin is predicted to increase the exposure to ticagrelor. Manufacturer advises use with caution or avoid. Severity of interaction: Severe Evidence for interaction: Study'], 'Topotecan': ['Severe', 'Azithromycin is predicted to increase the exposure to topotecan. Manufacturer advises monitor. Severity of interaction: Severe Evidence for interaction: Study'], 'Trametinib': ['Moderate', 'Azithromycin is predicted to increase the concentration of trametinib. Manufacturer advises caution. Severity of interaction: Moderate Evidence for interaction: Theoretical']}"
